
<html lang="en"     class="pb-page"  data-request-id="31db7294-b12c-4d79-b933-6622dd3a7fde"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c00305;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-10"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Design, Synthesis, and Biological Evaluation of HSP90 Inhibitor–SN38 Conjugates for Targeted Drug Accumulation" /></meta><meta name="dc.Creator" content="Shulei  Zhu" /></meta><meta name="dc.Creator" content="Qianqian  Shen" /></meta><meta name="dc.Creator" content="Yinglei  Gao" /></meta><meta name="dc.Creator" content="Lei  Wang" /></meta><meta name="dc.Creator" content="Yanfen  Fang" /></meta><meta name="dc.Creator" content="Yi  Chen" /></meta><meta name="dc.Creator" content="Wei  Lu" /></meta><meta name="dc.Description" content="Herein, a series of HSP90 inhibitor–SN38 conjugates through ester and carbamate linkage in the 20-OH and 10-OH positions of SN38 were developed for improving the tumor-specific penetration and accu..." /></meta><meta name="Description" content="Herein, a series of HSP90 inhibitor–SN38 conjugates through ester and carbamate linkage in the 20-OH and 10-OH positions of SN38 were developed for improving the tumor-specific penetration and accu..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 30, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00305" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00305" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00305" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00305" /></link>
        
    
    

<title>Design, Synthesis, and Biological Evaluation of HSP90 Inhibitor–SN38 Conjugates for Targeted Drug Accumulation | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00305" /></meta><meta property="og:title" content="Design, Synthesis, and Biological Evaluation of HSP90 Inhibitor–SN38 Conjugates for Targeted Drug Accumulation" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0022.jpeg" /></meta><meta property="og:description" content="Herein, a series of HSP90 inhibitor–SN38 conjugates through ester and carbamate linkage in the 20-OH and 10-OH positions of SN38 were developed for improving the tumor-specific penetration and accumulation of SN38 via extracellular HSP90 (eHSP90)-mediated endocytosis. Mechanistic analyses confirmed that these novel conjugates could bind to eHSP90 and be selectively internalized into the tumor cells, which led to prolonged tumor regression in multiple models of cancer. Among all studied conjugates, compound 18b showed excellent in vitro activities, including acceptable HSP90α affinity and potent antitumor activity. Moreover, compound 18b exhibited superior antitumor activity and low toxicity in HCT116 and Capan-1 xenograft models. Pharmacokinetic analyses in HCT116 and Capan-1 xenografts further confirmed that compound 18b treatment could lead to effective cleavage and extended SN38 exposure at tumor sites. All these encouraging data indicate that this compound is a promising new candidate for cancer therapy and merits further chemical and biological evaluation." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00305"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00305">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00305&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00305&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00305&amp;href=/doi/10.1021/acs.jmedchem.0c00305" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 5421-5441</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00245" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00215" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design, Synthesis, and Biological Evaluation of HSP90 Inhibitor–SN38 Conjugates for Targeted Drug Accumulation</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Shulei Zhu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shulei Zhu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shulei++Zhu">Shulei Zhu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qianqian Shen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qianqian Shen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qianqian++Shen">Qianqian Shen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yinglei Gao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yinglei Gao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yinglei++Gao">Yinglei Gao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lei Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lei Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lei++Wang">Lei Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yanfen Fang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yanfen Fang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, PR China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#e39a8585828d84a3908a8e8ecd8280cd808d"><span class="__cf_email__" data-cfemail="621b0404030c0522110b0f0f4c03014c010c">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yanfen++Fang">Yanfen Fang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yi Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yi Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yi++Chen">Yi Chen</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Wei Lu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wei Lu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, PR China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#42352e3702212a272f6c27212c376c2726376c212c"><span class="__cf_email__" data-cfemail="0473687144676c61692a61676a712a6160712a676a">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Lu">Wei Lu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3041-9200" title="Orcid link">http://orcid.org/0000-0003-3041-9200</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00305&amp;href=/doi/10.1021%2Facs.jmedchem.0c00305" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 5421–5441</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 30, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>20 February 2020</li><li><span class="item_label"><b>Published</b> online</span>30 April 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 May 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00305" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00305</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5421%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DShulei%2BZhu%252C%2BQianqian%2BShen%252C%2BYinglei%2BGao%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D10%26contentID%3Dacs.jmedchem.0c00305%26title%3DDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2BHSP90%2BInhibitor%25E2%2580%2593SN38%2BConjugates%2Bfor%2BTargeted%2BDrug%2BAccumulation%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5441%26publicationDate%3DMay%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00305"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1642</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">2</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00305" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design, Synthesis, and Biological Evaluation of HSP90 Inhibitor–SN38 Conjugates for Targeted Drug Accumulation&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Shulei&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Qianqian&quot;,&quot;last_name&quot;:&quot;Shen&quot;},{&quot;first_name&quot;:&quot;Yinglei&quot;,&quot;last_name&quot;:&quot;Gao&quot;},{&quot;first_name&quot;:&quot;Lei&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Yanfen&quot;,&quot;last_name&quot;:&quot;Fang&quot;},{&quot;first_name&quot;:&quot;Yi&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Lu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;30&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;5421-5441&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00305&quot;},&quot;abstract&quot;:&quot;Herein, a series of HSP90 inhibitor–SN38 conjugates through ester and carbamate linkage in the 20-OH and 10-OH positions of SN38 were developed for improving the tumor-specific penetration and accumulation of SN38 via extracellular HSP90 (eHSP90)-mediated endocytosis. Mechanistic analyses confirmed that these novel conjugates could bind to eHSP90 and be selectively internalized into the tumor cells, which led to prolonged tumor regression in multiple models of cancer. Among all studied conjugates, compound 18b showed excellent in vitro activities, including acceptable HSP90α affinity and potent antitumor activity. Moreover, compound 18b exhibited superior antitumor activity and low toxicity in HCT116 and Capan-1 xenograft models. Pharmacokinetic analyses in HCT116 and Capan-1 xenografts further confirmed that compound 18b treatment could lead to effective cleavage and extended SN38 exposure at tumor sites. All these encouraging data indicate that this compound is a promising new candidate for cancer therapy a&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00305&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00305" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00305&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00305" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00305&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00305" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00305&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00305&amp;href=/doi/10.1021/acs.jmedchem.0c00305" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00305" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00305" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00305%26sid%3Dliteratum%253Aachs%26pmid%3D32352777%26genre%3Darticle%26aulast%3DZhu%26date%3D2020%26atitle%3DDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2BHSP90%2BInhibitor%25E2%2580%2593SN38%2BConjugates%2Bfor%2BTargeted%2BDrug%2BAccumulation%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D10%26spage%3D5421%26epage%3D5441%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291089" title="Plasma">Plasma</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a>,</li><li><a href="/action/doSearch?ConceptID=291290" title="Conjugate acid-base pairs">Conjugate acid-base pairs</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/10" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/jmcmar.2020.63.issue-10/20200528/jmcmar.2020.63.issue-10.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Herein, a series of HSP90 inhibitor–SN38 conjugates through ester and carbamate linkage in the 20-OH and 10-OH positions of SN38 were developed for improving the tumor-specific penetration and accumulation of SN38 <i>via</i> extracellular HSP90 (eHSP90)-mediated endocytosis. Mechanistic analyses confirmed that these novel conjugates could bind to eHSP90 and be selectively internalized into the tumor cells, which led to prolonged tumor regression in multiple models of cancer. Among all studied conjugates, compound <b>18b</b> showed excellent <i>in vitro</i> activities, including acceptable HSP90α affinity and potent antitumor activity. Moreover, compound <b>18b</b> exhibited superior antitumor activity and low toxicity in HCT116 and Capan-1 xenograft models. Pharmacokinetic analyses in HCT116 and Capan-1 xenografts further confirmed that compound <b>18b</b> treatment could lead to effective cleavage and extended SN38 exposure at tumor sites. All these encouraging data indicate that this compound is a promising new candidate for cancer therapy and merits further chemical and biological evaluation.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85608" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85608" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Over the past decades, chemotherapy has been considered one of the most commonly used therapeutic approaches for cancer therapy because of its high efficiency.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> However, the application of ideal chemotherapy drugs with excellent therapeutic efficacy to tumor tissues and low toxicity to normal tissues has been severely hampered because of their poor properties and the complexity and heterogeneity of various tumors.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> 7-Ethyl-10-hydroxy-camptothecin (SN38) is an effective analog of camptothecin targeting DNA topoisomerase I (TOP1), which can lead to apoptosis induction in rapidly dividing tumor cells.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Nevertheless, SN38 cannot be administered directly because of its extremely poor physiological and pharmaceutical compatibility and low tumor-targeting capacity.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Previously, to improve the compatibility and bioavailability of SN38, a number of drug delivery systems have been extensively explored, such as prodrugs,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> lipophilic conjugate,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> the HSP90 inhibitor drug conjugate PEN-866 (HDC),<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> PEGylation conjugate,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> the antibody drug conjugate (ADC) IMMU-132<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), and so forth. Unfortunately, some inherent drawbacks are associated with these drug delivery systems, particularly poor tumor penetration, low drug loading, and complexity of synthesis, which may significantly limit their clinical application.<a onclick="showRef(event, 'ref6 ref7 ref8 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9 ref10 ref11">(6−11)</a> Therefore, there is an urgent need to develop a new strategy for SN38 administration and accumulation in tumor cells.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. SN38 drug delivery systems.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In recent years, there has been considerable interest in ligand–drug conjugates, which often have advantages in their <i>in vivo</i> and <i>in vitro</i> stability, capacity to penetrate tumors, and ease of manufacture.<a onclick="showRef(event, 'ref12 ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15">(12−15)</a> Ligands that selectively bind to heat shock protein 90 (HSP90), a molecular chaperone expressed in cells for targeting, could lead to enhanced accumulation of drugs and fluorescent probes in cells.<a onclick="showRef(event, 'ref8 ref16 ref17 ref18 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref8 ref16 ref17 ref18 ref19 ref20 ref21">(8,16−21)</a> As tumor-target drugs, the HSP90 inhibitors NVP-AUY922 and SNX-5422 were selected as ligands because of their high affinity for activated HSP90 in tumor cells and low affinity for latent HSP90 in normal cells. It was also reported that they could potently arrest cell proliferation and induce apoptosis in a wide variety of human tumor cell lines.<a onclick="showRef(event, 'ref8 ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref8 ref20 ref21 ref22">(8,20−22)</a> All these features suggest that HSP90 inhibitors could be used as potential tumor-targeting ligands for more selective tumor chemotherapy. HSP90 comprises approximately 1% of the cellular proteins and overexpresses in malignant tumor cells intracellularly and extracellularly.<a onclick="showRef(event, 'ref23 ref24 ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25 ref26 ref27">(23−27)</a> Additionally, it is also induced abundantly even within normal tissues.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> What we are interested in is an extracellular HSP90 (eHSP90) and its relationship with malignant characteristics.<a onclick="showRef(event, 'ref19 ref29'); return false;" href="javascript:void(0);" class="ref ref19 ref29">(19,29)</a> eHSP90 is one type of HSP90, secreted extracellularly under environmental stress and tumor conditions. Cancer cells under stress will release more HSP90 <i>via</i> stimulation of extracellular signal-related kinase 1 and 2 (ERK1/2) signaling<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> and <i>via</i> a pseudosignal sequence<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> in response to stress, which rarely occurs in the normal cells. Normal cells do not secrete HSP90 unless under environmental stress. eHSP90 has been identified as a novel role for HSP90 at the cell surface of cancer cells and was shown to be associated with the regulation of tumor invasiveness and metastasis.<a onclick="showRef(event, 'ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34">(32−34)</a> Several groups have confirmed HSP90 inhibitor-conjugates’ trafficking of eHSP90 to the cell surface and demonstrated reinternalization of eHSP90, which are critical features for tumor penetration and drug accumulation.<a onclick="showRef(event, 'ref15 ref19 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref15 ref19 ref35 ref36">(15,19,35,36)</a> Therefore, attaching SN38 to HSP90 inhibitors could efficiently deliver SN38 directly into tumor tissues and lead to a long retention time in the circulation.</div><div class="NLM_p">In this study, two different HSP90 inhibitors, NVP-AUY922 and SNX-5422, were conjugated with SN38 through ester and carbamate bonds in 20-OH and 10-OH, respectively, to construct a series of HSP90 inhibitor–SN38 conjugates (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Glycine (Gly), β-alanine (Ala), and 4-aminopiperidine were used as the basic linkers of the conjugates. Under a tumor microenvironment, the linkage in the conjugate could be rapidly cleaved by acid hydrolysis and/or enzyme cleavage to release SN38.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Stability studies in phosphate-buffered saline (PBS) at different pH values and in mouse and human plasma confirmed the stability of the conjugates when applied in <i>in vitro</i> and <i>in vivo</i> evaluations. Confocal microscopic analysis shows that the drug–drug conjugates were internalized into tumor cells <i>via</i> eHSP90-mediated endocytosis, which could improve the delivery of SN38 to tumors and lead to intratumor accumulation of SN38. In particular, compound <b>18b</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), with glycine linkage, exhibits excellent <i>in vitro</i> and <i>in vivo</i> antitumor activity and safety. Furthermore, pharmacokinetic analyses in HCT116 and Capan-1 xenografts confirmed that compound <b>18b</b> treatment could lead to effective cleavage <i>in vivo</i> and extended SN38 exposure, holding promise for becoming a new and potent anticancer drug.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0009.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design of HSP90 inhibitor–SN38 conjugates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0010.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structure of compound <b>18b</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58530" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58530" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1.  Chemistry</h3><div class="NLM_p">Compounds <b>4a–b</b> were prepared according to the general procedures<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. SN38 was first protected with a Boc group to give compound <b>2</b>, which was reacted with <i>N</i>-Boc-glycine and <i>N</i>-Boc-β-alanine in the presence of 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide (EDCI) and 4-dimethylaminopyridine (4-DMAP) to give a compound <b>3a–b</b> in high yields (92–96%). The compounds were further deprotected in 20% trifluoroacetic acid (TFA)/dichloromethane (DCM) to give a key intermediate <b>4a–b</b> in 90–92% yields.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route of Compounds <b>4a–b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc<sub>2</sub>O, pyridine, DCM, rt, 2 h, 98%; (b) <i>N</i>-Boc-glycine and <i>N</i>-Boc-β-alanine, EDCI, 4-DMAP, DMF, rt, 6 h, 92–96%; (c) 20% TFA in DCM, rt, 3 h, 90–92%.</p></p></figure><div class="NLM_p">Intermediate <b>7</b> was synthesized by using the procedure<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> described in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. SN38 was first activated with 4-nitrophenyl chloroformate to give compound <b>5</b> without further purification, which was then reacted with 4-<i>N</i>-Boc-aminopiperidine to generate compound <b>6</b> in 90% yield. Although, 4-nitrophenyl carbonate was also used to generate compound <b>5</b>, the reaction yield was much lower than using 4-nitrophenyl chloroformate. Subsequently, deprotection was also achieved in 20% TFA/DCM to afford key intermediate <b>7</b> in 93% yield.</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Route of Compound <b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-nitrophenyl chloroformate, DIEA, THF, rt, 6 h, 92%; (b) 4-<i>N</i>-Boc-aminopiperidine, 4-DMAP, DCM, rt, 2 h, 90%; (c) 20% TFA in DCM, rt, 2 h, 93%.</p></p></figure><div class="NLM_p">The detailed synthetic strategies for HSP90 inhibitor–SN38 conjugates <b>14a–c</b> are illustrated in <a class="ref internalNav" href="#sch3" aria-label="Schemes 3">Schemes 3</a> and <a class="ref internalNav" href="#sch4" aria-label="4">4</a>. According to published procedures,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> SNX-5422 analog <b>13</b> was prepared from commercially available 5,5-dimethylcyclohexane-1,3-dione (<b>8</b>). First, compound <b>8</b> was reacted with 4-methylbenzenesulfonhydrazide by using <i>p</i>-toluenesulfonic acid (PTSA) as a catalyst in toluene under reflux to give compound <b>9</b> in 88% yield. Subsequently, cyclization of compound <b>9</b> under the presence of trifluoromethanesulfonic anhydride (Tf<sub>2</sub>O) was achieved in 68% yield. Compound <b>9</b> was further reacted with synthetic <i>tert</i>-butyl (5-fluoro-2-cyanophenyl)glycinate with 60% NaH as the base to give compound <b>11</b>, which was then hydrolyzed and deprotected to give key intermediate <b>13</b> in 85% yield and 90% yields, respectively. Condensation of key intermediate <b>13</b> with compound <b>4a–b</b> and compound <b>7</b> in the presence of O-(7-azabenzotriazol-1-yl)uranium hexafluoro-phosphate (HATU) gave the final products <b>14a–c</b> in 48–55% yields. The coupling agents such as EDCI/HOBT and PyBOP also have been tried, the reaction yields were much lower than HATU and the reaction mixtures were more complex.</div><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Route of Key Intermediate <b>13</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TsNHNH<sub>2</sub>, PTSA, toluene, reflux, 2 h, 88%; (b) Tf<sub>2</sub>O, Et<sub>3</sub>N, THF, 50 °C, 3 h, 68%; (c) <i>tert</i>-butyl (5-bromo-2-cyanophenyl)glycinate, 60% NaH, anhydrous DMF, 90 °C, 8 h, 62%; (d) NaOH aq (1 M), 30% H<sub>2</sub>O<sub>2</sub>, EtOH, rt, 12 h, 85%; (e) 10% TFA/DCM, rt, 3 h, 90%.</p></p></figure><figure id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthetic Route of Compound <b>14a–c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) compound <b>4a–b</b> and compound <b>7</b>, HATU, DIPEA, anhydrous DMF, rt, 4 h, 32–42%.</p></p></figure><div class="NLM_p">The synthesis of another series of HSP90 inhibitor–SN38 conjugates <b>18a–c</b> is outlined in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. The starting material was synthesized according to the literature,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> which was further hydrolyzed by LiOH in THF/MeOH/H<sub>2</sub>O (1:1:1, v/v/v) and then deprotected by 10% Pd/C to give key intermediate <b>17</b>. Subsequent condensation with compound <b>4a–b</b> and compound <b>7</b> in the presence of HATU gave the final products <b>18a–c</b> in 50–54% yields. The chemical structures of newly synthesized compounds were confirmed by physicochemical and spectral means.</div><figure id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthetic Route of Compound <b>18a–c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) LiOH, THF/MeOH/H<sub>2</sub>O (1:1:1, v/v/v), rt, 2 h, 89%; (b) 10% Pd/C, MeOH, rt, 8 h, 85%; (c) compound <b>4a–b</b> and <b>7</b>, HATU, DIPEA, anhydrous DMF, rt, 4 h, 50–54%.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">2.2.  <i>In Vitro</i> Drug Release Behaviors</h3><div class="NLM_p">The stability and <i>in vitro</i> release behaviors of these compounds were tested, as these elements are critical for biological evaluation. The compounds at a concentration of 50 μM [1% dimethyl sulfoxide (DMSO) in MeOH] were evaluated in buffer with different pH values (simulated physiological pH 7.4 and acidic pH 6.0) for a period of 24 h at 37 °C using high-performance liquid chromatography (HPLC) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The results indicated that all the synthesized compounds were stable at pH 6.0 with half-life (<i>t</i><sub>1/2</sub>) values over 24 h (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). In the buffer at pH 7.4, the <i>t</i><sub>1/2</sub> values of compound <b>14a</b>, compound <b>14b</b>, compound <b>18a</b>, and compound <b>18b</b> were 12, 7, 14, and 10 h, respectively, and the <i>t</i><sub>1/2</sub> values of compounds <b>14c</b> and <b>18c</b> under this condition were found to be over 24 h (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B). We concluded that these compounds were sufficiently stable in different buffers at different pH values for <i>in vitro</i> assay. The stability of these compounds (25 μM, 1% DMSO in CH<sub>3</sub>CN) <i>in vitro</i> in mouse and human plasma was evaluated. It was known that a much higher level of esterase in mouse plasma than in human plasma may accelerate the hydrolysis of the ester and carbamate bonds. The t<sub>1/2</sub> values of compounds <b>14a–b</b> and <b>18a–b</b> in mouse plasma were 17, 10, 17, and 10.5 h, respectively, whereas those of compounds <b>14c</b> and <b>18c</b> were over 24 h (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C). As expected, the metabolic degradation rates of the compounds in human plasma were found to be much slower. The t<sub>1/2</sub> values of compounds <b>14b</b> and <b>18b</b> were both 13 h, whereas those of the rest compounds were over 24 h (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>D). Among them, compounds <b>14b</b> and <b>18b</b> with glycine linkers had the shortest t<sub>1/2</sub> values, which was consistent with the results in mouse plasma. Above all, these compounds exhibited considerable stability in buffers at different pH values and in human plasma and our results indicate that ester and carbamate bonds seem to be sufficiently stable for <i>in vitro</i> assay, which is a basic feature for the future development of novel conjugates.</div><figure id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0011.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Stability of conjugates in different buffers. (A) pH = 6.0 PBS; (B) pH = 7.4 PBS; (C) mouse plasma; (D) human plasma. Data were expressed as mean ± SD, <i>n</i> = 3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">2.3.  HSP90 Binding Affinity Assay</h3><div class="NLM_p">Given the above results, all synthesized compounds were then tested for their potential HSP90 inhibitory properties by fluorescence polarization (FP) assay.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The compounds NVP-AUY922 and SNX5422 were used as positive controls. The binding affinity values of all tested compounds are shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and expressed as IC<sub>50</sub> values. Compounds <b>14a–c</b>, conjugated from SNX-5422 and SN38, exhibited negligible impacts on HSP90 activity with IC<sub>50</sub> values of more than 1 μM, which were significantly weaker than SNX5422 (38 nM). In contrast, compounds <b>18a–c</b>, hybrids of NVP-AUY922 and SN38, showed appreciable binding affinity to the HSP90 protein. The IC<sub>50</sub> values were 70, 72, and 164 nM, respectively, which were in the same order of NVP-AUY922 (12 nM). These results showed that the conjugation of NVP-AUY922 and SN38 did not affect the binding affinity of the hybrids to HSP90; however, SNX-5422 may not be suitable for constructing HSP90 inhibitor conjugates. Together, these results inspired us to conduct further evaluations of compounds <b>18a–c</b>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Data for Compounds <b>14a–c</b> and <b>18a–c</b>: Binding Affinity on HSP90 (FP Assay)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">comp.</th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> (nM ± SD)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14a</b></td><td class="colsep0 rowsep0" align="char" char="±">1702 ± 85</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14b</b></td><td class="colsep0 rowsep0" align="char" char="±">1506 ± 78</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14c</b></td><td class="colsep0 rowsep0" align="char" char="±">1258 ± 91</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18a</b></td><td class="colsep0 rowsep0" align="char" char="±">70 ± 15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18b</b></td><td class="colsep0 rowsep0" align="char" char="±">72 ± 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18c</b></td><td class="colsep0 rowsep0" align="char" char="±">164 ± 37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SNX5422<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="±">38 ± 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NVP-AUY922<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char="±">12 ± 1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">The interaction of compounds with HSP90 was determined by the FP assay.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">IC<sub>50</sub> values are indicated as the mean ± SD (standard deviation) of at least three independent experiments.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Used as a positive control.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Used as a positive control.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">2.4.  Cellular Uptake</h3><div class="NLM_p">To test whether the conjugates could be efficiently internalized into tumor cells and increase intracellular drug accumulation, the cellular uptake behaviors of compounds <b>18a–c</b> were investigated in A549 cells.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> As SN38 and irinotecan are fluorescent molecules, their emission can be used directly to visualize cellular uptake without additional fluorescence probes. As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A, the UV–vis absorption levels of irinotecan, SN38, and compound <b>18a–c</b> were first investigated. Compared with the absorption peak of SN38, a blue shift of the absorption peak from 388 to 375 nm was observed from the absorption of irinotecan and compounds <b>18a–c</b>. Maximum fluorescence emission peaks of SN38, irinotecan, and <b>18a–c</b> (5 μM) were then evaluated, and the results showed that the emission peaks were approximately 430 nm. The normalized intensity of irinotecan and SN38 was higher than those of compounds <b>18a–c</b> at the equivalent concentration (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B), indicating that the fluorescence of irinotecan and SN38 should be stronger than those of compounds <b>18a–c</b> under equal cellular uptake of drugs.</div><figure id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0012.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) UV–vis–near-infrared absorbance spectra (EtOH as solvent) and (B) fluorescence emission spectra (EtOH as solvent) of compounds <b>18a–c</b>, irinotecan, and SN38. (C) CLSM images (scale bar = 25 μm) and (D) quantitative analysis of A549 cells incubated with compounds <b>18a–c</b>, irinotecan, and SN38 for 12 h by LC–MS/MS. The dosage was 5 μM. The scale bars are 25 μm in all images. Data were expressed as mean +SD, <i>n</i> = 3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We then treated A549 cells with <b>18a–c</b>, irinotecan, and SN38 at 5 μM for 12 h, and observed them under a confocal laser scanning microscope (CLSM). As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C, blue fluorescence could be observed in cells treated with <b>18a–c</b>. However, the fluorescence of A549 cells treated with SN38 was much weaker, whereas cells treated with irinotecan were almost undetectable. We further quantitated the cellular uptake of these compounds by liquid chromatography with tandem mass spectrometry (LC–MS/MS). As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>D, the amounts of intact compounds and released SN38 were recorded. The total cellular internalization percentages of cells treated with compounds <b>18a–c</b> were approximately 2.8–3.8-fold and 1.6–1.9-fold stronger than those of cells treated with irinotecan and SN38, respectively. Of these compounds, compound <b>18b</b> exhibited the highest release of SN38. The level of released SN38 in A549 cells treated with compound <b>18b</b> was slightly lower than cells treated with SN38. These differences might have resulted from the different cellular internalization mechanisms between the SN38 conjugates (endocytosis) and irinotecan/SN38 (diffusion). These data suggested that once the conjugates are internalized, they may not be pumped out of the cells for a relatively long period of time.</div><div class="NLM_p">To confirm the mechanism of cellular uptake of these HSP90 inhibitor–SN38 conjugates (<b>18a–c</b>), compound <b>18b</b> was selected for the competitive experiments. A549 and HCT116 cells were incubated with 100-fold molar free NVP-AUY922 mixed with compound <b>18b</b> (5 μM, 100:1 n/n) for 6 h, which can block the binding between compound <b>18b</b> and HSP90 and competitively inhibit the ATPase activity of HSP90. The vehicle mixed with compound <b>18b</b> in the culture medium (5 μM) was also incubated in the other groups for 6 h. Compared with the cells incubated with NVP-AUY922 and compound <b>18b</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A,B), brighter blue fluorescence was observed in both cell lines incubated with the vehicle and compound <b>18b</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A,B), indicating a higher compound <b>18b</b> cellular uptake. In the normal HL7702 cell groups, both test groups showed no obvious fluorescence (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C), which indicated the selectivity of tumor cells and eHSP90-mediated cellular uptake mechanism. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>D, the quantitative analysis results of compound <b>18b</b> uptake were further evaluated. Notably, the cellular internalization percentage in the vehicle and <b>18b</b> groups were much higher than those of the groups incubated with NVP-AUY922 and <b>18b</b>, suggesting the ATP-dependent cellular uptake behavior of the conjugate.</div><figure id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0013.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Cellular uptake of tumor cells treated with NVP-AUY922 mixed with compound <b>18b</b> (5 μM, 100:1, n/n) or compound <b>18b</b> mixed with the vehicle (5 μM) for 6 h. (A–C) Representative CLSM images of A549 cells (scale bar = 50 μm), HCT116 cells, and HL-7702 cells (scale bar = 75 μm), respectively. (D) Quantitative analysis of drugs in A549 cells, HCT116 cells, and HL7702 cells conducted by LC–MS/MS. Data were expressed as mean + SD, ***<i>P</i> < 0.001, <sup>###</sup><i>P</i> < 0.001, <i>n</i> = 3, multiple <i>t</i>-test. * represents the statistics between the intact compound; <sup>#</sup> represents the statistics between the released SN38. The statistics for the HL7702 cells group is “not significant (ns)”.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To prove our assumption that HSP90 inhibitor–SN38 conjugates could accumulate in cancer cells in a time-dependent manner, the intracellular compounds were further investigated by using CLSM (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). A549 cells were treated with compounds <b>18a–c</b> at the same equivalent concentration of dual drugs for different incubation time periods (1, 2, 4, and 6 h). As shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A, blue fluorescence was observed in A549 cells after incubation with all three conjugates for 1 h, indicating the successful internalization of the conjugates. In addition, with the increase of incubation time from 1 to 12 h, the intensity of blue fluorescence inside cells was greatly enhanced, suggesting the tumor cumulative effect of compounds <b>18a–c</b>. Quantitative analysis was also performed by using LC–MS/MS to evaluate the concentrations of intact compounds and released SN38. Although <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B shows that compound <b>18b</b> is 75% degraded over 12 h, the total concentrations of intact compounds and released SN38 increase with the increase of incubation time. <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B–D shows that the total cellular internalization percentage of the intact compounds <b>18a–c</b> and released SN38 in 12 h groups exhibited 4.3-, 4.3-, and 3.7-fold increase compared with those of 1 h groups (<i>P</i> < 0.001), respectively. Moreover, compound <b>18b</b> showed higher SN38 release than that of compound <b>18a</b> and <b>18c</b>, which could result in high antitumor potency and was consistent with previous <i>in vitro</i> stability studies. Collectively, the results indicated that HSP90 binding may result in a time-dependent increase in the accumulation of higher concentrations of drugs in tumor cells.</div><figure id="fig7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0014.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. CLSM images of tumor cells incubated with <b>18a–c</b> for different times. (A) A549 cells incubated with <b>18a–c</b> for 1, 4, 6, and 12 h. (B–D) Quantitative analysis of A549 cells incubated with compounds <b>18a–c</b> for 1, 4, 6, and 12 h using LC–MS/MS. The dosage was 5 μM. The scale bars are 25 μm in all images. Data were expressed as mean + SD, <i>P</i> < 0.001, <i>n</i> = 3, multiple <i>t</i>-test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">2.5.  <i>In Vitro</i> Cytotoxicity</h3><div class="NLM_p">Next, the antiproliferative capacities of compounds <b>18a–c</b> were evaluated against four cancer cell lines: human non-small cell lung cancer A549, human colon carcinoma HCT116, human pancreatic cancer MIA-PACA-2, Capan-1 and one normal cell line, normal human liver HL7702 cell, using sulforhodamine B (SRB) assay. Of all three compounds, compound <b>18b</b> exhibited the most potent cytotoxic effect against cancer cells, with IC<sub>50</sub> at dozens of nanomolar levels. In detail, the IC<sub>50</sub> value was 56 nM in A549, 22 nM in HCT116, 46 nM in MIA-PACA-2, and 36 nM in Capan-1, which were slightly weaker than those in the SN38 group (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). In addition, the cytotoxic effects of compounds <b>18a</b> and <b>18c</b> were observed at the micromolar level, which was consistent with previous stability and cellular uptake results. Compound <b>18b</b> was less stable compared with compounds <b>18a</b> and <b>18c</b> and was observed to release higher concentration of SN38 than compounds <b>18a</b> and <b>18c</b>, thus leading to more SN38 released and exhibiting higher cytotoxic activity. <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>D also shows that the levels of released SN38 in compounds <b>18a–c</b>-treated tumor cells were lower than that of SN38-treated tumor cells. These results resulted in the lower cytotoxic activities of compounds <b>18a–c</b>, compared with that of SN38. Besides, the binding affinity also influenced the cytotoxic activity. The higher binding affinities of compounds <b>18a</b> and <b>18b</b> could lead to more conjugates accumulating in tumor cells and result in more SN38 release, which could increase the cytotoxicity. The antiproliferative capacities of compounds <b>18a–c</b> were also evaluated against the normal human liver HL7702 cell line, and all three conjugates showed lower cytotoxic effects than those in cancer cell lines, suggesting the cancer-specific targeting properties. Above all, these results suggested that compound <b>18b</b> might be the most promising compound among these three conjugates of NVP-AUY922 and SN38.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Antiproliferative Activities of Compounds <b>18a–c</b> against Four Cancer Cell Lines and One Normal Cell Line<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center" char="±">antiproliferative activities IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">comp.</th><th class="colsep0 rowsep0" align="center" char="±">A549</th><th class="colsep0 rowsep0" align="center" char="±">HCT116</th><th class="colsep0 rowsep0" align="center" char="±">MIA-PACA-2</th><th class="colsep0 rowsep0" align="center" char="±">Capan-1</th><th class="colsep0 rowsep0" align="center" char="±">HL7702</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18a</b></td><td class="colsep0 rowsep0" align="char" char="±">324 ± 55</td><td class="colsep0 rowsep0" align="char" char="±">83 ± 15</td><td class="colsep0 rowsep0" align="char" char="±">205 ± 25</td><td class="colsep0 rowsep0" align="char" char="±">206 ± 18</td><td class="colsep0 rowsep0" align="char" char="±">7893 ± 1824</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18b</b></td><td class="colsep0 rowsep0" align="char" char="±">56 ± 9</td><td class="colsep0 rowsep0" align="char" char="±">22 ± 7</td><td class="colsep0 rowsep0" align="char" char="±">46 ± 4</td><td class="colsep0 rowsep0" align="char" char="±">36 ± 6</td><td class="colsep0 rowsep0" align="char" char="±">6872 ± 1048</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18c</b></td><td class="colsep0 rowsep0" align="char" char="±">1114 ± 63</td><td class="colsep0 rowsep0" align="char" char="±">614 ± 28</td><td class="colsep0 rowsep0" align="char" char="±">644 ± 21</td><td class="colsep0 rowsep0" align="char" char="±">6802 ± 2664</td><td class="colsep0 rowsep0" align="char" char="±">7357 ± 1052</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">irinotecan</td><td class="colsep0 rowsep0" align="char" char="±">1557 ± 57</td><td class="colsep0 rowsep0" align="char" char="±">498 ± 82</td><td class="colsep0 rowsep0" align="char" char="±">1329 ± 122</td><td class="colsep0 rowsep0" align="char" char="±">1121 ± 89</td><td class="colsep0 rowsep0" align="char" char="±">1305 ± 72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SN38</td><td class="colsep0 rowsep0" align="char" char="±">11 ± 3</td><td class="colsep0 rowsep0" align="char" char="±">4 ± 1</td><td class="colsep0 rowsep0" align="char" char="±">13 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">8 ± 1</td><td class="colsep0 rowsep0" align="char" char="±">18 ± 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NVP-AUY922</td><td class="colsep0 rowsep0" align="char" char="±">39 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">121 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">38 ± 1</td><td class="colsep0 rowsep0" align="char" char="±">657 ± 39</td><td class="colsep0 rowsep0" align="char" char="±">1364 ± 153</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Cells were treated with different concentrations of compounds for 72 h. Cell viability was measured by the SRB assay as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">IC<sub>50</sub> values are indicated as the mean ± SD (standard deviation) of at least three independent experiments.</p></div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">2.6.  Immunofluorescence Analysis</h3><div class="NLM_p">To further evaluate the surface eHSP90 expression of selected cell lines in the antiproliferative assay, the expression levels of eHSP90 in A549, HCT116, MIA-PACA-2, Capan-1 tumor cell lines, and HL7702 normal cell line were determined by immunofluorescence analysis. Cells with suitable densities were treated with anti-HSP90 rabbit polyclonal antibody, Cy3 conjugated goat antirabbit IgG, and DAPI. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>, anti-HSP90 rabbit polyclonal antibody was found to stain the surface of HSP90 and then colabeled with Cy3 conjugated goat antirabbit IgG to show the presence of HSP90 with red fluorescence. The red fluorescence of A549, HCT116, MIA-PACA-2, and Capan-1 tumor cell groups were stronger than that of HL7702 cell line groups, demonstrating higher surface expression of HSP90 in tumorigenic cells than that in nontumorigenic cells. These results are consistent with previous antiproliferative activities.</div><figure id="fig8" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0015.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. <i>In vitro</i> surface eHSP90 expression in A549, HCT116, MIA-PACA-2, Capan-1, and HL7702 cells. Representative immunofluorescence images of the cells following HSP90 staining, with anti-HSP90 rabbit polyclonal antibody, Cy3 conjugated goat antirabbit IgG, and DAPI. Red, Cy3-conjugated goat antirabbit IgG and blue, DAPI (scale bar = 100 μm).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">2.7.  Cell Cycle Distribution</h3><div class="NLM_p">Cell cycle analysis was also performed to evaluate the effects of <b>18a–c</b> on cell cycle progression. The results showed that compound <b>18a–c</b> induced an obvious G2/M phase arrest in a concentration-dependent manner. However, the cell cycle arrest effects of <b>18a–c</b> were weaker than those of SN38 at an equivalent or lower concentration in all three tested cell lines, consistent with the cell proliferation assay findings (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).</div><figure id="fig9" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0016.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Cell cycle distribution of A549, HCT116, and Capan-1 cells after compound treatment for 24 h with different concentrations.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">2.8.  Western Blot Assay</h3><div class="NLM_p">We next investigated the effects of <b>18a–c</b> on their targets intracellularly. KAP1 is a substrate of the DNA damage-sensing kinase ATM, and its phosphorylation has been identified as a readout for topoisomerase I inhibition.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, compounds <b>18a</b> and <b>18b</b> or SN38 treatment induced robust increases in pKAP1 expression in both A549 and HCT116 cells. These effects of compounds <b>18a</b> and <b>18b</b> were in a concentration-dependent manner. Of note, the levels of pKAP1 induced by compounds <b>18a–c</b> were lower than those induced by SN38 at equivalent or lower concentrations, which provided a reasonable explanation for the weaker cytotoxicity of <b>18a–c</b> compared to SN38. However, the effect of <b>18c</b> on inducing the expression of pKAP1 was relatively weaker than <b>18a</b> and <b>18b</b>, which was consistent with a lower release of SN38 in cells treated with <b>18c</b>. Topoisomerase I (TOP1) has been reported to be ubiquitinated and degraded in cells treated with camptothecin.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> As a metabolite of the camptothecin derivative irinotecan, SN38 treatment also induced downregulation of TOP1. Here, we observed that compounds <b>18a–c</b> decreased the protein levels of TOP1 in a concentration-dependent manner. Unexpectedly, NVP-AUY922 also downregulated the protein level of TOP1. Although previous studies have reported that topoisomerase II was inhibited by an HSP90 inhibitor 17-AAG, and topoisomerase II formed a complex with HSP90,<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45,46)</a> the correlation between topoisomerase I and HSP90 remains unknown and requires further investigation. Together, these results indicated that compounds <b>18a–c</b> could efficiently inhibit the activity of intracellular topoisomerase I.</div><figure id="fig10" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0002.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Western blot analysis of proteins correlated with topoisomerase I inhibition and HSP90 client protein in A549 and HCT116 cells after compounds <b>18a–c</b> treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">As HSP90 is an important chaperone for the maintenance of conformational stability for a suit of proteins (clients) involved in intracellular signaling, HSP90 inhibition induces regulation of its client proteins.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> HSP70, a sensitive and direct marker of HSP90 inhibition, was observed to evaluate the effects of compounds <b>18a–c</b> on HSP90. As shown in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, the upregulation of HSP70 was observed in compounds <b>18a</b> and <b>18c</b> treatment groups in both cell lines. The upregulation of HSP70 was weaker than that of NVP-AUY922, which was consistent with the antiproliferative results. The protein level of AKT, an important HSP90 client protein,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> was also detected. Treatment with compounds <b>18a</b> and <b>18c</b> led to an obvious downregulation of AKT protein level in a concentration-dependent manner. However, the upregulation of HSP70 and downregulation of AKT were not obvious in A549 and HCT116 cells treated with compound <b>18b</b>. These results could be mainly attributed to the relatively low concentration of compound <b>18b</b> used in the experiment. Together, these results indicated that cytotoxic effects of conjugate <b>18b</b> were mainly from the SN38 moiety, and the NVP-AUY922 moiety might serve as a delivery vehicle. The linker of compounds <b>18a</b> and <b>18c</b> decreased the cytotoxic activity of the SN38 moiety, and the NVP-AUY922 moiety also contributed to the cytotoxic activity of compounds <b>18a</b> and <b>18c</b>.</div></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">2.9.  <i>In Vitro</i> Metabolic Stability of Compounds <b>18a–c</b></h3><div class="NLM_p">Assessment of the preliminary ADME (absorption, distribution, metabolism, and excretion) properties of compounds <b>18a–c</b> was conducted to evaluate their potential for further development. The <i>in vitro</i> metabolic stability of the three compounds was assessed in human liver microsomes.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> As illustrated in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, compounds <b>18a–c</b> all possessed good human microsomal stability with half-life values from 2.1 to 2.6 h and intrinsic clearance values from 4.9 to 5.7 mL/kg.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. <i>In Vitro</i> Metabolic Stability of Compounds <b>18a–c</b> (1 μM) in Human Liver Microsomes</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char="±">comp.</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameters</th><th class="colsep0 rowsep0" align="center" char="±"><b>18a</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>18b</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>18c</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">60 min remaining (%)</td><td class="colsep0 rowsep0" align="char" char="±">75 ± 3</td><td class="colsep0 rowsep0" align="char" char="±">80 ± 1</td><td class="colsep0 rowsep0" align="char" char="±">87 ± 5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="char" char="±">2.4 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">2.1 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">2.6 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>lint</sub> (mL/kg)</td><td class="colsep0 rowsep0" align="char" char="±">5.3 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">5.7 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">4.9 ± 0.6</td></tr></tbody></table></div></div></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">2.10.  Pharmacokinetic Study of Compounds <b>18a–c</b></h3><div class="NLM_p">To evaluate the <i>in vivo</i> antitumor efficacy of compounds <b>18a–c</b>, PK studies of compounds <b>18a–c</b> in BALB/c male mice were initially performed, and the drugs were administered intravenously (i.v.) at 50 mg/kg. As summarized in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> and <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>, compounds <b>18a–c</b> demonstrated high plasma concentrations, volumes of distribution, and exhibited half-lives of 1.31–1.72 h.</div><figure id="fig11" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0003.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Pharmacokinetics analysis in healthy BALB/c male mice. Mice were treated with compounds <b>18a–c</b> (50 mg/kg) i.v. Plasma concentration <i>vs</i> time profiles of compounds <b>18a–c</b> are illustrated. Values are indicated as the mean ± SD, <i>n</i> = 4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Pharmacokinetic Parameters of Compounds <b>18a–c</b> (50 mg/kg) (i.v.) in BALB/c Male Mice (<i>n</i> = 4)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">comp.</th><th class="colsep0 rowsep0" align="center" char="±"><b>18a</b> (i.v.)</th><th class="colsep0 rowsep0" align="center" char="±"><b>18b</b> (i.v.)</th><th class="colsep0 rowsep0" align="center" char="±"><b>18c</b> (i.v.)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">1.51 ± 0.06</td><td class="colsep0 rowsep0" align="char" char="±">1.31 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">1.72 ± 0.07</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>(0–∞)</sub> (h × ng/mL)<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="±">151,360.92 ± 27,443.72</td><td class="colsep0 rowsep0" align="char" char="±">147,821.22 ± 9429.21</td><td class="colsep0 rowsep0" align="char" char="±">172,231.41 ± 14,427.32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (mL/kg)<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char="±">99.95 ± 2.31</td><td class="colsep0 rowsep0" align="char" char="±">101.33 ± 1.21</td><td class="colsep0 rowsep0" align="char" char="±">103.29 ± 1.92</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl (mL/h/kg)<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="char" char="±">330.36 ± 57.40</td><td class="colsep0 rowsep0" align="char" char="±">348.33 ± 68.80</td><td class="colsep0 rowsep0" align="char" char="±">414.32 ± 62.10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Values are indicated as the mean ± SD (standard deviation).</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Half-life.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">Area under the plasma concentration time curve.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">Steady-state apparent volume of distribution.</p></div><div class="footnote" id="t4fn5"><sup><sup>e</sup></sup><p class="last">Clearance.</p></div></div></div></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">2.11.  <i>In Vivo</i> Antitumor Effect Studies of Compounds <b>18a–c</b> in HCT116 Xenografts</h3><div class="NLM_p">Furthermore, to evaluate the <i>in vivo</i> antitumor efficacy of these three compounds, HCT116 tumor-bearing nude mice were administered vehicle (5% DMSO + 18% Cremophor EL in 5% glucose solution) or compounds <b>18a–c</b> i.v. on 5 consecutive days per week. Irinotecan served as a positive control for this experiment. Tumor sizes and body weights of HCT116 tumor-bearing nude mice were monitored every 3 or 4 days for 14 days. As shown in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>A, compared with vehicle-treated mice, the tumor growth of mice with compounds <b>18b</b> (50 mg/kg) or <b>18c</b> (50 mg/kg) treatment was significantly suppressed. At the end of the experiment, tumor volume was significantly reduced (<i>P</i> < 0.001), with T/C values of 16.7 and 33.8%, respectively (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>A). Moreover, the average tumor weights of compounds <b>18b</b> (50 mg/kg) and <b>18c</b> (50 mg/kg) were 0.32 ± 0.19 g and 0.47 ± 0.23 g, respectively, and both were significantly lower (<i>P</i> < 0.001) than that of vehicle-treated mice (1.73 ± 0.53 g) (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>B). Excised tumor volume data also confirmed the results (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>C). Previously, single NVP-AUY922 treatment (50 mg/kg/day) on HCT116 xenografts was reported to have a T/C of 49.9%, which was higher than those of mice treated with compounds <b>18b</b> (50 mg/kg) or <b>18c</b> (50 mg/kg) treatment. Throughout the experiments, mice treated with compounds <b>18a–c</b> displayed no remarkable body weight loss of more than 20% (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>D). Taken together, these results indicated that compound <b>18b</b> exhibited the most promising antitumor effects <i>in vivo</i>, which was in line with <i>in vitro</i> studies.</div><figure id="fig12" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0004.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. <i>In vivo</i> therapeutic efficacy of <b>18a–c</b> in HCT116 xenografts. HCT116 xenograft-bearing nude mice were treated with the vehicle (5% glucose solution), irinotecan (15 mg/kg), <b>18a–c</b> (10 mg/kg), and <b>18a–c</b> (50 mg/kg) i.v. (A) Tumor volume was recorded, and relative tumor volume was plotted. (B) Tumor weight. (C) Excised tumor volume (mm<sup>3</sup>). (D) Body weight change. ***<i>P</i> < 0.001, **<i>P</i> < 0.01, and *<i>P</i> < 0.05 <i>vs</i> vehicle-treated group. Data were expressed as mean ± SD, <i>n</i> = 6, multiple <i>t</i>-test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24">2.12.  Pharmacokinetic Analysis in HCT116 Xenografts</h3><div class="NLM_p">To better interpret the results in previous <i>in vivo</i> therapeutic efficacy in HCT116 xenografts, pharmacokinetic analyses at the same dosage were also performed to evaluate intact compounds and released SN38 exposures that resulted from single administered compound <b>18b</b> (50 mg/kg) and irinotecan (15 mg/kg) treatment in HCT116 xenografts. Blood samples were collected from the tails at different time intervals (30 min, 1, 3, 6, 24, and 72 h) and were analyzed by LC–MS/MS. As shown in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>A, compound <b>18b</b> treatment groups displayed higher compound <b>18b</b> exposure in plasma compared with irinotecan and compound <b>18b</b> in plasma exhibited a longer half-life than irinotecan. <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>B also confirmed the expectations that compound <b>18b</b> treatment resulted in a higher concentration of extended SN38 payload release than irinotecan. Next, drug concentrations in tumors were measured in both compound <b>18b</b> and irinotecan treatment groups. Compound <b>18b</b> maintained a relatively higher concentration over a long time, but the concentration was lower at 1 h (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>C). Moreover, the degree of SN38 derived from compound <b>18b</b> within the tumor showed longer retention over 72 h and the liberated SN38 from compound <b>18b</b> was higher than that of irinotecan (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>D), which further interprets the results from the previous <i>in vivo</i> studies. Above all, these PK profiles provided further evidence that compound <b>18b</b> could enhance the intratumor accumulation and extend SN38 liberation and exposure.</div><figure id="fig13" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0005.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Pharmacokinetic analyses in HCT116 xenografts. HCT116 xenograft-bearing nude mice were treated with compound <b>18b</b> (50 mg/kg) and irinotecan (15 mg/kg) i.v. for different time points. (A) Plasma concentration <i>vs</i> time of intact compound <b>18b</b> and irinotecan. (B) Plasma concentration <i>vs</i> time of released SN38 from compound <b>18b</b> and irinotecan. (C) Tumor concentration <i>vs</i> time of intact compound <b>18b</b> and irinotecan. (D) Tumor concentration <i>vs</i> time of released SN38 from compound <b>18b</b> and irinotecan. Data were expressed as mean ± SD, <i>n</i> = 3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25">2.13.  <i>In Vivo</i> Antitumor Effect Studies of <b>18b</b> in Capan-1 Xenografts</h3><div class="NLM_p">Encouraged by the results of HCT116 tumor-bearing nude mice, we further investigated the therapeutic efficacies of compound <b>18b</b>, irinotecan at the same molar SN38 dose, and NVP-AUY922 at the same HSP90 inhibitor dose in Capan-1 tumor models. Mice with similar tumor sizes were randomly selected and i.v. administered with compound <b>18b</b> (50 mg/kg) every 2 days. Mice that i.v. received the vehicle (containing 5% DMSO + 18% Cremophor EL), irinotecan (36 mg/kg), and NVP-AUY922 (28 mg/kg) every 2 days were employed as negative and positive controls. The tumor volumes, tumor weights, and body weights of the mice treated with different formulations were regularly monitored. As shown in <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>A, flourishing tumor growth was observed in mice receiving 5% glucose solution and NVP-AUY922 (with a T/C of 57.03%). In glaring contrast, compound <b>18b</b> and irinotecan treatment groups showed obvious inhibition of tumor growth. Even more notably, the compound <b>18b</b> treatment group exhibited almost complete tumor elimination with a T/C of 1.86% even better than that of the irinotecan treatment group, with a T/C of 7.92%, which could be ascribed to the tumor-targeting of compound <b>18b</b>. Furthermore, the average weights of the tumors dissected from mice treated with compound <b>18b</b> were also obviously smaller than those treated with mice treated with vehicle and NVP-AUY922 (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>B). In addition, the body weight change of the compound <b>18b</b>-treated mice increased by approximately 10% during the experiment, indicating the low toxicity of compound <b>18b</b> (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>C).</div><figure id="fig14" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0006.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. <i>In vivo</i> therapeutic efficacy of compound <b>18b</b> in Capan-1 xenografts. Capan-1 xenograft-bearing nude mice were treated with the vehicle (5% glucose solution), irinotecan (36 mg/kg), compound <b>18b</b> (50 mg/kg), and NVP-AUY922 (28 mg/kg) i.v.. (A) Tumor volume was recorded, and relative tumor volume was plotted. (B) Tumor weight. (C) Body weight change (%). (D) Western blot analysis of the pharmacodynamic biomarker changes in tumor xenografts. GAPDH is used as the internal control. Data were expressed as mean ± SD, <i>n</i> = 6, ***<i>P</i> < 0.001, Student’s <i>t</i>-test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The pharmacodynamic biomarker changes in Capan-1 xenografts of compound <b>18b</b>, irinotecan, and NVP-AUY922 were assessed by western blot 2 h after the final treatment to investigate the effects of compound <b>18b</b> on their targets. As shown in <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>D, compound <b>18b</b> exhibited higher upregulation of pKAP1 expression and downregulation of Top 1, which are the readouts for topoisomerase I inhibition. These results indicated that the targeting capacity of compound <b>18b</b> generates a highly effective treatment response in tumors. Notably, the levels of pKAP1 upregulation and Top 1 downregulation were higher than those of irinotecan at an equivalent molar SN38 concentration, consistent with the <i>in vivo</i> data. Moreover, compound <b>18b</b> slightly upregulated HSP70 and induced a slight decrease in the AKT protein expression, whereas irinotecan did not display these properties. The effects of NVP-AUY922 were weak, which were mainly due to the low dose. Taken together, these results further indicated that compound <b>18b</b> was on target and exhibited enhanced efficacy <i>in vivo</i>.</div></div><div id="sec2_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26">2.14.  Pharmacokinetics Analysis of <b>18b</b> and Irinotecan in Capan-1 Xenografts</h3><div class="NLM_p">Pharmacokinetic analyses were also undertaken in Capan-1 xenografts to evaluate intact compounds and released SN38 exposures that resulted from compound <b>18b</b> (50 mg/kg) and irinotecan (36 mg/kg) treatment at the same molar SN38 amount. Blood samples were collected from the tails at different time intervals (30 min, 1, 3, 6, 24, and 72 h) and were analyzed by LC–MS/MS. As shown in <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>A, compound <b>18b</b> treatment groups displayed similar exposure in plasma compared with irinotecan at 30 min, but irinotecan declined quickly with a shorter half-life. Confirming expectations, compound <b>18b</b> treatment resulted in extended SN38 payload release and much longer duration of time than irinotecan (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>B). Next, drug concentrations in tumors were measured in both compound <b>18b</b> and irinotecan treatment groups. Compound <b>18b</b> maintained a relatively higher concentration over a long time, showing retention out to at least 72 h, unlike the rapid decline observed with irinotecan (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>C). Moreover, the degree of SN38 derived from compound <b>18b</b> within the tumor showed enhanced accumulation over 72 h (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>D). In contrast, SN38 liberated from irinotecan disappeared at 24 h. Together, these PK profiles provided further evidence of effective <b>18b</b> cleavage <i>in vivo</i> and enhanced intratumor accumulation of SN38, which was consistent with the <i>in vivo</i> efficacy studies.</div><figure id="fig15" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0007.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Pharmacokinetics analyses in Capan-1 xenografts. Capan-1 xenograft-bearing nude mice were treated with compound <b>18b</b> (50 mg/kg) and irinotecan (36 mg/kg) i.v. for different time points. (A) Plasma concentration <i>vs</i> time of intact compound <b>18b</b> and irinotecan. (B) Plasma concentration <i>vs</i> time of released SN38 from compound <b>18b</b> and irinotecan. (C) Tumor concentration <i>vs</i> time of intact compound <b>18b</b> and irinotecan. (D) Plasma concentration <i>vs</i> time of released SN38 from compound <b>18b</b> and irinotecan. Data were expressed as mean ± SD, <i>n</i> = 3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27">2.15.  Histological Analysis</h3><div class="NLM_p">Finally, therapeutic efficacy and potential toxicities were demonstrated by histological [hematoxylin and eosin (H&E) and <i>in situ</i> terminal deoxynucleotidyltransferase-mediated UTP end labeling (TUNEL)] and immunohistochemical (IHC) analyses of Capan-1 xenografts. From the H&E staining of normal tissues (heart, liver, spleen, lung, and kidney) (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>A), irinotecan and vehicle treatment groups exhibited varying degrees of tissue necrosis, abnormality, cell lysis, and nuclear shrinkage and fragmentation, whereas the compound <b>18b</b> treatment group exhibited lower pathological toxicity. As shown in the H&E staining of the tumors in <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>A, tumor cells treated with compound <b>18b</b> and irinotecan decreased and demonstrated more nuclear lysis than the vehicle group, suggesting the highly effective therapeutic efficacy of compound <b>18b</b>. In the TUNEL assay (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>B), tumor slices from compound <b>18b</b>-treated mice showed an increase in green fluorescence compared with the other groups, suggesting the higher apoptosis of tumor cells in the compound <b>18b</b> group. Ki67 (a marker of cell proliferation) was also evaluated by IHC analyses to examine cell proliferation (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>B). The Ki67 expression level following compound <b>18b</b> treatment was lower than those following irinotecan and vehicle treatment, demonstrating the suppression of tumor cell proliferation.</div><figure id="fig16" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0008.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Representative images of histological analyses of female nude mice with Capan-1 xenografts at 14 days after the first treatment with <b>18b</b> (50 mg/kg), irinotecan (36 mg/kg), and 5% glucose solution. (A) Representative H&E staining images of major organs. (B) TUNEL, and Ki67 protein analysis images of tumor sections. Scale bar = 100 μm.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">3.  Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22617" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22617" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, a series of HSP90 inhibitor–SN38 conjugates have been successfully developed in order to improve the delivery of SN38 and to mediate SN38 accumulation in tumor cells. Unlike the simple simultaneous administration of two free chemotherapeutic drugs, the conjugates with ester bond and carbamate linkers could maintain a synergistic property, which had therapeutic relevance of selectively targeting eHSP90 and then entering tumor cells by eHSP90-mediated cellular internalization. Moreover, cellular uptake results further indicated that these conjugates could be internalized into A549 cells to deliver the therapeutically active SN38. In the preliminary ADME assessment, compounds <b>18a–c</b> showed good human microsomal stability. After i.v. administration in healthy BALB/c mice, all conjugates showed acceptable half-lives. As the conjugates could accumulate in tumor cells, they can combine to produce a remarkable therapeutic index. Among the studied conjugates, compound <b>18b</b> was determined to show promising <i>in vitro</i> and superior <i>in vivo</i> anticancer activity. PK analyses in HCT116 and Capan-1 xenografts further confirmed that compound <b>18b</b> treatment could lead to effective compound <b>18b</b> cleavage and extended SN38 exposure in tumor sites. Overall, our data suggested that these novel series of conjugates showed low toxicities and markedly enhanced therapeutic efficiency, indicating their promise as new candidates for cancer treatment and suggesting them for further chemical and biological evaluations. However, compound <b>18b</b> still resulted in some spleen toxicity during the treatment. Moreover, the PK profiles of compound <b>18b</b> still need to be improved to achieve better <i>in vivo</i> antitumor activities. Such conjugates’ optimization studies are in progress.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">4.  Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62614" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62614" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30">4.1.  Chemistry</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31">4.1.1.  General Methods</h4><div class="NLM_p last">All reagents were obtained from commercial sources and dried prior to use unless noted otherwise. Anhydrous solutions of reaction mixtures were transferred <i>via</i> an oven-dried syringe or cannula. Reactions were monitored by thin-layer chromatography on 0.25 mm silicon gel plates (GF254) and visualized under UV light. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded at 23 °C in CDCl<sub>3</sub> and DMSO-<i>d</i><sub>6</sub> on a Bruker DRX-400 (400 MHz) using TMS as the internal standard. Chemical shifts were reported as δ (ppm) and signal splitting patterns were described as singlet (s), doublet (d), triplet (t), quartet (q), quintet (quint), or multiplet (m), with coupling constants (<i>J</i>) in hertz. The mass spectra (MS) were recorded on a Finnigan MAT-95 mass spectrometer. High-resolution mass spectra (HRMS) were obtained on an electron spray injection (ESI) Thermo Fisher Scientific LTQ FTICR mass spectrometer. Purity of all tested compounds was ≥95%, as estimated by HPLC analysis performed on Agilent Diamonsil C18 (250 mm × 4.6 mm) and method 1: a mobile phase gradient from 5% CH<sub>3</sub>CN/buffer (0.1% TFA/H<sub>2</sub>O) for 2 min, 5% CH<sub>3</sub>CN/buffer (0.1% TFA/H<sub>2</sub>O) to 95% CH<sub>3</sub>CN/buffer (0.1% TFA/H<sub>2</sub>O) for 20 min, 95% CH<sub>3</sub>CN/buffer (0.1% TFA/H<sub>2</sub>O) to 5% CH<sub>3</sub>CN/buffer (0.1% TFA/H<sub>2</sub>O) for 3 min, a flow rate of 1.0 mL min<sup>–1</sup>, and plotted at 373 nm; method 2: a mobile phase gradient from 5% MeOH/H<sub>2</sub>O for 2 min, 5% MeOH/H<sub>2</sub>O to 95% MeOH/H<sub>2</sub>O for 15 min, 95% MeOH/H<sub>2</sub>O for 5 min, 95% MeOH/H<sub>2</sub>O to 5% MeOH/H<sub>2</sub>O for 3 min, a flow rate of 1.0 mL min, and plotted at 373 nm. Method 1 was also used in stability studies. The resulting slides were mounted and observed with a LEICA TCS SP8 fluorescence microscopy.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32">4.1.2.  Compounds <b>2–4</b> Were Synthesized according to a Literature Report<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></h4><div id="sec4_1_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33">4.1.2.1.  (<i>S</i>)-<i>tert</i>-Butyl(4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1<i>H</i>-pyrano[3′,4′:6,7]indolizino[1,2-<i>b</i>]quinolin-9-yl)carbonate <b>2</b></h5><div class="NLM_p last">(Yield 98%): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.22 (d, <i>J</i> = 9.2 Hz, 1H), 7.85 (d, <i>J</i> = 2.5 Hz, 1H), 7.67 (s, 1H), 7.63 (dd, <i>J</i> = 9.2, 2.5 Hz, 1H), 5.72 (d, <i>J</i> = 16.3 Hz, 1H), 5.29 (d, <i>J</i> = 16.3 Hz, 1H), 5.23 (d, <i>J</i> = 0.8 Hz, 2H), 4.25 (s, 1H), 3.14 (q, <i>J</i> = 7.7 Hz, 2H), 1.94–1.85 (m, 2H), 1.62 (s, 9H), 1.40 (t, <i>J</i> = 7.7 Hz, 3H), 1.02 (t, <i>J</i> = 7.4 Hz, 3H). LC–MS (ESI) <i>m</i>/<i>z</i>: (M + H)<sup>+</sup>, 493.3; calcd for C<sub>27</sub>H<sub>28</sub>N<sub>2</sub>O<sub>7</sub> [M + H]<sup>+</sup>, 493.2.</div></div><div id="sec4_1_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34">4.1.2.2.  (<i>S</i>)-9-((<i>tert</i>-Butoxycarbonyl)oxy)-4,11-diethyl-3,14-dioxo-3,4,12,14-tetrahydro-1<i>H</i>-pyrano[3′,4′:6,7]indolizino[1,2-<i>b</i>]quinolin-4-yl 3-((<i>tert</i>-Butoxycarbonyl)amino)propanoate <b>3a</b></h5><div class="NLM_p last">(Yield 92%): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.22 (d, <i>J</i> = 9.2 Hz, 1H), 7.91 (d, <i>J</i> = 2.1 Hz, 1H), 7.68 (dd, <i>J</i> = 9.2, 2.1 Hz, 1H), 7.17 (s, 1H), 5.70 (d, <i>J</i> = 17.2 Hz, 1H), 5.42 (d, <i>J</i> = 17.2 Hz, 1H), 5.25 (s, 2H), 3.42 (dd, <i>J</i> = 22.3, 16.7 Hz, 1H), 3.16 (q, <i>J</i> = 7.5 Hz, 2H), 2.82–2.59 (m, 2H), 1.39 (s, 9H), 1.28 (m, 3H), 1.0 (t, <i>J</i> = 7.3 Hz, 3H). LC–MS (ESI) <i>m</i>/<i>z</i>: (M + H)<sup>+</sup>, 664.3; calcd for C<sub>35</sub>H<sub>41</sub>N<sub>3</sub>O<sub>10</sub> [M + H]<sup>+</sup>, 664.3.</div></div><div id="sec4_1_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35">4.1.2.3.  (<i>S</i>)-9-((<i>tert</i>-Butoxycarbonyl)oxy)-4,11-diethyl-3,14-dioxo-3,4,12,14-tetrahydro-1<i>H</i>-pyrano[3′,4′:6,7]indolizino[1,2-<i>b</i>]quinolin-4-yl (<i>tert</i>-butoxycarbonyl)glycinate <b>3b</b></h5><div class="NLM_p last">(Yield 96%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.17 (d, <i>J</i> = 9.2 Hz, 1H), 8.08 (d, <i>J</i> = 2.1 Hz, 1H), 7.74 (dd, <i>J</i> = 9.2, 2.3 Hz, 1H), 7.44 (t, <i>J</i> = 6.0 Hz, 1H), 7.22 (s, 1H), 5.52 (s, 2H), 5.32 (d, <i>J</i> = 6.9 Hz, 2H), 3.95 (dd, <i>J</i> = 17.9, 6.0 Hz, 1H), 3.82 (dd, <i>J</i> = 17.9, 5.9 Hz, 1H), 3.19 (dd, <i>J</i> = 14.1, 6.6 Hz, 2H), 2.15 (td, <i>J</i> = 13.6, 7.1 Hz, 2H), 1.54 (s, 9H), 1.43–1.36 (m, 9H), 1.28 (t, <i>J</i> = 7.5 Hz, 3H), 0.93 (t, <i>J</i> = 7.3 Hz, 3H). LC–MS (ESI) <i>m</i>/<i>z</i>: (M + H)<sup>+</sup>, 650.2; calcd for C<sub>34</sub>H<sub>39</sub>N<sub>3</sub>O<sub>10</sub> [M + H]<sup>+</sup>, 650.3.</div></div><div id="sec4_1_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36">4.1.2.4.  (<i>S</i>)-9-((<i>tert</i>-Butoxycarbonyl)oxy)-4,11-diethyl-3,14-dioxo-3,4,12,14-tetrahydro-1<i>H</i>-pyrano[3′,4′:6,7]indolizino[1,2-<i>b</i>]quinolin-4-yl-3-aminopropanoate <b>4a</b></h5><div class="NLM_p last">(Yield 90%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.22 (d, <i>J</i> = 9.2 Hz, 1H), 7.91 (d, <i>J</i> = 9.2 Hz, 1H), 7.68 (dd, <i>J</i> = 9.2, 2.1 Hz, 2H), 7.18 (s, 1H), 5.70 (d, <i>J</i> = 17.2 Hz, 1H), 5.25 (s, 2H), 3.42 (dd, <i>J</i> = 22.3, 16.7 Hz, 2H), 3.16 (q, <i>J</i> = 7.5 Hz, 2H), 2.82–2.59 (m, 2H), 2.31–2.11 (m, 2H), 1.30 (t, <i>J</i> = 7.5 Hz, 3H), 0.95 (t, <i>J</i> = 7.3 Hz, 3H). LC–MS (ESI) <i>m</i>/<i>z</i>: (M + H)<sup>+</sup>, 464.4; calcd for C<sub>25</sub>H<sub>25</sub>N<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup>, 464.5.</div></div><div id="sec4_1_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37">4.1.2.5.  (<i>S</i>)-9-((<i>tert</i>-Butoxycarbonyl)oxy)-4,11-diethyl-3,14-dioxo-3,4,12,14-tetrahydro-1<i>H</i>-pyrano[3′,4′:6,7]indolizino[1,2-<i>b</i>]quinolin-4-yl Glycinate <b>4b</b></h5><div class="NLM_p last">(Yield 92%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.49 (s, 1H), 8.17–7.91 (m, 1H), 7.44 (dd, <i>J</i> = 6.4, 2.5 Hz, 2H), 7.18 (s, 1H), 5.54 (s, 2H), 5.31 (d, <i>J</i> = 4.8 Hz, 2H), 4.34 (d, <i>J</i> = 18.0 Hz, 1H), 4.10 (d, <i>J</i> = 18.0 Hz, 2H), 3.10 (dt, <i>J</i> = 14.1, 7.1 Hz, 2H), 2.25–2.11 (m, 2H), 1.30 (t, <i>J</i> = 7.5 Hz, 3H), 0.95 (t, <i>J</i> = 7.3 Hz, 3H). LC–MS (ESI) <i>m</i>/<i>z</i>: (M + H)<sup>+</sup>, 449.3; calcd for C<sub>24</sub>H<sub>23</sub>N<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup>, 449.2.</div></div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38">4.1.3.  Compounds <b>6–7</b> Were Synthesized according to a Literature Report<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></h4><div id="sec4_1_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39">4.1.3.1.  (<i>S</i>)-4,11-Diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1<i>H</i>-pyrano[3′,4′:6,7]indolizino[1,2-<i>b</i>]quinolin-9-yl-4-((<i>tert</i>-butoxycarbonyl)amino)piperidine-1-carboxylate <b>6</b></h5><div class="NLM_p last">(Yield 90%): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.22 (d, <i>J</i> = 9.1 Hz, 1H), 7.83 (d, <i>J</i> = 1.9 Hz, 1H), 7.65 (s, 1H), 7.60–7.54 (m, 1H), 5.75 (d, <i>J</i> = 16.3 Hz, 1H), 5.29 (d, <i>J</i> = 5.4 Hz, 1H), 5.26 (s, 2H), 4.54 (s, 1H), 4.28 (dd, <i>J</i> = 36.9, 12.0 Hz, 2H), 3.80 (d, <i>J</i> = 53.7 Hz, 2H), 3.16 (d, <i>J</i> = 7.5 Hz, 4H), 2.07 (d, <i>J</i> = 17.4 Hz, 2H), 1.90 (dd, <i>J</i> = 10.5, 7.4 Hz, 2H), 1.47 (s, 9H), 1.41 (dd, <i>J</i> = 10.2, 4.8 Hz, 3H), 1.04 (t, <i>J</i> = 7.3 Hz, 3H). LC–MS (ESI) <i>m</i>/<i>z</i>: (M + H)<sup>+</sup>, 619.3; calcd for C<sub>33</sub>H<sub>38</sub>N<sub>4</sub>O<sub>8</sub> [M + H]<sup>+</sup>, 619.3.</div></div><div id="sec4_1_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40">4.1.3.2.  (<i>S</i>)-4,11-Diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1<i>H</i>-pyrano[3′,4′:6,7]indolizino[1,2-<i>b</i>]quinolin-9-yl 4-Aminopiperidine-1-carboxylate <b>7</b></h5><div class="NLM_p last">(Yield 93%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.18 (dd, <i>J</i> = 17.2, 8.1 Hz, 3H), 7.98 (s, 1H), 7.69–7.60 (m, 1H), 7.33 (s, 1H), 6.52 (s, 1H), 5.44 (s, 2H), 5.32 (d, <i>J</i> = 7.6 Hz, 2H), 4.37–4.03 (m, 2H), 3.19 (d, <i>J</i> = 7.0 Hz, 3H), 3.02 (s, 1H), 2.02 (s, 2H), 1.93–1.81 (m, 2H), 1.57 (s, 2H), 1.30 (t, <i>J</i> = 7.0 Hz, 3H), 0.89 (t, <i>J</i> = 7.2 Hz, 3H). LC–MS (ESI) <i>m</i>/<i>z</i>: (M + H)<sup>+</sup>, 519.3; calcd for C<sub>28</sub>H<sub>30</sub>N<sub>4</sub>O<sub>6</sub> [M + H]<sup>+</sup>, 519.4.</div></div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41">4.1.4.  Compounds <b>9–10</b> Were Synthesized according to a Literature Report<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></h4><div id="sec4_1_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42">4.1.4.1.  (<i>E</i>)-<i>N</i>′-(3,3-Dimethyl-5-oxocyclohexylidene)-4-methylbenzenesulfonohydrazide <b>9</b></h5><div class="NLM_p last">(Yield 88%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.78 (s, 1H), 8.67 (s, 1H), 7.68 (d, <i>J</i> = 8.1 Hz, 2H), 7.44 (dd, <i>J</i> = 27.7, 8.0 Hz, 2H), 5.06 (s, 1H), 2.38 (s, 3H), 2.06 (s, 2H), 1.92 (s, 2H), 0.87 (d, <i>J</i> = 12.6 Hz, 6H). LC–MS (ESI) <i>m</i>/<i>z</i>: (M + H)<sup>+</sup>, 309.4; calcd for C<sub>15</sub>H<sub>20</sub>N<sub>2</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 309.5.</div></div><div id="sec4_1_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43">4.1.4.2.  6,6-Dimethyl-3-(trifluoromethyl)-1,5,6,7-tetrahydro-4<i>H</i>-indazol-4-one <b>10</b></h5><div class="NLM_p last">(Yield 68%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 2.80 (s, 2H), 2.37 (s, 2H), 1.04 (s, 6H). LC–MS (ESI) <i>m</i>/<i>z</i>: (M + H)<sup>+</sup>, 233.3; calcd for C<sub>10</sub>H<sub>11</sub>F<sub>3</sub>N<sub>2</sub>O [M + H]<sup>+</sup>, 233.1.</div></div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44">4.1.5.  <i>tert</i>-Butyl(2-cyano-5-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1<i>H</i>-indazol-1-yl)phenyl)glycinate <b>11</b></h4><div class="NLM_p last">To a solution of compound <b>10</b> (500 mg, 2.15 mmol) in anhydrous <i>N</i>,<i>N</i>-dimethylformamide (DMF) 5 mL was added 60% NaH (172 mg, 4.31 mmol). After stirring for 15 min, <i>tert</i>-butyl (5-bromo-2-cyanophenyl) glycinate (1007 mg, 3.23 mmol) was added in one portion. The mixture was stirred at 90 °C for 8 h and then quenched by H<sub>2</sub>O (50 mL). The residue was extracted with EtOAc (3 × 50 mL), and the combined organic layers were then washed with saturated brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo to afford the crude product, which was purified by column chromatography with petroleum/ethyl acetate (2:1) to give <b>11</b> (616 mg, 62% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.26 (dd, <i>J</i> = 8.2, 3.3 Hz, 1H), 6.85 (d, <i>J</i> = 8.2 Hz, 1H), 6.70 (s, 1H), 5.28 (d, <i>J</i> = 16.0 Hz, 1H), 3.85 (d, <i>J</i> = 4.6 Hz, 2H), 1.50 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 168.21, 149.78, 133.82, 129.26, 120.48, 116.85, 114.07, 95.43, 82.99, 45.49, 28.03. LC–MS (ESI) <i>m</i>/<i>z</i>: (M + H)<sup>+</sup>, 463.7; calcd for C<sub>23</sub>H<sub>25</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 463.5.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45">4.1.6.  <i>tert</i>-Butyl(2-carbamoyl-5-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1<i>H</i>-indazol-1-yl)phenyl)glycinate <b>12</b></h4><div class="NLM_p last">To a solution of compound <b>11</b> (600 mg, 1.30 mmol) in EtOH 10 mL was added aqueous NaOH (1 M, 2.6 mL, 2.6 mmol). After stirring for 5 min, 30% H<sub>2</sub>O<sub>2</sub> (2 mL) was added in one portion. The mixture was stirred at room temperature for 12 h. After the reaction completed, the residue was extracted with EtOAc (3 × 20 mL), and the combined organic layers were then washed with HCl (0.1 M), saturated brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo to afford the crude product, which was purified by column chromatography with DCM/MeOH (20:1) to give <b>12</b> (530 mg, 85% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.42 (s, 1H), 7.47 (dd, <i>J</i> = 27.6, 8.6 Hz, 1H), 6.53 (s, 1H), 6.47 (d, <i>J</i> = 8.2 Hz, 1H), 3.84 (d, <i>J</i> = 5.0 Hz, 2H), 2.78–2.65 (m, 2H), 2.41–2.26 (m, 2H), 1.45 (s, 9H), 1.02 (d, <i>J</i> = 12.8 Hz, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 189.2, 170.3, 168.8, 149.7, 148.9, 140.2, 128.9, 115.0, 113.5, 109.1, 105.9, 81.6, 51.1, 44.6, 35.9, 34.7, 28.7, 27.1. LC–MS (ESI) <i>m</i>/<i>z</i>: (M + H)<sup>+</sup>, 481.3; calcd for C<sub>23</sub>H<sub>25</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 481.5.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46">4.1.7.  (2-Carbamoyl-5-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1<i>H</i>-indazol-1-yl)phenyl)glycine <b>13</b></h4><div class="NLM_p last">A solution of compound <b>12</b> (400 mg, 0.84 mmol) in 10% TFA/DCM (0.5 mL/5 mL) was stirred at room temperature for 3 h. After the reaction completed, the mixture was concentrated in vacuo to afford the crude products, which was purified by column chromatography with DCM/MeOH (10:1) to give <b>13</b> (320 mg, 90% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.45 (s, 1H), 7.47 (dd, <i>J</i> = 27.6, 8.6 Hz, 1H), 6.55 (s, 1H), 6.49 (d, <i>J</i> = 8.1 Hz, 1H), 3.87 (d, <i>J</i> = 5.1 Hz, 2H), 2.77–2.65 (m, 2H), 2.41–2.24 (m, 2H), 1.12 (d, <i>J</i> = 12.8 Hz, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 189.3, 170.4, 169.8, 149.6, 148.9, 141.2, 128.9, 115.6, 113.6, 109.1, 106.3, 51.1, 45.7, 37.0, 35.9, 28.7. LC–MS (ESI) <i>m</i>/<i>z</i>: (M + H)<sup>+</sup>, 425.4; calcd for C<sub>23</sub>H<sub>25</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 425.5.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47">4.1.8.  General Procedures for the Preparation of Compounds <b>14a–c</b></h4><div class="NLM_p">To a solution of <b>13</b> (100 mg, 0.236 mmol) in anhydrous DMF 5 mL was added HATU (135 mg, 0.354 mmol) and DIEA (130 μL, 0.708 mmol). After stirring in an ice bath for 0.5 h, <b>4a</b> (120 mg, 0.260 mmol), <b>4b</b> (135 mg, 0.260 mmol), or <b>8</b> (183 mg, 0.260 mmol) was added. The mixture was stirred at room temperature overnight. After the reaction completed, the residue was diluted with H<sub>2</sub>O (50 mL) and extracted with EtOAc (3 × 40 mL). The combined organic layers were then washed with HCl (0.1 M), saturated brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo to afford the crude product, which was purified by column chromatography with DCM/MeOH (20:1–15:1) to give <b>14a–c</b>.</div><div id="sec4_1_8_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48">4.1.8.1.  (<i>S</i>)-4,11-Diethyl-9-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1<i>H</i>-pyrano[3′,4′:6,7]indolizino[1,2-<i>b</i>]quinolin-4-yl-3-(2-((2-carbamoyl-5-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1<i>H</i>-indazol-1-yl)phenyl)amino)acetamido)propanoate <b>14a</b></h5><div class="NLM_p last">Yellow solid (64 mg, yield 32.1%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.65 (s, 1H), 8.19 (t, <i>J</i> = 7.6 Hz, 2H), 8.01 (s, 1H), 7.81 (s, 1H), 7.79 (d, <i>J</i> = 8.4 Hz, 1H), 7.65 (d, <i>J</i> = 9.1 Hz, 1H), 7.47 (s, 1H), 7.27 (s, 1H), 6.81 (t, <i>J</i> = 15.1 Hz, 1H), 6.71 (s, 1H), 6.57 (s, 1H), 5.75 (s, 1H), 5.44 (s, 2H), 5.34 (s, 2H), 4.11 (s, 1H), 3.94 (d, <i>J</i> = 4.2 Hz, 2H), 3.51 (d, <i>J</i> = 4.2 Hz, 2H), 3.17 (d, <i>J</i> = 14.5 Hz, 3H), 2.91 (s, 2H), 2.65 (s, 2H), 2.46 (s, 2H), 2.01 (d, <i>J</i> = 19.3 Hz, 4H), 1.51 (d, <i>J</i> = 12.6 Hz, 2H), 1.34 (d, <i>J</i> = 15.1, 7.8 Hz, 4H), 1.24 (d, <i>J</i> = 7.2 Hz, 2H), 1.11 (s, 6H), 0.90 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 192.2, 171.9, 171.6, 168.5, 154.8, 154.3, 148.1, 145.6, 144.0, 143.4, 142.8, 139.6, 135.4, 132.3, 130.5, 127.3, 124.3, 122.2, 120.9, 119.8, 119.1, 114.2, 112.3, 106.6, 101.1, 96.5, 74.3, 65.6, 49.1, 47.9, 47.2, 38.9, 38.8, 34.3, 30.8, 27.37, 22.3, 13.3, 7.4. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>44</sub>H<sub>42</sub>F<sub>3</sub>N<sub>7</sub>O<sub>9</sub> [M + Na]<sup>+</sup>, 892.2894; found, 892.2894.</div></div><div id="sec4_1_8_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49">4.1.8.2.  (<i>S</i>)-4,11-Diethyl-9-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1<i>H</i>-pyrano[3′,4′:6,7]indolizino[1,2-<i>b</i>]quinolin-4-yl-(2-carbamoyl-5-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1<i>H</i>-indazol-1-yl)phenyl)glycylglycinate <b>14b</b></h5><div class="NLM_p last">Yellow solid (80 mg, yield 41.1%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.65 (s, 1H), 8.17 (t, <i>J</i> = 7.6 Hz, 2H), 8.02 (s, 1H), 7.97 (s, 1H), 7.82 (d, <i>J</i> = 8.2 Hz, 1H), 7.65 (d, <i>J</i> = 9.1 Hz, 1H), 7.37 (d, <i>J</i> = 27.7 Hz, 1H), 7.29 (d, <i>J</i> = 31.8 Hz, 1H), 6.79 (t, <i>J</i> = 14.6 Hz, 1H), 6.69 (s, 1H), 6.53 (s, 1H), 5.75 (s, 1H), 5.44 (s, 2H), 5.34 (s, 2H), 4.11 (s, 1H), 3.92 (s, 2H), 3.86 (d, <i>J</i> = 4.2 Hz, 2H), 3.17 (dd, <i>J</i> = 19.8, 14.5 Hz, 3H), 2.97 (s, 2H), 2.46 (s, 2H), 1.90 (dd, <i>J</i> = 29.5, 22.3 Hz, 4H), 1.46 (d, <i>J</i> = 12.5 Hz, 2H), 1.30 (dt, <i>J</i> = 15.1, 7.5 Hz, 4H), 1.24 (d, <i>J</i> = 7.1 Hz, 2H), 1.05 (s, 6H), 0.89 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 190.2, 172.5, 170.4, 168.2, 156.8, 152.6, 151.8, 151.7, 150.0, 149.9, 146.2, 145.9, 145.2, 140.4, 130.9, 130.3, 128.5, 127.1, 125.9, 118.87, 115.1, 109.4, 106.6, 96.5, 72.4, 65.2, 54.9, 51.7, 49.5, 45.5, 35.8, 35.2, 30.3, 27.5, 22.2, 13.8, 7.7. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>43</sub>H<sub>40</sub>N<sub>7</sub>O<sub>9</sub>F<sub>3</sub> [M + Na]<sup>+</sup>, 878.2737; found, 878.2749.</div></div><div id="sec4_1_8_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50">4.1.8.3.  (<i>S</i>)-4,11-Diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1<i>H</i>-pyrano[3′,4′:6,7]indolizino[1,2-<i>b</i>]quinolin-9-yl-4-(2-((2-carbamoyl-5-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1<i>H</i>-indazol-1-yl)phenyl)amino)acetamido)piperidine-1-carboxylate <b>14c</b></h5><div class="NLM_p last">Yellow solid (98 mg, yield 45.2%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.94 (s, 1H), 8.02 (d, <i>J</i> = 7.5 Hz, 1H), 7.94 (t, <i>J</i> = 6.9 Hz, 1H), 7.80 (d, <i>J</i> = 7.6 Hz, 1H), 7.70 (s, 2H), 7.36 (d, <i>J</i> = 1.5 Hz, 1H), 7.34–7.31 (s, 1H), 7.30 (d, <i>J</i> = 8.1 Hz, 1H), 7.14 (t, <i>J</i> = 1.0 Hz, 1H), 7.13 (d, <i>J</i> = 1.6 Hz, 1H), 7.11 (dd, <i>J</i> = 7.5, 1.6 Hz, 1H), 5.17 (t, <i>J</i> = 1.0 Hz, 2H), 4.92 (s, 2H), 3.86 (d, <i>J</i> = 4.2 Hz, 2H), 3.56–3.39 (m, 2H), 3.38 (s, 2H), 3.09 (s, 2H), 2.79–2.69 (m, 2H), 2.67 (d, <i>J</i> = 7.0 Hz, 2H), 2.12–1.93 (m, 2H), 1.21 (t, <i>J</i> = 8.0 Hz, 3H), 1.15 (s, 6H), 1.06 (t, <i>J</i> = 8.0 Hz, 3H).·<sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 190.1, 170.3, 169.7, 168.7, 167.0, 156.8, 156.5, 151.8, 149.8, 146.9, 144.9, 143.6, 142.8, 140.4, 131.5, 130.4, 127.9, 122.4, 117.9, 115.3, 115.01, 109.8, 106.4, 104.8, 94.1, 76.2, 66.3, 51.5, 49.4, 45.8, 35.8, 35.1, 30.3, 28.9, 27.5, 27.2, 22.2, 13.3, 7.4. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>47</sub>H<sub>48</sub>N<sub>8</sub>O<sub>9</sub>F<sub>3</sub> [M + H]<sup>+</sup>, 925.3496; found, 925.3468.</div></div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51">4.1.9.  5-(2,4-Bis(benzyloxy)-5-isopropylphenyl)-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carboxylic Acid <b>16</b></h4><div class="NLM_p last">Ethyl-5-(2,4-bis(benzyloxy)-5-isopropylphenyl)-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carboxylate (<b>15</b>) was synthesized according to a literature report.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> To a solution of <b>15</b> (3.1 g, 4.7 mmol) in tetrahydrofuran/methanol/water (1:1:1, v/v) (50 mL) was added lithium hydroxide monohydrate (0.40 g, 9.4 mmol) and stirred at room temperature for 2 h. After the reaction completed, the mixture was then adjusted to pH 7 with hydrochloric acid (1 M) and concentrated in vacuo. The residue was extracted with EtOAc (3 × 40 mL). The combined organic layers were then washed with saturated brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo to afford <b>15</b> as a pale yellow solid (2.6 g, yield 89%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.12 (s, 1H), 7.40 (m, 14H), 6.98 (d, <i>J</i> = 17.6 Hz, 2H), 5.18 (s, 2H), 5.09 (s, 2H), 4.27 (s, 2H), 3.85 (s, 4H), 3.38 (s, 4H), 3.07 (m, 1H), 0.96 (d, <i>J</i> = 6.8 Hz, 6H). LC–MS (ESI) <i>m</i>/<i>z</i>: (M + H)<sup>+</sup>, 619.3; calcd for C<sub>38</sub>H<sub>38</sub>N<sub>2</sub>O<sub>6</sub> [M + H]<sup>+</sup>, 619.5.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52">4.1.10.  5-(2,4-Dihydroxy-5-isopropylphenyl)-4-(4-(morpholinomethyl)phenyl)isoxazole-3-Carboxylic Acid <b>17</b></h4><div class="NLM_p last">To a solution of <b>16</b> (2.0 g, 3.2 mmol) in methanol 20 mL was added 10% Pd/C (5:1, m/m) (400 mg). The mixture was purged with nitrogen, then hydrogen and stirred at room temperature for 8 h. After the reaction completed, the mixture was then filtered through celatom and concentrated in vacuo to afford the crude product, which was purified by column chromatography with DCM/MeOH (30:1–8:1) to give <b>17</b> as a pale white soild (1.1 g, yield 85%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.62 (s, 2H), 9.78 (s, 1H), 9.68 (s, 1H), 7.69 (s, 2H), 7.37–7.16 (m, 5H), 6.80 (s, 2H), 6.74 (s, 1H), 3.47 (s, 4H), 3.19 (m, 1H), 2.40 (s, 4H), 1.17 (d, <i>J</i> = 6.9 Hz, 6H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 173.2, 161.9, 158.3, 151.9, 132.46, 132.1, 130.9, 129.1, 122.2, 114.5, 100.8, 97.8, 66.0, 62.3, 53.0, 26.2, 22.4. LC–MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup>, 439.5; calcd for C<sub>24</sub>H<sub>26</sub>N<sub>2</sub>O<sub>6</sub> [M + H]<sup>+</sup>, 439.4.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53">4.1.11.  General Procedures for the Preparation of Compounds <b>18a–c</b></h4><div class="NLM_p">To a solution of <b>17</b> (100 mg, 0.228 mmol) in anhydrous DMF 5 mL was added HATU (130 mg, 0.342 mmol) and DIEA (126 μL, 0.684 mmol). After stirring at 0 °C in an ice bath for 0.5 h, <b>4a</b> (112 mg, 0.250 mmol), <b>4b</b> (106 mg, 0.250 mmol), or <b>8</b> (128 mg, 0.250 mmol) was added. The mixture was stirred at room temperature overnight. After the reaction completed, the residue was diluted with H<sub>2</sub>O (50 mL) and extracted with EtOAc (3 × 40 mL). The combined organic layers were then washed with HCl (0.1 M), saturated brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo to afford the crude product, which was purified by column chromatography with DCM/MeOH (20:1–15:1) to give <b>18a–c</b>.</div><div id="sec4_1_11_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54">4.1.11.1.  (<i>S</i>)-4,11-Diethyl-9-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1<i>H</i>-pyrano[3′,4′:6,7]indolizino[1,2-<i>b</i>]quinolin-4-yl-3-(5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carboxamido)propanoate <b>18a</b></h5><div class="NLM_p last">Yellow solid (88 mg, yield 45.3%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.33 (s, 1H), 9.76 (s, 1H), 9.66 (s, 1H), 8.89 (s, 1H), 8.01 (d, <i>J</i> = 9.5 Hz, 1H), 7.39 (s, 3H), 7.19 (q, <i>J</i> = 7.0 Hz, 4H), 7.02 (s, 1H), 6.69 (s, 1H), 6.44 (s, 1H), 5.50 (s, 2H), 5.27 (s, 2H), 3.54 (s, 5H), 3.47 (s, 3H), 3.13–3.02 (m, 2H), 2.95 (dd, <i>J</i> = 12.9, 6.4 Hz, 1H), 2.81 (s, 2H), 2.32 (s, 4H), 2.21–2.09 (m, 2H), 1.28 (t, <i>J</i> = 6.7 Hz, 3H), 0.95–0.83 (m, 9H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.1, 167.3, 166.6, 159.9, 157.4, 157.1, 156.8, 156.6, 154.7, 148.6, 147.0, 145.3, 142.8, 136.8, 129.0, 128.6, 128.3, 128.2, 128.0, 127.7, 125.5, 122.4, 117.8, 114.9, 104.7, 102.7, 93.9, 76.1, 66.3, 66.1, 53.1, 49.4, 34.6, 30.2, 25.3, 22.3, 13.3, 7.5. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>49</sub>H<sub>49</sub>N<sub>5</sub>O<sub>11</sub> [M + Na]<sup>+</sup>, 906.9551; found, 906.9558.</div></div><div id="sec4_1_11_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55">4.1.11.2.  (<i>S</i>)-4,11-Diethyl-9-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1<i>H</i>-pyrano[3′,4′:6,7]indolizino[1,2-<i>b</i>]quinolin-4-yl-(5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carbonyl)glycinate <b>18b</b></h5><div class="NLM_p last">Yellow solid (89 mg, yield 44.5%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.31 (s, 1H), 9.74 (s, 1H), 9.64 (s, 1H), 9.35 (t, <i>J</i> = 5.9 Hz, 1H), 8.00 (d, <i>J</i> = 9.3 Hz, 1H), 7.40 (d, <i>J</i> = 8.2 Hz, 2H), 7.21 (d, <i>J</i> = 8.1 Hz, 2H), 7.10 (s, 1H), 7.08 (s, 2H), 6.70 (s, 1H), 6.42 (s, 1H), 5.76 (s, 1H), 5.49 (s, 2H), 5.30 (s, 2H), 4.22 (ddd, <i>J</i> = 56.2, 17.9, 6.0 Hz, 2H), 3.47 (s, 4H), 3.26 (s, 2H), 3.17 (d, <i>J</i> = 5.2 Hz, 1H), 3.09 (d, <i>J</i> = 7.6 Hz, 2H), 2.94 (dt, <i>J</i> = 13.5, 6.8 Hz, 1H), 2.23 (s, 4H), 2.08 (dd, <i>J</i> = 14.3, 6.9 Hz, 2H), 1.29 (t, <i>J</i> = 7.5 Hz, 3H), 0.92–0.82 (m, 9H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 168.2, 167.0, 160.4, 157.4, 156.8, 156.5, 154.7, 148.7, 146.9, 145.1, 143.7, 142.7, 131.5, 129.2, 128.5, 128.2, 127.9, 127.8, 125.6, 122.4, 117.9, 115.0, 104.8, 104.4, 102.7, 94.3, 76.4, 66.2, 66.0, 61.9, 53.0, 30.3, 26.2, 25.3, 22.9, 13.3, 8.2, 7.4. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>48</sub>H<sub>47</sub>N<sub>5</sub>O<sub>11</sub> [M + H]<sup>+</sup>, 869.9280; found, 869.9288.</div></div><div id="sec4_1_11_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56">4.1.11.3.  (<i>S</i>)-4,11-Diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1<i>H</i>-pyrano[3′,4′:6,7]indolizino[1,2-<i>b</i>]quinolin-9-yl-4-(5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carboxamido)piperidine-1-carboxylate <b>18c</b></h5><div class="NLM_p">Yellow solid (104 mg, yield 49.2%).</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.78 (s, 1H), 9.68 (s, 1H), 8.95 (d, <i>J</i> = 7.7 Hz, 1H), 8.16 (d, <i>J</i> = 9.1 Hz, 1H), 7.98 (s, 1H), 7.66 (d, <i>J</i> = 9.3 Hz, 1H), 7.32 (s, 1H), 7.29–7.15 (m, 4H), 6.77 (s, 1H), 6.53 (s, 1H), 6.46 (s, 1H), 5.44 (s, 2H), 5.32 (s, 2H), 4.18 (d, <i>J</i> = 13.2 Hz, 1H), 4.02 (dd, <i>J</i> = 25.7, 13.0 Hz, 2H), 3.56 (t, <i>J</i> = 4.6 Hz, 4H), 3.17 (t, <i>J</i> = 7.8 Hz, 2H), 2.99 (p, <i>J</i> = 6.8 Hz, 1H), 2.33 (d, <i>J</i> = 5.8 Hz, 4H), 1.89 (dh, <i>J</i> = 14.0, 6.7 Hz, 4H), 1.64–1.46 (m, 2H), 1.30 (t, <i>J</i> = 7.6 Hz, 3H), 0.93 (d, <i>J</i> = 7.1 Hz, 6H), 0.88 (d, <i>J</i> = 7.2 Hz, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 172.4, 157.9, 157.5, 154.7, 152.7, 149.9, 149.89, 146.2, 145.1, 136.9, 130.9, 128.7, 128.7, 128.4, 128.4, 127.7, 125.9, 125.6, 118.9, 114.9, 104.5, 102.7, 96.5, 72.4, 66.1, 65.2, 62.1, 53.1, 49.5, 45.9, 30.3, 25.4, 22.2, 13.8. HRMS (ESI) <i>m</i>/<i>z</i>: calcd for C<sub>50</sub>H<sub>52</sub>N<sub>6</sub>O<sub>11</sub> [M + Na]<sup>+</sup>, 935.3592; found, 935.3577.</div></div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57">4.2.  Chemical Reagents for Biology</h3><div class="NLM_p last">The primary antibodies TOP1, pKAP1, Akt, and HSP70 were purchased from Cell Signaling Technology (MA, USA), and GAPDH (GA) was purchased from Proteintech (Rosemont, IL, USA). Recombinant HSP90 alpha protein and fluorescein isothiocyanate (FITC)-labeled geldanamycin were obtained from Abcam (Cambridge, UK).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58">4.3.  Cell Lines and Culture Methods</h3><div class="NLM_p last">Human pancreatic cancer Capan-1 and MIA-PACA-2, colon cancer HCT116, non-small cell lung cancer A549 cell lines and human normal liver HL7702 cell line were purchased from the American Type Culture Collection (Manassas, VA, USA).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59">4.4.  <i>In Vitro</i> Stability in PBS</h3><div class="NLM_p last">The compounds were dissolved in DMSO at a concentration of 5 mM, and then were diluted in PBS (pH 6.0 and pH 7.4, 0.01 M) at a final concentration of 50 μM. The mixtures were incubated at 37 °C and 50 μL of reaction mixtures were taken out at different time points. Then, the samples were analyzed by HPLC.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60">4.5.  <i>In Vitro</i> Stability in Mouse and Human Plasma</h3><div class="NLM_p last">The compounds were dissolved in DMSO at a concentration of 5 mM, and then added to mouse or human plasma at a final concentration of 50 μM. The mixtures were incubated at 37 °C. At different time points, 50 μL of the mixtures were taken out and quenched by 50 μL of MeCN. After being centrifuged at 4 °C for 5 min, the supernatant was transferred to a vial for analysis using HPLC.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61">4.6.  <i>In Vitro</i> HSP90 Assay</h3><div class="NLM_p last">To assess the effects on HSP90 activity <i>in vitro</i>, FP assay was performed. Briefly, various concentrations of compounds and FITC-labeled geldanamycin were added to each reaction well. Recombinant HSP90 protein was diluted with the reaction buffer (20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid pH 7.3, 50 mM KCl, 5 mM MgCl<sub>2</sub>, 20 mM Na<sub>2</sub>MoO<sub>4</sub>, 0.01% Triton X-100, 100 μg/mL bovine serum albumin, and 2 mM dithiothreitol) and added to each well to get the final concentration of 22.2 nM. The enzyme reaction was initiated as soon as the purified HSP90 was added. After incubation for 60 min at 4 °C, the fluorescent polarization of the samples was determined by a microtiter-plate reader (Envision, PerkinElmer).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62">4.7.  <i>In Vitro</i> Cellular Uptake</h3><div class="NLM_p last">The cellular uptakes of compounds, irinotecan and SN38 against A549 cells, HCT116 cells, and HL7702 cells were investigated using a live cell imaging system (Leica SP8). A549 cells, HCT116 cells, and HL7702 cells were routinely maintained in F12, McCoy’s 5A, and RPMI-1640, respectively, supplemented with 10% fetal bovine serum and 1% of penicillin/streptomycin were seeded in a 12-well plate at a density of 5 × 10<sup>4</sup> cells per well. The culture dish was mounted in the incubation system of a live cell imaging system at 37 °C under a 5% CO<sub>2</sub> atmosphere. Afterward, the culture medium was removed, and cells were carefully washed with PBS. Then, 0.2 mL of fresh culture medium containing the compounds, irinotecan and SN38 (the final concentration of SN38 was 5 μM) was added. After incubation for different times, the images were then captured at excitation wavelengths of 405 nm.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63">4.8.  <i>In Vitro</i> Competitive Experiments</h3><div class="NLM_p last">A549 cells, HCT116 cells, and HL-7702 cells were plated in 20 mm glass bottomed culture dishes at proper densities and incubated for 24 h. Afterward, compound <b>18b</b>/NVP-AUY922 (1/100, n/n) and compound <b>18b</b> in PBS solution at a concentration of 5 μmol L<sup>–1</sup> were added to the above cells and the mixtures were incubated for 4 h. The cells were washed with PBS and stained with 4% paraformaldehyde and subsequently imaged using a Leica TCS SP8 confocal fluorescence microscope by excitation at λ<sub>ex</sub> 405 nm (Germany).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64">4.9.  Cellular Internalization Analysis</h3><div class="NLM_p last">Cells were plated in 20 mm glass bottomed culture dishes at proper densities and incubated for 24 h. Afterward, the culture medium was removed, and cells were carefully washed with PBS. Then, 0.2 mL of fresh culture medium containing the test compounds was added and incubated for different times. Subsequently, culture media was removed, and the wells were washed with cold PBS; 1 mL of DMSO and cold PBS mixture (v/v, 1:1) was added to each well, and the cells were mechanically removed from the wells using a cell scraper. Then, the cells were transferred to a 15 mL polypropylene centrifuge tube. The cell number was counted. The tube was placed in a thermostatic ice bath at 0 °C, and then the cell suspension was sonicated with alternative cycles of 20 s pulses after every 10 s intervals for 10 min using an ultrasonicator probe (Vibra-Cell 750). After sonication, the cell suspensions were centrifuged for 10 min at 4 °C and 1500 rpm. Then, the supernatant was collected by centrifugation, evaporated, and lyophilized. The obtained sample was dissolved in acetonitrile and centrifuged for 5 min at 5000 rpm. Finally, the supernatant was analyzed using LC–MS/MS.<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_m001.gif" alt="" id="_i65" /></img></span><i>C</i><sub>f</sub> represents the final tested concentration; <i>C</i><sub>i</sub> represents the initial concentration; <i>V</i><sub>f</sub> represents the final volume; <i>V</i><sub>i</sub> represents the initial volume; <i>N</i><sub>f</sub> represents the final cell numbers; and <i>N</i><sub>i</sub> represents the initial cell numbers.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66">4.10.  Cytotoxicity/Proliferation Assay</h3><div class="NLM_p last">Cells were seeded in 96-well plates at proper density in growth media. After 24 h, a range of concentrations of the test compounds were added and the plates were incubated at 37 °C for 72 h. Cell proliferation was determined by SRB assay. IC<sub>50</sub> values were calculated by concentration–response curve fitting using a SoftMax probased four-parameter method.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67">4.11.  Cell Cycle Assay</h3><div class="NLM_p last">The effects of compounds on cell cycle progression were determined by flow cytometry. Cells at logarithmic phase were seeded in six-well plates and treated with compounds at the indicated concentration or with the vehicle as a control. After 24 h, cells were collected, fixed, and stained with RNase A (50 μg/mL) and propidium iodide (50 μg/mL) for 30 min and were then analyzed on a FACSCalibur flow cytometer using CellQuest Pro software (BD Biosciences, San Jose, CA). The percentage of each population was measured using ModFIT software (BD Biosciences). At least 20,000 cells were analyzed for each data point.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68">4.12.  Western Blot Assay</h3><div class="NLM_p last">Cells at the logarithmic phase were seeded in six-well plates and cultured overnight. Compounds were added to the wells and cells were incubated at 37 °C for 24 h. Cells without any treatment were used as the control. The cells were harvested and washed with cold PBS three times. The proteins of whole cell lysates were prepared in RIPA buffer and quantified by the bicinchoninic acid (BCA) method. Proteins were separated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes by using the semidry method. The membranes were blocked with 5% nonfat dry milk and incubated with the respective primary antibodies and HRP-conjugated secondary antibodies. Western blot was visualized using a ChemiDoc MP detection system (Bio-Rad).</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69">4.13.  Human Microsomal Stability</h3><div class="NLM_p last">The stabilities of compounds <b>18a–c</b> were monitored in the presence of human liver microsomal enzymes.<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(48,49)</a> Briefly, compounds at a concentration of 10 μM were incubated at 37 °C for 5 min with human microsomes (0.5 mg/mL) in phosphate buffer (100 mM, PH 7.4) in triplicate. Then, 1 mM NADPH was added to initiate the reaction. Serial samples of 100 μL were taken at 0, 15, 30, 60, 120, 240, and 360 min after initiation of the reaction. The reaction was terminated by adding 0 °C ice-cold acetonitrile. The obtained mixtures were vortexed and centrifuged at 20,000 g for 20 min at 4 °C. Supernatant aliquots of 50 μL were collected from each sample and stored at −80 °C until LC–MS/MS analysis.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70">4.14.  Pharmacokinetic Analysis in Healthy Mice</h3><div class="NLM_p last">Male BALB/c mice (18–22 g) were dosed with the test compound i.v. at 50 mg/kg (<i>n</i> = 4 mice for the experimental groups). The compound was dissolved in a vehicle of 5% DMSO, 18% Cremophor, and 77% glucose solution. After a single administration, whole blood samples (30 μL) were obtained from the orbital venous plexus at the following time points: 5, 15, 30 min, 1, 2, 4, 6, and 24 h. Whole blood samples were collected in heparinized tubes. The plasma fraction was immediately separated by centrifugation (6800 g, 6 min, 4 °C) and stored at −80 °C until LC–MS/MS analysis. Test sample concentrations were determined by LC–MS/MS using propranolol as an internal standard. Pharmacokinetic parameters were calculated using Phoenix WinNonlin 7.0 software (Pharsight, USA). The mice were humanely euthanized without pain by carbon dioxide 24 h after the experiment.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71">4.15.  <i>In Vivo</i> Assay</h3><div class="NLM_p last">Nude mice used for all <i>in vivo</i> studies were obtained from Shanghai Institute of Material Medica, Chinese Academy of sciences. The mice were housed and maintained under specific pathogen-free conditions with a 12 h light/dark cycle at 25 ± 1 °C and received food and water ad libitum. All experiment procedures with animals were in accordance with the guidelines of the Institutional Animal Care and Use Committee at Shanghai Institute of Materia Medica (No. 2018-05-DJ-37 and 2019-05-DJ-48). HCT-116 and Capan-1 cells (5 × 10<sup>6</sup>) were s.c. injected into right flank of nude mice, the tumors formed in mice were passed in nude mice to make tumors stable, and then tumors (2–3 passage) were cut into 1 mm<sup>3</sup> fragments and transplanted s.c. into the right flank of nude mice using a trocar. When the tumor reached a volume of 100–200 mm<sup>3</sup>, the mice were randomly assigned into control and treatment groups, six mice per group. Control groups were given vehicle alone, and treatment groups received indicated compounds (i.v.). The compounds were administrated 5 days per week for the duration indicated in each treatment. The sizes of the tumors were measured twice per week using microcalipers. The tumor volume (<i>V</i>) was calculated as follows: <i>V</i> = (length × width<sup>2</sup>)/2. The individual relative tumor volume (RTV) was calculated as follows: RTV = <i>V</i><sub><i>t</i></sub>/<i>V</i><sub>0</sub>, where <i>V</i><sub><i>t</i></sub> is the volume on each day, and <i>V</i><sub>0</sub> is the volume at the beginning of the treatment. The therapeutic effect of the compounds was expressed as the volume ratio of treatment to control (T/C): T/C (%) = 100% × (mean RTV of the treated group/mean RTV of the control group).</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72">4.16.  Pharmacokinetic Analysis in Tumor-Bearing Mice</h3><div class="NLM_p last">Tumor-bearing male nude mice (18–22 g) were dosed with the test compounds i.v. (<i>n</i> = 3 mice for the experimental groups). The compound was dissolved in a vehicle of 5% DMSO, 18% Cremophor, and 77% glucose solution. After a single administration, whole blood samples (30 μL) were obtained from the orbital venous plexus at the following time points: 5, 15, 30 min, 1, 2, 4, 6, 24, and 72 h. Whole blood samples were collected in heparinized tubes. The plasma fraction was immediately separated by centrifugation (6800 g, 6 min, 4 °C) and stored at −80 °C until LC–MS/MS analysis. Test sample concentrations were determined by LC–MS/MS using propranolol as an internal standard. Pharmacokinetic parameters were calculated using Phoenix WinNonlin 7.0 software (Pharsight, USA). The mice were humanely euthanized without pain by carbon dioxide 24 h after the experiment.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73">4.17.  Histological Analysis</h3><div class="NLM_p last">Tumors and major organs were harvested 2 h after the final treatment and immediately flash-frozen in −80 °C. Half of the tumors were used for western blot to analyze changes in the pharmacodynamic biomarkers after treatment. The tumors were homogenized, and the concentrations of the protein lysates were determined using a BCA kit. Then, the protein lysates were analyzed by western blot. The remaining tumors were embedded in paraffin for sectioning, and the sections were subjected to histological staining analysis.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i74"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00305" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55888" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55888" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00305?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00305</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Additional information for the NMR spectrums, HPLC spectrums, and HRMS data for compounds <b>18a–c</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00305/suppl_file/jm0c00305_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">HSP90 FP assay, SRB assay, and Molecular Formula Strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00305/suppl_file/jm0c00305_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00305/suppl_file/jm0c00305_si_001.pdf">jm0c00305_si_001.pdf (1.39 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00305/suppl_file/jm0c00305_si_002.csv">jm0c00305_si_002.csv (1.62 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00305" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28816" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28816" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yanfen Fang</span> - <span class="hlFld-Affiliation affiliation">Division
of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research,
Shanghai Institute of Materia Medica, Chinese
Academy of Sciences, Shanghai 201203, PR China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d5acb3b3b4bbb295a6bcb8b8fbb4b6fbb6bb"><span class="__cf_email__" data-cfemail="c6bfa0a0a7a8a186b5afababe8a7a5e8a5a8">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Lu</span> - <span class="hlFld-Affiliation affiliation">Shanghai
Engineering Research Center of Molecular Therapeutics and New Drug
Development, School of Chemistry and Molecular Engineering, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, PR China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3041-9200" title="Orcid link">http://orcid.org/0000-0003-3041-9200</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f2859e87b2919a979fdc97919c87dc979687dc919c"><span class="__cf_email__" data-cfemail="60170c15200308050d4e05030e154e0504154e030e">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shulei Zhu</span> - <span class="hlFld-Affiliation affiliation">Shanghai
Engineering Research Center of Molecular Therapeutics and New Drug
Development, School of Chemistry and Molecular Engineering, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qianqian Shen</span> - <span class="hlFld-Affiliation affiliation">Division
of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research,
Shanghai Institute of Materia Medica, Chinese
Academy of Sciences, Shanghai 201203, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yinglei Gao</span> - <span class="hlFld-Affiliation affiliation">Division
of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research,
Shanghai Institute of Materia Medica, Chinese
Academy of Sciences, Shanghai 201203, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lei Wang</span> - <span class="hlFld-Affiliation affiliation">Shanghai
Engineering Research Center of Molecular Therapeutics and New Drug
Development, School of Chemistry and Molecular Engineering, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yi Chen</span> - <span class="hlFld-Affiliation affiliation">Division
of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research,
Shanghai Institute of Materia Medica, Chinese
Academy of Sciences, Shanghai 201203, PR China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>S.Z. and Q.S. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br><p class="inlineNote">We state that all experiments with live subjects were performed in compliance with the Laboratory Animal Management Regulations of the People’s Republic of China and the Three Rs (Replacement, Reduction, and Refinement) strategy of William Russell and Rex Burch, and the Animal Ethical and Welfare Committee of Chinese Academy of Sciences and East China Normal University have approved the experiments.</p><br /></br><p class="inlineNote">All statistical analyses were done by the GraphPad Prism. The statistical significance was analyzed by performing Student’s <i>t</i>-test. Multiple group comparisons with the vehicle or compound-treated group were followed by the One-way ANOVA and Multiple <i>t</i>-test. ns, ***<i>P</i> < 0.001, *<i>P</i> < 0.05.</p></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i78">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42855" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42855" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by grants from the China Postdoctoral Science Foundation (Grant 2019M651435).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">HSP90</td><td class="NLM_def"><p class="first last">heat shock protein 90</p></td></tr><tr><td class="NLM_term">SN38</td><td class="NLM_def"><p class="first last">7-ethyl-10-hydroxy-camptothecin</p></td></tr><tr><td class="NLM_term">ADC</td><td class="NLM_def"><p class="first last">antibody drug conjugates</p></td></tr><tr><td class="NLM_term">HDC</td><td class="NLM_def"><p class="first last">HSP90 inhibitor drug conjugates</p></td></tr><tr><td class="NLM_term">eHSP90</td><td class="NLM_def"><p class="first last">extracellular HSP90</p></td></tr><tr><td class="NLM_term">Comp</td><td class="NLM_def"><p class="first last">compound</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i80">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12243" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12243" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 49 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torre, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bray, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferlay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lortet-Tieulent, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Global Cancer Statistics, 2012</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.3322/caac.21262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.3322%2Fcaac.21262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=25651787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A280%3ADC%252BC2Mris1Ggsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2015&pages=87-108&author=L.+A.+Torreauthor=F.+Brayauthor=R.+L.+Siegelauthor=J.+Ferlayauthor=J.+Lortet-Tieulentauthor=A.+Jemal&title=Global+Cancer+Statistics%2C+2012&doi=10.3322%2Fcaac.21262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Global cancer statistics, 2012</span></div><div class="casAuthors">Torre Lindsey A; Bray Freddie; Siegel Rebecca L; Ferlay Jacques; Lortet-Tieulent Joannie; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-108</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer constitutes an enormous burden on society in more and less economically developed countries alike.  The occurrence of cancer is increasing because of the growth and aging of the population, as well as an increasing prevalence of established risk factors such as smoking, overweight, physical inactivity, and changing reproductive patterns associated with urbanization and economic development.  Based on GLOBOCAN estimates, about 14.1 million new cancer cases and 8.2 million deaths occurred in 2012 worldwide.  Over the years, the burden has shifted to less developed countries, which currently account for about 57% of cases and 65% of cancer deaths worldwide.  Lung cancer is the leading cause of cancer death among males in both more and less developed countries, and has surpassed breast cancer as the leading cause of cancer death among females in more developed countries; breast cancer remains the leading cause of cancer death among females in less developed countries.  Other leading causes of cancer death in more developed countries include colorectal cancer among males and females and prostate cancer among males.  In less developed countries, liver and stomach cancer among males and cervical cancer among females are also leading causes of cancer death.  Although incidence rates for all cancers combined are nearly twice as high in more developed than in less developed countries in both males and females, mortality rates are only 8% to 15% higher in more developed countries.  This disparity reflects regional differences in the mix of cancers, which is affected by risk factors and detection practices, and/or the availability of treatment.  Risk factors associated with the leading causes of cancer death include tobacco use (lung, colorectal, stomach, and liver cancer), overweight/obesity and physical inactivity (breast and colorectal cancer), and infection (liver, stomach, and cervical cancer).  A substantial portion of cancer cases and deaths could be prevented by broadly applying effective prevention measures, such as tobacco control, vaccination, and the use of early detection tests.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS93OidvnAA79ts4TFFB11gfW6udTcc2ebVrUJIkBHn5rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mris1Ggsg%253D%253D&md5=f008b208320b129e10c7c383193ff772</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21262%26sid%3Dliteratum%253Aachs%26aulast%3DTorre%26aufirst%3DL.%2BA.%26aulast%3DBray%26aufirst%3DF.%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DFerlay%26aufirst%3DJ.%26aulast%3DLortet-Tieulent%26aufirst%3DJ.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DGlobal%2520Cancer%2520Statistics%252C%25202012%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2015%26volume%3D65%26spage%3D87%26epage%3D108%26doi%3D10.3322%2Fcaac.21262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y.</span></span> <span> </span><span class="NLM_article-title">Rapidly Cell-Penetrating and Reductive Milieu-Responsive Nanoaggregates Assembled from an Amphiphilic Folate-camptothecin Prodrug for Enhanced Drug Delivery and Controlled Release</span>. <i>Biomater. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">454</span>, <span class="refDoi"> DOI: 10.1039/c6bm00800c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1039%2FC6BM00800C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=28058423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvVWiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=444-454&author=Z.+Xuauthor=M.+Houauthor=X.+Shiauthor=Y.-E.+Gaoauthor=P.+Xueauthor=S.+Liuauthor=Y.+Kang&title=Rapidly+Cell-Penetrating+and+Reductive+Milieu-Responsive+Nanoaggregates+Assembled+from+an+Amphiphilic+Folate-camptothecin+Prodrug+for+Enhanced+Drug+Delivery+and+Controlled+Release&doi=10.1039%2Fc6bm00800c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Rapidly cell-penetrating and reductive milieu-responsive nanoaggregates assembled from an amphiphilic folate-camptothecin prodrug for enhanced drug delivery and controlled release</span></div><div class="casAuthors">Xu, Zhigang; Hou, Meili; Shi, Xiaoxiao; Gao, Yong-E.; Xue, Peng; Liu, Shiying; Kang, Yuejun</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">444-454</span>CODEN:
                <span class="NLM_cas:coden">BSICCH</span>;
        ISSN:<span class="NLM_cas:issn">2047-4849</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Accurate diagnosis and treatment based on small mol. prodrugs can enhance drug efficiency and reduce side-effects during cancer therapy.  Herein, we report the prepn. of a type of glutathione (GSH)-responsive small prodrug delivery system based on targeting folic acid (FA) and conjugating with the hydrophobic antitumor drug camptothecin (CPT) via disulfide bonds.  The obtained prodrug is capable of high and precise drug loading (36.8 wt%) and can self-assemble into nanoaggregates with an av. size of 46.4 nm in an aq. soln.  The GSH-triggered release of CPT can reach a max. of 82% under 10 mM GSH in 60 h, which is dramatically higher than 12% of CPT released in a physiol. environment.  More interestingly, the resulting prodrug can also work as a "switchable" fluorescence probe, which exhibits fluorescence changes in response to GSH stimulus or FA receptors on the membranes of tumor cells.  Specifically, the fluorescence of the prodrug is quenched in the physiol. environments, whereas strong fluorescence is activated in the tumoral microenvironment expressing high levels of GSH or when the FA terminal is conjugated with the receptors on the membranes of tumor cells.  Furthermore, the FA-CPT prodrug shows a superior specificity and higher cytotoxicity for FA receptor-pos. KB tumor cells as compared to those of FA receptor-neg. A549 tumor cells.  Therefore, we believe that this FA-CPT prodrug can be used for the recognition and diagnosis of tumor cells and it also provides a promising modality towards an effective cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkahxTHDZNN7Vg90H21EOLACvtfcHk0ljjw1JCAXMmuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvVWiuw%253D%253D&md5=c511be918116ad8305d26c0591c2bea2</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1039%2FC6BM00800C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6BM00800C%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DHou%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DY.-E.%26aulast%3DXue%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DKang%26aufirst%3DY.%26atitle%3DRapidly%2520Cell-Penetrating%2520and%2520Reductive%2520Milieu-Responsive%2520Nanoaggregates%2520Assembled%2520from%2520an%2520Amphiphilic%2520Folate-camptothecin%2520Prodrug%2520for%2520Enhanced%2520Drug%2520Delivery%2520and%2520Controlled%2520Release%26jtitle%3DBiomater.%2520Sci.%26date%3D2017%26volume%3D5%26spage%3D444%26epage%3D454%26doi%3D10.1039%2Fc6bm00800c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Denzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Della Valle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apollonio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mir, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liberti, M.</span></span> <span> </span><span class="NLM_article-title">Exploring the Applicability of Nano-Poration for Remote Control in Smart Drug Delivery Systems</span>. <i>J. Membr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>250</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1007/s00232-016-9922-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1007%2Fs00232-016-9922-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=27561639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVSlt77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=250&publication_year=2017&pages=31-40&author=A.+Denziauthor=E.+Della+Valleauthor=F.+Apollonioauthor=M.+Bretonauthor=L.+M.+Mirauthor=M.+Liberti&title=Exploring+the+Applicability+of+Nano-Poration+for+Remote+Control+in+Smart+Drug+Delivery+Systems&doi=10.1007%2Fs00232-016-9922-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring the Applicability of Nano-Poration for Remote Control in Smart Drug Delivery Systems</span></div><div class="casAuthors">Denzi, Agnese; della Valle, Elena; Apollonio, Francesca; Breton, Marie; Mir, Lluis M.; Liberti, Micaela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Membrane Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">250</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-40</span>CODEN:
                <span class="NLM_cas:coden">JMBBBO</span>;
        ISSN:<span class="NLM_cas:issn">0022-2631</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Smart drug delivery systems represent an interesting tool to significantly improve the efficiency and the precision in the treatment of a broad category of diseases.  In this context, a drug delivery mediated by nanosecond pulsed elec. fields seems a promising technique, allowing for a controlled release and uptake of drugs by the synergy between the electropulsation and nanocarriers with encapsulated drugs.  The main concern about the use of electroporation for drug delivery applications is the difference in dimension between the liposome (nanometer range) and the cell (micrometer range).  The choice of liposome dimension is not trivial.  Liposomes larger than 500 nm of diam. could be recognized as pathogen agents by the immune system, while liposomes of smaller size would require external elec. field of high amplitudes for the membrane electroporation that could compromise the cell viability.  The aim of this work is to theor. study the possibility of a simultaneous cell and liposomes electroporation.  The numerical simulations reported the possibility to electroporate the cell and a significant percentage of liposomes with comparable values of external elec. field, when a 12 nsPEF is used.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5DffbnF5rkbVg90H21EOLACvtfcHk0ljjw1JCAXMmuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVSlt77M&md5=3b2b99a670c27df7d681436c91c2322c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2Fs00232-016-9922-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00232-016-9922-1%26sid%3Dliteratum%253Aachs%26aulast%3DDenzi%26aufirst%3DA.%26aulast%3DDella%2BValle%26aufirst%3DE.%26aulast%3DApollonio%26aufirst%3DF.%26aulast%3DBreton%26aufirst%3DM.%26aulast%3DMir%26aufirst%3DL.%2BM.%26aulast%3DLiberti%26aufirst%3DM.%26atitle%3DExploring%2520the%2520Applicability%2520of%2520Nano-Poration%2520for%2520Remote%2520Control%2520in%2520Smart%2520Drug%2520Delivery%2520Systems%26jtitle%3DJ.%2520Membr.%2520Biol.%26date%3D2017%26volume%3D250%26spage%3D31%26epage%3D40%26doi%3D10.1007%2Fs00232-016-9922-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span> <span> </span><span class="NLM_article-title">Redox-Responsive Dual Chemophotothermal Therapeutic Nanomedicine for Imaging-Guided Combinational Therapy</span>. <i>J. Mater. Chem. B</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">5362</span>– <span class="NLM_lpage">5367</span>, <span class="refDoi"> DOI: 10.1039/c8tb01360h</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1039%2FC8TB01360H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=30931124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOjt7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=5362-5367&author=F.+Yuauthor=F.+Zhangauthor=L.+Tangauthor=J.+Maauthor=D.+Lingauthor=X.+Chenauthor=X.+Sun&title=Redox-Responsive+Dual+Chemophotothermal+Therapeutic+Nanomedicine+for+Imaging-Guided+Combinational+Therapy&doi=10.1039%2Fc8tb01360h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Redox-responsive dual chemophotothermal therapeutic nanomedicine for imaging-guided combinational therapy</span></div><div class="casAuthors">Yu, Fei; Zhang, Fuwu; Tang, Longguang; Ma, Jingwen; Ling, Daishun; Chen, Xiaoyuan; Sun, Xiaolian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Materials Chemistry B: Materials for Biology and Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">5362-5367</span>CODEN:
                <span class="NLM_cas:coden">JMCBDV</span>;
        ISSN:<span class="NLM_cas:issn">2050-7518</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Chemotherapy is currently the major therapeutic method against cancer.  However, chemo drugs are usually lacking in specificity towards cancer cells over normal cells.  In this study, we prepd. a novel multifunctional trimeric prodrug by linking the chemo drug camptothecin (CPT) and the exceptionally photostable near IR (NIR) croconaine dye (CR) via a glutathione (GSH)-sensitive disulfide linker.  Compared with CPT, our novel trimeric CR-(SS-CPT)2 is more hydrophobic and bulky, making it highly efficient to be encapsulated into biocompatible polymeric nanocarriers.  The prodrug underwent rapid drug release specifically in cancer cells with high GSH concn.  The hyperthermia produced by CR upon laser irradn. could further accelerate the break of disulfide bonds, which makes the release of CPT even more controllable.  We further loaded CR-(SS-CPT)2 into folate modified lipid-polymer nanoparticles, which demonstrated high in vivo tumor accumulation and retention.  The biodistribution of these nanoparticles can be directly monitored in real time via NIR fluorescence and photoacoustic imaging.  Under imaging guided chemo- and photothermal-synergistic therapy, the tumors were completely ablated with no recurrence.  The design not only highly enhanced the therapeutic specificity and efficiency of CPT, but also provided an "all in one" nanomedicine for imaging-guided dual modality therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoSTWH9LOdL7Vg90H21EOLACvtfcHk0li6w_pShvCicg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOjt7vO&md5=a1b2972d6ea4d041f15d200141be674d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1039%2FC8TB01360H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8TB01360H%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLing%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DX.%26atitle%3DRedox-Responsive%2520Dual%2520Chemophotothermal%2520Therapeutic%2520Nanomedicine%2520for%2520Imaging-Guided%2520Combinational%2520Therapy%26jtitle%3DJ.%2520Mater.%2520Chem.%2520B%26date%3D2018%26volume%3D6%26spage%3D5362%26epage%3D5367%26doi%3D10.1039%2Fc8tb01360h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whang, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jo, S.</span></span> <span> </span><span class="NLM_article-title">A Highly GSH-sensitive SN-38 Prodrug with an “OFF-to-ON” Fluorescence Switch as a Bifunctional Anticancer Agent</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">9031</span>– <span class="NLM_lpage">9034</span>, <span class="refDoi"> DOI: 10.1039/c8cc05010d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1039%2FC8CC05010D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=30047958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlGiu7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2018&pages=9031-9034&author=C.-H.+Whangauthor=E.+Yooauthor=S.+K.+Hurauthor=K.+S.+Kimauthor=D.+Kimauthor=S.+Jo&title=A+Highly+GSH-sensitive+SN-38+Prodrug+with+an+%E2%80%9COFF-to-ON%E2%80%9D+Fluorescence+Switch+as+a+Bifunctional+Anticancer+Agent&doi=10.1039%2Fc8cc05010d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">A highly GSH-sensitive SN-38 prodrug with an "OFF-to-ON" fluorescence switch as a bifunctional anticancer agent</span></div><div class="casAuthors">Whang, Chang-Hee; Yoo, Eunsoo; Hur, Seong Kwon; Kim, Kyeong Soo; Kim, Dongin; Jo, Seongbong</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">65</span>),
    <span class="NLM_cas:pages">9031-9034</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">SN-38 (7-ethyl-10-hydroxy-camptothecin) is an active metabolite of irinotecan (CPT-11) and the most potent camptothecin analog.  In this study, 2,4-dinitrobenzene sulfonyl (DNS) was covalently conjugated as a GSH-sensitive trigger to 10' -OH of SN-38 to yield a GSH-sensitive prodrug, denoted as DNS-SN38, with virtually quenched fluorescence due to donor-excited photo-induced electron transfer (d-PeT).  By investigating DNS-SN38's activation properties upon fluorescence restoration and cytotoxic potency against ovarian cancer cell lines (A2780 and m-Cherry + OCSC1-F2), its potential applicability as a useful chemotherapeutic agent was demonstrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJEqIaTMFOTLVg90H21EOLACvtfcHk0li6w_pShvCicg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlGiu7zF&md5=186c1018a8542a9cd36e81c3d08372a8</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1039%2FC8CC05010D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8CC05010D%26sid%3Dliteratum%253Aachs%26aulast%3DWhang%26aufirst%3DC.-H.%26aulast%3DYoo%26aufirst%3DE.%26aulast%3DHur%26aufirst%3DS.%2BK.%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DKim%26aufirst%3DD.%26aulast%3DJo%26aufirst%3DS.%26atitle%3DA%2520Highly%2520GSH-sensitive%2520SN-38%2520Prodrug%2520with%2520an%2520%25E2%2580%259COFF-to-ON%25E2%2580%259D%2520Fluorescence%2520Switch%2520as%2520a%2520Bifunctional%2520Anticancer%2520Agent%26jtitle%3DChem.%2520Commun.%26date%3D2018%26volume%3D54%26spage%3D9031%26epage%3D9034%26doi%3D10.1039%2Fc8cc05010d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanizawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimori, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">Comparison of Topoisomerase I Inhibition, DNA Damage, and Cytotoxicity of Camptothecin Derivatives Presently in Clinical Trials</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">836</span>– <span class="NLM_lpage">842</span>, <span class="refDoi"> DOI: 10.1093/jnci/86.11.836</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1093%2Fjnci%2F86.11.836" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=8182764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADyaK2cXlvFGiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=1994&pages=836-842&author=A.+Tanizawaauthor=A.+Fujimoriauthor=Y.+Fujimoriauthor=Y.+Pommier&title=Comparison+of+Topoisomerase+I+Inhibition%2C+DNA+Damage%2C+and+Cytotoxicity+of+Camptothecin+Derivatives+Presently+in+Clinical+Trials&doi=10.1093%2Fjnci%2F86.11.836"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials</span></div><div class="casAuthors">Tanizawa, Akihiko; Fujimori, Akira; Fujimori, Yuko; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">836-42</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    </div><div class="casAbstract">Camptothecins (CPTs) belong to a group of anticancer agents with a unique mechanism of action: poisoning of eukaryotic DNA topoisomerase I.  Two camptothecin derivs., topotecan (TPT) and CPT-11, are in clin. trials and their chemotherapeutic efficacy appears promising.  Our aim was to compare simultaneously the mol. and cellular pharmacol. of the various camptothecin derivs. that are presently in clin. trials.  Cytotoxicity of drugs toward human colon carcinoma was detd. by colony-forming assays.  DNA single-strand breaks (SSB) were measured by alk. elution.  Drug potency to induce topoisomerase 1-mediated DNA cleavage and the sequence selectivity of the breaks were detd. by sequencing gel autoradiog.  SN-38 and CPT were more cytotoxic than 9-aminocamptothecin (9-AC) and TPT, and CPT-11 was almost inactive toward HT-29 cells.  IC50 values were 8.8 nM for SN-38, 10 nM for CPT, 19 nM for 9-AC, 33 nM for TPT, and greater than 100 nM for CPT-11.  In drug-induced DNA damage measured by alk. elution drug concns. producing 1000-rad-equiv. (C1000), values were 0.037 μM for SN-38, 0.051 μM for CPT, 0.085 μM for 9-AC, 0.28 μM for TPT, and greater than 1 μM for CPT-11.  SN-38 remained the most potent compd. in isolated nuclei, and CPT-11 was still inactive.  The potency ranking was the same as in whole cells, and the C1000 values were 0.0025 μM for SN-38, 0.012 μM for CPT, 0.021 μM for 9-AC, 0.44 μM for TPT, and greater than 0.1 μM for CPT-11.  Potency difference between SN-38 and the other compds. was greater in isolated nuclei than in whole cells.  Kinetics of the reversal of drug-induced SSB in isolated nuclei suggest that dissocn. of SN-38 from cleavable complexes is much slower than that of CPT.  Cleavage patterns of CPT and 9-AC were similar but differed from those of TPT and SN-38.  Although in vitro analyses do not necessarily reflect chemotherapeutic efficacy, this study found that SN-38 is the most potent compd. and that 9-AC and TPT are less active than CPT in this system.  The effect of CPT-11 is minimal.  Therefore, the clin. activity of CPT-11 may strongly depend on its hydrolysis to SN-38.  Differences in DNA sequence selectivity and the stability of cleavable complexes induced by the drugs may also contribute to differences among CPT derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_v-LigezeSrVg90H21EOLACvtfcHk0li6w_pShvCicg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlvFGiu74%253D&md5=2248f154bab19a06c7365d11120530d8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F86.11.836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F86.11.836%26sid%3Dliteratum%253Aachs%26aulast%3DTanizawa%26aufirst%3DA.%26aulast%3DFujimori%26aufirst%3DA.%26aulast%3DFujimori%26aufirst%3DY.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DComparison%2520of%2520Topoisomerase%2520I%2520Inhibition%252C%2520DNA%2520Damage%252C%2520and%2520Cytotoxicity%2520of%2520Camptothecin%2520Derivatives%2520Presently%2520in%2520Clinical%2520Trials%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D1994%26volume%3D86%26spage%3D836%26epage%3D842%26doi%3D10.1093%2Fjnci%2F86.11.836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span> <span> </span><span class="NLM_article-title">PEGylation of Lipophilic SN38 Prodrug with DSPE-mPEG2000 Versus Cremophor EL: Comparative Study for Intravenous Chemotherapy</span>. <i>Drug Delivery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.1080/10717544.2019.1587045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1080%2F10717544.2019.1587045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=30909751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvVWqt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=354-362&author=J.+Zengauthor=C.+Liauthor=X.+Duanauthor=F.+Liuauthor=A.+Liauthor=C.+Luoauthor=L.+Jiaauthor=Y.+Ganauthor=L.+Yanauthor=Y.+Zheng&title=PEGylation+of+Lipophilic+SN38+Prodrug+with+DSPE-mPEG2000+Versus+Cremophor+EL%3A+Comparative+Study+for+Intravenous+Chemotherapy&doi=10.1080%2F10717544.2019.1587045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">PEGylation of lipophilic SN38 prodrug with DSPE-mPEG2000 versus cremophor EL: comparative study for intravenous chemotherapy</span></div><div class="casAuthors">Zeng, Jun; Li, Chen; Duan, Xing; Liu, Fuyue; Li, Anqin; Luo, Chunhan; Jia, Li; Gan, Yifang; Yan, Lu; Zheng, Yaxin</div><div class="citationInfo"><span class="NLM_cas:title">Drug Delivery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">354-362</span>CODEN:
                <span class="NLM_cas:coden">DDELEB</span>;
        ISSN:<span class="NLM_cas:issn">1071-7544</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The lipophilic prodrug of hydrophobic drugs with well-designed mol. structures can form stable pure prodrug nanoparticles (NPs), but rapid NPs aggregation in plasma greatly restricted their direct use for i.v. chemotherapy.  To address this, DSPE-mPEG2000 and Cremophor EL are two of the most widely used lipophilic PEG derivs. to enhance their colloidal stability in plasma.  However, their drug delivery performances have never been comparatively studied.  Here, a redox-responsive lipophilic prodrug of SN38 was chosen as the model drug for such comparative investigations.  We found that Cremophor EL/NPs having a small diam. (∼15 nm) and poor kinetic stability displayed an enhanced cell internalization, higher cytotoxicity and prolonged circulation time as compared with DSPE-mPEG2000/NPs.  Most importantly, these superiorities further resulted in a much more potent antitumor activity in CT26 colorectal cancer xenograft, but the increased loss of body wt. was also noted.  These results suggested that Cremophor EL could be more advantageous than DSPE-mPEG2000 in terms of the improvement of antitumor activity, but the enhanced toxicity warranted further attention in the future study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnjqE3kIgZcLVg90H21EOLACvtfcHk0lhH7-kO3bqa2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvVWqt7w%253D&md5=d4598f8afc5faf19cd151437f98ce67c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1080%2F10717544.2019.1587045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10717544.2019.1587045%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DDuan%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DGan%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DY.%26atitle%3DPEGylation%2520of%2520Lipophilic%2520SN38%2520Prodrug%2520with%2520DSPE-mPEG2000%2520Versus%2520Cremophor%2520EL%253A%2520Comparative%2520Study%2520for%2520Intravenous%2520Chemotherapy%26jtitle%3DDrug%2520Delivery%26date%3D2019%26volume%3D26%26spage%3D354%26epage%3D362%26doi%3D10.1080%2F10717544.2019.1587045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proia, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequeira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acquaviva, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khazak, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astsaturov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatsuta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimmanamada, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ying, W.</span></span> <span> </span><span class="NLM_article-title">HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2422</span>– <span class="NLM_lpage">2432</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-15-0455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1158%2F1535-7163.MCT-15-0455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=26271675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslOgt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=2422-2432&author=D.+A.+Proiaauthor=D.+L.+Smithauthor=J.+Zhangauthor=J.-P.+Jimenezauthor=J.+Sangauthor=L.+S.+Ogawaauthor=M.+Sequeiraauthor=J.+Acquavivaauthor=S.+Heauthor=C.+Zhangauthor=V.+Khazakauthor=I.+Astsaturovauthor=T.+Inoueauthor=N.+Tatsutaauthor=S.+Osmanauthor=R.+C.+Batesauthor=D.+Chimmanamadaauthor=W.+Ying&title=HSP90+Inhibitor-SN-38+Conjugate+Strategy+for+Targeted+Delivery+of+Topoisomerase+I+Inhibitor+to+Tumors&doi=10.1158%2F1535-7163.mct-15-0455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors</span></div><div class="casAuthors">Proia, David A.; Smith, Donald L.; Zhang, Junyi; Jimenez, John-Paul; Sang, Jim; Ogawa, Luisa Shin; Sequeira, Manuel; Acquaviva, Jaime; He, Suqin; Zhang, Chaohua; Khazak, Vladimir; Astsaturov, Igor; Inoue, Takayo; Tatsuta, Noriaki; Osman, Sami; Bates, Richard C.; Chimmanamada, Dinesh; Ying, Weiwen</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2422-2432</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The clin. benefits of chemotherapy are commonly offset by insufficient drug exposures, narrow safety margins, and/or systemic toxicities.  Over recent decades, a no. of conjugate-based targeting approaches designed to overcome these limitations have been explored.  Here, we report on an innovative strategy that utilizes HSP90 inhibitor-drug conjugates (HDC) for directed tumor targeting of chemotherapeutic agents.  STA-12-8666 is an HDC that comprises an HSP90 inhibitor fused to SN-38, the active metabolite of irinotecan.  Mechanistic analyses in vitro established that high-affinity HSP90 binding conferred by the inhibitor backbone could be exploited for conjugate accumulation within tumor cells.  In vivo modeling showed that the HSP90 inhibitor moiety was required for selective retention of STA-12-8666, and this enrichment promoted extended release of active SN-38 within the tumor compartment.  Indeed, controlled intratumoral payload release by STA-12-8666 contributed to a broad therapeutic window, sustained biomarker activity, and remarkable degree of efficacy and durability of response in multiple cell line and patient-derived xenograft models.  Overall, STA-12-8666 has been developed as a unique HDC agent that employs a distinct mechanism of targeted drug delivery to achieve potent and sustained antitumor effects.  These findings identify STA-12-8666 as a promising new candidate for evaluation as novel anticancer therapeutic.  Mol Cancer Ther; 14(11); 2422-32. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLebQAGQQV6rVg90H21EOLACvtfcHk0lhH7-kO3bqa2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslOgt7%252FM&md5=b51a2c0bcd0fdc775dd6a6ce32ae9830</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0455%26sid%3Dliteratum%253Aachs%26aulast%3DProia%26aufirst%3DD.%2BA.%26aulast%3DSmith%26aufirst%3DD.%2BL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DJimenez%26aufirst%3DJ.-P.%26aulast%3DSang%26aufirst%3DJ.%26aulast%3DOgawa%26aufirst%3DL.%2BS.%26aulast%3DSequeira%26aufirst%3DM.%26aulast%3DAcquaviva%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DKhazak%26aufirst%3DV.%26aulast%3DAstsaturov%26aufirst%3DI.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DTatsuta%26aufirst%3DN.%26aulast%3DOsman%26aufirst%3DS.%26aulast%3DBates%26aufirst%3DR.%2BC.%26aulast%3DChimmanamada%26aufirst%3DD.%26aulast%3DYing%26aufirst%3DW.%26atitle%3DHSP90%2520Inhibitor-SN-38%2520Conjugate%2520Strategy%2520for%2520Targeted%2520Delivery%2520of%2520Topoisomerase%2520I%2520Inhibitor%2520to%2520Tumors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D2422%26epage%3D2432%26doi%3D10.1158%2F1535-7163.mct-15-0455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubio, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sapra, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozanguiez, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberger, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horak, I. D.</span></span> <span> </span><span class="NLM_article-title">Novel Prodrugs of SN38 Using Multiarm Poly(ethylene glycol) Linkers</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">849</span>– <span class="NLM_lpage">859</span>, <span class="refDoi"> DOI: 10.1021/bc700333s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc700333s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjvFOltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=849-859&author=H.+Zhaoauthor=B.+Rubioauthor=P.+Sapraauthor=D.+Wuauthor=P.+Reddyauthor=P.+Saiauthor=A.+Martinezauthor=Y.+Gaoauthor=Y.+Lozanguiezauthor=C.+Longleyauthor=L.+M.+Greenbergerauthor=I.+D.+Horak&title=Novel+Prodrugs+of+SN38+Using+Multiarm+Poly%28ethylene+glycol%29+Linkers&doi=10.1021%2Fbc700333s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Prodrugs of SN38 Using Multiarm Poly(ethylene glycol) Linkers</span></div><div class="casAuthors">Zhao, Hong; Rubio, Belen; Sapra, Puja; Wu, Dechun; Reddy, Prasanna; Sai, Prakash; Martinez, Anthony; Gao, Ying; Lozanguiez, Yoany; Longley, Clifford; Greenberger, Lee M.; Horak, Ivan D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">849-859</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">CPT-11, also known as irinotecan, is a prodrug that is approved for the treatment of advanced colorectal cancer.  The active metabolite of CPT-11, SN38 (7-ethyl-10-hydroxy-camptothecin), has 100- to 1000-fold more potent cytotoxic activity in tissue cell culture compared with CPT-11.  However, parental administration of SN38 is not possible because of its inherently poor water soly.  It is reported here that a multiarm poly(ethylene glycol) (PEG) backbone linked to four SN38 mols. (PEG-SN38) has been successfully prepd. with high drug loading and significantly improved water soly. (400- to 1000-fold increase).  Three different protecting strategies have been developed in order to selectively acylate the 20-OH of SN38 to preserve its E-ring in the lactone form (the active form of SN38 with cytotoxic activities) while PEG is still attached.  One chem. process has been optimized to make a large quantity of the PEG-SN38 conjugate with a high yield that can be readily adapted for scale-up prodn.  The PEG-SN38 conjugates have shown excellent in vitro anticancer activity, with potency similar to that of native SN38, in a panel of cancer cell lines.  The PEG-SN38 conjugates also have demonstrated superior anticancer activity in the MX-1 xenograft mice model compared with CPT-11.  Among the four conjugates, PEG-Gly-(20)-SN38 (I) has been selected as the lead candidate for further preclin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo90Brw-JYmLrVg90H21EOLACvtfcHk0ljaRDdnyVsJDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjvFOltbc%253D&md5=6cc7b5208908d885f5c89868521b1ca7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fbc700333s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc700333s%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DRubio%26aufirst%3DB.%26aulast%3DSapra%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DReddy%26aufirst%3DP.%26aulast%3DSai%26aufirst%3DP.%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DLozanguiez%26aufirst%3DY.%26aulast%3DLongley%26aufirst%3DC.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DHorak%26aufirst%3DI.%2BD.%26atitle%3DNovel%2520Prodrugs%2520of%2520SN38%2520Using%2520Multiarm%2520Poly%2528ethylene%2520glycol%2529%2520Linkers%26jtitle%3DBioconjugate%2520Chem.%26date%3D2008%26volume%3D19%26spage%3D849%26epage%3D859%26doi%3D10.1021%2Fbc700333s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cardillo, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindan, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharkey, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trisal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrojo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, D. M.</span></span> <span> </span><span class="NLM_article-title">Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">919</span>– <span class="NLM_lpage">931</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.5b00223</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.5b00223" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntF2lsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=919-931&author=T.+M.+Cardilloauthor=S.+V.+Govindanauthor=R.+M.+Sharkeyauthor=P.+Trisalauthor=R.+Arrojoauthor=D.+Liuauthor=E.+A.+Rossiauthor=C.-H.+Changauthor=D.+M.+Goldenberg&title=Sacituzumab+Govitecan+%28IMMU-132%29%2C+an+Anti-Trop-2%2FSN-38+Antibody-Drug+Conjugate%3A+Characterization+and+Efficacy+in+Pancreatic%2C+Gastric%2C+and+Other+Cancers&doi=10.1021%2Facs.bioconjchem.5b00223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers</span></div><div class="casAuthors">Cardillo, Thomas M.; Govindan, Serengulam V.; Sharkey, Robert M.; Trisal, Preeti; Arrojo, Roberto; Liu, Donglin; Rossi, Edmund A.; Chang, Chien-Hsing; Goldenberg, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">919-931</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) made from a humanized anti-Trop-2 monoclonal antibody (hRS7) conjugated with the active metabolite of irinotecan, SN-38.  In addn. to its further characterization, as the clin. utility of IMMU-132 expands to an ever-widening range of Trop-2-expressing solid tumor types, its efficacy in new disease models needs to be explored in a nonclin. setting.  Unlike most ADCs that use ultratoxic drugs and stable linkers, IMMU-132 uses a moderately toxic drug with a moderately stable carbonate bond between SN-38 and the linker.  Flow cytometry and immunohistochem. disclosed that Trop-2 is expressed in a wide range of tumor types, including gastric, pancreatic, triple-neg. breast (TNBC), colonic, prostate, and lung.  While cell-binding expts. reveal no significant differences between IMMU-132 and parental hRS7 antibody, surface plasmon resonance anal. using a Trop-2 CM5 chip shows a significant binding advantage for IMMU-132 over hRS7.  The conjugate retained binding to the neonatal receptor, but it lost greater than 60% of the antibody-dependent cell-mediated cytotoxicity activity compared to that of hRS7.  Exposure of tumor cells to either free SN-38 or IMMU-132 demonstrated the same signaling pathways, with pJNK1/2 and p21WAF1/Cip1 upregulation followed by cleavage of caspases 9, 7, and 3, ultimately leading to poly-ADP-ribose polymerase cleavage and double-stranded DNA breaks.  Pharmacokinetics of the intact ADC in mice reveals a mean residence time (MRT) of 15.4 h, while the carrier hRS7 antibody cleared at a similar rate as that of the unconjugated antibody (MRT ∼ 300 h).  IMMU-132 treatment of mice bearing human gastric cancer xenografts (17.5 mg/kg; twice weekly × 4 wk) resulted in significant antitumor effects compared to that of mice treated with a nonspecific control.  Clin. relevant dosing schemes of IMMU-132 administered either every other week, weekly, or twice weekly in mice bearing human pancreatic or gastric cancer xenografts demonstrate similar, significant antitumor effects in both models.  Current Phase I/II clin. trials (ClinicalTrials.gov, NCT01631552) confirm anticancer activity of IMMU-132 in cancers expressing Trop-2, including gastric and pancreatic cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3wWMahyB2oLVg90H21EOLACvtfcHk0ljaRDdnyVsJDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntF2lsbg%253D&md5=30c0b123cd3e392e53c8eaf50f31aa7e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.5b00223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.5b00223%26sid%3Dliteratum%253Aachs%26aulast%3DCardillo%26aufirst%3DT.%2BM.%26aulast%3DGovindan%26aufirst%3DS.%2BV.%26aulast%3DSharkey%26aufirst%3DR.%2BM.%26aulast%3DTrisal%26aufirst%3DP.%26aulast%3DArrojo%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DRossi%26aufirst%3DE.%2BA.%26aulast%3DChang%26aufirst%3DC.-H.%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26atitle%3DSacituzumab%2520Govitecan%2520%2528IMMU-132%2529%252C%2520an%2520Anti-Trop-2%252FSN-38%2520Antibody-Drug%2520Conjugate%253A%2520Characterization%2520and%2520Efficacy%2520in%2520Pancreatic%252C%2520Gastric%252C%2520and%2520Other%2520Cancers%26jtitle%3DBioconjugate%2520Chem.%26date%3D2015%26volume%3D26%26spage%3D919%26epage%3D931%26doi%3D10.1021%2Facs.bioconjchem.5b00223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lock, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span> <span> </span><span class="NLM_article-title">The Role of Micelle Size in Tumor Accumulation, Penetration, and Treatment</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">7195</span>– <span class="NLM_lpage">7206</span>, <span class="refDoi"> DOI: 10.1021/acsnano.5b02017</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsnano.5b02017" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFWqtLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=7195-7206&author=J.+Wangauthor=W.+Maoauthor=L.+L.+Lockauthor=J.+Tangauthor=M.+Suiauthor=W.+Sunauthor=H.+Cuiauthor=D.+Xuauthor=Y.+Shen&title=The+Role+of+Micelle+Size+in+Tumor+Accumulation%2C+Penetration%2C+and+Treatment&doi=10.1021%2Facsnano.5b02017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Micelle Size in Tumor Accumulation, Penetration, and Treatment</span></div><div class="casAuthors">Wang, Jinqiang; Mao, Weiwei; Lock, Lye Lin; Tang, Jianbin; Sui, Meihua; Sun, Weilin; Cui, Honggang; Xu, Dong; Shen, Youqing</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">7195-7206</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The specific sizes that det. optimal nanoparticle tumor accumulation, penetration, and treatment remain inconclusive because many studies compared nanoparticles with multiple physicochem. variables (e.g., chem. structures, shapes, and other phys. properties) in addn. to the size.  In this study, we synthesized amphiphilic block copolymers of 7-ethyl-10-hydroxylcamptothecin (SN38) prodrug and fabricated micelles with sizes ranging from 20 to 300 nm from a single copolymer.  The as-prepd. micelles had exactly the same chem. structures and similar phys. properties except for size, which provided an ideal platform for a systematic investigation of the size effects in cancer drug delivery.  We found that the micelle's blood circulation time and tumor accumulation increased with the increase in their diams., with optimal diam. range of 100 to 160 nm.  However, the much higher tumor accumulation of the large micelles (100 nm) did not result in significantly improved therapeutic efficacy, because the large micelles had poorer tumor penetration than the small ones (30 nm).  An optimal size that balances drug accumulation and penetration in tumors is crit. for improving the therapeutic efficacy of nanoparticulate drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMSw6MW2XoQrVg90H21EOLACvtfcHk0ljWPcbd6CYkIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFWqtLnE&md5=c647c3258f683f45bbcf8278d5f2f39c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facsnano.5b02017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsnano.5b02017%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMao%26aufirst%3DW.%26aulast%3DLock%26aufirst%3DL.%2BL.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DSui%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DCui%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DShen%26aufirst%3DY.%26atitle%3DThe%2520Role%2520of%2520Micelle%2520Size%2520in%2520Tumor%2520Accumulation%252C%2520Penetration%252C%2520and%2520Treatment%26jtitle%3DACS%2520Nano%26date%3D2015%26volume%3D9%26spage%3D7195%26epage%3D7206%26doi%3D10.1021%2Facsnano.5b02017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasarao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, P. S.</span></span> <span> </span><span class="NLM_article-title">Ligand-Targeted Drug Delivery</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">12133</span>– <span class="NLM_lpage">12164</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.7b00013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.7b00013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKksLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2017&pages=12133-12164&author=M.+Srinivasaraoauthor=P.+S.+Low&title=Ligand-Targeted+Drug+Delivery&doi=10.1021%2Facs.chemrev.7b00013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand-Targeted Drug Delivery</span></div><div class="casAuthors">Srinivasarao, Madduri; Low, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">12133-12164</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Safety and efficacy constitute the major criteria governing regulatory approval of any new drug.  The best method to maximize safety and efficacy is to deliver a proven therapeutic agent with a targeting ligand that exhibits little affinity for healthy cells but high affinity for pathol. cells.  The probability of regulatory approval can conceivably be further enhanced by exploiting the same targeting ligand, conjugated to an imaging agent, to select patients whose diseased tissues display sufficient targeted receptors for therapeutic efficacy.  The focus of this Review is to summarize criteria that must be met during design of ligand-targeted drugs (LTDs) to achieve the required therapeutic potency with minimal toxicity.  Because most LTDs are composed of a targeting ligand (e.g., org. mol., aptamer, protein scaffold, or antibody), spacer, cleavable linker, and therapeutic warhead, criteria for successful design of each component will be described.  Moreover, because obstacles to successful drug design can differ among human pathologies, limitations to drug delivery imposed by the unique characteristics of different diseases will be considered.  With the explosion of genomic and transcriptomic data providing an ever-expanding selection of disease-specific targets, and with tools for high-throughput chem. offering an escalating diversity of warheads, opportunities for innovating safe and effective LTDs has never been greater.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAbg140AL2mLVg90H21EOLACvtfcHk0ljWPcbd6CYkIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKksLnE&md5=d0c909cfbc04e18fa3b0de35b3ebde60</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.7b00013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.7b00013%26sid%3Dliteratum%253Aachs%26aulast%3DSrinivasarao%26aufirst%3DM.%26aulast%3DLow%26aufirst%3DP.%2BS.%26atitle%3DLigand-Targeted%2520Drug%2520Delivery%26jtitle%3DChem.%2520Rev.%26date%3D2017%26volume%3D117%26spage%3D12133%26epage%3D12164%26doi%3D10.1021%2Facs.chemrev.7b00013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poon, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flagella, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tibbitts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saad, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girish, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dybdal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, T.</span></span> <span> </span><span class="NLM_article-title">Preclinical Safety Profile of Trastuzumab Emtansine (T-DM1): Mechanism of Action of its Cytotoxic Component Retained with Improved Tolerability</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>273</i></span>,  <span class="NLM_fpage">298</span>– <span class="NLM_lpage">313</span>, <span class="refDoi"> DOI: 10.1016/j.taap.2013.09.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1016%2Fj.taap.2013.09.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=24035823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslGlsbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=2013&pages=298-313&author=K.+A.+Poonauthor=K.+Flagellaauthor=J.+Beyerauthor=J.+Tibbittsauthor=S.+Kaurauthor=O.+Saadauthor=J.-H.+Yiauthor=S.+Girishauthor=N.+Dybdalauthor=T.+Reynolds&title=Preclinical+Safety+Profile+of+Trastuzumab+Emtansine+%28T-DM1%29%3A+Mechanism+of+Action+of+its+Cytotoxic+Component+Retained+with+Improved+Tolerability&doi=10.1016%2Fj.taap.2013.09.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability</span></div><div class="casAuthors">Poon, Kirsten Achilles; Flagella, Kelly; Beyer, Joseph; Tibbitts, Jay; Kaur, Surinder; Saad, Ola; Yi, Joo-Hee; Girish, Sandhya; Dybdal, Noel; Reynolds, Theresa</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">298-313</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Trastuzumab emtansine (T-DM1) is the first antibody-drug conjugate (ADC) approved for patients with human epidermal growth factor receptor 2 (HER2)-pos. metastatic breast cancer.  The therapeutic premise of ADCs is based on the hypothesis that targeted delivery of potent cytotoxic drugs to tumors will provide better tolerability and efficacy compared with non-targeted delivery, where poor tolerability can limit efficacious doses.  Here, we present results from preclin. studies characterizing the toxicity profile of T-DM1, including limited assessment of unconjugated DM1.  T-DM1 binds primate ErbB2 and human HER2 but not the rodent homolog c-neu.  Therefore, antigen-dependent and non-antigen-dependent toxicity was evaluated in monkeys and rats, resp., in both single- and repeat-dose studies; toxicity of DM1 was assessed in rats only.  T-DM1 was well tolerated at doses up to 40 mg/kg (~ 4400 μg DM1/m2) and 30 mg/kg (~ 6000 μg DM1/m2) in rats and monkeys, resp.  In contrast, DM1 was only tolerated up to 0.2 mg/kg (1600 μg DM1/m2).  This suggests that at least two-fold higher doses of the cytotoxic agent are tolerated in T-DM1, supporting the premise of ADCs to improve the therapeutic index.  In addn., T-DM1 and DM1 safety profiles were similar and consistent with the mechanism of action of DM1 (i.e., microtubule disruption).  Findings included hepatic, bone marrow/hematol. (primarily platelet), lymphoid organ, and neuronal toxicities, and increased nos. of cells of epithelial and phagocytic origin in metaphase arrest.  These adverse effects did not worsen with chronic dosing in monkeys and are consistent with those reported in T-DM1-treated patients to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp36u8JDO92mbVg90H21EOLACvtfcHk0ljWPcbd6CYkIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslGlsbbO&md5=f2ae6f6fc865d8ad027752e1301be3cc</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2013.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2013.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DPoon%26aufirst%3DK.%2BA.%26aulast%3DFlagella%26aufirst%3DK.%26aulast%3DBeyer%26aufirst%3DJ.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DKaur%26aufirst%3DS.%26aulast%3DSaad%26aufirst%3DO.%26aulast%3DYi%26aufirst%3DJ.-H.%26aulast%3DGirish%26aufirst%3DS.%26aulast%3DDybdal%26aufirst%3DN.%26aulast%3DReynolds%26aufirst%3DT.%26atitle%3DPreclinical%2520Safety%2520Profile%2520of%2520Trastuzumab%2520Emtansine%2520%2528T-DM1%2529%253A%2520Mechanism%2520of%2520Action%2520of%2520its%2520Cytotoxic%2520Component%2520Retained%2520with%2520Improved%2520Tolerability%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2013%26volume%3D273%26spage%3D298%26epage%3D313%26doi%3D10.1016%2Fj.taap.2013.09.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goetsch, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumontet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corvaïa, N.</span></span> <span> </span><span class="NLM_article-title">Strategies and Challenges for the Next Generation of Antibody-drug Conjugates</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.268</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1038%2Fnrd.2016.268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=28303026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1Onsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=315-337&author=A.+Beckauthor=L.+Goetschauthor=C.+Dumontetauthor=N.+Corva%C3%AFa&title=Strategies+and+Challenges+for+the+Next+Generation+of+Antibody-drug+Conjugates&doi=10.1038%2Fnrd.2016.268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies and challenges for the next generation of antibody-drug conjugates</span></div><div class="casAuthors">Beck, Alain; Goetsch, Liliane; Dumontet, Charles; Corvaia, Nathalie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">315-337</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Antibody-drug conjugates (ADCs) are one of the fastest growing classes of oncol. therapeutics.  After half a century of research, the approvals of brentuximab vedotin (in 2011) and trastuzumab emtansine (in 2013) have paved the way for ongoing clin. trials that are evaluating more than 60 further ADC candidates.  The limited success of first-generation ADCs (developed in the early 2000s) informed strategies to bring second-generation ADCs to the market, which have higher levels of cytotoxic drug conjugation, lower levels of naked antibodies and more-stable linkers between the drug and the antibody.  Furthermore, lessons learned during the past decade are now being used in the development of third-generation ADCs.  In this Review, we discuss strategies to select the best target antigens as well as suitable cytotoxic drugs; the design of optimized linkers; the discovery of bioorthogonal conjugation chemistries; and toxicity issues.  The selection and engineering of antibodies for site-specific drug conjugation, which will result in higher homogeneity and increased stability, as well as the quest for new conjugation chemistries and mechanisms of action, are priorities in ADC research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP7lV63Ws8rbVg90H21EOLACvtfcHk0ljY8RwY_NBB7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1Onsbc%253D&md5=7358b6080dd1aed1d21e98c078cd9ef1</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.268%26sid%3Dliteratum%253Aachs%26aulast%3DBeck%26aufirst%3DA.%26aulast%3DGoetsch%26aufirst%3DL.%26aulast%3DDumontet%26aufirst%3DC.%26aulast%3DCorva%25C3%25AFa%26aufirst%3DN.%26atitle%3DStrategies%2520and%2520Challenges%2520for%2520the%2520Next%2520Generation%2520of%2520Antibody-drug%2520Conjugates%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D315%26epage%3D337%26doi%3D10.1038%2Fnrd.2016.268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span> <span> </span><span class="NLM_article-title">A Tumor-Targeted Ganetespib-Zinc Phthalocyanine Conjugate for Synergistic Chemo-photodynamic Therapy</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">294</span>– <span class="NLM_lpage">303</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1016%2Fj.ejmech.2018.03.077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=29627724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1ejsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=294-303&author=L.+Huangauthor=G.+Weiauthor=X.+Sunauthor=Y.+Jiangauthor=Z.+Huangauthor=Y.+Huangauthor=Y.+Shenauthor=X.+Xuauthor=Y.+Liaoauthor=C.+Zhao&title=A+Tumor-Targeted+Ganetespib-Zinc+Phthalocyanine+Conjugate+for+Synergistic+Chemo-photodynamic+Therapy&doi=10.1016%2Fj.ejmech.2018.03.077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">A tumor-targeted Ganetespib-zinc phthalocyanine conjugate for synergistic chemo-photodynamic therapy</span></div><div class="casAuthors">Huang, Liangfeng; Wei, Gaofei; Sun, Xiaoqi; Jiang, Yali; Huang, Zeqian; Huang, Yanjuan; Shen, Yifeng; Xu, Xiaoyu; Liao, Yunhui; Zhao, Chunshun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">294-303</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Therapeutic effects of photodynamic therapy (PDT) are limited by the selectivity of photosensitizer (PS).  Herein, a novel tumor-targeted drug-PS conjugate (Gan-ZnPc) which integrated with zinc phthalocyanine (ZnPc) and Ganetespib has been developed.  ZnPc is a promising PS with remarkable photosensitization ability.  Ganetespib is a heat shock protein 90 (Hsp90) inhibitor with preferential tumor selectivity and conjugated to ZnPc as a tumor-targeted ligand.  The multifunctional small mol. conjugate, Gan-ZnPc, could be bound to extracellular Hsp90 and then selectively internalized into the tumor cells, followed by the generation of abundant intracellular reactive oxygen species (ROS) upon irradn.  Besides, Gan-ZnPc can arrest cell proliferation and induce apoptosis by the inhibition of Hsp90.  Herein, with combination of the inhibition of Hsp90 and the generation of cytotoxic ROS, Gan-ZnPc implements tumor selectivity, concd. PDT and chemotherapy in a synergistic manner, which results in highly effective anti-tumor activity in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoas66UM4KbibVg90H21EOLACvtfcHk0ljY8RwY_NBB7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1ejsL4%253D&md5=1be58069058458ab8034a8f25d307000</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.077%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DLiao%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DC.%26atitle%3DA%2520Tumor-Targeted%2520Ganetespib-Zinc%2520Phthalocyanine%2520Conjugate%2520for%2520Synergistic%2520Chemo-photodynamic%2520Therapy%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D294%26epage%3D303%26doi%3D10.1016%2Fj.ejmech.2018.03.077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohlson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Triple Inhibitors of Janus Kinase (JAK), Histone Deacetylase (HDAC) and Heat Shock Protein 90 (HSP90)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1357</span>– <span class="NLM_lpage">1362</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1016%2Fj.bmcl.2018.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=29545103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslWqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=1357-1362&author=L.+Yaoauthor=S.+Ohlsonauthor=B.+W.+Dymock&title=Design+and+Synthesis+of+Triple+Inhibitors+of+Janus+Kinase+%28JAK%29%2C+Histone+Deacetylase+%28HDAC%29+and+Heat+Shock+Protein+90+%28HSP90%29&doi=10.1016%2Fj.bmcl.2018.03.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of triple inhibitors of janus kinase (JAK), histone deacetylase (HDAC) and Heat Shock Protein 90 (HSP90)</span></div><div class="casAuthors">Yao, Lianbin; Ohlson, Sten; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1357-1362</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Inhibition of multiple signaling pathways in a cancer cell with a single mol. could result in better therapies that are simpler to administer.  Efficacy may be achieved with reduced potency against individual targets if there is synergy through multiple pathway inhibition.  To achieve this, it is necessary to be able to build multi-component ligands by joining together key pharmacophores in a way which maintains sufficient activity against the individual pathways.  Designed triple inhibiting ligands are explored aiming to block three completely different target types: a kinase (JAK2), an epigenetic target (HDAC) and a chaperone (HSP90).  Although these enzymes have totally different functions they are related through inter-dependent pathways in the developing cancer cell.  Synthesis of several complex multi-inhibiting ligands are presented along with initial enzyme inhibition data against 3 biol. target classes of interest.  A lead compd., 47 (I), was discovered which had low micromolar activity for all 3 targets.  Further development of these complex trispecific designed multiple ligands could result in a 'transient drug', an alternative combination therapy for treating cancer mediated via a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDUq3YMXAAJ7Vg90H21EOLACvtfcHk0ljY8RwY_NBB7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslWqtr0%253D&md5=e53b440497676faa53b614072e0a3f37</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DL.%26aulast%3DOhlson%26aufirst%3DS.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Triple%2520Inhibitors%2520of%2520Janus%2520Kinase%2520%2528JAK%2529%252C%2520Histone%2520Deacetylase%2520%2528HDAC%2529%2520and%2520Heat%2520Shock%2520Protein%252090%2520%2528HSP90%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D1357%26epage%3D1362%26doi%3D10.1016%2Fj.bmcl.2018.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Biocompatible Heat-Shock Protein Inhibitor-Delivered Flowerlike Short-Wave Infrared Nanoprobe for Mild Temperature-Driven Highly Efficient Tumor Ablation</span>. <i>ACS Appl. Mater. Interfaces</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">6820</span>– <span class="NLM_lpage">6828</span>, <span class="refDoi"> DOI: 10.1021/acsami.8b21483</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsami.8b21483" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVSltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=6820-6828&author=A.+Jiangauthor=Y.+Liuauthor=L.+Maauthor=F.+Maoauthor=L.+Liuauthor=X.+Zhaiauthor=J.+Zhou&title=Biocompatible+Heat-Shock+Protein+Inhibitor-Delivered+Flowerlike+Short-Wave+Infrared+Nanoprobe+for+Mild+Temperature-Driven+Highly+Efficient+Tumor+Ablation&doi=10.1021%2Facsami.8b21483"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Biocompatible Heat-Shock Protein Inhibitor-Delivered Flowerlike Short-Wave Infrared Nanoprobe for Mild Temperature-Driven Highly Efficient Tumor Ablation</span></div><div class="casAuthors">Jiang, Anqi; Liu, Yuxin; Ma, Liyi; Mao, Fang; Liu, Lidong; Zhai, Xuejiao; Zhou, Jing</div><div class="citationInfo"><span class="NLM_cas:title">ACS Applied Materials & Interfaces</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">6820-6828</span>CODEN:
                <span class="NLM_cas:coden">AAMICK</span>;
        ISSN:<span class="NLM_cas:issn">1944-8244</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multifunctional nanomaterials for dual-mode imaging guided cancer therapy are highly desirable in clin. applications.  Herein, a flowerlike NiS2-coated NaLuF4:Nd (Lu:<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="236d47636d4a7011">[email protected]</a>) nanoparticle was synthesized as a novel therapeutic agent for short-wave IR light imaging and magnetic resonance imaging to guide photothermal therapy (PTT).  The material was then loaded with phenolic epigallocatechin 3-gallate (EGCG), which is a natural heat-shock protein 90 (HSP90) inhibitor.  Upon near IR irradn., EGCG was released from the Lu:<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="c18fa5818fa892f3ec84868286">[email protected]</a>, which bound HSP90 and reduced cell tolerance to heat, resulting in a better therapeutic effect at the same elevated temp.  Therefore, with minimal side effects and remarkable antitumor efficacy in vivo, Lu:<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="66280226280f35544b23212521">[email protected]</a> appeared to be a promising photothermal agent for enhanced PTT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolEQ5-NsfPNLVg90H21EOLACvtfcHk0lgcQjqS7wDinA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVSltrY%253D&md5=1c376dd6fd82b138313486cae8aa59f2</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facsami.8b21483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsami.8b21483%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DMao%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DZhai%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DBiocompatible%2520Heat-Shock%2520Protein%2520Inhibitor-Delivered%2520Flowerlike%2520Short-Wave%2520Infrared%2520Nanoprobe%2520for%2520Mild%2520Temperature-Driven%2520Highly%2520Efficient%2520Tumor%2520Ablation%26jtitle%3DACS%2520Appl.%2520Mater.%2520Interfaces%26date%3D2019%26volume%3D11%26spage%3D6820%26epage%3D6828%26doi%3D10.1021%2Facsami.8b21483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong-Thi, M.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohlson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8336</span>– <span class="NLM_lpage">8357</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00678</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00678" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8336-8357&author=L.+Yaoauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+Singhauthor=M.-D.+Duong-Thiauthor=J.+X.+T.+Leeauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Y.+Yenauthor=S.+Ohlsonauthor=B.+W.+Dymock&title=Design+and+Synthesis+of+Ligand+Efficient+Dual+Inhibitors+of+Janus+Kinase+%28JAK%29+and+Histone+Deacetylase+%28HDAC%29+Based+on+Ruxolitinib+and+Vorinostat&doi=10.1021%2Facs.jmedchem.7b00678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat</span></div><div class="casAuthors">Yao, Lianbin; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Singh, Prachi; Duong-Thi, Minh-Dao; Lee, Jeannie X. T.; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Ohlson, Sten; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8336-8357</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Concomitant inhibition of multiple oncogenic pathways is a desirable goal in cancer therapy.  To achieve such an outcome with a single mol. would simplify treatment regimes.  Herein the core features of ruxolitinib, a marketed JAK1/2 inhibitor, have been merged with the HDAC inhibitor vorinostat, leading to new mols. that are bispecific targeted JAK/HDAC inhibitors.  A preferred pyrazole substituted pyrrolopyrimidine, I (R = H), inhibits JAK1 and HDACs 1, 2, 3, 6, and 10 with IC50 values of less than 20 nM, is <100 nM potent against JAK2 and HDAC11, and is selective for the JAK family against a panel of 97 kinases.  Broad cellular antiproliferative potency of I (R = H) is supported by demonstration of JAK-STAT and HDAC pathway blockade in hematol. cell lines.  Me analog I (R = Me) has an even more selective profile.  This study provides new leads for assessment of JAK and HDAC pathway dual inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocWx3JXIW8YbVg90H21EOLACvtfcHk0lgcQjqS7wDinA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ&md5=5ac471ee0cc413b08b926803790de7f9</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00678%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DL.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DDuong-Thi%26aufirst%3DM.-D.%26aulast%3DLee%26aufirst%3DJ.%2BX.%2BT.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%2BY.%26aulast%3DOhlson%26aufirst%3DS.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Ligand%2520Efficient%2520Dual%2520Inhibitors%2520of%2520Janus%2520Kinase%2520%2528JAK%2529%2520and%2520Histone%2520Deacetylase%2520%2528HDAC%2529%2520Based%2520on%2520Ruxolitinib%2520and%2520Vorinostat%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8336%26epage%3D8357%26doi%3D10.1021%2Facs.jmedchem.7b00678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crowe, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcorta, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totzke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loiselle, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gargesha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roques, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyerly, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spector, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haystead, T. A. J.</span></span> <span> </span><span class="NLM_article-title">A Fluorescent HSP90 Probe Demonstrates the Unique Association between Extracellular HSP90 and Malignancy in Vivo</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1047</span>– <span class="NLM_lpage">1055</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00006</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00006" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1ehsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1047-1055&author=L.+B.+Croweauthor=P.+F.+Hughesauthor=D.+A.+Alcortaauthor=T.+Osadaauthor=A.+P.+Smithauthor=J.+Totzkeauthor=D.+R.+Loiselleauthor=I.+D.+Lutzauthor=M.+Gargeshaauthor=D.+Royauthor=J.+Roquesauthor=D.+Darrauthor=H.+K.+Lyerlyauthor=N.+L.+Spectorauthor=T.+A.+J.+Haystead&title=A+Fluorescent+HSP90+Probe+Demonstrates+the+Unique+Association+between+Extracellular+HSP90+and+Malignancy+in+Vivo&doi=10.1021%2Facschembio.7b00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A Fluorescent Hsp90 Probe Demonstrates the Unique Association between Extracellular Hsp90 and Malignancy in Vivo</span></div><div class="casAuthors">Crowe, Lauren B.; Hughes, Philip F.; Alcorta, David A.; Osada, Takuya; Smith, Aaron P.; Totzke, Juliane; Loiselle, David R.; Lutz, Isaac D.; Gargesha, Madhusudhana; Roy, Debasish; Roques, Jose; Darr, David; Lyerly, H. Kim; Spector, Neil L.; Haystead, Timothy A. J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1047-1055</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Extracellular expression of heat shock protein 90 (eHsp90) by tumor cells is correlated with malignancy.  Development of small mol. probes that can detect eHsp90 in vivo may therefore have utility in the early detection of malignancy.  The authors synthesized a cell impermeable far-red fluorophore-tagged Hsp90 inhibitor to target eHsp90 in vivo.  High resoln. confocal and lattice light sheet microscopy show that probe-bound eHsp90 accumulates in punctate structures on the plasma membrane of breast tumor cells and is actively internalized.  The extent of internalization correlates with tumor cell aggressiveness, and this process can be induced in benign cells by over-expressing p110HER2.  Whole body cryoslicing, imaging and histol. of flank and spontaneous tumor-bearing mice strongly suggests that eHsp90 expression and internalization is a phenomenon unique to tumor cells in vivo and may provide an Achilles heel for the early diagnosis of metastatic disease and targeted drug delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWtkg9Hh_AZLVg90H21EOLACvtfcHk0liDcT2yXO8ZhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1ehsrc%253D&md5=05f2c31fdcfbd238f461f557dcc7d6e7</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00006%26sid%3Dliteratum%253Aachs%26aulast%3DCrowe%26aufirst%3DL.%2BB.%26aulast%3DHughes%26aufirst%3DP.%2BF.%26aulast%3DAlcorta%26aufirst%3DD.%2BA.%26aulast%3DOsada%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DA.%2BP.%26aulast%3DTotzke%26aufirst%3DJ.%26aulast%3DLoiselle%26aufirst%3DD.%2BR.%26aulast%3DLutz%26aufirst%3DI.%2BD.%26aulast%3DGargesha%26aufirst%3DM.%26aulast%3DRoy%26aufirst%3DD.%26aulast%3DRoques%26aufirst%3DJ.%26aulast%3DDarr%26aufirst%3DD.%26aulast%3DLyerly%26aufirst%3DH.%2BK.%26aulast%3DSpector%26aufirst%3DN.%2BL.%26aulast%3DHaystead%26aufirst%3DT.%2BA.%2BJ.%26atitle%3DA%2520Fluorescent%2520HSP90%2520Probe%2520Demonstrates%2520the%2520Unique%2520Association%2520between%2520Extracellular%2520HSP90%2520and%2520Malignancy%2520in%2520Vivo%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2017%26volume%3D12%26spage%3D1047%26epage%3D1055%26doi%3D10.1021%2Facschembio.7b00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaponova, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikonova, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deneka, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopp, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudinov, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skobeleva, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khazak, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, K. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egleston, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proia, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boumber, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golemis, E. A.</span></span> <span> </span><span class="NLM_article-title">A Novel HSP90 Inhibitor-Drug Conjugate to SN38 is Highly Effective in Small Cell Lung Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">5120</span>– <span class="NLM_lpage">5129</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-15-3068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1158%2F1078-0432.CCR-15-3068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=27267850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOhs77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=5120-5129&author=A.+V.+Gaponovaauthor=A.+S.+Nikonovaauthor=A.+Y.+Denekaauthor=M.+C.+Koppauthor=A.+E.+Kudinovauthor=N.+Skobelevaauthor=V.+Khazakauthor=L.+S.+Ogawaauthor=K.+Q.+Caiauthor=K.+E.+Duncanauthor=J.+S.+Duncanauthor=B.+L.+Eglestonauthor=D.+A.+Proiaauthor=Y.+Boumberauthor=E.+A.+Golemis&title=A+Novel+HSP90+Inhibitor-Drug+Conjugate+to+SN38+is+Highly+Effective+in+Small+Cell+Lung+Cancer&doi=10.1158%2F1078-0432.ccr-15-3068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer</span></div><div class="casAuthors">Gaponova, Anna V.; Nikonova, Anna S.; Deneka, Alexander Y.; Kopp, Meghan C.; Kudinov, Alexander E.; Skobeleva, Natalia; Khazak, Vladimir; Ogawa, Luisa S.; Cai, Kathy Q.; Duncan, Kelly E.; Duncan, James S.; Egleston, Brian L.; Proia, David A.; Boumber, Yanis; Golemis, Erica A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5120-5129</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Small cell lung cancer (SCLC) is a highly aggressive disease representing 12% to 13% of total lung cancers, with median survival of <2 years.  No targeted therapies have proven effective in SCLC.  Although most patients respond initially to cytotoxic chemotherapies, resistance rapidly emerges, response to second-line agents is limited, and dose-limiting toxicities (DLT) are a major issue.  This study performs preclin. evaluation of a new compd., STA-8666, in SCLC.  To avoid DLT for useful cytotoxic agents, the recently developed drug STA-8666 combines a chem. moiety targeting active HSP90 (concd. in tumors) fused via cleavable linker to SN38, the active metabolite of irinotecan.  We compare potency and mechanism of action of STA-8666 and irinotecan in vitro and in vivo.  In two SCLC xenograft and patient-derived xenograft models, STA-8666 was tolerated without side effects up to 150 mg/kg.  At this dose, STA-8666 controlled or eliminated established tumors whether used in a first-line setting or in tumors that had progressed following treatment on std. first- and second-line agents for SCLC.  At 50 mg/kg, STA-8666 strongly enhanced the action of carboplatin.  Pharmacokinetic profiling confirmed durable STA-8666 exposure in tumors compared with irinotecan.  STA-8666 induced a more rapid, robust, and stable induction of cell-cycle arrest, expression of signaling proteins assocd. with DNA damage and cell-cycle checkpoints, and apoptosis in vitro and in vivo, in comparison with irinotecan.  Together, these results strongly support clin. development of STA-8666 for use in the first- or second-line setting for SCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5QHHBGAoXOLVg90H21EOLACvtfcHk0liDcT2yXO8ZhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOhs77N&md5=01caf2635048f4a66000af3702b0c451</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-3068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-3068%26sid%3Dliteratum%253Aachs%26aulast%3DGaponova%26aufirst%3DA.%2BV.%26aulast%3DNikonova%26aufirst%3DA.%2BS.%26aulast%3DDeneka%26aufirst%3DA.%2BY.%26aulast%3DKopp%26aufirst%3DM.%2BC.%26aulast%3DKudinov%26aufirst%3DA.%2BE.%26aulast%3DSkobeleva%26aufirst%3DN.%26aulast%3DKhazak%26aufirst%3DV.%26aulast%3DOgawa%26aufirst%3DL.%2BS.%26aulast%3DCai%26aufirst%3DK.%2BQ.%26aulast%3DDuncan%26aufirst%3DK.%2BE.%26aulast%3DDuncan%26aufirst%3DJ.%2BS.%26aulast%3DEgleston%26aufirst%3DB.%2BL.%26aulast%3DProia%26aufirst%3DD.%2BA.%26aulast%3DBoumber%26aufirst%3DY.%26aulast%3DGolemis%26aufirst%3DE.%2BA.%26atitle%3DA%2520Novel%2520HSP90%2520Inhibitor-Drug%2520Conjugate%2520to%2520SN38%2520is%2520Highly%2520Effective%2520in%2520Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D5120%26epage%3D5129%26doi%3D10.1158%2F1078-0432.ccr-15-3068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heske, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendoza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edessa, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgart, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trepel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proia, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helman, L. J.</span></span> <span> </span><span class="NLM_article-title">STA-8666, a Novel HSP90 Inhibitor/SN-38 Drug Conjugate, Causes Complete Tumor Regression in Preclinical Mouse Models of Pediatric Sarcoma</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">65540</span>– <span class="NLM_lpage">65552</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.11869</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.18632%2Foncotarget.11869" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=27608846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A280%3ADC%252BC2szoslOjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=65540-65552&author=C.+M.+Heskeauthor=A.+Mendozaauthor=L.+D.+Edessaauthor=J.+T.+Baumgartauthor=S.+Leeauthor=J.+Trepelauthor=D.+A.+Proiaauthor=L.+Neckersauthor=L.+J.+Helman&title=STA-8666%2C+a+Novel+HSP90+Inhibitor%2FSN-38+Drug+Conjugate%2C+Causes+Complete+Tumor+Regression+in+Preclinical+Mouse+Models+of+Pediatric+Sarcoma&doi=10.18632%2Foncotarget.11869"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma</span></div><div class="casAuthors">Heske Christine M; Mendoza Arnulfo; Edessa Leah D; Baumgart Joshua T; Helman Lee J; Lee Sunmin; Trepel Jane; Proia David A; Neckers Len</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">65540-65552</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Long-term survival in patients with metastatic, relapsed, or recurrent Ewing sarcoma and rhabdomyosarcoma is dismal.  Irinotecan, a topoisomerase 1 inhibitor, has activity in these sarcomas, but due to poor bioavailability of its active metabolite (SN-38) has had limited clinical efficacy.  In this study we have evaluated the efficacy and toxicity of STA-8666, a novel drug conjugate which uses an HSP90 inhibitor to facilitate intracellular, tumor-targeted delivery of the topoisomerase 1 inhibitor SN-38, thus preferentially delivering and concentrating SN-38 within tumor tissue.  We present in vivo evidence from mouse xenograft models that STA-8666 results in more persistent inhibition of topoisomerase 1 and prolonged DNA damage compared to irinotecan.  This translates into superior antitumor efficacy and survival in multiple aggressive models of both diseases in mouse xenografts, as well as in an irinotecan-resistant model of pediatric osteosarcoma, demonstrated by dramatic tumor shrinkage, durable remission and prolonged complete regressions following short-term treatment, compared to conventional irinotecan.  Gene expression analysis performed on xenograft tumors treated with either irinotecan or STA-8666 showed that STA-8666 affected expression of DNA damage and repair genes more robustly than irinotecan.  These results suggest that STA-8666 may be a promising new agent for patients with pediatric-type sarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDMnjuYNWUMMKL0FlyGHDofW6udTcc2eZpZgs18ZXq7Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szoslOjsw%253D%253D&md5=5cf387bb6fc02851e66abbf8f08586d2</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.11869&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.11869%26sid%3Dliteratum%253Aachs%26aulast%3DHeske%26aufirst%3DC.%2BM.%26aulast%3DMendoza%26aufirst%3DA.%26aulast%3DEdessa%26aufirst%3DL.%2BD.%26aulast%3DBaumgart%26aufirst%3DJ.%2BT.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DTrepel%26aufirst%3DJ.%26aulast%3DProia%26aufirst%3DD.%2BA.%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DHelman%26aufirst%3DL.%2BJ.%26atitle%3DSTA-8666%252C%2520a%2520Novel%2520HSP90%2520Inhibitor%252FSN-38%2520Drug%2520Conjugate%252C%2520Causes%2520Complete%2520Tumor%2520Regression%2520in%2520Preclinical%2520Mouse%2520Models%2520of%2520Pediatric%2520Sarcoma%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D65540%26epage%3D65552%26doi%3D10.18632%2Foncotarget.11869" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Pharmacological Evaluation of ALK and HSP90 Dual Inhibitors Bearing Resorcinol and 2,4-Diaminopyrimidine Motifs</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">76</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.04.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1016%2Fj.ejmech.2018.04.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=29698859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosVWmsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2018&pages=76-86&author=K.+Gengauthor=H.+Liuauthor=Z.+Songauthor=C.+Zhangauthor=M.+Zhangauthor=H.+Yangauthor=J.+Caoauthor=M.+Gengauthor=A.+Shenauthor=A.+Zhang&title=Design%2C+Synthesis+and+Pharmacological+Evaluation+of+ALK+and+HSP90+Dual+Inhibitors+Bearing+Resorcinol+and+2%2C4-Diaminopyrimidine+Motifs&doi=10.1016%2Fj.ejmech.2018.04.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2,4-diaminopyrimidine motifs</span></div><div class="casAuthors">Geng, Kaijun; Liu, Hongchun; Song, Zilan; Zhang, Chi; Zhang, Minmin; Yang, Hong; Cao, Jingchen; Geng, Meiyu; Shen, Aijun; Zhang, Ao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">76-86</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Rather than by directly focusing on the ever-changing ALK mutants, here we report an alternative strategy to overcome the drug resistance caused by treatment of ALK inhibitors by developing ALK and Hsp90 dual targeting inhibitors.  Since Hsp90 is a mol. chaperone that regulates the maturation, activation and stability of numerous "client proteins" including ALK, dual targeting ALK and Hsp90 may bring more benefits and efficacy against drug resistance of ALK inhibitors.  By using our previously developed ALK inhibitor 6 and the clin. Hsp90 inhibitors AUY922 or AT13387 as the templates, we developed several series of resorcinol tethered 2,4-diaminopyrimidines as ALK/Hsp90 dual inhibitors bearing various linkers at different linking sites.  Compd. 10h and 10j showed high potency against ALK (17.3 vs 9.8 nM) and Hsp90α (100 vs 40 nM).  They also have high potency against ALK resistant mutants, esp. the gatekeeper mutation ALKL1196M.  Both compds. showed strong antiproliferative activity against the ALK-addictive H3122 cells (11 vs 13 nM).  The dual functioning mechanism is further confirmed by their down-regulation of the Hsp90 clients ALK and AKT, and up-regulation of the chaperone protein Hsp70 in H3122 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmqigxUQsz8bVg90H21EOLACvtfcHk0lhwG4gCc-sECA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosVWmsLY%253D&md5=a64e43ba5d725642af62313c1dbc8111</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.04.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.04.019%26sid%3Dliteratum%253Aachs%26aulast%3DGeng%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Pharmacological%2520Evaluation%2520of%2520ALK%2520and%2520HSP90%2520Dual%2520Inhibitors%2520Bearing%2520Resorcinol%2520and%25202%252C4-Diaminopyrimidine%2520Motifs%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D152%26spage%3D76%26epage%3D86%26doi%3D10.1016%2Fj.ejmech.2018.04.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, Q.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Q.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.-L.</span></span> <span> </span><span class="NLM_article-title">Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10498</span>– <span class="NLM_lpage">10519</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00912</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00912" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVehs7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10498-10519&author=F.+Jiangauthor=H.-J.+Wangauthor=Y.-H.+Jinauthor=Q.+Zhangauthor=Z.-H.+Wangauthor=J.-M.+Jiaauthor=F.+Liuauthor=L.+Wangauthor=Q.-C.+Baoauthor=D.-D.+Liauthor=Q.-D.+Youauthor=X.-L.+Xu&title=Novel+Tetrahydropyrido%5B4%2C3-d%5Dpyrimidines+as+Potent+Inhibitors+of+Chaperone+Heat+Shock+Protein+90&doi=10.1021%2Facs.jmedchem.6b00912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90</span></div><div class="casAuthors">Jiang, Fen; Wang, Hui-Jie; Jin, Yu-Hui; Zhang, Qiong; Wang, Zhi-Hui; Jia, Jian-Min; Liu, Fang; Wang, Lei; Bao, Qi-Chao; Li, Dong-Dong; You, Qi-Dong; Xu, Xiao-Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10498-10519</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Heat-shock protein 90 (Hsp90) is a potential target for oncol. therapeutics.  Some inhibitors have shown anti-tumor effects in clin. trials, spurring the discovery of small-mol. Hsp90 inhibitors.  Here, the authors describe the structural optimization studies of a hit compd., tetrahydropyrido[4,3-d]pyrimidine-based Hsp90 inhibitor, which exhibits inhibitory activity against Hsp90.  A series of analogs were synthesized, and their structure-activity relationships and structure-property relationships were analyzed.  These explorations led to the discovery of compd. 73 ((2,4-dihydroxy-5-isopropylphenyl)(4-(ethylamino)-2-(2-methoxyethoxy)-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)methanone), which exhibited potent in vitro activities, good physicochem. properties, favorable ADME properties and potent anti-tumor effect in an HCT116 xenograft model.  Furthermore, 73 exhibited no ocular toxicity in a rat retinal damage model, suggesting it is a relatively safe Hsp90 inhibitor.  As a promising anti-tumor agent, 73 was progressed for further pre-clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhftxgoZ3blLVg90H21EOLACvtfcHk0lhwG4gCc-sECA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVehs7nF&md5=d3ab4651aa7d68854edf7c0b6e712ee2</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00912%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DH.-J.%26aulast%3DJin%26aufirst%3DY.-H.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DZ.-H.%26aulast%3DJia%26aufirst%3DJ.-M.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBao%26aufirst%3DQ.-C.%26aulast%3DLi%26aufirst%3DD.-D.%26aulast%3DYou%26aufirst%3DQ.-D.%26aulast%3DXu%26aufirst%3DX.-L.%26atitle%3DNovel%2520Tetrahydropyrido%255B4%252C3-d%255Dpyrimidines%2520as%2520Potent%2520Inhibitors%2520of%2520Chaperone%2520Heat%2520Shock%2520Protein%252090%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10498%26epage%3D10519%26doi%3D10.1021%2Facs.jmedchem.6b00912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshiumi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shigeno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohkubo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muraoka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funabashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohkubo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitade, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01085</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01085" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVGnsLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=531-551&author=T.+Unoauthor=Y.+Kawaiauthor=S.+Yamashitaauthor=H.+Oshiumiauthor=C.+Yoshimuraauthor=T.+Mizutaniauthor=T.+Suzukiauthor=K.+T.+Chongauthor=K.+Shigenoauthor=M.+Ohkuboauthor=Y.+Kodamaauthor=H.+Muraokaauthor=K.+Funabashiauthor=K.+Takahashiauthor=S.+Ohkuboauthor=M.+Kitade&title=Discovery+of+3-Ethyl-4-%283-isopropyl-4-%284-%281-methyl-1H-pyrazol-4-yl%29-1H-imidazol-1-yl%29-1H-pyrazolo%5B3%2C4-b%5Dpyridin-1-yl%29benzamide+%28TAS-116%29+as+a+Potent%2C+Selective%2C+and+Orally+Available+HSP90+Inhibitor&doi=10.1021%2Facs.jmedchem.8b01085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-ethyl-4-(3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl)benzamide (TAS-116) as a potent, selective, and orally available HSP90 inhibitor</span></div><div class="casAuthors">Uno, Takao; Kawai, Yuichi; Yamashita, Satoshi; Oshiumi, Hiromi; Yoshimura, Chihoko; Mizutani, Takashi; Suzuki, Tatsuya; Chong, Khoon Tee; Shigeno, Kazuhiko; Ohkubo, Mitsuru; Kodama, Yasuo; Muraoka, Hiromi; Funabashi, Kaoru; Takahashi, Koichi; Ohkubo, Shuichi; Kitade, Makoto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">531-551</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The mol. chaperone heat shock protein 90 (HSP90) is a promising target for cancer therapy, as it assists in the stabilization of cancer-related proteins, promoting cancer cell growth, and survival.  A novel series of HSP90 inhibitors were discovered by structure-activity relationship (SAR)-based optimization of an initial hit compd. having a 4-(4-(quinolin-3-yl)-1H-indol-1-yl)benzamide structure.  The pyrazolo[3,4-b]pyridine deriv., I (TAS-116), is a selective inhibitor of HSP90α and HSP90β among the HSP90 family proteins and exhibits oral availability in mice.  The X-ray cocrystal structure of the I analog II demonstrated a unique binding mode at the N-terminal ATP binding site.  Oral administration of I demonstrated potent antitumor effects in an NCI-H1975 xenograft mouse model without significant body wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLBSBSC2j6FrVg90H21EOLACvtfcHk0lj6iUf_sd5bjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVGnsLjK&md5=0e7673a985350bd5cb52a1263449a9da</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01085%26sid%3Dliteratum%253Aachs%26aulast%3DUno%26aufirst%3DT.%26aulast%3DKawai%26aufirst%3DY.%26aulast%3DYamashita%26aufirst%3DS.%26aulast%3DOshiumi%26aufirst%3DH.%26aulast%3DYoshimura%26aufirst%3DC.%26aulast%3DMizutani%26aufirst%3DT.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DChong%26aufirst%3DK.%2BT.%26aulast%3DShigeno%26aufirst%3DK.%26aulast%3DOhkubo%26aufirst%3DM.%26aulast%3DKodama%26aufirst%3DY.%26aulast%3DMuraoka%26aufirst%3DH.%26aulast%3DFunabashi%26aufirst%3DK.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DOhkubo%26aufirst%3DS.%26aulast%3DKitade%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25203-Ethyl-4-%25283-isopropyl-4-%25284-%25281-methyl-1H-pyrazol-4-yl%2529-1H-imidazol-1-yl%2529-1H-pyrazolo%255B3%252C4-b%255Dpyridin-1-yl%2529benzamide%2520%2528TAS-116%2529%2520as%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Available%2520HSP90%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D531%26epage%3D551%26doi%3D10.1021%2Facs.jmedchem.8b01085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummalapalli, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotella, D. P.</span></span> <span> </span><span class="NLM_article-title">Progress in the Discovery and Development of Heat Shock Protein 90 (HSP90) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8718</span>– <span class="NLM_lpage">8728</span>, <span class="refDoi"> DOI: 10.1021/jm500823a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500823a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSnsrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8718-8728&author=R.+Bhatauthor=S.+R.+Tummalapalliauthor=D.+P.+Rotella&title=Progress+in+the+Discovery+and+Development+of+Heat+Shock+Protein+90+%28HSP90%29+Inhibitors&doi=10.1021%2Fjm500823a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in the Discovery and Development of Heat Shock Protein 90 (Hsp90) Inhibitors</span></div><div class="casAuthors">Bhat, Rohit; Tummalapalli, Sreedhar R.; Rotella, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8718-8728</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The discovery and clin. development of heat shock protein 90 (Hsp90) inhibitors continue to progress.  A no. of Hsp90 inhibitors are in clin. trials, and preclin. discoveries of new chemotypes that bind to distinct regions in the protein as well as isoform selective compds. are active areas of research.  This review will highlight progress in the field since 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-SwLv_-B9xLVg90H21EOLACvtfcHk0lj6iUf_sd5bjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSnsrfK&md5=132784687bbbcf62cfa8fe04a22577ce</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm500823a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500823a%26sid%3Dliteratum%253Aachs%26aulast%3DBhat%26aufirst%3DR.%26aulast%3DTummalapalli%26aufirst%3DS.%2BR.%26aulast%3DRotella%26aufirst%3DD.%2BP.%26atitle%3DProgress%2520in%2520the%2520Discovery%2520and%2520Development%2520of%2520Heat%2520Shock%2520Protein%252090%2520%2528HSP90%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8718%26epage%3D8728%26doi%3D10.1021%2Fjm500823a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brough, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aherne, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barril, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgognoni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boxall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cansfield, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, K.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drysdale, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northfield, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearl, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prodromou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roughley, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surgenor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walmsley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L.</span></span> <span> </span><span class="NLM_article-title">4,5-Diarylisoxazole HSP90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">196</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1021/jm701018h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701018h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlWqsL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=196-218&author=P.+A.+Broughauthor=W.+Aherneauthor=X.+Barrilauthor=J.+Borgognoniauthor=K.+Boxallauthor=J.+E.+Cansfieldauthor=K.-M.+Cheungauthor=I.+Collinsauthor=N.+G.+Daviesauthor=M.+J.+Drysdaleauthor=B.+Dymockauthor=S.+A.+Ecclesauthor=H.+Finchauthor=A.+Finkauthor=A.+Hayesauthor=R.+Howesauthor=R.+E.+Hubbardauthor=K.+Jamesauthor=A.+M.+Jordanauthor=A.+Lockieauthor=V.+Martinsauthor=A.+Masseyauthor=T.+P.+Matthewsauthor=E.+McDonaldauthor=C.+J.+Northfieldauthor=L.+H.+Pearlauthor=C.+Prodromouauthor=S.+Rayauthor=F.+I.+Raynaudauthor=S.+D.+Roughleyauthor=S.+Y.+Sharpauthor=A.+Surgenorauthor=D.+L.+Walmsleyauthor=P.+Webbauthor=M.+Woodauthor=P.+Workmanauthor=L.+Wright&title=4%2C5-Diarylisoxazole+HSP90+Chaperone+Inhibitors%3A+Potential+Therapeutic+Agents+for+the+Treatment+of+Cancer&doi=10.1021%2Fjm701018h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer</span></div><div class="casAuthors">Brough, Paul A.; Aherne, Wynne; Barril, Xavier; Borgognoni, Jennifer; Boxall, Kathy; Cansfield, Julie E.; Cheung, Kwai-Ming J.; Collins, Ian; Davies, Nicholas G. M.; Drysdale, Martin J.; Dymock, Brian; Eccles, Suzanne A.; Finch, Harry; Fink, Alexandra; Hayes, Angela; Howes, Robert; Hubbard, Roderick E.; James, Karen; Jordan, Allan M.; Lockie, Andrea; Martins, Vanessa; Massey, Andrew; Matthews, Thomas P.; McDonald, Edward; Northfield, Christopher J.; Pearl, Laurence H.; Prodromou, Chrisostomos; Ray, Stuart; Raynaud, Florence I.; Roughley, Stephen D.; Sharp, Swee Y.; Surgenor, Allan; Walmsley, D. Lee; Webb, Paul; Wood, Mike; Workman, Paul; Wright, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">196-218</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of the Hsp90 [heat shock protein 90] mol. chaperone show considerable promise as potential chemotherapeutic agents for cancer.  The structure-based design, synthesis, structure-activity relationships, and pharmacokinetics of potent small-mol. inhibitors of Hsp90 based on the 4,5-diarylisoxazole scaffold were studied.  Analogs from this series have high affinity for Hsp90, as measured in a fluorescence polarization competitive binding assay, and are active in cancer cell lines where they inhibit proliferation and exhibit a characteristic profile of depletion of oncogenic proteins and concomitant elevation of Hsp72.  The [(morpholinomethyl)phenyl]isoxazolecarboxamide I (VER-52296/NVP-AUY922) is potent in the Hsp90 FP binding assay and inhibits proliferation of various human cancer cell lines in vitro, with GI50 averaging 9 nM.  I is retained in tumors in vivo when administered i.p., as evaluated by cassette dosing in tumor-bearing mice.  In a human colon cancer xenograft model, I inhibits tumor growth by ∼50%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTNA9AoWb8gLVg90H21EOLACvtfcHk0litBZaTGB8zXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlWqsL%252FK&md5=fdb98dec600987e862b9b05555427948</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm701018h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701018h%26sid%3Dliteratum%253Aachs%26aulast%3DBrough%26aufirst%3DP.%2BA.%26aulast%3DAherne%26aufirst%3DW.%26aulast%3DBarril%26aufirst%3DX.%26aulast%3DBorgognoni%26aufirst%3DJ.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DCansfield%26aufirst%3DJ.%2BE.%26aulast%3DCheung%26aufirst%3DK.-M.%26aulast%3DCollins%26aufirst%3DI.%26aulast%3DDavies%26aufirst%3DN.%2BG.%26aulast%3DDrysdale%26aufirst%3DM.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DFinch%26aufirst%3DH.%26aulast%3DFink%26aufirst%3DA.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHowes%26aufirst%3DR.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DJordan%26aufirst%3DA.%2BM.%26aulast%3DLockie%26aufirst%3DA.%26aulast%3DMartins%26aufirst%3DV.%26aulast%3DMassey%26aufirst%3DA.%26aulast%3DMatthews%26aufirst%3DT.%2BP.%26aulast%3DMcDonald%26aufirst%3DE.%26aulast%3DNorthfield%26aufirst%3DC.%2BJ.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26aulast%3DProdromou%26aufirst%3DC.%26aulast%3DRay%26aufirst%3DS.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DRoughley%26aufirst%3DS.%2BD.%26aulast%3DSharp%26aufirst%3DS.%2BY.%26aulast%3DSurgenor%26aufirst%3DA.%26aulast%3DWalmsley%26aufirst%3DD.%2BL.%26aulast%3DWebb%26aufirst%3DP.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DWright%26aufirst%3DL.%26atitle%3D4%252C5-Diarylisoxazole%2520HSP90%2520Chaperone%2520Inhibitors%253A%2520Potential%2520Therapeutic%2520Agents%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D196%26epage%3D218%26doi%3D10.1021%2Fjm701018h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khandelwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzbeierlein, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matts, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S. J.</span></span> <span> </span><span class="NLM_article-title">Structure-Guided Design of an HSP90beta N-terminal Isoform-Selective Inhibitor</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-02013-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1038%2Fs41467-017-02013-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=29382832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A280%3ADC%252BC1MvlsFyksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=425-431&author=A.+Khandelwalauthor=C.+N.+Kentauthor=M.+Balchauthor=S.+Pengauthor=S.+J.+Mishraauthor=J.+Dengauthor=V.+W.+Dayauthor=W.+Liuauthor=C.+Subramanianauthor=M.+Cohenauthor=J.+M.+Holzbeierleinauthor=R.+Mattsauthor=B.+S.+J.+Blagg&title=Structure-Guided+Design+of+an+HSP90beta+N-terminal+Isoform-Selective+Inhibitor&doi=10.1038%2Fs41467-017-02013-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor</span></div><div class="casAuthors">Khandelwal Anuj; Mishra Sanket J; Kent Caitlin N; Blagg Brian S J; Balch Maurie; Peng Shuxia; Deng Junpeng; Matts Robert; Day Victor W; Liu Weiya; Holzbeierlein Jeffery M; Subramanian Chitra; Cohen Mark</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">425</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The 90 kDa heat shock protein (Hsp90) is a molecular chaperone responsible for folding proteins that are directly associated with cancer progression.  Consequently, inhibition of the Hsp90 protein folding machinery results in a combinatorial attack on numerous oncogenic pathways.  Seventeen small-molecule inhibitors of Hsp90 have entered clinical trials, all of which bind the Hsp90 N-terminus and exhibit pan-inhibitory activity against all four Hsp90 isoforms. pan-Inhibition of Hsp90 appears to be detrimental as toxicities have been reported alongside induction of the pro-survival heat shock response.  The development of Hsp90 isoform-selective inhibitors represents an alternative approach towards the treatment of cancer that may limit some of the detriments.  Described herein is a structure-based approach to design isoform-selective inhibitors of Hsp90β, which induces the degradation of select Hsp90 clients without concomitant induction of Hsp90 levels.  Together, these initial studies support the development of Hsp90β-selective inhibitors as a method to overcome the detriments associated with pan-inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmyRre9-yoQBpyrDyM_m9cfW6udTcc2ebaxoW2jXseT7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvlsFyksA%253D%253D&md5=cfa47e314c9bdbc1c38802108330cba7</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-02013-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-02013-1%26sid%3Dliteratum%253Aachs%26aulast%3DKhandelwal%26aufirst%3DA.%26aulast%3DKent%26aufirst%3DC.%2BN.%26aulast%3DBalch%26aufirst%3DM.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DMishra%26aufirst%3DS.%2BJ.%26aulast%3DDeng%26aufirst%3DJ.%26aulast%3DDay%26aufirst%3DV.%2BW.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DSubramanian%26aufirst%3DC.%26aulast%3DCohen%26aufirst%3DM.%26aulast%3DHolzbeierlein%26aufirst%3DJ.%2BM.%26aulast%3DMatts%26aufirst%3DR.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DStructure-Guided%2520Design%2520of%2520an%2520HSP90beta%2520N-terminal%2520Isoform-Selective%2520Inhibitor%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D425%26epage%3D431%26doi%3D10.1038%2Fs41467-017-02013-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banerji, U.</span></span> <span> </span><span class="NLM_article-title">Heat Shock Protein 90 as a Drug Target: Some Like It Hot</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-08-0132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1158%2F1078-0432.CCR-08-0132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=19118027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Cjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=9-14&author=U.+Banerji&title=Heat+Shock+Protein+90+as+a+Drug+Target%3A+Some+Like+It+Hot&doi=10.1158%2F1078-0432.ccr-08-0132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Heat Shock Protein 90 as a Drug Target: Some Like It Hot</span></div><div class="casAuthors">Banerji, Udai</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-14</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Heat shock protein 90 (HSP90) is a ubiquitously expressed chaperone that is involved in the posttranslational folding and stability of proteins.  Inhibition at the NH2-terminal ATP-binding site leads to the degrdn. of client proteins by the ubiquitin proteasome pathway.  Inhibition of HSP90 leads to the degrdn. of known oncogenes, such as ERB-B2, BRAF, and BCR-ABL, leading to the combinatorial blockade of multiple signal transduction pathways, such as the RAS-RAF-mitogen-activated protein/extracellular signal-regulated kinase kinase-extracellular signal-regulated kinase and phosphatidylinositol 3-kinase pathways.  Multiple structurally diverse HSP90 inhibitors are undergoing early clin. evaluation.  The clin. focus of these drugs should be solid tumors, such as breast, prostate, and lung cancers, along with malignant melanoma, in addn. to hematol. malignancies, such as chronic myeloid leukemia and multiple myeloma.  HSP90 inhibitors can be used as single agents or in combination with other targeted treatments or conventional forms of treatment such as chemotherapy and radiotherapy.  Clin. trials evaluating efficacy of these agents should include innovative designs to capture cytostasis evidenced by clin. nonprogression and enrichment of patient populations by mol. characterization.  The results of clin. trials evaluating the efficacy of drugs targeting this exciting target are awaited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5QTJOiPz3ebVg90H21EOLACvtfcHk0litBZaTGB8zXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Cjug%253D%253D&md5=8ae4c833ac80987facd9a93300a2efb9</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0132%26sid%3Dliteratum%253Aachs%26aulast%3DBanerji%26aufirst%3DU.%26atitle%3DHeat%2520Shock%2520Protein%252090%2520as%2520a%2520Drug%2520Target%253A%2520Some%2520Like%2520It%2520Hot%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D9%26epage%3D14%26doi%3D10.1158%2F1078-0432.ccr-08-0132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sidera, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patsavoudi, E.</span></span> <span> </span><span class="NLM_article-title">Extracellular HSP90: Conquering the Cell Surface</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1564</span>– <span class="NLM_lpage">1568</span>, <span class="refDoi"> DOI: 10.4161/cc.7.11.6054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.4161%2Fcc.7.11.6054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=18469526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptF2nur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1564-1568&author=K.+Sideraauthor=E.+Patsavoudi&title=Extracellular+HSP90%3A+Conquering+the+Cell+Surface&doi=10.4161%2Fcc.7.11.6054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Extracellular HSP90. Conquering the cell surface</span></div><div class="casAuthors">Sidera, Katerina; Patsavoudi, Evangelia</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1564-1568</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  Recently, a pool of HSP90 has been identified at the cell surface, where it was shown to be involved in cancer cell invasion.  Here, we propose a model concerning the mol. mechanism underlying the role of HSP90 in cancer cell invasion.  We suggest that surface HSP90 interacts specifically with the extracellular domain of HER-2 and that this interaction is necessary for the receptor's activation and heterodimerization with ErbB-3, which in turn will mediate signal transduction pathways via MAPK and PI3K-Akt, leading to actin rearrangement and cell motility.  Furthermore we propose that the selective inhibition of cell surface HSP90 with a cell-impermeable function blocking monoclonal antibody, mAb 4C5, may have clin. benefits in limiting cancer cell invasion and metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqniZKVLPY5NrVg90H21EOLACvtfcHk0liuCEdu8VKkyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptF2nur8%253D&md5=f6e688635673aabb0a727d713c53b49b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.4161%2Fcc.7.11.6054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.7.11.6054%26sid%3Dliteratum%253Aachs%26aulast%3DSidera%26aufirst%3DK.%26aulast%3DPatsavoudi%26aufirst%3DE.%26atitle%3DExtracellular%2520HSP90%253A%2520Conquering%2520the%2520Cell%2520Surface%26jtitle%3DCell%2520Cycle%26date%3D2008%26volume%3D7%26spage%3D1564%26epage%3D1568%26doi%3D10.4161%2Fcc.7.11.6054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, D.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baas, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daum, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gygi, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aebersold, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berk, B. C.</span></span> <span> </span><span class="NLM_article-title">Purification and Identification of Secreted Oxidative Stress-Induced Factors from Vascular Smooth Muscle Cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1074/jbc.275.1.189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1074%2Fjbc.275.1.189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10617604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjvVGrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=189-196&author=D.-F.+Liaoauthor=Z.-G.+Jinauthor=A.+S.+Baasauthor=G.+Daumauthor=S.+P.+Gygiauthor=R.+Aebersoldauthor=B.+C.+Berk&title=Purification+and+Identification+of+Secreted+Oxidative+Stress-Induced+Factors+from+Vascular+Smooth+Muscle+Cells&doi=10.1074%2Fjbc.275.1.189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells</span></div><div class="casAuthors">Liao, Duan-Fang; Jin, Zheng-Gen; Baas, Arnold S.; Daum, Guenter; Gygi, Steven P.; Aebersold, Ruedi; Berk, Bradford C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">189-196</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Reactive oxygen species have been implicated in the pathogenesis of atherosclerosis and hypertension, in part by promoting vascular smooth muscle cell (VSMC) growth.  The authors have previously shown that LY 83583, a generator of superoxide, activated extracellular signal-regulated kinases (ERK1/2) with early (10 min) and late (2 h) peaks and stimulated VSMC growth.  To investigate whether secreted oxidative stress-induced factors (termed SOXF) from VSMC were responsible for late ERK1/2 activation in response to LY 83583, the authors purified putative SOXF proteins from conditioned medium (2 h of LY 83583 exposure) by sequential chromatog. based on activation of ERK1/2.  Proteins identified by capillary chromatog., electrospray ionization tandem mass spectrometry, and data base searching included heat shock protein 90-α (HSP90-α) and cyclophilin B.  Western blot anal. of conditioned medium showed specific secretion of HSP90-α but not HSP90-β.  Immunodepletion of HSP90-α from conditioned medium significantly inhibited conditioned medium-induced ERK1/2 activation.  Human recombinant HSP90-α reproduced the effect of conditioned medium on ERK1/2 activation.  These results show that brief oxidative stress causes sustained release of protein factors from VSMC that can stimulate ERK1/2.  These factors may be important mediators for the effects of reactive oxygen species on vascular function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj7WiE93zqhrVg90H21EOLACvtfcHk0liuCEdu8VKkyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjvVGrsA%253D%253D&md5=29fb2575a2ed0ce9db8ebfc34a4c039a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1074%2Fjbc.275.1.189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.275.1.189%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DD.-F.%26aulast%3DJin%26aufirst%3DZ.-G.%26aulast%3DBaas%26aufirst%3DA.%2BS.%26aulast%3DDaum%26aufirst%3DG.%26aulast%3DGygi%26aufirst%3DS.%2BP.%26aulast%3DAebersold%26aufirst%3DR.%26aulast%3DBerk%26aufirst%3DB.%2BC.%26atitle%3DPurification%2520and%2520Identification%2520of%2520Secreted%2520Oxidative%2520Stress-Induced%2520Factors%2520from%2520Vascular%2520Smooth%2520Muscle%2520Cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D189%26epage%3D196%26doi%3D10.1074%2Fjbc.275.1.189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Picard, D.</span></span> <span> </span><span class="NLM_article-title">Hsp90 Invades the Outside</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">479</span>– <span class="NLM_lpage">480</span>, <span class="refDoi"> DOI: 10.1038/ncb0604-479</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1038%2Fncb0604-479" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=15170457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVaisL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=479-480&author=D.+Picard&title=Hsp90+Invades+the+Outside&doi=10.1038%2Fncb0604-479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 invades the outside</span></div><div class="casAuthors">Picard, Didier</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">479-480</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review of the research of B. K. Eustace et al. (ibid., 507-10) is given.  Metalloproteases are required for the invasive nature of cancer cells.  Surprisingly, the cytosolic mol. chaperone Hsp90 is now shown to promote maturation of the extracellular metalloprotease MMP2.  This finding extends the multiplicity of roles assigned to the Hsp90 family to a new function outside the cell.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNjYXyhjjre7Vg90H21EOLACvtfcHk0liuCEdu8VKkyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVaisL8%253D&md5=470530d5c8190d910f00647dd2025ae8</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fncb0604-479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb0604-479%26sid%3Dliteratum%253Aachs%26aulast%3DPicard%26aufirst%3DD.%26atitle%3DHsp90%2520Invades%2520the%2520Outside%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2004%26volume%3D6%26spage%3D479%26epage%3D480%26doi%3D10.1038%2Fncb0604-479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
la Mare, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurgens, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edkins, A. L.</span></span> <span> </span><span class="NLM_article-title">Extracellular HSP90 and TGFbeta Regulate Adhesion, Migration and Anchorage Independent Growth in a Paired Colon Cancer Cell Line Model</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">202</span>– <span class="NLM_lpage">217</span>, <span class="refDoi"> DOI: 10.1186/s12885-017-3190-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1186%2Fs12885-017-3190-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=28302086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvVWiu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=202-217&author=J.+A.+de%0Ala+Mareauthor=T.+Jurgensauthor=A.+L.+Edkins&title=Extracellular+HSP90+and+TGFbeta+Regulate+Adhesion%2C+Migration+and+Anchorage+Independent+Growth+in+a+Paired+Colon+Cancer+Cell+Line+Model&doi=10.1186%2Fs12885-017-3190-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Extracellular Hsp90 and TGFβ regulate adhesion, migration and anchorage independent growth in a paired colon cancer cell line model</span></div><div class="casAuthors">de la Mare, Jo-Anne; Jurgens, Tamarin; Edkins, Adrienne L.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">202/1-202/16</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Tumor metastasis remains the major cause of death in cancer patients and, to date, the mechanism and signalling pathways governing this process are not completely understood.  The TGF-β pathway is the most commonly mutated pathway in cancer, however its role in cancer progression is controversial as it can function as both a promoter and a suppressor of metastasis.  Although previous studies have suggested a role for the mol. chaperone Hsp90 in regulating the TGF-β pathway, the level at which this occurs as well as the consequences in terms of colon cancer metastasis are unknown.  The paired SW480 and SW620 colon cancer cell lines, derived from a primary tumor and its lymph node metastasis, resp., were used as an in vitro model to study key cellular processes required for metastasis.  The status of the TGF-β pathway was examd. in these cells using ELISA, flow cytometry, western blot anal. and confocal microscopy.  Furthermore, the effect of addn. or inhibition of the TGF-β pathway and Hsp90 on adhesion, migration and anchorage-independent growth, was detd. in the cell lines.  When comparing the canonical TGF-β1 pathway in the genetically paired cell lines our data suggests that this pathway may be constitutively active in the SW620 metastasis-derived cell line and not the SW480 primary tumor-derived line.  In addn., we report that, when present in combination, TGF-β1 and Hsp90β stimulate anchorage-independent growth, reduce adhesion and stimulate migration.  This effect is potentiated by inhibition of the TGF-β1 receptor and occurs via an alternate TGF-β1 pathway, mediated by αvβ6 integrin.  Interestingly, in the SW620 cells, activation of this alternate TGF-β1 signalling machinery does not appear to require inhibition of the canonical TGF-β1 receptor, which would allow them to respond more effectively to the pro-metastasis stimulus of a combination of Hsp90β and TGF-β1 and this could account for the increased migratory capacity of these cells.  In this study we report an apparent synergy between TGF-β1 and Hsp90β in stimulating migratory behavior of colon cancer cells when signalling occurs via αvβ6 integrin as opposed to the canonical TGF-β1 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpddZ758vu_XbVg90H21EOLACvtfcHk0ljj8otaCdOfTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvVWiu7s%253D&md5=587c86e668f0f5b48b52bb5d24b04e29</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1186%2Fs12885-017-3190-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-017-3190-z%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2Bla%2BMare%26aufirst%3DJ.%2BA.%26aulast%3DJurgens%26aufirst%3DT.%26aulast%3DEdkins%26aufirst%3DA.%2BL.%26atitle%3DExtracellular%2520HSP90%2520and%2520TGFbeta%2520Regulate%2520Adhesion%252C%2520Migration%2520and%2520Anchorage%2520Independent%2520Growth%2520in%2520a%2520Paired%2520Colon%2520Cancer%2520Cell%2520Line%2520Model%26jtitle%3DBMC%2520Cancer%26date%3D2017%26volume%3D17%26spage%3D202%26epage%3D217%26doi%3D10.1186%2Fs12885-017-3190-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fitrolaki, M.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitriou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venihaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katrinaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briassoulis, G.</span></span> <span> </span><span class="NLM_article-title">Increased Extracellular Heat Shock Protein 90α in Severe Sepsis and SIRS Associated with Multiple Organ Failure and Related to Acute Inflammatory-metabolic Stress Response in Children</span>. <i>Medicine</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>95</i></span>, <span class="NLM_elocation-id">e4651</span> <span class="refDoi"> DOI: 10.1097/md.0000000000004651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1097%2FMD.0000000000004651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=27583886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKrtb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2016&author=M.-D.+Fitrolakiauthor=H.+Dimitriouauthor=M.+Venihakiauthor=M.+Katrinakiauthor=S.+Iliaauthor=G.+Briassoulis&title=Increased+Extracellular+Heat+Shock+Protein+90%CE%B1+in+Severe+Sepsis+and+SIRS+Associated+with+Multiple+Organ+Failure+and+Related+to+Acute+Inflammatory-metabolic+Stress+Response+in+Children&doi=10.1097%2Fmd.0000000000004651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Increased extracellular heat shock protein 90α in severe sepsis and SIRS associated with multiple organ failure and related to acute inflammatory-metabolic stress response in children</span></div><div class="casAuthors">Fitrolaki, Michaela-Diana; Dimitriou, Helen; Venihaki, Maria; Katrinaki, Marianna; Ilia, Stavroula; Briassoulis, George</div><div class="citationInfo"><span class="NLM_cas:title">Medicine (Philadelphia, PA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">e4651</span>CODEN:
                <span class="NLM_cas:coden">MEDIAV</span>;
        ISSN:<span class="NLM_cas:issn">0025-7974</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Mammalian heat-shock-protein (HSP) 90α rapidly responses to environmental insults.  We examd. the hypothesis that not only serum HSP72 but also HSP90α is increased in the systemic inflammatory response syndrome (SIRS), severe-sepsis (SS), and/or sepsis (S) compared to healthy children (H); we assessed HSP90α relation to (a) multiple organ system failure (MOSF) and (b) inflammatory-metabolic response and severity of illness.  A total of 65 children with S, SS, or SIRS and 25 H were included.  ELISA was used to evaluate extracellular HSP90α and HSP72, chemiluminescence interleukins (ILs), flow-cytometry neutrophil-CD64 (nCD64)-expression.  HSP90α, along with HSP72, were dramatically increased among MOSF patients.  Patients in septic groups and SIRS had elevated HSP90α compared to H (P<0.01).  HSP90α was independently related to predicted death rate and severity of illness; pos. to HSP72, nCD64, ILs, length of stay, days on ventilator, and fever; neg. to HDL and LDL (P<0.05).  The HSP72 was increased in SS/S and related neg. to HDL and LDL (P<0.05).Serum HSP90α is markedly elevated in children with severe sepsis and is assocd. with MOSF.  Better than the HSP72, also increased in SS, SIRS, and MOSF, HSP90α is related to the inflammatory stress, fever, outcome endpoints, and predicted mortality and inversely related to the low-LDL/low-HDL stress metabolic pattern.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-0mE30n-hW7Vg90H21EOLACvtfcHk0ljj8otaCdOfTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKrtb%252FJ&md5=985e22fc1d9e9d6eb183b7ab3f6a6acf</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1097%2FMD.0000000000004651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMD.0000000000004651%26sid%3Dliteratum%253Aachs%26aulast%3DFitrolaki%26aufirst%3DM.-D.%26aulast%3DDimitriou%26aufirst%3DH.%26aulast%3DVenihaki%26aufirst%3DM.%26aulast%3DKatrinaki%26aufirst%3DM.%26aulast%3DIlia%26aufirst%3DS.%26aulast%3DBriassoulis%26aufirst%3DG.%26atitle%3DIncreased%2520Extracellular%2520Heat%2520Shock%2520Protein%252090%25CE%25B1%2520in%2520Severe%2520Sepsis%2520and%2520SIRS%2520Associated%2520with%2520Multiple%2520Organ%2520Failure%2520and%2520Related%2520to%2520Acute%2520Inflammatory-metabolic%2520Stress%2520Response%2520in%2520Children%26jtitle%3DMedicine%26date%3D2016%26volume%3D95%26doi%3D10.1097%2Fmd.0000000000004651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hance, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, J.</span></span> <span> </span><span class="NLM_article-title">The Double-Edged Sword: Conserved Functions of Extracellular HSP90 in Wound Healing and Cancer</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1065</span>– <span class="NLM_lpage">1097</span>, <span class="refDoi"> DOI: 10.3390/cancers6021065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.3390%2Fcancers6021065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=24805867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Crs7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1065-1097&author=M.+Hanceauthor=K.+Nolanauthor=J.+Isaacs&title=The+Double-Edged+Sword%3A+Conserved+Functions+of+Extracellular+HSP90+in+Wound+Healing+and+Cancer&doi=10.3390%2Fcancers6021065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The double-edged sword: conserved functions of extracellular Hsp90 in wound healing and cancer</span></div><div class="casAuthors">Hance, Michael W.; Nolan, Krystal D.; Isaacs, Jennifer S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1065-1097, 33</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Heat shock proteins (Hsps) represent a diverse group of chaperones that play a vital role in the protection of cells against numerous environmental stresses.  Although our understanding of chaperone biol. has deepened over the last decade, the "atypical" extracellular functions of Hsps have remained somewhat enigmatic and comparatively understudied.  The heat shock protein 90 (Hsp90) chaperone is a prototypic model for an Hsp family member exhibiting a duality of intracellular and extracellular functions.  Intracellular Hsp90 is best known as a master regulator of protein folding.  Cancers are particularly adept at exploiting this function of Hsp90, providing the impetus for the robust clin. development of small mol. Hsp90 inhibitors.  However, in addn. to its maintenance of protein homeostasis, Hsp90 has also been identified as an extracellular protein.  Although early reports ascribed immunoregulatory functions to extracellular Hsp90 (eHsp90), recent studies have illuminated expanded functions for eHsp90 in wound healing and cancer.  While the intended physiol. role of eHsp90 remains enigmatic, its evolutionarily conserved functions in wound healing are easily co-opted during malignancy, a pathol. sharing many properties of wounded tissue.  This review will highlight the emerging functions of eHsp90 and shed light on its seemingly dichotomous roles as a benevolent facilitator of wound healing and as a sinister effector of tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiZA1xjDcTz7Vg90H21EOLACvtfcHk0ljj8otaCdOfTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Crs7bL&md5=ca3a5f3fe7e7c562fe8a5164a45a1bd9</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.3390%2Fcancers6021065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers6021065%26sid%3Dliteratum%253Aachs%26aulast%3DHance%26aufirst%3DM.%26aulast%3DNolan%26aufirst%3DK.%26aulast%3DIsaacs%26aufirst%3DJ.%26atitle%3DThe%2520Double-Edged%2520Sword%253A%2520Conserved%2520Functions%2520of%2520Extracellular%2520HSP90%2520in%2520Wound%2520Healing%2520and%2520Cancer%26jtitle%3DCancers%26date%3D2014%26volume%3D6%26spage%3D1065%26epage%3D1097%26doi%3D10.3390%2Fcancers6021065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barrott, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loiselle, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spector, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajaram, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujam, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidyanathan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalutsky, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyerly, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haystead, T. A.</span></span> <span> </span><span class="NLM_article-title">Optical and Radioiodinated Tethered HSP90 Inhibitors Reveal Selective Internalization of Ectopic HSP90 in Malignant Breast Tumor Cells</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1187</span>– <span class="NLM_lpage">1197</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2013.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1016%2Fj.chembiol.2013.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=24035283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVClur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1187-1197&author=J.+J.+Barrottauthor=P.+F.+Hughesauthor=T.+Osadaauthor=X.-Y.+Yangauthor=Z.+C.+Hartmanauthor=D.+R.+Loiselleauthor=N.+L.+Spectorauthor=L.+Neckersauthor=N.+Rajaramauthor=F.+Huauthor=N.+Ramanujamauthor=G.+Vaidyanathanauthor=M.+R.+Zalutskyauthor=H.+K.+Lyerlyauthor=T.+A.+Haystead&title=Optical+and+Radioiodinated+Tethered+HSP90+Inhibitors+Reveal+Selective+Internalization+of+Ectopic+HSP90+in+Malignant+Breast+Tumor+Cells&doi=10.1016%2Fj.chembiol.2013.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Optical and Radioiodinated Tethered Hsp90 Inhibitors Reveal Selective Internalization of Ectopic Hsp90 in Malignant Breast Tumor Cells</span></div><div class="casAuthors">Barrott, Jared J.; Hughes, Philip F.; Osada, Takuya; Yang, Xiao-Yi; Hartman, Zachary C.; Loiselle, David R.; Spector, Neil L.; Neckers, Len; Rajaram, Narasimhan; Hu, Fangyao; Ramanujam, Nimmi; Vaidyanathan, Ganesan; Zalutsky, Michael R.; Lyerly, H. Kim; Haystead, Timothy A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1187-1197</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Inhibitors of heat-shock protein 90 (Hsp90) have demonstrated an unusual selectivity for tumor cells despite its ubiquitous expression.  This phenomenon has remained unexplained, but could be influenced by ectopically expressed Hsp90 in tumors.  In this work, we synthesized Hsp90 inhibitors that can carry optical or radioiodinated probes via a polyethyleneglycol tether.  We show that these tethered inhibitors selectively recognize cells expressing ectopic Hsp90 and become internalized.  The internalization process is blocked by Hsp90 antibodies, suggesting that active cycling of the protein occurs at the plasma membrane.  In mice, we obsd. exquisite accumulation of the fluor-tethered versions within breast tumors at very sensitive levels.  Cell-based assays with the radiolabeled version showed picomolar detection in cells that express ectopic Hsp90.  Our findings show that fluor-tethered or radiolabeled inhibitors that target ectopic Hsp90 can be used to detect breast cancer malignancies through noninvasive imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFFmoDjspa5LVg90H21EOLACvtfcHk0ljFUEcOi-ljWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVClur7I&md5=050b3c588d30bfcd78d99512c5d88003</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2013.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2013.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DBarrott%26aufirst%3DJ.%2BJ.%26aulast%3DHughes%26aufirst%3DP.%2BF.%26aulast%3DOsada%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DX.-Y.%26aulast%3DHartman%26aufirst%3DZ.%2BC.%26aulast%3DLoiselle%26aufirst%3DD.%2BR.%26aulast%3DSpector%26aufirst%3DN.%2BL.%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DRajaram%26aufirst%3DN.%26aulast%3DHu%26aufirst%3DF.%26aulast%3DRamanujam%26aufirst%3DN.%26aulast%3DVaidyanathan%26aufirst%3DG.%26aulast%3DZalutsky%26aufirst%3DM.%2BR.%26aulast%3DLyerly%26aufirst%3DH.%2BK.%26aulast%3DHaystead%26aufirst%3DT.%2BA.%26atitle%3DOptical%2520and%2520Radioiodinated%2520Tethered%2520HSP90%2520Inhibitors%2520Reveal%2520Selective%2520Internalization%2520of%2520Ectopic%2520HSP90%2520in%2520Malignant%2520Breast%2520Tumor%2520Cells%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D1187%26epage%3D1197%26doi%3D10.1016%2Fj.chembiol.2013.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kajiwara, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizukami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishige, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichiyanagi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hikida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udono, H.</span></span> <span> </span><span class="NLM_article-title">Heat Shock Protein 90 (HSP90) Contributes to Cytosolic Translocation of Extracellular Antigen for Cross-Presentation by Dendritic Cells</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">16363</span>– <span class="NLM_lpage">16368</span>, <span class="refDoi"> DOI: 10.1073/pnas.1108372108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1073%2Fpnas.1108372108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=21930907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Kmtb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=16363-16368&author=T.+Imaiauthor=Y.+Katoauthor=C.+Kajiwaraauthor=S.+Mizukamiauthor=I.+Ishigeauthor=T.+Ichiyanagiauthor=M.+Hikidaauthor=J.-Y.+Wangauthor=H.+Udono&title=Heat+Shock+Protein+90+%28HSP90%29+Contributes+to+Cytosolic+Translocation+of+Extracellular+Antigen+for+Cross-Presentation+by+Dendritic+Cells&doi=10.1073%2Fpnas.1108372108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Heat shock protein 90 (HSP90) contributes to cytosolic translocation of extracellular antigen for cross-presentation by dendritic cells</span></div><div class="casAuthors">Imai, Takashi; Kato, Yu; Kajiwara, Chiaki; Mizukami, Shusaku; Ishige, Ikuo; Ichiyanag, Tomoko; Hikid, Masaki; Wang, Ji-Yang; Udono, Heiichiro</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">16363-16368, S16363/1-S16363/10</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">In antigen (Ag) cross-presentation, dendritic cells (DCs) take up extracellular Ag and translocate them from the endosome to the cytosol for proteasomal degrdn.  The processed peptides can enter the conventional MHC I pathway.  The mols. responsible for the translocation of Ag across the endosomal membrane into the cytosol are unknown.  Here we demonstrate that heat shock protein 90 (HSP90) is crit. for this step.  Cross-presentation and -priming were decreased in both HSP90α-null DCs and mice.  CD8+ DC apoptosis mediated by translocation of exogenous cytochrome c to the cytosol was also eliminated in HSP90α-null mice.  Ag translocation into the cytosol was diminished in HSP90α-null DCs and in DCs treated with an HSP90 inhibitor.  Internalized Ag was assocd. with HSP90 and translocated to the cytosol, a process abrogated by the HSP90 inhibitor.  Ag within purified phagosomes was released in an HSP90-dependent manner.  These results demonstrate the important role of HSP90 in cross-presentation by pulling endosomal Ag out into the cytosol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7VtbQwVgGTLVg90H21EOLACvtfcHk0ljFUEcOi-ljWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Kmtb3N&md5=b1b8c8d2846ae66a1eac717005e7b9d4</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1108372108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1108372108%26sid%3Dliteratum%253Aachs%26aulast%3DImai%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DY.%26aulast%3DKajiwara%26aufirst%3DC.%26aulast%3DMizukami%26aufirst%3DS.%26aulast%3DIshige%26aufirst%3DI.%26aulast%3DIchiyanagi%26aufirst%3DT.%26aulast%3DHikida%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DJ.-Y.%26aulast%3DUdono%26aufirst%3DH.%26atitle%3DHeat%2520Shock%2520Protein%252090%2520%2528HSP90%2529%2520Contributes%2520to%2520Cytosolic%2520Translocation%2520of%2520Extracellular%2520Antigen%2520for%2520Cross-Presentation%2520by%2520Dendritic%2520Cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2011%26volume%3D108%26spage%3D16363%26epage%3D16368%26doi%3D10.1073%2Fpnas.1108372108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span> <span> </span><span class="NLM_article-title">A Series of Camptothecin Prodrugs Exhibit HDAC Inhibition Activity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">4706</span>– <span class="NLM_lpage">4715</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1016%2Fj.bmc.2018.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=30115492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2ktr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=4706-4715&author=Q.+Zhuauthor=X.+Yuauthor=Q.+Shenauthor=Q.+Zhangauthor=M.+Suauthor=Y.+Zhouauthor=J.+Liauthor=Y.+Chenauthor=W.+Lu&title=A+Series+of+Camptothecin+Prodrugs+Exhibit+HDAC+Inhibition+Activity&doi=10.1016%2Fj.bmc.2018.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A series of camptothecin prodrugs exhibit HDAC inhibition activity</span></div><div class="casAuthors">Zhu, Qiwen; Yu, Xumeng; Shen, Qianqian; Zhang, Qiumeng; Su, Mingbo; Zhou, Yubo; Li, Jia; Chen, Yi; Lu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4706-4715</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Camptothecin plays an important role in clin. cancer treatment, and its derivs. are a favorite of pharmaceutical chemists.  Herein, we have designed a series of camptothecin prodrugs that exhibit histone deacetylase (HDAC) inhibition activity based on the synergy effect between HDAC inhibitors and camptothecin derivs.  With the evaluation of stability in buffers or plasma from human or mouse model, an appropriate linker was found, so the active drug can be released efficiently and compd. 21a exhibited strong antiproliferative activity in A549 and HCT-116 cell lines.  These results indicated that the well-designed prodrug can be promising in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx5LUHT80gE7Vg90H21EOLACvtfcHk0ljFUEcOi-ljWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2ktr7L&md5=42b4b841a2be5cc98623923481eded7c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DW.%26atitle%3DA%2520Series%2520of%2520Camptothecin%2520Prodrugs%2520Exhibit%2520HDAC%2520Inhibition%2520Activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D4706%26epage%3D4715%26doi%3D10.1016%2Fj.bmc.2018.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vijayalakshmi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malugin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghandehari, H.</span></span> <span> </span><span class="NLM_article-title">Carboxyl-Terminated PAMAM-SN38 Conjugates: Synthesis, Characterization, and in Vitro Evaluation</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1804</span>– <span class="NLM_lpage">1810</span>, <span class="refDoi"> DOI: 10.1021/bc100094z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc100094z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFCkt7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=1804-1810&author=N.+Vijayalakshmiauthor=A.+Rayauthor=A.+Maluginauthor=H.+Ghandehari&title=Carboxyl-Terminated+PAMAM-SN38+Conjugates%3A+Synthesis%2C+Characterization%2C+and+in+Vitro+Evaluation&doi=10.1021%2Fbc100094z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Carboxyl-Terminated PAMAM-SN38 Conjugates: Synthesis, Characterization, and in Vitro Evaluation</span></div><div class="casAuthors">Vijayalakshmi, Nirmalkumar; Ray, Abhijit; Malugin, Alexander; Ghandehari, Hamidreza</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1804-1810</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this work, carboxyl-terminated PAMAM G-3.5 was covalently attached to SN38 via glycine and β-alanine spacers.  The conjugates were stable at pH 7.4 and moderately hydrolyzed in cell culture media and rat plasma.  Similarly to SN38 but to a lesser extent, both conjugates inhibited proliferation of human colorectal cancer HCT-116 cells, arrested the cell cycle in the G2/M phase, and led to nuclear fragmentation.  However, activity of the conjugate with glycine spacer (IC50 = 129 nM) was higher compared to that of the β-alanine linked conjugate (IC50 = 387 nM).  These PAMAM-SN38 conjugates have the potential for targeted therapy of colorectal carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4Dx2W3JD1ULVg90H21EOLACvtfcHk0lhkEo2YfZeItA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFCkt7zK&md5=993a0efab7337858508ed10df2004d13</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fbc100094z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc100094z%26sid%3Dliteratum%253Aachs%26aulast%3DVijayalakshmi%26aufirst%3DN.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DMalugin%26aufirst%3DA.%26aulast%3DGhandehari%26aufirst%3DH.%26atitle%3DCarboxyl-Terminated%2520PAMAM-SN38%2520Conjugates%253A%2520Synthesis%252C%2520Characterization%252C%2520and%2520in%2520Vitro%2520Evaluation%26jtitle%3DBioconjugate%2520Chem.%26date%3D2010%26volume%3D21%26spage%3D1804%26epage%3D1810%26doi%3D10.1021%2Fbc100094z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, K.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, C.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jan, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pak, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, T.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsou, L. K.</span></span> <span> </span><span class="NLM_article-title">Targeting Tumor Associated Phosphatidylserine with New Zinc Dipicolylamine-Based Drug Conjugates</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1878</span>– <span class="NLM_lpage">1892</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.7b00225</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.7b00225" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1eku7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&pages=1878-1892&author=Y.-W.+Liuauthor=K.-S.+Shiaauthor=C.-H.+Wuauthor=K.-L.+Liuauthor=Y.-C.+Yehauthor=C.-F.+Loauthor=C.-T.+Chenauthor=Y.-Y.+Chenauthor=T.-K.+Yehauthor=W.-H.+Chenauthor=J.-J.+Janauthor=Y.-C.+Huangauthor=C.-L.+Huangauthor=M.-Y.+Fangauthor=B.+D.+Grayauthor=K.+Y.+Pakauthor=T.-A.+Hsuauthor=K.-H.+Huangauthor=L.+K.+Tsou&title=Targeting+Tumor+Associated+Phosphatidylserine+with+New+Zinc+Dipicolylamine-Based+Drug+Conjugates&doi=10.1021%2Facs.bioconjchem.7b00225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Tumor Associated Phosphatidylserine with New Zinc Dipicolylamine-Based Drug Conjugates</span></div><div class="casAuthors">Liu, Yu-Wei; Shia, Kak-Shan; Wu, Chien-Huang; Liu, Kuan-Liang; Yeh, Yu-Cheng; Lo, Chen-Fu; Chen, Chiung-Tong; Chen, Yun-Yu; Yeh, Teng-Kuang; Chen, Wei-Han; Jan, Jiing-Jyh; Huang, Yu-Chen; Huang, Chen-Lung; Fang, Ming-Yu; Gray, Brian D.; Pak, Koon Y.; Hsu, Tsu-An; Huang, Kuan-Hsun; Tsou, Lun K.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1878-1892</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of zinc(II) dipicolylamine (ZnDPA)-based drug conjugates have been synthesized to probe the potential of phosphatidylserine (PS) as a new antigen for small mol. drug conjugate (SMDC) development.  Using in vitro cytotoxicity and plasma stability studies, PS-binding assay, in vivo pharmacokinetic studies, and max. tolerated dose profiles, the authors provided a road-map and the key parameters required for the development of the ZnDPA based drug conjugate.  In particular, conjugate 24 (I) induced tumor regression in the COLO 205 xenograft model and exhibited a more potent antitumor effect with a 70% redn. of cytotoxic payload compared to that of the marketed irinotecan when dosed at the same regimen.  In addn. to the validation of PS as an effective pharmaco-delivery target for SMDC, the authors' work also provided the foundation that, if applicable, a variety of therapeutic agents could be conjugated in the same manner to treat other PS-assocd. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-tzlnmny8VrVg90H21EOLACvtfcHk0lhkEo2YfZeItA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1eku7w%253D&md5=d34ce65c240dee8168e3639b19136c8a</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.7b00225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.7b00225%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.-W.%26aulast%3DShia%26aufirst%3DK.-S.%26aulast%3DWu%26aufirst%3DC.-H.%26aulast%3DLiu%26aufirst%3DK.-L.%26aulast%3DYeh%26aufirst%3DY.-C.%26aulast%3DLo%26aufirst%3DC.-F.%26aulast%3DChen%26aufirst%3DC.-T.%26aulast%3DChen%26aufirst%3DY.-Y.%26aulast%3DYeh%26aufirst%3DT.-K.%26aulast%3DChen%26aufirst%3DW.-H.%26aulast%3DJan%26aufirst%3DJ.-J.%26aulast%3DHuang%26aufirst%3DY.-C.%26aulast%3DHuang%26aufirst%3DC.-L.%26aulast%3DFang%26aufirst%3DM.-Y.%26aulast%3DGray%26aufirst%3DB.%2BD.%26aulast%3DPak%26aufirst%3DK.%2BY.%26aulast%3DHsu%26aufirst%3DT.-A.%26aulast%3DHuang%26aufirst%3DK.-H.%26aulast%3DTsou%26aufirst%3DL.%2BK.%26atitle%3DTargeting%2520Tumor%2520Associated%2520Phosphatidylserine%2520with%2520New%2520Zinc%2520Dipicolylamine-Based%2520Drug%2520Conjugates%26jtitle%3DBioconjugate%2520Chem.%26date%3D2017%26volume%3D28%26spage%3D1878%26epage%3D1892%26doi%3D10.1021%2Facs.bioconjchem.7b00225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulysse, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mobele, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawless, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garigipati, R.</span></span> <span> </span><span class="NLM_article-title">Process Development and Scale-Up of an HSP90 Inhibitor</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1787</span>– <span class="NLM_lpage">1793</span>, <span class="refDoi"> DOI: 10.1021/op300262z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op300262z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFGmurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=1787-1793&author=S.+Duanauthor=S.+Venkatramanauthor=X.+Hongauthor=K.+Huangauthor=L.+Ulysseauthor=B.+I.+Mobeleauthor=A.+Smithauthor=L.+Lawlessauthor=A.+Lockeauthor=R.+Garigipati&title=Process+Development+and+Scale-Up+of+an+HSP90+Inhibitor&doi=10.1021%2Fop300262z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Process Development and Scale-Up of an Hsp90 Inhibitor</span></div><div class="casAuthors">Duan, Shengquan; Venkatraman, Sripathy; Hong, Xuechuan; Huang, Kenneth; Ulysse, Luckner; Mobele, Bingidimi I.; Smith, Alexander; Lawless, Lawrence; Locke, Andrew; Garigipati, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1787-1793</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A scalable process for the manuf. of a Hsp90 inhibitor was developed and optimized.  Key features in the seven-step process include a selective SNAr reaction followed by an Ullmann-type coupling of indazolone to an aryl halide.  This improved process afforded 65% yield over two crit. steps compared to 25% following the Medicinal Chem. route.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMdQ2WiapIA7Vg90H21EOLACvtfcHk0lhEbSyqzxV6LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFGmurzL&md5=5008804715694ce424e4e7a7a9a76df1</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fop300262z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop300262z%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DS.%26aulast%3DVenkatraman%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DK.%26aulast%3DUlysse%26aufirst%3DL.%26aulast%3DMobele%26aufirst%3DB.%2BI.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DLawless%26aufirst%3DL.%26aulast%3DLocke%26aufirst%3DA.%26aulast%3DGarigipati%26aufirst%3DR.%26atitle%3DProcess%2520Development%2520and%2520Scale-Up%2520of%2520an%2520HSP90%2520Inhibitor%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2012%26volume%3D16%26spage%3D1787%26epage%3D1793%26doi%3D10.1021%2Fop300262z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of Paclitaxel and Camptothecin Prodrugs on the Basis of 2-Nitroimidazole</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">762</span>– <span class="NLM_lpage">765</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00189</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00189" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVOntrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=762-765&author=C.+Jinauthor=S.+Wenauthor=Q.+Zhangauthor=Q.+Zhuauthor=J.+Yuauthor=W.+Lu&title=Synthesis+and+Biological+Evaluation+of+Paclitaxel+and+Camptothecin+Prodrugs+on+the+Basis+of+2-Nitroimidazole&doi=10.1021%2Facsmedchemlett.7b00189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of Paclitaxel and Camptothecin Prodrugs on the Basis of 2-Nitroimidazole</span></div><div class="casAuthors">Jin, Chen; Wen, Shuai; Zhang, Qiumeng; Zhu, Qiwen; Yu, Jiahui; Lu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">762-765</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Due to the low esterase activity in human plasma, many ester and carbonate prodrugs tested in humans may be less effective than that in preclin. animals.  In this letter, PTX and SN-38 were attached to the N-1 position of 2-nitroimidazole via a carbonate linker.  Presumably, 2-aminoimidazole may help promote the intramol. hydrolysis of the carbonate bond.  The prodrugs exhibited a considerable stability in buffers at different pH values as well as in human plasma.  Furthermore, a rapid redn. was exhibited in the presence of nitroreductase.  An in vitro cytotoxicity assay demonstrated that hypoxic conditions could increase the toxicity of prodrugs.  Potentially, the compd. species may form a new class of promising antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnej5sz_niErVg90H21EOLACvtfcHk0lhEbSyqzxV6LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVOntrbN&md5=b0bb3465cda518dba368eeb0549f3bcb</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00189%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DC.%26aulast%3DWen%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DW.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%2520Paclitaxel%2520and%2520Camptothecin%2520Prodrugs%2520on%2520the%2520Basis%2520of%25202-Nitroimidazole%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D762%26epage%3D765%26doi%3D10.1021%2Facsmedchemlett.7b00189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Z.</span></span> <span> </span><span class="NLM_article-title">Methotrexate-Camptothecin Prodrug Nanoassemblies as a Versatile Nanoplatform for Biomodal Imaging-Guided Self-Active Targeted and Synergistic Chemotherapy</span>. <i>ACS Appl. Mater. Interfaces</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">34650</span>– <span class="NLM_lpage">34665</span>, <span class="refDoi"> DOI: 10.1021/acsami.7b10027</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsami.7b10027" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWjtL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=34650-34665&author=Y.+Liauthor=J.+Linauthor=J.+Maauthor=L.+Songauthor=H.+Linauthor=B.+Tangauthor=D.+Chenauthor=G.+Suauthor=S.+Yeauthor=X.+Zhuauthor=F.+Luoauthor=Z.+Hou&title=Methotrexate-Camptothecin+Prodrug+Nanoassemblies+as+a+Versatile+Nanoplatform+for+Biomodal+Imaging-Guided+Self-Active+Targeted+and+Synergistic+Chemotherapy&doi=10.1021%2Facsami.7b10027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Methotrexate-Camptothecin Prodrug Nanoassemblies as a Versatile Nanoplatform for Biomodal Imaging-Guided Self-Active Targeted and Synergistic Chemotherapy</span></div><div class="casAuthors">Li, Yang; Lin, Jinyan; Ma, Jinyuan; Song, Liang; Lin, Huirong; Tang, Bowen; Chen, Dengyue; Su, Guanghao; Ye, Shefang; Zhu, Xuan; Luo, Fanghong; Hou, Zhenqing</div><div class="citationInfo"><span class="NLM_cas:title">ACS Applied Materials & Interfaces</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">34650-34665</span>CODEN:
                <span class="NLM_cas:coden">AAMICK</span>;
        ISSN:<span class="NLM_cas:issn">1944-8244</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">"All-in-one" carrier-free-based nano-multi-drug self-delivery system could combine triple advantages of small mols., nanoscale characteristics, and synergistic combination therapy together.  Researches have showed that dual-acting small-mol. methotrexate (MTX) could target and kill the folate-receptor-overexpressing cancer cells.  Inspired by this mechanism, a novel collaborative early-phase tumor-selective targeting and late-phase synergistic anticancer approach was developed for the self-assembly of chemotherapeutic drug-drug conjugate, which showed various advantages of more simplicity, efficiency, and flexibility over the conventional approach based only on single or combination cancer chemotherapy.  MTX and 10-hydroxyl camptothecin (CPT) were chosen to conjugate through ester linkage.  Because of the amphiphilicity and ionicity, MTX-CPT conjugates as mol. building blocks could self-assemble into MTX-CPT nanoparticles (MTX-CPT NPs) in aq. soln., thus notably improving the aq. soly. of CPT and the membrane permeability of MTX.  The MTX-CPT NPs with a precise drug-to-drug ratio showed pH-/esterase-responsive drug release, sequential function "Targeting-Anticancer" switch, and real-time monitoring fluorescence "Off-On" switch.  By doping with a lipophilic near-IR (NIR) cyanine dye (e.g., 1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide, DiR), the prepd. DiR-loaded MTX-CPT NPs acted as an effective probe for in vivo NIR fluorescence (NIRF) and photoacoustic (PA) dual-modal imaging.  Both in vitro and in vivo studies demonstrated that MTX-CPT NPs could specifically codeliver multidrug to different sites of action with distinct anticancer mechanisms to kill folate-receptor-overexpressing tumor cells in a synergistic way.  This novel, simple, and highly convergent self-targeting nanomulti-drug codelivery system exhibited great potential in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolahiNrDCJt7Vg90H21EOLACvtfcHk0ljGU15HmZyMHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWjtL7F&md5=1b0aafe2552823a974b2e082130e8b7b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facsami.7b10027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsami.7b10027%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DTang%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DSu%26aufirst%3DG.%26aulast%3DYe%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLuo%26aufirst%3DF.%26aulast%3DHou%26aufirst%3DZ.%26atitle%3DMethotrexate-Camptothecin%2520Prodrug%2520Nanoassemblies%2520as%2520a%2520Versatile%2520Nanoplatform%2520for%2520Biomodal%2520Imaging-Guided%2520Self-Active%2520Targeted%2520and%2520Synergistic%2520Chemotherapy%26jtitle%3DACS%2520Appl.%2520Mater.%2520Interfaces%26date%3D2017%26volume%3D9%26spage%3D34650%26epage%3D34665%26doi%3D10.1021%2Facsami.7b10027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockwin, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingshead, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, D. L.</span></span> <span> </span><span class="NLM_article-title">Proteomic Analysis of Nuclei Isolated from Cancer Cell Lines Treated with Indenoisoquinoline NSC 724998, a Novel Topoisomerase I Inhibitor</span>. <i>J. Proteome Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4016</span>– <span class="NLM_lpage">4027</span>, <span class="refDoi"> DOI: 10.1021/pr100194d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/pr100194d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnsFyhurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=4016-4027&author=B.+Hanauthor=L.+H.+Stockwinauthor=C.+Hancockauthor=S.+X.+Yuauthor=M.+G.+Hollingsheadauthor=D.+L.+Newton&title=Proteomic+Analysis+of+Nuclei+Isolated+from+Cancer+Cell+Lines+Treated+with+Indenoisoquinoline+NSC+724998%2C+a+Novel+Topoisomerase+I+Inhibitor&doi=10.1021%2Fpr100194d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Proteomic Analysis of Nuclei Isolated from Cancer Cell Lines Treated with Indenoisoquinoline NSC 724998, a Novel Topoisomerase I Inhibitor</span></div><div class="casAuthors">Han, Bingnan; Stockwin, Luke H.; Hancock, Chad; Yu, Sherry X.; Hollingshead, Melinda G.; Newton, Dianne L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteome Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4016-4027</span>CODEN:
                <span class="NLM_cas:coden">JPROBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-3893</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The indenoisoquinoline NSC724998 is a novel topoisomerase I (Top1) inhibitor entering Phase I clin. trials at the National Cancer Institute, USA.  In this study, 2-D PAGE anal. was performed on nuclear lysates prepd. from HCT-116 and A375 cells treated with 1 μM NSC724998 for 24 h and the differentially regulated spots identified by LC-MS/MS.  One-hundred fourteen protein spot differentials were identified, 66 from A375 cells and 48 from HCT-116 cells.  Proteins related to apoptosis changed specifically in A375 cells, whereas proteins involved in the ubiquitin-proteasome system were highly enriched in treated HCT-116 cells.  Importantly, 12 differentially expressed proteins (ETFA, HCC1, HNRCL, KAP1, NPM, NUCL, PRDX1, PRP19, PSB6, RAE1L, RU2A, and SFRS9) were common to both cell lines.  Western blotting and immunocytochem. confirmed significant nuclear upregulation of both the proteasome subunit PSB6 and the transcriptional repressor KAP1.  Interestingly, increased KAP1 polypeptide was accompanied by enhanced phosphorylation at Ser824.  Similar to γH2AX, KAP1 phosphorylation was consistently enhanced in a panel of 12 cell lines and in A375 xenografts following NSC 724998 treatment.  In summary, these data enhance our understanding of protein dynamics in the nucleus following DNA damage and provide an alternate marker (pKAP1) with potential for monitoring clin. responses to Top1 poisons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjtMiyLNqSgbVg90H21EOLACvtfcHk0ljGU15HmZyMHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnsFyhurg%253D&md5=377e79c823812cec28ddd4fefd5097f9</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fpr100194d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fpr100194d%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DB.%26aulast%3DStockwin%26aufirst%3DL.%2BH.%26aulast%3DHancock%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DS.%2BX.%26aulast%3DHollingshead%26aufirst%3DM.%2BG.%26aulast%3DNewton%26aufirst%3DD.%2BL.%26atitle%3DProteomic%2520Analysis%2520of%2520Nuclei%2520Isolated%2520from%2520Cancer%2520Cell%2520Lines%2520Treated%2520with%2520Indenoisoquinoline%2520NSC%2520724998%252C%2520a%2520Novel%2520Topoisomerase%2520I%2520Inhibitor%26jtitle%3DJ.%2520Proteome%2520Res.%26date%3D2010%26volume%3D9%26spage%3D4016%26epage%3D4027%26doi%3D10.1021%2Fpr100194d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desai, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez-Abad, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arpa, P.</span></span> <span> </span><span class="NLM_article-title">Ubiquitin-dependent Destruction of Topoisomerase I is Stimulated by the Antitumor Drug Camptothecin</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>272</i></span>,  <span class="NLM_fpage">24159</span>– <span class="NLM_lpage">24164</span>, <span class="refDoi"> DOI: 10.1074/jbc.272.39.24159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1074%2Fjbc.272.39.24159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=9305865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADyaK2sXmsFanu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=24159-24164&author=S.+D.+Desaiauthor=L.+F.+Liuauthor=D.+Vazquez-Abadauthor=P.+D%E2%80%99Arpa&title=Ubiquitin-dependent+Destruction+of+Topoisomerase+I+is+Stimulated+by+the+Antitumor+Drug+Camptothecin&doi=10.1074%2Fjbc.272.39.24159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin</span></div><div class="casAuthors">Desai, Shyamal D.; Liu, Leroy F.; Vazquez-Abad, Dolores; D'arpa, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">24159-24164</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Topoisomerase I (TOP1) relaxes superhelical DNA through a breakage/rejoining reaction in which the active site tyrosine links covalently to a 3' phosphate at the break site as a transient intermediate.  The antitumor drug camptothecin (CPT) and its analogs inhibit the rejoining step of the breakage/rejoining reaction, which traps the enzyme in covalent linkage with DNA (the cleavable complex).  Little is known about the fate of cellular TOP1 trapped in the cleavable complex.  We have analyzed TOP1 in mammalian cell lines treated with CPT.  When CPT-treated cells were lysed with either SDS or alkali and analyzed by Western blotting, greater than 90% of the TOP1 was linked to DNA.  Nuclease treatment of the cell lysate to remove the covalently linked DNA from TOP1 revealed a distinct ladder of higher mol. wt. bands having properties indicative of multi-ubiquitin (Ub) conjugates of TOP1.  Approx. 5-10% of TOP1 was present as these conjugates within minutes of CPT treatment.  Consistent with ubiquitination, TOP1 was not modified in ts85 cells at the restrictive temp. for its thermolabile ubiquitin-activating enzyme (E1).  Because conjugation with ubiquitin can mark proteins for destruction by the 26S proteasome, we analyzed TOP1 protein levels during prolonged CPT treatment.  TOP1 protein levels were reduced to about 25% during CPT treatments of 2-4 h resulting from increased destruction, with the half-life dropping from 10-16 h down to 1-2 h.  The destruction of TOP1, like the formation of Ub-TOP1 conjugates, was not obsd. in ts85 cells at the restrictive temp.  The destruction of TOP1 was also prevented in cells treated with MG-132 and lactacystin, specific inhibitors of the 26S proteasome.  Finally, the multi-Ub conjugates of TOP1 were obsd. whether or not aphidicolin was included in cotreatment with CPT, indicating that replication fork activity was not involved in making TOP1 a substrate for ubiquitination.  These results demonstrate that independent of DNA replication, the TOP1 cleavable complex is ubiquitinated and destroyed in cells treated with antitumor drugs that block the religation step of the TOP1 reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjEG1WhFh4prVg90H21EOLACvtfcHk0ljGU15HmZyMHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmsFanu74%253D&md5=56f78f9480b55130ffb906764c265516</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1074%2Fjbc.272.39.24159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.272.39.24159%26sid%3Dliteratum%253Aachs%26aulast%3DDesai%26aufirst%3DS.%2BD.%26aulast%3DLiu%26aufirst%3DL.%2BF.%26aulast%3DVazquez-Abad%26aufirst%3DD.%26aulast%3DD%25E2%2580%2599Arpa%26aufirst%3DP.%26atitle%3DUbiquitin-dependent%2520Destruction%2520of%2520Topoisomerase%2520I%2520is%2520Stimulated%2520by%2520the%2520Antitumor%2520Drug%2520Camptothecin%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D24159%26epage%3D24164%26doi%3D10.1074%2Fjbc.272.39.24159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kersey, J.</span></span> <span> </span><span class="NLM_article-title">Synergism Between Etoposide and 17-AAG in Leukemia Cells: Critical Roles for HSP90, FLT3, Topoisomerase II, Chk1, and Rad51</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1591</span>– <span class="NLM_lpage">1600</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-06-1750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1158%2F1078-0432.CCR-06-1750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=17332306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitlSjtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1591-1600&author=Q.+Yaoauthor=B.+Weigelauthor=J.+Kersey&title=Synergism+Between+Etoposide+and+17-AAG+in+Leukemia+Cells%3A+Critical+Roles+for+HSP90%2C+FLT3%2C+Topoisomerase+II%2C+Chk1%2C+and+Rad51&doi=10.1158%2F1078-0432.ccr-06-1750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51</span></div><div class="casAuthors">Yao, Qing; Weigel, Brenda; Kersey, John</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1591-1600</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">DNA-damaging agents, such as etoposide, while clin. useful in leukemia therapy, are limited by DNA repair pathways that are not well understood.  17-(Allylamino)-17-demethoxygeldanamycin (17-AAG), an inhibitor of the mol. chaperone heat shock protein 90 (Hsp90), inhibits growth and induces apoptosis in FLT3+ leukemia cells.  In this study, we evaluated the effects of etoposide and 17-AAG in leukemia cells and the roles of Hsp90, FMS-like tyrosine kinase 3 (FLT3), checkpoint kinase 1 (Chk1), Rad51, and topoisomerase II in this inhibition.  The single and combined effects of 17-AAG and etoposide and the mechanism of these effects were evaluated.  FLT3 and the DNA repair-related proteins, Chk1 and Rad51, were studied in small interfering RNA (siRNA)-induced cell growth inhibition expts. in human leukemia cells with wild-type or mutated FLT3.  We found that etoposide and the Hsp90/FLT3 inhibitor 17-AAG, had synergistic inhibitory effects on FLT3+ MLL-fusion gene leukemia cells.  Cells with an internal tandem duplication (ITD) FLT3 (Molm13 and MV4;11) were more sensitive to etoposide/17-AAG than leukemias with wild-type FLT3 (HPB-Null and RS4;11).  A crit. role for FLT3 was shown in expts. with FLT3 ligand and siRNA targeted to FLT3.  An important role for topoisomerase II and the DNA repair-related proteins, Chk1 and Rad51, in the synergistic effects was suggested from the results.  The repair of potentially lethal DNA damage by etoposide in leukemia cells is dependent on intact and functioning FLT3 esp. leukemias with ITD-FLT3.  These data suggest a rational therapeutic strategy for FLT3+ leukemias that combines etoposide or other DNA-damaging agents with Hsp90/FLT3 inhibitors such as 17-AAG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYkcf05rkfnbVg90H21EOLACvtfcHk0lgliX9Z8df_xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitlSjtLY%253D&md5=1baa24d5f1f46ce7eb7ee2eda7075da1</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1750%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DQ.%26aulast%3DWeigel%26aufirst%3DB.%26aulast%3DKersey%26aufirst%3DJ.%26atitle%3DSynergism%2520Between%2520Etoposide%2520and%252017-AAG%2520in%2520Leukemia%2520Cells%253A%2520Critical%2520Roles%2520for%2520HSP90%252C%2520FLT3%252C%2520Topoisomerase%2520II%252C%2520Chk1%252C%2520and%2520Rad51%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D1591%26epage%3D1600%26doi%3D10.1158%2F1078-0432.ccr-06-1750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barker, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamlett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundgren, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lough, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, A. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, J. R.</span></span> <span> </span><span class="NLM_article-title">The Topoisomerase II-HSP90 Complex: a New Chemotherapeutic Target?</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">2685</span>– <span class="NLM_lpage">2693</span>, <span class="refDoi"> DOI: 10.1002/ijc.21717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1002%2Fijc.21717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=16385570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BD28Xks1Sis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2006&pages=2685-2693&author=C.+R.+Barkerauthor=J.+Hamlettauthor=S.+R.+Penningtonauthor=F.+Burrowsauthor=K.+Lundgrenauthor=R.+Loughauthor=A.+J.+M.+Watsonauthor=J.+R.+Jenkins&title=The+Topoisomerase+II-HSP90+Complex%3A+a+New+Chemotherapeutic+Target%3F&doi=10.1002%2Fijc.21717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The topoisomerase II-Hsp90 complex: a new chemotherapeutic target?</span></div><div class="casAuthors">Barker, Catherine R.; Hamlett, Jane; Pennington, Stephen R.; Burrows, Francis; Lundgren, Karen; Lough, Rachel; Watson, Alastair J. M.; Jenkins, John R.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2685-2693</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The modulation of DNA topol. by topoisomerase II plays a crucial role during chromosome condensation and segregation in mitosis and has thus become a highly attractive target for chemotherapeutic drugs.  However, these drugs are highly toxic, and so new approaches are required.  One such strategy is to target topoisomerase II-interacting proteins.  Here the authors report the identification of potential topoisomerase II-assocd. proteins using immunopptn., followed by 1-D and 2-D gel electrophoresis and MALDI-TOF mass spectrometry.  A total of 23 proteins were identified and, of these, 17 were further validated as topoisomerase IIα-assocd. proteins by coimmunopptn. and Western blot.  Six of the interacting proteins were cellular chaperones, including 3 members of the heat shock protein-90 (Hsp90) family, and so the effect of Hsp90 modulation on the antitumor activity of topoisomerase II drugs was tested using the sulforhodamine B assay, clonogenic assays and a xenograft model.  The Hsp90 inhibitors geldanamycin, 17-AAG (17-allylamino-17-demethoxygeldanamycin) and radicicol significantly enhanced the activity of the topoisomerase II poisons etoposide and mitoxantrone in vitro and in vivo.  Thus, our method of identifying topoisomerase II-interacting proteins appears to be effective, and at least 1 novel topoisomerase IIα-assocd. protein, Hsp90, may represent a valid drug target in the context of topoisomerase II-directed chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlEn2KpNPi8rVg90H21EOLACvtfcHk0lgliX9Z8df_xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xks1Sis78%253D&md5=60da6950c1625ded6e925ee745fb645f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fijc.21717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.21717%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DC.%2BR.%26aulast%3DHamlett%26aufirst%3DJ.%26aulast%3DPennington%26aufirst%3DS.%2BR.%26aulast%3DBurrows%26aufirst%3DF.%26aulast%3DLundgren%26aufirst%3DK.%26aulast%3DLough%26aufirst%3DR.%26aulast%3DWatson%26aufirst%3DA.%2BJ.%2BM.%26aulast%3DJenkins%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520Topoisomerase%2520II-HSP90%2520Complex%253A%2520a%2520New%2520Chemotherapeutic%2520Target%253F%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2006%26volume%3D118%26spage%3D2685%26epage%3D2693%26doi%3D10.1002%2Fijc.21717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pennisi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascenzi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">di Masi, A.</span></span> <span> </span><span class="NLM_article-title">HSP90: A New Player in DNA Repair?</span>. <i>Biomolecules</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">2589</span>– <span class="NLM_lpage">2618</span>, <span class="refDoi"> DOI: 10.3390/biom5042589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.3390%2Fbiom5042589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=26501335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslWqtrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=2589-2618&author=R.+Pennisiauthor=P.+Ascenziauthor=A.+di+Masi&title=HSP90%3A+A+New+Player+in+DNA+Repair%3F&doi=10.3390%2Fbiom5042589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90: a new player in DNA repair?</span></div><div class="casAuthors">Pennisi, Rosa; Ascenzi, Paolo; di Masi, Alessandra</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecules</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2589-2618</span>CODEN:
                <span class="NLM_cas:coden">BIOMHC</span>;
        ISSN:<span class="NLM_cas:issn">2218-273X</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) is an evolutionary conserved mol. chaperone that, together with Hsp70 and co-chaperones makes up the Hsp90 chaperone machinery, stabilizing and activating more than 200 proteins, involved in protein homeostasis (i.e., proteostasis), transcriptional regulation, chromatin remodeling, and DNA repair.  Cells respond to DNA damage by activating complex DNA damage response (DDR) pathways that include: (i) cell cycle arrest; (ii) transcriptional and post-translational activation of a subset of genes, including those assocd. with DNA repair; and (iii) triggering of programmed cell death.  The efficacy of the DDR pathways is influenced by the nuclear levels of DNA repair proteins, which are regulated by balancing between protein synthesis and degrdn. as well as by nuclear import and export.  The inability to respond properly to either DNA damage or to DNA repair leads to genetic instability, which in turn may enhance the rate of cancer development.  Multiple components of the DNA double strand breaks repair machinery, including BRCA1, BRCA2, CHK1, DNA-PKcs, FANCA, and the MRE11/RAD50/NBN complex, have been described to be client proteins of Hsp90, which acts as a regulator of the diverse DDR pathways.  Inhibition of Hsp90 actions leads to the altered localization and stabilization of DDR proteins after DNA damage and may represent a cell-specific and tumor-selective radiosensibilizer.  Here, the role of Hsp90-dependent mol. mechanisms involved in cancer onset and in the maintenance of the genome integrity is discussed and highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0Z1A7csYOK7Vg90H21EOLACvtfcHk0lgliX9Z8df_xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslWqtrbJ&md5=ba0f35f4e2c58df42ee9258b7da5c1f5</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.3390%2Fbiom5042589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fbiom5042589%26sid%3Dliteratum%253Aachs%26aulast%3DPennisi%26aufirst%3DR.%26aulast%3DAscenzi%26aufirst%3DP.%26aulast%3Ddi%2BMasi%26aufirst%3DA.%26atitle%3DHSP90%253A%2520A%2520New%2520Player%2520in%2520DNA%2520Repair%253F%26jtitle%3DBiomolecules%26date%3D2015%26volume%3D5%26spage%3D2589%26epage%3D2618%26doi%3D10.3390%2Fbiom5042589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L.</span></span> <span> </span><span class="NLM_article-title">HSP90 Inhibitors as Novel Cancer Chemotherapeutic Agents</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">S55</span>– <span class="NLM_lpage">S61</span>, <span class="refDoi"> DOI: 10.1016/s1471-4914(02)02316-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1016%2FS1471-4914%2802%2902316-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=11927289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BD38XitlGhsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=S55-S61&author=L.+Neckers&title=HSP90+Inhibitors+as+Novel+Cancer+Chemotherapeutic+Agents&doi=10.1016%2Fs1471-4914%2802%2902316-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 inhibitors as novel cancer chemotherapeutic agents</span></div><div class="casAuthors">Neckers, Len</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4, Suppl.</span>),
    <span class="NLM_cas:pages">S55-S61</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Heat shock protein 90 (Hsp90) is a mol. chaperone whose assocn. is required for the stability and function of multiple mutated, chimeric, and over-expressed signaling proteins that promote the growth and/or survival of cancer cells.  Hsp90 client proteins include mutated p53, Bcr-Abl, Raf-1, Akt, ErbB2, and hypoxia-inducible factor 1α (HIF-1α).  Hsp90 inhibitors, by interacting specifically with a single mol. target, cause the destabilization and eventual degrdn. of Hsp90 client proteins, and they have shown promising antitumor activity in preclin. model systems.  One Hsp90 inhibitor, 17-allylaminogeldanamycin (17AAG), is currently in phase I clin. trial.  Because of the chemoprotective activity of several proteins that are Hsp90 clients, the combination of an Hsp90 inhibitor with a std. chemotherapeutic agent could dramatically increase the in vivo efficacy of the therapeutic agent.  Hsp90 inhibitors are unique in that, although they are directed towards a specific mol. target, they simultaneously inhibit multiple signaling pathways on which cancer cells depend for growth and survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlxGwoIjoNFbVg90H21EOLACvtfcHk0lh6ABulDEjxXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitlGhsb4%253D&md5=451ae753ae1ef5a171647d29c49d6866</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2FS1471-4914%2802%2902316-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1471-4914%252802%252902316-X%26sid%3Dliteratum%253Aachs%26aulast%3DNeckers%26aufirst%3DL.%26atitle%3DHSP90%2520Inhibitors%2520as%2520Novel%2520Cancer%2520Chemotherapeutic%2520Agents%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2002%26volume%3D8%26spage%3DS55%26epage%3DS61%26doi%3D10.1016%2Fs1471-4914%2802%2902316-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newton, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, A. Y.</span></span> <span> </span><span class="NLM_article-title">Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">158</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=7720520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADyaK2MXjtVOrur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1995&pages=154-158&author=D.+J.+Newtonauthor=R.+W.+Wangauthor=A.+Y.+Lu&title=Cytochrome+P450+inhibitors.+Evaluation+of+specificities+in+the+in+vitrometabolism+of+therapeutic+agents+by+human+liver+microsomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes</span></div><div class="casAuthors">Newton, Deborah J.; Wang, Regina W.; Lu, Anthony Y. H.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">154-8</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Identifying selective inhibitors of cytochrome P 450 isoforms is a useful tool in defining the role of individual cytochrome P450s in the metab. process.  In this study, nine chem. inhibitors were selected based on literature data and were examd. for their specificity toward cytochrome P 450-mediated reactions in human liver microsomes.  Furafylline was a potent, mechanism-based inhibitor for CYP1A2-mediated phenacetin O-deethylation.  The probes sulfaphenazole (CYP2C9) and quinidine (CYP2D6) selectively inhibited tolbutamide methylhydroxylation and bufuralol 1'-hydroxylation, resp.  Addnl., the CYP2E1-catalyzed chlorzoxazone 6-hydroxylation was significantly inhibited by diethyldithiocarbamate.  Of the CYP3A4 inhibitor probes used, troleandomycin proved to be the most specific for testosterone 6β-hydroxylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVbGHnMzGJ1rVg90H21EOLACvtfcHk0lh6ABulDEjxXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjtVOrur4%253D&md5=a004605e3bd07d868fef19b38c48a9a5</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNewton%26aufirst%3DD.%2BJ.%26aulast%3DWang%26aufirst%3DR.%2BW.%26aulast%3DLu%26aufirst%3DA.%2BY.%26atitle%3DCytochrome%2520P450%2520inhibitors.%2520Evaluation%2520of%2520specificities%2520in%2520the%2520in%2520vitrometabolism%2520of%2520therapeutic%2520agents%2520by%2520human%2520liver%2520microsomes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1995%26volume%3D23%26spage%3D154%26epage%3D158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 2 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xue‐Yan  Yang</span>, <span class="hlFld-ContribAuthor ">Hong‐Yi  Zhao</span>, <span class="hlFld-ContribAuthor ">Hao  Lei</span>, <span class="hlFld-ContribAuthor ">Bo  Yuan</span>, <span class="hlFld-ContribAuthor ">Shuai  Mao</span>, <span class="hlFld-ContribAuthor ">Minghang  Xin</span>, <span class="hlFld-ContribAuthor ">San‐Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Biological Evaluation of 10‐Substituted Camptothecin Derivatives with Improved Water Solubility and Activity. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (6)
                                     , 1000-1010. <a href="https://doi.org/10.1002/cmdc.202000753" title="DOI URL">https://doi.org/10.1002/cmdc.202000753</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000753%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252B10%2525E2%252580%252590Substituted%252BCamptothecin%252BDerivatives%252Bwith%252BImproved%252BWater%252BSolubility%252Band%252BActivity%26aulast%3DYang%26aufirst%3DXue%25E2%2580%2590Yan%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D6%26spage%3D1000%26epage%3D1010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiujuan  Li</span>, <span class="hlFld-ContribAuthor ">Yan  Gao</span>. </span><span class="cited-content_cbyCitation_article-title">Synergistically fabricated polymeric nanoparticles featuring dual drug delivery system to enhance the nursing care of cervical cancer. </span><span class="cited-content_cbyCitation_journal-name">Process Biochemistry</span><span> <strong>2020,</strong> <em>98 </em>, 254-261. <a href="https://doi.org/10.1016/j.procbio.2020.09.010" title="DOI URL">https://doi.org/10.1016/j.procbio.2020.09.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.procbio.2020.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.procbio.2020.09.010%26sid%3Dliteratum%253Aachs%26jtitle%3DProcess%2520Biochemistry%26atitle%3DSynergistically%252Bfabricated%252Bpolymeric%252Bnanoparticles%252Bfeaturing%252Bdual%252Bdrug%252Bdelivery%252Bsystem%252Bto%252Benhance%252Bthe%252Bnursing%252Bcare%252Bof%252Bcervical%252Bcancer%26aulast%3DLi%26aufirst%3DXiujuan%26date%3D2020%26volume%3D98%26spage%3D254%26epage%3D261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. SN38 drug delivery systems.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0009.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design of HSP90 inhibitor–SN38 conjugates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0010.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structure of compound <b>18b</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route of Compounds <b>4a–b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc<sub>2</sub>O, pyridine, DCM, rt, 2 h, 98%; (b) <i>N</i>-Boc-glycine and <i>N</i>-Boc-β-alanine, EDCI, 4-DMAP, DMF, rt, 6 h, 92–96%; (c) 20% TFA in DCM, rt, 3 h, 90–92%.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Route of Compound <b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-nitrophenyl chloroformate, DIEA, THF, rt, 6 h, 92%; (b) 4-<i>N</i>-Boc-aminopiperidine, 4-DMAP, DCM, rt, 2 h, 90%; (c) 20% TFA in DCM, rt, 2 h, 93%.</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Route of Key Intermediate <b>13</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TsNHNH<sub>2</sub>, PTSA, toluene, reflux, 2 h, 88%; (b) Tf<sub>2</sub>O, Et<sub>3</sub>N, THF, 50 °C, 3 h, 68%; (c) <i>tert</i>-butyl (5-bromo-2-cyanophenyl)glycinate, 60% NaH, anhydrous DMF, 90 °C, 8 h, 62%; (d) NaOH aq (1 M), 30% H<sub>2</sub>O<sub>2</sub>, EtOH, rt, 12 h, 85%; (e) 10% TFA/DCM, rt, 3 h, 90%.</p></p></figure><figure data-id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthetic Route of Compound <b>14a–c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) compound <b>4a–b</b> and compound <b>7</b>, HATU, DIPEA, anhydrous DMF, rt, 4 h, 32–42%.</p></p></figure><figure data-id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthetic Route of Compound <b>18a–c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) LiOH, THF/MeOH/H<sub>2</sub>O (1:1:1, v/v/v), rt, 2 h, 89%; (b) 10% Pd/C, MeOH, rt, 8 h, 85%; (c) compound <b>4a–b</b> and <b>7</b>, HATU, DIPEA, anhydrous DMF, rt, 4 h, 50–54%.</p></p></figure><figure data-id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0011.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Stability of conjugates in different buffers. (A) pH = 6.0 PBS; (B) pH = 7.4 PBS; (C) mouse plasma; (D) human plasma. Data were expressed as mean ± SD, <i>n</i> = 3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0012.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) UV–vis–near-infrared absorbance spectra (EtOH as solvent) and (B) fluorescence emission spectra (EtOH as solvent) of compounds <b>18a–c</b>, irinotecan, and SN38. (C) CLSM images (scale bar = 25 μm) and (D) quantitative analysis of A549 cells incubated with compounds <b>18a–c</b>, irinotecan, and SN38 for 12 h by LC–MS/MS. The dosage was 5 μM. The scale bars are 25 μm in all images. Data were expressed as mean +SD, <i>n</i> = 3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0013.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Cellular uptake of tumor cells treated with NVP-AUY922 mixed with compound <b>18b</b> (5 μM, 100:1, n/n) or compound <b>18b</b> mixed with the vehicle (5 μM) for 6 h. (A–C) Representative CLSM images of A549 cells (scale bar = 50 μm), HCT116 cells, and HL-7702 cells (scale bar = 75 μm), respectively. (D) Quantitative analysis of drugs in A549 cells, HCT116 cells, and HL7702 cells conducted by LC–MS/MS. Data were expressed as mean + SD, ***<i>P</i> < 0.001, <sup>###</sup><i>P</i> < 0.001, <i>n</i> = 3, multiple <i>t</i>-test. * represents the statistics between the intact compound; <sup>#</sup> represents the statistics between the released SN38. The statistics for the HL7702 cells group is “not significant (ns)”.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0014.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. CLSM images of tumor cells incubated with <b>18a–c</b> for different times. (A) A549 cells incubated with <b>18a–c</b> for 1, 4, 6, and 12 h. (B–D) Quantitative analysis of A549 cells incubated with compounds <b>18a–c</b> for 1, 4, 6, and 12 h using LC–MS/MS. The dosage was 5 μM. The scale bars are 25 μm in all images. Data were expressed as mean + SD, <i>P</i> < 0.001, <i>n</i> = 3, multiple <i>t</i>-test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0015.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. <i>In vitro</i> surface eHSP90 expression in A549, HCT116, MIA-PACA-2, Capan-1, and HL7702 cells. Representative immunofluorescence images of the cells following HSP90 staining, with anti-HSP90 rabbit polyclonal antibody, Cy3 conjugated goat antirabbit IgG, and DAPI. Red, Cy3-conjugated goat antirabbit IgG and blue, DAPI (scale bar = 100 μm).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0016.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Cell cycle distribution of A549, HCT116, and Capan-1 cells after compound treatment for 24 h with different concentrations.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0002.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Western blot analysis of proteins correlated with topoisomerase I inhibition and HSP90 client protein in A549 and HCT116 cells after compounds <b>18a–c</b> treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0003.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Pharmacokinetics analysis in healthy BALB/c male mice. Mice were treated with compounds <b>18a–c</b> (50 mg/kg) i.v. Plasma concentration <i>vs</i> time profiles of compounds <b>18a–c</b> are illustrated. Values are indicated as the mean ± SD, <i>n</i> = 4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0004.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. <i>In vivo</i> therapeutic efficacy of <b>18a–c</b> in HCT116 xenografts. HCT116 xenograft-bearing nude mice were treated with the vehicle (5% glucose solution), irinotecan (15 mg/kg), <b>18a–c</b> (10 mg/kg), and <b>18a–c</b> (50 mg/kg) i.v. (A) Tumor volume was recorded, and relative tumor volume was plotted. (B) Tumor weight. (C) Excised tumor volume (mm<sup>3</sup>). (D) Body weight change. ***<i>P</i> < 0.001, **<i>P</i> < 0.01, and *<i>P</i> < 0.05 <i>vs</i> vehicle-treated group. Data were expressed as mean ± SD, <i>n</i> = 6, multiple <i>t</i>-test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0005.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Pharmacokinetic analyses in HCT116 xenografts. HCT116 xenograft-bearing nude mice were treated with compound <b>18b</b> (50 mg/kg) and irinotecan (15 mg/kg) i.v. for different time points. (A) Plasma concentration <i>vs</i> time of intact compound <b>18b</b> and irinotecan. (B) Plasma concentration <i>vs</i> time of released SN38 from compound <b>18b</b> and irinotecan. (C) Tumor concentration <i>vs</i> time of intact compound <b>18b</b> and irinotecan. (D) Tumor concentration <i>vs</i> time of released SN38 from compound <b>18b</b> and irinotecan. Data were expressed as mean ± SD, <i>n</i> = 3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0006.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. <i>In vivo</i> therapeutic efficacy of compound <b>18b</b> in Capan-1 xenografts. Capan-1 xenograft-bearing nude mice were treated with the vehicle (5% glucose solution), irinotecan (36 mg/kg), compound <b>18b</b> (50 mg/kg), and NVP-AUY922 (28 mg/kg) i.v.. (A) Tumor volume was recorded, and relative tumor volume was plotted. (B) Tumor weight. (C) Body weight change (%). (D) Western blot analysis of the pharmacodynamic biomarker changes in tumor xenografts. GAPDH is used as the internal control. Data were expressed as mean ± SD, <i>n</i> = 6, ***<i>P</i> < 0.001, Student’s <i>t</i>-test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0007.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Pharmacokinetics analyses in Capan-1 xenografts. Capan-1 xenograft-bearing nude mice were treated with compound <b>18b</b> (50 mg/kg) and irinotecan (36 mg/kg) i.v. for different time points. (A) Plasma concentration <i>vs</i> time of intact compound <b>18b</b> and irinotecan. (B) Plasma concentration <i>vs</i> time of released SN38 from compound <b>18b</b> and irinotecan. (C) Tumor concentration <i>vs</i> time of intact compound <b>18b</b> and irinotecan. (D) Plasma concentration <i>vs</i> time of released SN38 from compound <b>18b</b> and irinotecan. Data were expressed as mean ± SD, <i>n</i> = 3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/medium/jm0c00305_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0008.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Representative images of histological analyses of female nude mice with Capan-1 xenografts at 14 days after the first treatment with <b>18b</b> (50 mg/kg), irinotecan (36 mg/kg), and 5% glucose solution. (A) Representative H&E staining images of major organs. (B) TUNEL, and Ki67 protein analysis images of tumor sections. Scale bar = 100 μm.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-10/acs.jmedchem.0c00305/20200520/images/large/jm0c00305_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00305&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i80">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52347" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52347" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 49 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torre, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bray, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferlay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lortet-Tieulent, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Global Cancer Statistics, 2012</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.3322/caac.21262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.3322%2Fcaac.21262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=25651787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A280%3ADC%252BC2Mris1Ggsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2015&pages=87-108&author=L.+A.+Torreauthor=F.+Brayauthor=R.+L.+Siegelauthor=J.+Ferlayauthor=J.+Lortet-Tieulentauthor=A.+Jemal&title=Global+Cancer+Statistics%2C+2012&doi=10.3322%2Fcaac.21262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Global cancer statistics, 2012</span></div><div class="casAuthors">Torre Lindsey A; Bray Freddie; Siegel Rebecca L; Ferlay Jacques; Lortet-Tieulent Joannie; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-108</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer constitutes an enormous burden on society in more and less economically developed countries alike.  The occurrence of cancer is increasing because of the growth and aging of the population, as well as an increasing prevalence of established risk factors such as smoking, overweight, physical inactivity, and changing reproductive patterns associated with urbanization and economic development.  Based on GLOBOCAN estimates, about 14.1 million new cancer cases and 8.2 million deaths occurred in 2012 worldwide.  Over the years, the burden has shifted to less developed countries, which currently account for about 57% of cases and 65% of cancer deaths worldwide.  Lung cancer is the leading cause of cancer death among males in both more and less developed countries, and has surpassed breast cancer as the leading cause of cancer death among females in more developed countries; breast cancer remains the leading cause of cancer death among females in less developed countries.  Other leading causes of cancer death in more developed countries include colorectal cancer among males and females and prostate cancer among males.  In less developed countries, liver and stomach cancer among males and cervical cancer among females are also leading causes of cancer death.  Although incidence rates for all cancers combined are nearly twice as high in more developed than in less developed countries in both males and females, mortality rates are only 8% to 15% higher in more developed countries.  This disparity reflects regional differences in the mix of cancers, which is affected by risk factors and detection practices, and/or the availability of treatment.  Risk factors associated with the leading causes of cancer death include tobacco use (lung, colorectal, stomach, and liver cancer), overweight/obesity and physical inactivity (breast and colorectal cancer), and infection (liver, stomach, and cervical cancer).  A substantial portion of cancer cases and deaths could be prevented by broadly applying effective prevention measures, such as tobacco control, vaccination, and the use of early detection tests.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS93OidvnAA79ts4TFFB11gfW6udTcc2eZg7SO4EMJNELntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mris1Ggsg%253D%253D&md5=f008b208320b129e10c7c383193ff772</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21262%26sid%3Dliteratum%253Aachs%26aulast%3DTorre%26aufirst%3DL.%2BA.%26aulast%3DBray%26aufirst%3DF.%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DFerlay%26aufirst%3DJ.%26aulast%3DLortet-Tieulent%26aufirst%3DJ.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DGlobal%2520Cancer%2520Statistics%252C%25202012%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2015%26volume%3D65%26spage%3D87%26epage%3D108%26doi%3D10.3322%2Fcaac.21262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y.</span></span> <span> </span><span class="NLM_article-title">Rapidly Cell-Penetrating and Reductive Milieu-Responsive Nanoaggregates Assembled from an Amphiphilic Folate-camptothecin Prodrug for Enhanced Drug Delivery and Controlled Release</span>. <i>Biomater. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">454</span>, <span class="refDoi"> DOI: 10.1039/c6bm00800c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1039%2FC6BM00800C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=28058423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvVWiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=444-454&author=Z.+Xuauthor=M.+Houauthor=X.+Shiauthor=Y.-E.+Gaoauthor=P.+Xueauthor=S.+Liuauthor=Y.+Kang&title=Rapidly+Cell-Penetrating+and+Reductive+Milieu-Responsive+Nanoaggregates+Assembled+from+an+Amphiphilic+Folate-camptothecin+Prodrug+for+Enhanced+Drug+Delivery+and+Controlled+Release&doi=10.1039%2Fc6bm00800c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Rapidly cell-penetrating and reductive milieu-responsive nanoaggregates assembled from an amphiphilic folate-camptothecin prodrug for enhanced drug delivery and controlled release</span></div><div class="casAuthors">Xu, Zhigang; Hou, Meili; Shi, Xiaoxiao; Gao, Yong-E.; Xue, Peng; Liu, Shiying; Kang, Yuejun</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">444-454</span>CODEN:
                <span class="NLM_cas:coden">BSICCH</span>;
        ISSN:<span class="NLM_cas:issn">2047-4849</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Accurate diagnosis and treatment based on small mol. prodrugs can enhance drug efficiency and reduce side-effects during cancer therapy.  Herein, we report the prepn. of a type of glutathione (GSH)-responsive small prodrug delivery system based on targeting folic acid (FA) and conjugating with the hydrophobic antitumor drug camptothecin (CPT) via disulfide bonds.  The obtained prodrug is capable of high and precise drug loading (36.8 wt%) and can self-assemble into nanoaggregates with an av. size of 46.4 nm in an aq. soln.  The GSH-triggered release of CPT can reach a max. of 82% under 10 mM GSH in 60 h, which is dramatically higher than 12% of CPT released in a physiol. environment.  More interestingly, the resulting prodrug can also work as a "switchable" fluorescence probe, which exhibits fluorescence changes in response to GSH stimulus or FA receptors on the membranes of tumor cells.  Specifically, the fluorescence of the prodrug is quenched in the physiol. environments, whereas strong fluorescence is activated in the tumoral microenvironment expressing high levels of GSH or when the FA terminal is conjugated with the receptors on the membranes of tumor cells.  Furthermore, the FA-CPT prodrug shows a superior specificity and higher cytotoxicity for FA receptor-pos. KB tumor cells as compared to those of FA receptor-neg. A549 tumor cells.  Therefore, we believe that this FA-CPT prodrug can be used for the recognition and diagnosis of tumor cells and it also provides a promising modality towards an effective cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkahxTHDZNN7Vg90H21EOLACvtfcHk0lhvrw7W2wdU5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvVWiuw%253D%253D&md5=c511be918116ad8305d26c0591c2bea2</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1039%2FC6BM00800C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6BM00800C%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DHou%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DY.-E.%26aulast%3DXue%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DKang%26aufirst%3DY.%26atitle%3DRapidly%2520Cell-Penetrating%2520and%2520Reductive%2520Milieu-Responsive%2520Nanoaggregates%2520Assembled%2520from%2520an%2520Amphiphilic%2520Folate-camptothecin%2520Prodrug%2520for%2520Enhanced%2520Drug%2520Delivery%2520and%2520Controlled%2520Release%26jtitle%3DBiomater.%2520Sci.%26date%3D2017%26volume%3D5%26spage%3D444%26epage%3D454%26doi%3D10.1039%2Fc6bm00800c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Denzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Della Valle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apollonio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mir, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liberti, M.</span></span> <span> </span><span class="NLM_article-title">Exploring the Applicability of Nano-Poration for Remote Control in Smart Drug Delivery Systems</span>. <i>J. Membr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>250</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1007/s00232-016-9922-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1007%2Fs00232-016-9922-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=27561639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVSlt77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=250&publication_year=2017&pages=31-40&author=A.+Denziauthor=E.+Della+Valleauthor=F.+Apollonioauthor=M.+Bretonauthor=L.+M.+Mirauthor=M.+Liberti&title=Exploring+the+Applicability+of+Nano-Poration+for+Remote+Control+in+Smart+Drug+Delivery+Systems&doi=10.1007%2Fs00232-016-9922-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring the Applicability of Nano-Poration for Remote Control in Smart Drug Delivery Systems</span></div><div class="casAuthors">Denzi, Agnese; della Valle, Elena; Apollonio, Francesca; Breton, Marie; Mir, Lluis M.; Liberti, Micaela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Membrane Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">250</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-40</span>CODEN:
                <span class="NLM_cas:coden">JMBBBO</span>;
        ISSN:<span class="NLM_cas:issn">0022-2631</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Smart drug delivery systems represent an interesting tool to significantly improve the efficiency and the precision in the treatment of a broad category of diseases.  In this context, a drug delivery mediated by nanosecond pulsed elec. fields seems a promising technique, allowing for a controlled release and uptake of drugs by the synergy between the electropulsation and nanocarriers with encapsulated drugs.  The main concern about the use of electroporation for drug delivery applications is the difference in dimension between the liposome (nanometer range) and the cell (micrometer range).  The choice of liposome dimension is not trivial.  Liposomes larger than 500 nm of diam. could be recognized as pathogen agents by the immune system, while liposomes of smaller size would require external elec. field of high amplitudes for the membrane electroporation that could compromise the cell viability.  The aim of this work is to theor. study the possibility of a simultaneous cell and liposomes electroporation.  The numerical simulations reported the possibility to electroporate the cell and a significant percentage of liposomes with comparable values of external elec. field, when a 12 nsPEF is used.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5DffbnF5rkbVg90H21EOLACvtfcHk0lhvrw7W2wdU5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVSlt77M&md5=3b2b99a670c27df7d681436c91c2322c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2Fs00232-016-9922-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00232-016-9922-1%26sid%3Dliteratum%253Aachs%26aulast%3DDenzi%26aufirst%3DA.%26aulast%3DDella%2BValle%26aufirst%3DE.%26aulast%3DApollonio%26aufirst%3DF.%26aulast%3DBreton%26aufirst%3DM.%26aulast%3DMir%26aufirst%3DL.%2BM.%26aulast%3DLiberti%26aufirst%3DM.%26atitle%3DExploring%2520the%2520Applicability%2520of%2520Nano-Poration%2520for%2520Remote%2520Control%2520in%2520Smart%2520Drug%2520Delivery%2520Systems%26jtitle%3DJ.%2520Membr.%2520Biol.%26date%3D2017%26volume%3D250%26spage%3D31%26epage%3D40%26doi%3D10.1007%2Fs00232-016-9922-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span> <span> </span><span class="NLM_article-title">Redox-Responsive Dual Chemophotothermal Therapeutic Nanomedicine for Imaging-Guided Combinational Therapy</span>. <i>J. Mater. Chem. B</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">5362</span>– <span class="NLM_lpage">5367</span>, <span class="refDoi"> DOI: 10.1039/c8tb01360h</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1039%2FC8TB01360H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=30931124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOjt7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=5362-5367&author=F.+Yuauthor=F.+Zhangauthor=L.+Tangauthor=J.+Maauthor=D.+Lingauthor=X.+Chenauthor=X.+Sun&title=Redox-Responsive+Dual+Chemophotothermal+Therapeutic+Nanomedicine+for+Imaging-Guided+Combinational+Therapy&doi=10.1039%2Fc8tb01360h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Redox-responsive dual chemophotothermal therapeutic nanomedicine for imaging-guided combinational therapy</span></div><div class="casAuthors">Yu, Fei; Zhang, Fuwu; Tang, Longguang; Ma, Jingwen; Ling, Daishun; Chen, Xiaoyuan; Sun, Xiaolian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Materials Chemistry B: Materials for Biology and Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">5362-5367</span>CODEN:
                <span class="NLM_cas:coden">JMCBDV</span>;
        ISSN:<span class="NLM_cas:issn">2050-7518</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Chemotherapy is currently the major therapeutic method against cancer.  However, chemo drugs are usually lacking in specificity towards cancer cells over normal cells.  In this study, we prepd. a novel multifunctional trimeric prodrug by linking the chemo drug camptothecin (CPT) and the exceptionally photostable near IR (NIR) croconaine dye (CR) via a glutathione (GSH)-sensitive disulfide linker.  Compared with CPT, our novel trimeric CR-(SS-CPT)2 is more hydrophobic and bulky, making it highly efficient to be encapsulated into biocompatible polymeric nanocarriers.  The prodrug underwent rapid drug release specifically in cancer cells with high GSH concn.  The hyperthermia produced by CR upon laser irradn. could further accelerate the break of disulfide bonds, which makes the release of CPT even more controllable.  We further loaded CR-(SS-CPT)2 into folate modified lipid-polymer nanoparticles, which demonstrated high in vivo tumor accumulation and retention.  The biodistribution of these nanoparticles can be directly monitored in real time via NIR fluorescence and photoacoustic imaging.  Under imaging guided chemo- and photothermal-synergistic therapy, the tumors were completely ablated with no recurrence.  The design not only highly enhanced the therapeutic specificity and efficiency of CPT, but also provided an "all in one" nanomedicine for imaging-guided dual modality therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoSTWH9LOdL7Vg90H21EOLACvtfcHk0lhvrw7W2wdU5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOjt7vO&md5=a1b2972d6ea4d041f15d200141be674d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1039%2FC8TB01360H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8TB01360H%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLing%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DX.%26atitle%3DRedox-Responsive%2520Dual%2520Chemophotothermal%2520Therapeutic%2520Nanomedicine%2520for%2520Imaging-Guided%2520Combinational%2520Therapy%26jtitle%3DJ.%2520Mater.%2520Chem.%2520B%26date%3D2018%26volume%3D6%26spage%3D5362%26epage%3D5367%26doi%3D10.1039%2Fc8tb01360h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whang, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jo, S.</span></span> <span> </span><span class="NLM_article-title">A Highly GSH-sensitive SN-38 Prodrug with an “OFF-to-ON” Fluorescence Switch as a Bifunctional Anticancer Agent</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">9031</span>– <span class="NLM_lpage">9034</span>, <span class="refDoi"> DOI: 10.1039/c8cc05010d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1039%2FC8CC05010D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=30047958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlGiu7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2018&pages=9031-9034&author=C.-H.+Whangauthor=E.+Yooauthor=S.+K.+Hurauthor=K.+S.+Kimauthor=D.+Kimauthor=S.+Jo&title=A+Highly+GSH-sensitive+SN-38+Prodrug+with+an+%E2%80%9COFF-to-ON%E2%80%9D+Fluorescence+Switch+as+a+Bifunctional+Anticancer+Agent&doi=10.1039%2Fc8cc05010d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">A highly GSH-sensitive SN-38 prodrug with an "OFF-to-ON" fluorescence switch as a bifunctional anticancer agent</span></div><div class="casAuthors">Whang, Chang-Hee; Yoo, Eunsoo; Hur, Seong Kwon; Kim, Kyeong Soo; Kim, Dongin; Jo, Seongbong</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">65</span>),
    <span class="NLM_cas:pages">9031-9034</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">SN-38 (7-ethyl-10-hydroxy-camptothecin) is an active metabolite of irinotecan (CPT-11) and the most potent camptothecin analog.  In this study, 2,4-dinitrobenzene sulfonyl (DNS) was covalently conjugated as a GSH-sensitive trigger to 10' -OH of SN-38 to yield a GSH-sensitive prodrug, denoted as DNS-SN38, with virtually quenched fluorescence due to donor-excited photo-induced electron transfer (d-PeT).  By investigating DNS-SN38's activation properties upon fluorescence restoration and cytotoxic potency against ovarian cancer cell lines (A2780 and m-Cherry + OCSC1-F2), its potential applicability as a useful chemotherapeutic agent was demonstrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJEqIaTMFOTLVg90H21EOLACvtfcHk0livkaHSSQ7sfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlGiu7zF&md5=186c1018a8542a9cd36e81c3d08372a8</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1039%2FC8CC05010D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8CC05010D%26sid%3Dliteratum%253Aachs%26aulast%3DWhang%26aufirst%3DC.-H.%26aulast%3DYoo%26aufirst%3DE.%26aulast%3DHur%26aufirst%3DS.%2BK.%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DKim%26aufirst%3DD.%26aulast%3DJo%26aufirst%3DS.%26atitle%3DA%2520Highly%2520GSH-sensitive%2520SN-38%2520Prodrug%2520with%2520an%2520%25E2%2580%259COFF-to-ON%25E2%2580%259D%2520Fluorescence%2520Switch%2520as%2520a%2520Bifunctional%2520Anticancer%2520Agent%26jtitle%3DChem.%2520Commun.%26date%3D2018%26volume%3D54%26spage%3D9031%26epage%3D9034%26doi%3D10.1039%2Fc8cc05010d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanizawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimori, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">Comparison of Topoisomerase I Inhibition, DNA Damage, and Cytotoxicity of Camptothecin Derivatives Presently in Clinical Trials</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">836</span>– <span class="NLM_lpage">842</span>, <span class="refDoi"> DOI: 10.1093/jnci/86.11.836</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1093%2Fjnci%2F86.11.836" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=8182764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADyaK2cXlvFGiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=1994&pages=836-842&author=A.+Tanizawaauthor=A.+Fujimoriauthor=Y.+Fujimoriauthor=Y.+Pommier&title=Comparison+of+Topoisomerase+I+Inhibition%2C+DNA+Damage%2C+and+Cytotoxicity+of+Camptothecin+Derivatives+Presently+in+Clinical+Trials&doi=10.1093%2Fjnci%2F86.11.836"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials</span></div><div class="casAuthors">Tanizawa, Akihiko; Fujimori, Akira; Fujimori, Yuko; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">836-42</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    </div><div class="casAbstract">Camptothecins (CPTs) belong to a group of anticancer agents with a unique mechanism of action: poisoning of eukaryotic DNA topoisomerase I.  Two camptothecin derivs., topotecan (TPT) and CPT-11, are in clin. trials and their chemotherapeutic efficacy appears promising.  Our aim was to compare simultaneously the mol. and cellular pharmacol. of the various camptothecin derivs. that are presently in clin. trials.  Cytotoxicity of drugs toward human colon carcinoma was detd. by colony-forming assays.  DNA single-strand breaks (SSB) were measured by alk. elution.  Drug potency to induce topoisomerase 1-mediated DNA cleavage and the sequence selectivity of the breaks were detd. by sequencing gel autoradiog.  SN-38 and CPT were more cytotoxic than 9-aminocamptothecin (9-AC) and TPT, and CPT-11 was almost inactive toward HT-29 cells.  IC50 values were 8.8 nM for SN-38, 10 nM for CPT, 19 nM for 9-AC, 33 nM for TPT, and greater than 100 nM for CPT-11.  In drug-induced DNA damage measured by alk. elution drug concns. producing 1000-rad-equiv. (C1000), values were 0.037 μM for SN-38, 0.051 μM for CPT, 0.085 μM for 9-AC, 0.28 μM for TPT, and greater than 1 μM for CPT-11.  SN-38 remained the most potent compd. in isolated nuclei, and CPT-11 was still inactive.  The potency ranking was the same as in whole cells, and the C1000 values were 0.0025 μM for SN-38, 0.012 μM for CPT, 0.021 μM for 9-AC, 0.44 μM for TPT, and greater than 0.1 μM for CPT-11.  Potency difference between SN-38 and the other compds. was greater in isolated nuclei than in whole cells.  Kinetics of the reversal of drug-induced SSB in isolated nuclei suggest that dissocn. of SN-38 from cleavable complexes is much slower than that of CPT.  Cleavage patterns of CPT and 9-AC were similar but differed from those of TPT and SN-38.  Although in vitro analyses do not necessarily reflect chemotherapeutic efficacy, this study found that SN-38 is the most potent compd. and that 9-AC and TPT are less active than CPT in this system.  The effect of CPT-11 is minimal.  Therefore, the clin. activity of CPT-11 may strongly depend on its hydrolysis to SN-38.  Differences in DNA sequence selectivity and the stability of cleavable complexes induced by the drugs may also contribute to differences among CPT derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_v-LigezeSrVg90H21EOLACvtfcHk0livkaHSSQ7sfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlvFGiu74%253D&md5=2248f154bab19a06c7365d11120530d8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F86.11.836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F86.11.836%26sid%3Dliteratum%253Aachs%26aulast%3DTanizawa%26aufirst%3DA.%26aulast%3DFujimori%26aufirst%3DA.%26aulast%3DFujimori%26aufirst%3DY.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DComparison%2520of%2520Topoisomerase%2520I%2520Inhibition%252C%2520DNA%2520Damage%252C%2520and%2520Cytotoxicity%2520of%2520Camptothecin%2520Derivatives%2520Presently%2520in%2520Clinical%2520Trials%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D1994%26volume%3D86%26spage%3D836%26epage%3D842%26doi%3D10.1093%2Fjnci%2F86.11.836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span> <span> </span><span class="NLM_article-title">PEGylation of Lipophilic SN38 Prodrug with DSPE-mPEG2000 Versus Cremophor EL: Comparative Study for Intravenous Chemotherapy</span>. <i>Drug Delivery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.1080/10717544.2019.1587045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1080%2F10717544.2019.1587045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=30909751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvVWqt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=354-362&author=J.+Zengauthor=C.+Liauthor=X.+Duanauthor=F.+Liuauthor=A.+Liauthor=C.+Luoauthor=L.+Jiaauthor=Y.+Ganauthor=L.+Yanauthor=Y.+Zheng&title=PEGylation+of+Lipophilic+SN38+Prodrug+with+DSPE-mPEG2000+Versus+Cremophor+EL%3A+Comparative+Study+for+Intravenous+Chemotherapy&doi=10.1080%2F10717544.2019.1587045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">PEGylation of lipophilic SN38 prodrug with DSPE-mPEG2000 versus cremophor EL: comparative study for intravenous chemotherapy</span></div><div class="casAuthors">Zeng, Jun; Li, Chen; Duan, Xing; Liu, Fuyue; Li, Anqin; Luo, Chunhan; Jia, Li; Gan, Yifang; Yan, Lu; Zheng, Yaxin</div><div class="citationInfo"><span class="NLM_cas:title">Drug Delivery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">354-362</span>CODEN:
                <span class="NLM_cas:coden">DDELEB</span>;
        ISSN:<span class="NLM_cas:issn">1071-7544</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The lipophilic prodrug of hydrophobic drugs with well-designed mol. structures can form stable pure prodrug nanoparticles (NPs), but rapid NPs aggregation in plasma greatly restricted their direct use for i.v. chemotherapy.  To address this, DSPE-mPEG2000 and Cremophor EL are two of the most widely used lipophilic PEG derivs. to enhance their colloidal stability in plasma.  However, their drug delivery performances have never been comparatively studied.  Here, a redox-responsive lipophilic prodrug of SN38 was chosen as the model drug for such comparative investigations.  We found that Cremophor EL/NPs having a small diam. (∼15 nm) and poor kinetic stability displayed an enhanced cell internalization, higher cytotoxicity and prolonged circulation time as compared with DSPE-mPEG2000/NPs.  Most importantly, these superiorities further resulted in a much more potent antitumor activity in CT26 colorectal cancer xenograft, but the increased loss of body wt. was also noted.  These results suggested that Cremophor EL could be more advantageous than DSPE-mPEG2000 in terms of the improvement of antitumor activity, but the enhanced toxicity warranted further attention in the future study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnjqE3kIgZcLVg90H21EOLACvtfcHk0livkaHSSQ7sfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvVWqt7w%253D&md5=d4598f8afc5faf19cd151437f98ce67c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1080%2F10717544.2019.1587045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10717544.2019.1587045%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DDuan%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DGan%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DY.%26atitle%3DPEGylation%2520of%2520Lipophilic%2520SN38%2520Prodrug%2520with%2520DSPE-mPEG2000%2520Versus%2520Cremophor%2520EL%253A%2520Comparative%2520Study%2520for%2520Intravenous%2520Chemotherapy%26jtitle%3DDrug%2520Delivery%26date%3D2019%26volume%3D26%26spage%3D354%26epage%3D362%26doi%3D10.1080%2F10717544.2019.1587045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proia, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequeira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acquaviva, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khazak, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astsaturov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatsuta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimmanamada, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ying, W.</span></span> <span> </span><span class="NLM_article-title">HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2422</span>– <span class="NLM_lpage">2432</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-15-0455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1158%2F1535-7163.MCT-15-0455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=26271675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslOgt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=2422-2432&author=D.+A.+Proiaauthor=D.+L.+Smithauthor=J.+Zhangauthor=J.-P.+Jimenezauthor=J.+Sangauthor=L.+S.+Ogawaauthor=M.+Sequeiraauthor=J.+Acquavivaauthor=S.+Heauthor=C.+Zhangauthor=V.+Khazakauthor=I.+Astsaturovauthor=T.+Inoueauthor=N.+Tatsutaauthor=S.+Osmanauthor=R.+C.+Batesauthor=D.+Chimmanamadaauthor=W.+Ying&title=HSP90+Inhibitor-SN-38+Conjugate+Strategy+for+Targeted+Delivery+of+Topoisomerase+I+Inhibitor+to+Tumors&doi=10.1158%2F1535-7163.mct-15-0455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors</span></div><div class="casAuthors">Proia, David A.; Smith, Donald L.; Zhang, Junyi; Jimenez, John-Paul; Sang, Jim; Ogawa, Luisa Shin; Sequeira, Manuel; Acquaviva, Jaime; He, Suqin; Zhang, Chaohua; Khazak, Vladimir; Astsaturov, Igor; Inoue, Takayo; Tatsuta, Noriaki; Osman, Sami; Bates, Richard C.; Chimmanamada, Dinesh; Ying, Weiwen</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2422-2432</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The clin. benefits of chemotherapy are commonly offset by insufficient drug exposures, narrow safety margins, and/or systemic toxicities.  Over recent decades, a no. of conjugate-based targeting approaches designed to overcome these limitations have been explored.  Here, we report on an innovative strategy that utilizes HSP90 inhibitor-drug conjugates (HDC) for directed tumor targeting of chemotherapeutic agents.  STA-12-8666 is an HDC that comprises an HSP90 inhibitor fused to SN-38, the active metabolite of irinotecan.  Mechanistic analyses in vitro established that high-affinity HSP90 binding conferred by the inhibitor backbone could be exploited for conjugate accumulation within tumor cells.  In vivo modeling showed that the HSP90 inhibitor moiety was required for selective retention of STA-12-8666, and this enrichment promoted extended release of active SN-38 within the tumor compartment.  Indeed, controlled intratumoral payload release by STA-12-8666 contributed to a broad therapeutic window, sustained biomarker activity, and remarkable degree of efficacy and durability of response in multiple cell line and patient-derived xenograft models.  Overall, STA-12-8666 has been developed as a unique HDC agent that employs a distinct mechanism of targeted drug delivery to achieve potent and sustained antitumor effects.  These findings identify STA-12-8666 as a promising new candidate for evaluation as novel anticancer therapeutic.  Mol Cancer Ther; 14(11); 2422-32. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLebQAGQQV6rVg90H21EOLACvtfcHk0lj9KLyhUiLFXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslOgt7%252FM&md5=b51a2c0bcd0fdc775dd6a6ce32ae9830</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0455%26sid%3Dliteratum%253Aachs%26aulast%3DProia%26aufirst%3DD.%2BA.%26aulast%3DSmith%26aufirst%3DD.%2BL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DJimenez%26aufirst%3DJ.-P.%26aulast%3DSang%26aufirst%3DJ.%26aulast%3DOgawa%26aufirst%3DL.%2BS.%26aulast%3DSequeira%26aufirst%3DM.%26aulast%3DAcquaviva%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DKhazak%26aufirst%3DV.%26aulast%3DAstsaturov%26aufirst%3DI.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DTatsuta%26aufirst%3DN.%26aulast%3DOsman%26aufirst%3DS.%26aulast%3DBates%26aufirst%3DR.%2BC.%26aulast%3DChimmanamada%26aufirst%3DD.%26aulast%3DYing%26aufirst%3DW.%26atitle%3DHSP90%2520Inhibitor-SN-38%2520Conjugate%2520Strategy%2520for%2520Targeted%2520Delivery%2520of%2520Topoisomerase%2520I%2520Inhibitor%2520to%2520Tumors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D2422%26epage%3D2432%26doi%3D10.1158%2F1535-7163.mct-15-0455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubio, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sapra, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozanguiez, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberger, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horak, I. D.</span></span> <span> </span><span class="NLM_article-title">Novel Prodrugs of SN38 Using Multiarm Poly(ethylene glycol) Linkers</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">849</span>– <span class="NLM_lpage">859</span>, <span class="refDoi"> DOI: 10.1021/bc700333s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc700333s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjvFOltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=849-859&author=H.+Zhaoauthor=B.+Rubioauthor=P.+Sapraauthor=D.+Wuauthor=P.+Reddyauthor=P.+Saiauthor=A.+Martinezauthor=Y.+Gaoauthor=Y.+Lozanguiezauthor=C.+Longleyauthor=L.+M.+Greenbergerauthor=I.+D.+Horak&title=Novel+Prodrugs+of+SN38+Using+Multiarm+Poly%28ethylene+glycol%29+Linkers&doi=10.1021%2Fbc700333s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Prodrugs of SN38 Using Multiarm Poly(ethylene glycol) Linkers</span></div><div class="casAuthors">Zhao, Hong; Rubio, Belen; Sapra, Puja; Wu, Dechun; Reddy, Prasanna; Sai, Prakash; Martinez, Anthony; Gao, Ying; Lozanguiez, Yoany; Longley, Clifford; Greenberger, Lee M.; Horak, Ivan D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">849-859</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">CPT-11, also known as irinotecan, is a prodrug that is approved for the treatment of advanced colorectal cancer.  The active metabolite of CPT-11, SN38 (7-ethyl-10-hydroxy-camptothecin), has 100- to 1000-fold more potent cytotoxic activity in tissue cell culture compared with CPT-11.  However, parental administration of SN38 is not possible because of its inherently poor water soly.  It is reported here that a multiarm poly(ethylene glycol) (PEG) backbone linked to four SN38 mols. (PEG-SN38) has been successfully prepd. with high drug loading and significantly improved water soly. (400- to 1000-fold increase).  Three different protecting strategies have been developed in order to selectively acylate the 20-OH of SN38 to preserve its E-ring in the lactone form (the active form of SN38 with cytotoxic activities) while PEG is still attached.  One chem. process has been optimized to make a large quantity of the PEG-SN38 conjugate with a high yield that can be readily adapted for scale-up prodn.  The PEG-SN38 conjugates have shown excellent in vitro anticancer activity, with potency similar to that of native SN38, in a panel of cancer cell lines.  The PEG-SN38 conjugates also have demonstrated superior anticancer activity in the MX-1 xenograft mice model compared with CPT-11.  Among the four conjugates, PEG-Gly-(20)-SN38 (I) has been selected as the lead candidate for further preclin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo90Brw-JYmLrVg90H21EOLACvtfcHk0liYd-NaC4nLSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjvFOltbc%253D&md5=6cc7b5208908d885f5c89868521b1ca7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fbc700333s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc700333s%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DRubio%26aufirst%3DB.%26aulast%3DSapra%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DReddy%26aufirst%3DP.%26aulast%3DSai%26aufirst%3DP.%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DLozanguiez%26aufirst%3DY.%26aulast%3DLongley%26aufirst%3DC.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DHorak%26aufirst%3DI.%2BD.%26atitle%3DNovel%2520Prodrugs%2520of%2520SN38%2520Using%2520Multiarm%2520Poly%2528ethylene%2520glycol%2529%2520Linkers%26jtitle%3DBioconjugate%2520Chem.%26date%3D2008%26volume%3D19%26spage%3D849%26epage%3D859%26doi%3D10.1021%2Fbc700333s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cardillo, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindan, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharkey, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trisal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrojo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, D. M.</span></span> <span> </span><span class="NLM_article-title">Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">919</span>– <span class="NLM_lpage">931</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.5b00223</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.5b00223" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntF2lsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=919-931&author=T.+M.+Cardilloauthor=S.+V.+Govindanauthor=R.+M.+Sharkeyauthor=P.+Trisalauthor=R.+Arrojoauthor=D.+Liuauthor=E.+A.+Rossiauthor=C.-H.+Changauthor=D.+M.+Goldenberg&title=Sacituzumab+Govitecan+%28IMMU-132%29%2C+an+Anti-Trop-2%2FSN-38+Antibody-Drug+Conjugate%3A+Characterization+and+Efficacy+in+Pancreatic%2C+Gastric%2C+and+Other+Cancers&doi=10.1021%2Facs.bioconjchem.5b00223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers</span></div><div class="casAuthors">Cardillo, Thomas M.; Govindan, Serengulam V.; Sharkey, Robert M.; Trisal, Preeti; Arrojo, Roberto; Liu, Donglin; Rossi, Edmund A.; Chang, Chien-Hsing; Goldenberg, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">919-931</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) made from a humanized anti-Trop-2 monoclonal antibody (hRS7) conjugated with the active metabolite of irinotecan, SN-38.  In addn. to its further characterization, as the clin. utility of IMMU-132 expands to an ever-widening range of Trop-2-expressing solid tumor types, its efficacy in new disease models needs to be explored in a nonclin. setting.  Unlike most ADCs that use ultratoxic drugs and stable linkers, IMMU-132 uses a moderately toxic drug with a moderately stable carbonate bond between SN-38 and the linker.  Flow cytometry and immunohistochem. disclosed that Trop-2 is expressed in a wide range of tumor types, including gastric, pancreatic, triple-neg. breast (TNBC), colonic, prostate, and lung.  While cell-binding expts. reveal no significant differences between IMMU-132 and parental hRS7 antibody, surface plasmon resonance anal. using a Trop-2 CM5 chip shows a significant binding advantage for IMMU-132 over hRS7.  The conjugate retained binding to the neonatal receptor, but it lost greater than 60% of the antibody-dependent cell-mediated cytotoxicity activity compared to that of hRS7.  Exposure of tumor cells to either free SN-38 or IMMU-132 demonstrated the same signaling pathways, with pJNK1/2 and p21WAF1/Cip1 upregulation followed by cleavage of caspases 9, 7, and 3, ultimately leading to poly-ADP-ribose polymerase cleavage and double-stranded DNA breaks.  Pharmacokinetics of the intact ADC in mice reveals a mean residence time (MRT) of 15.4 h, while the carrier hRS7 antibody cleared at a similar rate as that of the unconjugated antibody (MRT ∼ 300 h).  IMMU-132 treatment of mice bearing human gastric cancer xenografts (17.5 mg/kg; twice weekly × 4 wk) resulted in significant antitumor effects compared to that of mice treated with a nonspecific control.  Clin. relevant dosing schemes of IMMU-132 administered either every other week, weekly, or twice weekly in mice bearing human pancreatic or gastric cancer xenografts demonstrate similar, significant antitumor effects in both models.  Current Phase I/II clin. trials (ClinicalTrials.gov, NCT01631552) confirm anticancer activity of IMMU-132 in cancers expressing Trop-2, including gastric and pancreatic cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3wWMahyB2oLVg90H21EOLACvtfcHk0liYd-NaC4nLSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntF2lsbg%253D&md5=30c0b123cd3e392e53c8eaf50f31aa7e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.5b00223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.5b00223%26sid%3Dliteratum%253Aachs%26aulast%3DCardillo%26aufirst%3DT.%2BM.%26aulast%3DGovindan%26aufirst%3DS.%2BV.%26aulast%3DSharkey%26aufirst%3DR.%2BM.%26aulast%3DTrisal%26aufirst%3DP.%26aulast%3DArrojo%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DRossi%26aufirst%3DE.%2BA.%26aulast%3DChang%26aufirst%3DC.-H.%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26atitle%3DSacituzumab%2520Govitecan%2520%2528IMMU-132%2529%252C%2520an%2520Anti-Trop-2%252FSN-38%2520Antibody-Drug%2520Conjugate%253A%2520Characterization%2520and%2520Efficacy%2520in%2520Pancreatic%252C%2520Gastric%252C%2520and%2520Other%2520Cancers%26jtitle%3DBioconjugate%2520Chem.%26date%3D2015%26volume%3D26%26spage%3D919%26epage%3D931%26doi%3D10.1021%2Facs.bioconjchem.5b00223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lock, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span> <span> </span><span class="NLM_article-title">The Role of Micelle Size in Tumor Accumulation, Penetration, and Treatment</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">7195</span>– <span class="NLM_lpage">7206</span>, <span class="refDoi"> DOI: 10.1021/acsnano.5b02017</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsnano.5b02017" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFWqtLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=7195-7206&author=J.+Wangauthor=W.+Maoauthor=L.+L.+Lockauthor=J.+Tangauthor=M.+Suiauthor=W.+Sunauthor=H.+Cuiauthor=D.+Xuauthor=Y.+Shen&title=The+Role+of+Micelle+Size+in+Tumor+Accumulation%2C+Penetration%2C+and+Treatment&doi=10.1021%2Facsnano.5b02017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Micelle Size in Tumor Accumulation, Penetration, and Treatment</span></div><div class="casAuthors">Wang, Jinqiang; Mao, Weiwei; Lock, Lye Lin; Tang, Jianbin; Sui, Meihua; Sun, Weilin; Cui, Honggang; Xu, Dong; Shen, Youqing</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">7195-7206</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The specific sizes that det. optimal nanoparticle tumor accumulation, penetration, and treatment remain inconclusive because many studies compared nanoparticles with multiple physicochem. variables (e.g., chem. structures, shapes, and other phys. properties) in addn. to the size.  In this study, we synthesized amphiphilic block copolymers of 7-ethyl-10-hydroxylcamptothecin (SN38) prodrug and fabricated micelles with sizes ranging from 20 to 300 nm from a single copolymer.  The as-prepd. micelles had exactly the same chem. structures and similar phys. properties except for size, which provided an ideal platform for a systematic investigation of the size effects in cancer drug delivery.  We found that the micelle's blood circulation time and tumor accumulation increased with the increase in their diams., with optimal diam. range of 100 to 160 nm.  However, the much higher tumor accumulation of the large micelles (100 nm) did not result in significantly improved therapeutic efficacy, because the large micelles had poorer tumor penetration than the small ones (30 nm).  An optimal size that balances drug accumulation and penetration in tumors is crit. for improving the therapeutic efficacy of nanoparticulate drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMSw6MW2XoQrVg90H21EOLACvtfcHk0lhoBlwtFaq_ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFWqtLnE&md5=c647c3258f683f45bbcf8278d5f2f39c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facsnano.5b02017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsnano.5b02017%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMao%26aufirst%3DW.%26aulast%3DLock%26aufirst%3DL.%2BL.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DSui%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DCui%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DShen%26aufirst%3DY.%26atitle%3DThe%2520Role%2520of%2520Micelle%2520Size%2520in%2520Tumor%2520Accumulation%252C%2520Penetration%252C%2520and%2520Treatment%26jtitle%3DACS%2520Nano%26date%3D2015%26volume%3D9%26spage%3D7195%26epage%3D7206%26doi%3D10.1021%2Facsnano.5b02017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasarao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, P. S.</span></span> <span> </span><span class="NLM_article-title">Ligand-Targeted Drug Delivery</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">12133</span>– <span class="NLM_lpage">12164</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.7b00013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.7b00013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKksLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2017&pages=12133-12164&author=M.+Srinivasaraoauthor=P.+S.+Low&title=Ligand-Targeted+Drug+Delivery&doi=10.1021%2Facs.chemrev.7b00013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand-Targeted Drug Delivery</span></div><div class="casAuthors">Srinivasarao, Madduri; Low, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">12133-12164</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Safety and efficacy constitute the major criteria governing regulatory approval of any new drug.  The best method to maximize safety and efficacy is to deliver a proven therapeutic agent with a targeting ligand that exhibits little affinity for healthy cells but high affinity for pathol. cells.  The probability of regulatory approval can conceivably be further enhanced by exploiting the same targeting ligand, conjugated to an imaging agent, to select patients whose diseased tissues display sufficient targeted receptors for therapeutic efficacy.  The focus of this Review is to summarize criteria that must be met during design of ligand-targeted drugs (LTDs) to achieve the required therapeutic potency with minimal toxicity.  Because most LTDs are composed of a targeting ligand (e.g., org. mol., aptamer, protein scaffold, or antibody), spacer, cleavable linker, and therapeutic warhead, criteria for successful design of each component will be described.  Moreover, because obstacles to successful drug design can differ among human pathologies, limitations to drug delivery imposed by the unique characteristics of different diseases will be considered.  With the explosion of genomic and transcriptomic data providing an ever-expanding selection of disease-specific targets, and with tools for high-throughput chem. offering an escalating diversity of warheads, opportunities for innovating safe and effective LTDs has never been greater.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAbg140AL2mLVg90H21EOLACvtfcHk0lhoBlwtFaq_ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKksLnE&md5=d0c909cfbc04e18fa3b0de35b3ebde60</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.7b00013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.7b00013%26sid%3Dliteratum%253Aachs%26aulast%3DSrinivasarao%26aufirst%3DM.%26aulast%3DLow%26aufirst%3DP.%2BS.%26atitle%3DLigand-Targeted%2520Drug%2520Delivery%26jtitle%3DChem.%2520Rev.%26date%3D2017%26volume%3D117%26spage%3D12133%26epage%3D12164%26doi%3D10.1021%2Facs.chemrev.7b00013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poon, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flagella, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tibbitts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saad, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girish, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dybdal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, T.</span></span> <span> </span><span class="NLM_article-title">Preclinical Safety Profile of Trastuzumab Emtansine (T-DM1): Mechanism of Action of its Cytotoxic Component Retained with Improved Tolerability</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>273</i></span>,  <span class="NLM_fpage">298</span>– <span class="NLM_lpage">313</span>, <span class="refDoi"> DOI: 10.1016/j.taap.2013.09.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1016%2Fj.taap.2013.09.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=24035823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslGlsbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=2013&pages=298-313&author=K.+A.+Poonauthor=K.+Flagellaauthor=J.+Beyerauthor=J.+Tibbittsauthor=S.+Kaurauthor=O.+Saadauthor=J.-H.+Yiauthor=S.+Girishauthor=N.+Dybdalauthor=T.+Reynolds&title=Preclinical+Safety+Profile+of+Trastuzumab+Emtansine+%28T-DM1%29%3A+Mechanism+of+Action+of+its+Cytotoxic+Component+Retained+with+Improved+Tolerability&doi=10.1016%2Fj.taap.2013.09.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability</span></div><div class="casAuthors">Poon, Kirsten Achilles; Flagella, Kelly; Beyer, Joseph; Tibbitts, Jay; Kaur, Surinder; Saad, Ola; Yi, Joo-Hee; Girish, Sandhya; Dybdal, Noel; Reynolds, Theresa</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">298-313</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Trastuzumab emtansine (T-DM1) is the first antibody-drug conjugate (ADC) approved for patients with human epidermal growth factor receptor 2 (HER2)-pos. metastatic breast cancer.  The therapeutic premise of ADCs is based on the hypothesis that targeted delivery of potent cytotoxic drugs to tumors will provide better tolerability and efficacy compared with non-targeted delivery, where poor tolerability can limit efficacious doses.  Here, we present results from preclin. studies characterizing the toxicity profile of T-DM1, including limited assessment of unconjugated DM1.  T-DM1 binds primate ErbB2 and human HER2 but not the rodent homolog c-neu.  Therefore, antigen-dependent and non-antigen-dependent toxicity was evaluated in monkeys and rats, resp., in both single- and repeat-dose studies; toxicity of DM1 was assessed in rats only.  T-DM1 was well tolerated at doses up to 40 mg/kg (~ 4400 μg DM1/m2) and 30 mg/kg (~ 6000 μg DM1/m2) in rats and monkeys, resp.  In contrast, DM1 was only tolerated up to 0.2 mg/kg (1600 μg DM1/m2).  This suggests that at least two-fold higher doses of the cytotoxic agent are tolerated in T-DM1, supporting the premise of ADCs to improve the therapeutic index.  In addn., T-DM1 and DM1 safety profiles were similar and consistent with the mechanism of action of DM1 (i.e., microtubule disruption).  Findings included hepatic, bone marrow/hematol. (primarily platelet), lymphoid organ, and neuronal toxicities, and increased nos. of cells of epithelial and phagocytic origin in metaphase arrest.  These adverse effects did not worsen with chronic dosing in monkeys and are consistent with those reported in T-DM1-treated patients to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp36u8JDO92mbVg90H21EOLACvtfcHk0lhoBlwtFaq_ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslGlsbbO&md5=f2ae6f6fc865d8ad027752e1301be3cc</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2013.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2013.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DPoon%26aufirst%3DK.%2BA.%26aulast%3DFlagella%26aufirst%3DK.%26aulast%3DBeyer%26aufirst%3DJ.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DKaur%26aufirst%3DS.%26aulast%3DSaad%26aufirst%3DO.%26aulast%3DYi%26aufirst%3DJ.-H.%26aulast%3DGirish%26aufirst%3DS.%26aulast%3DDybdal%26aufirst%3DN.%26aulast%3DReynolds%26aufirst%3DT.%26atitle%3DPreclinical%2520Safety%2520Profile%2520of%2520Trastuzumab%2520Emtansine%2520%2528T-DM1%2529%253A%2520Mechanism%2520of%2520Action%2520of%2520its%2520Cytotoxic%2520Component%2520Retained%2520with%2520Improved%2520Tolerability%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2013%26volume%3D273%26spage%3D298%26epage%3D313%26doi%3D10.1016%2Fj.taap.2013.09.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goetsch, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumontet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corvaïa, N.</span></span> <span> </span><span class="NLM_article-title">Strategies and Challenges for the Next Generation of Antibody-drug Conjugates</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.268</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1038%2Fnrd.2016.268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=28303026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1Onsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=315-337&author=A.+Beckauthor=L.+Goetschauthor=C.+Dumontetauthor=N.+Corva%C3%AFa&title=Strategies+and+Challenges+for+the+Next+Generation+of+Antibody-drug+Conjugates&doi=10.1038%2Fnrd.2016.268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies and challenges for the next generation of antibody-drug conjugates</span></div><div class="casAuthors">Beck, Alain; Goetsch, Liliane; Dumontet, Charles; Corvaia, Nathalie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">315-337</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Antibody-drug conjugates (ADCs) are one of the fastest growing classes of oncol. therapeutics.  After half a century of research, the approvals of brentuximab vedotin (in 2011) and trastuzumab emtansine (in 2013) have paved the way for ongoing clin. trials that are evaluating more than 60 further ADC candidates.  The limited success of first-generation ADCs (developed in the early 2000s) informed strategies to bring second-generation ADCs to the market, which have higher levels of cytotoxic drug conjugation, lower levels of naked antibodies and more-stable linkers between the drug and the antibody.  Furthermore, lessons learned during the past decade are now being used in the development of third-generation ADCs.  In this Review, we discuss strategies to select the best target antigens as well as suitable cytotoxic drugs; the design of optimized linkers; the discovery of bioorthogonal conjugation chemistries; and toxicity issues.  The selection and engineering of antibodies for site-specific drug conjugation, which will result in higher homogeneity and increased stability, as well as the quest for new conjugation chemistries and mechanisms of action, are priorities in ADC research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP7lV63Ws8rbVg90H21EOLACvtfcHk0liBbbQR_dv9ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1Onsbc%253D&md5=7358b6080dd1aed1d21e98c078cd9ef1</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.268%26sid%3Dliteratum%253Aachs%26aulast%3DBeck%26aufirst%3DA.%26aulast%3DGoetsch%26aufirst%3DL.%26aulast%3DDumontet%26aufirst%3DC.%26aulast%3DCorva%25C3%25AFa%26aufirst%3DN.%26atitle%3DStrategies%2520and%2520Challenges%2520for%2520the%2520Next%2520Generation%2520of%2520Antibody-drug%2520Conjugates%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D315%26epage%3D337%26doi%3D10.1038%2Fnrd.2016.268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span> <span> </span><span class="NLM_article-title">A Tumor-Targeted Ganetespib-Zinc Phthalocyanine Conjugate for Synergistic Chemo-photodynamic Therapy</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">294</span>– <span class="NLM_lpage">303</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1016%2Fj.ejmech.2018.03.077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=29627724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1ejsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=294-303&author=L.+Huangauthor=G.+Weiauthor=X.+Sunauthor=Y.+Jiangauthor=Z.+Huangauthor=Y.+Huangauthor=Y.+Shenauthor=X.+Xuauthor=Y.+Liaoauthor=C.+Zhao&title=A+Tumor-Targeted+Ganetespib-Zinc+Phthalocyanine+Conjugate+for+Synergistic+Chemo-photodynamic+Therapy&doi=10.1016%2Fj.ejmech.2018.03.077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">A tumor-targeted Ganetespib-zinc phthalocyanine conjugate for synergistic chemo-photodynamic therapy</span></div><div class="casAuthors">Huang, Liangfeng; Wei, Gaofei; Sun, Xiaoqi; Jiang, Yali; Huang, Zeqian; Huang, Yanjuan; Shen, Yifeng; Xu, Xiaoyu; Liao, Yunhui; Zhao, Chunshun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">294-303</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Therapeutic effects of photodynamic therapy (PDT) are limited by the selectivity of photosensitizer (PS).  Herein, a novel tumor-targeted drug-PS conjugate (Gan-ZnPc) which integrated with zinc phthalocyanine (ZnPc) and Ganetespib has been developed.  ZnPc is a promising PS with remarkable photosensitization ability.  Ganetespib is a heat shock protein 90 (Hsp90) inhibitor with preferential tumor selectivity and conjugated to ZnPc as a tumor-targeted ligand.  The multifunctional small mol. conjugate, Gan-ZnPc, could be bound to extracellular Hsp90 and then selectively internalized into the tumor cells, followed by the generation of abundant intracellular reactive oxygen species (ROS) upon irradn.  Besides, Gan-ZnPc can arrest cell proliferation and induce apoptosis by the inhibition of Hsp90.  Herein, with combination of the inhibition of Hsp90 and the generation of cytotoxic ROS, Gan-ZnPc implements tumor selectivity, concd. PDT and chemotherapy in a synergistic manner, which results in highly effective anti-tumor activity in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoas66UM4KbibVg90H21EOLACvtfcHk0liBbbQR_dv9ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1ejsL4%253D&md5=1be58069058458ab8034a8f25d307000</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.077%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DLiao%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DC.%26atitle%3DA%2520Tumor-Targeted%2520Ganetespib-Zinc%2520Phthalocyanine%2520Conjugate%2520for%2520Synergistic%2520Chemo-photodynamic%2520Therapy%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D294%26epage%3D303%26doi%3D10.1016%2Fj.ejmech.2018.03.077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohlson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Triple Inhibitors of Janus Kinase (JAK), Histone Deacetylase (HDAC) and Heat Shock Protein 90 (HSP90)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1357</span>– <span class="NLM_lpage">1362</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1016%2Fj.bmcl.2018.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=29545103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslWqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=1357-1362&author=L.+Yaoauthor=S.+Ohlsonauthor=B.+W.+Dymock&title=Design+and+Synthesis+of+Triple+Inhibitors+of+Janus+Kinase+%28JAK%29%2C+Histone+Deacetylase+%28HDAC%29+and+Heat+Shock+Protein+90+%28HSP90%29&doi=10.1016%2Fj.bmcl.2018.03.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of triple inhibitors of janus kinase (JAK), histone deacetylase (HDAC) and Heat Shock Protein 90 (HSP90)</span></div><div class="casAuthors">Yao, Lianbin; Ohlson, Sten; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1357-1362</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Inhibition of multiple signaling pathways in a cancer cell with a single mol. could result in better therapies that are simpler to administer.  Efficacy may be achieved with reduced potency against individual targets if there is synergy through multiple pathway inhibition.  To achieve this, it is necessary to be able to build multi-component ligands by joining together key pharmacophores in a way which maintains sufficient activity against the individual pathways.  Designed triple inhibiting ligands are explored aiming to block three completely different target types: a kinase (JAK2), an epigenetic target (HDAC) and a chaperone (HSP90).  Although these enzymes have totally different functions they are related through inter-dependent pathways in the developing cancer cell.  Synthesis of several complex multi-inhibiting ligands are presented along with initial enzyme inhibition data against 3 biol. target classes of interest.  A lead compd., 47 (I), was discovered which had low micromolar activity for all 3 targets.  Further development of these complex trispecific designed multiple ligands could result in a 'transient drug', an alternative combination therapy for treating cancer mediated via a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDUq3YMXAAJ7Vg90H21EOLACvtfcHk0liBbbQR_dv9ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslWqtr0%253D&md5=e53b440497676faa53b614072e0a3f37</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DL.%26aulast%3DOhlson%26aufirst%3DS.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Triple%2520Inhibitors%2520of%2520Janus%2520Kinase%2520%2528JAK%2529%252C%2520Histone%2520Deacetylase%2520%2528HDAC%2529%2520and%2520Heat%2520Shock%2520Protein%252090%2520%2528HSP90%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D1357%26epage%3D1362%26doi%3D10.1016%2Fj.bmcl.2018.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Biocompatible Heat-Shock Protein Inhibitor-Delivered Flowerlike Short-Wave Infrared Nanoprobe for Mild Temperature-Driven Highly Efficient Tumor Ablation</span>. <i>ACS Appl. Mater. Interfaces</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">6820</span>– <span class="NLM_lpage">6828</span>, <span class="refDoi"> DOI: 10.1021/acsami.8b21483</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsami.8b21483" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVSltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=6820-6828&author=A.+Jiangauthor=Y.+Liuauthor=L.+Maauthor=F.+Maoauthor=L.+Liuauthor=X.+Zhaiauthor=J.+Zhou&title=Biocompatible+Heat-Shock+Protein+Inhibitor-Delivered+Flowerlike+Short-Wave+Infrared+Nanoprobe+for+Mild+Temperature-Driven+Highly+Efficient+Tumor+Ablation&doi=10.1021%2Facsami.8b21483"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Biocompatible Heat-Shock Protein Inhibitor-Delivered Flowerlike Short-Wave Infrared Nanoprobe for Mild Temperature-Driven Highly Efficient Tumor Ablation</span></div><div class="casAuthors">Jiang, Anqi; Liu, Yuxin; Ma, Liyi; Mao, Fang; Liu, Lidong; Zhai, Xuejiao; Zhou, Jing</div><div class="citationInfo"><span class="NLM_cas:title">ACS Applied Materials & Interfaces</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">6820-6828</span>CODEN:
                <span class="NLM_cas:coden">AAMICK</span>;
        ISSN:<span class="NLM_cas:issn">1944-8244</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multifunctional nanomaterials for dual-mode imaging guided cancer therapy are highly desirable in clin. applications.  Herein, a flowerlike NiS2-coated NaLuF4:Nd (Lu:<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="08466c4846615b3a">[email protected]</a>) nanoparticle was synthesized as a novel therapeutic agent for short-wave IR light imaging and magnetic resonance imaging to guide photothermal therapy (PTT).  The material was then loaded with phenolic epigallocatechin 3-gallate (EGCG), which is a natural heat-shock protein 90 (HSP90) inhibitor.  Upon near IR irradn., EGCG was released from the Lu:<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="77391337391e24455a32303430">[email protected]</a>, which bound HSP90 and reduced cell tolerance to heat, resulting in a better therapeutic effect at the same elevated temp.  Therefore, with minimal side effects and remarkable antitumor efficacy in vivo, Lu:<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="28664c6866417b1a056d6f6b6f">[email protected]</a> appeared to be a promising photothermal agent for enhanced PTT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolEQ5-NsfPNLVg90H21EOLACvtfcHk0lju_vcRJK7oxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVSltrY%253D&md5=1c376dd6fd82b138313486cae8aa59f2</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facsami.8b21483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsami.8b21483%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DMao%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DZhai%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DBiocompatible%2520Heat-Shock%2520Protein%2520Inhibitor-Delivered%2520Flowerlike%2520Short-Wave%2520Infrared%2520Nanoprobe%2520for%2520Mild%2520Temperature-Driven%2520Highly%2520Efficient%2520Tumor%2520Ablation%26jtitle%3DACS%2520Appl.%2520Mater.%2520Interfaces%26date%3D2019%26volume%3D11%26spage%3D6820%26epage%3D6828%26doi%3D10.1021%2Facsami.8b21483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong-Thi, M.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohlson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8336</span>– <span class="NLM_lpage">8357</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00678</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00678" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8336-8357&author=L.+Yaoauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+Singhauthor=M.-D.+Duong-Thiauthor=J.+X.+T.+Leeauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Y.+Yenauthor=S.+Ohlsonauthor=B.+W.+Dymock&title=Design+and+Synthesis+of+Ligand+Efficient+Dual+Inhibitors+of+Janus+Kinase+%28JAK%29+and+Histone+Deacetylase+%28HDAC%29+Based+on+Ruxolitinib+and+Vorinostat&doi=10.1021%2Facs.jmedchem.7b00678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat</span></div><div class="casAuthors">Yao, Lianbin; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Singh, Prachi; Duong-Thi, Minh-Dao; Lee, Jeannie X. T.; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Ohlson, Sten; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8336-8357</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Concomitant inhibition of multiple oncogenic pathways is a desirable goal in cancer therapy.  To achieve such an outcome with a single mol. would simplify treatment regimes.  Herein the core features of ruxolitinib, a marketed JAK1/2 inhibitor, have been merged with the HDAC inhibitor vorinostat, leading to new mols. that are bispecific targeted JAK/HDAC inhibitors.  A preferred pyrazole substituted pyrrolopyrimidine, I (R = H), inhibits JAK1 and HDACs 1, 2, 3, 6, and 10 with IC50 values of less than 20 nM, is <100 nM potent against JAK2 and HDAC11, and is selective for the JAK family against a panel of 97 kinases.  Broad cellular antiproliferative potency of I (R = H) is supported by demonstration of JAK-STAT and HDAC pathway blockade in hematol. cell lines.  Me analog I (R = Me) has an even more selective profile.  This study provides new leads for assessment of JAK and HDAC pathway dual inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocWx3JXIW8YbVg90H21EOLACvtfcHk0lju_vcRJK7oxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOjtLzJ&md5=5ac471ee0cc413b08b926803790de7f9</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00678%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DL.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DDuong-Thi%26aufirst%3DM.-D.%26aulast%3DLee%26aufirst%3DJ.%2BX.%2BT.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%2BY.%26aulast%3DOhlson%26aufirst%3DS.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Ligand%2520Efficient%2520Dual%2520Inhibitors%2520of%2520Janus%2520Kinase%2520%2528JAK%2529%2520and%2520Histone%2520Deacetylase%2520%2528HDAC%2529%2520Based%2520on%2520Ruxolitinib%2520and%2520Vorinostat%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8336%26epage%3D8357%26doi%3D10.1021%2Facs.jmedchem.7b00678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crowe, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcorta, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totzke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loiselle, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gargesha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roques, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyerly, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spector, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haystead, T. A. J.</span></span> <span> </span><span class="NLM_article-title">A Fluorescent HSP90 Probe Demonstrates the Unique Association between Extracellular HSP90 and Malignancy in Vivo</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1047</span>– <span class="NLM_lpage">1055</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00006</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00006" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1ehsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1047-1055&author=L.+B.+Croweauthor=P.+F.+Hughesauthor=D.+A.+Alcortaauthor=T.+Osadaauthor=A.+P.+Smithauthor=J.+Totzkeauthor=D.+R.+Loiselleauthor=I.+D.+Lutzauthor=M.+Gargeshaauthor=D.+Royauthor=J.+Roquesauthor=D.+Darrauthor=H.+K.+Lyerlyauthor=N.+L.+Spectorauthor=T.+A.+J.+Haystead&title=A+Fluorescent+HSP90+Probe+Demonstrates+the+Unique+Association+between+Extracellular+HSP90+and+Malignancy+in+Vivo&doi=10.1021%2Facschembio.7b00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A Fluorescent Hsp90 Probe Demonstrates the Unique Association between Extracellular Hsp90 and Malignancy in Vivo</span></div><div class="casAuthors">Crowe, Lauren B.; Hughes, Philip F.; Alcorta, David A.; Osada, Takuya; Smith, Aaron P.; Totzke, Juliane; Loiselle, David R.; Lutz, Isaac D.; Gargesha, Madhusudhana; Roy, Debasish; Roques, Jose; Darr, David; Lyerly, H. Kim; Spector, Neil L.; Haystead, Timothy A. J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1047-1055</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Extracellular expression of heat shock protein 90 (eHsp90) by tumor cells is correlated with malignancy.  Development of small mol. probes that can detect eHsp90 in vivo may therefore have utility in the early detection of malignancy.  The authors synthesized a cell impermeable far-red fluorophore-tagged Hsp90 inhibitor to target eHsp90 in vivo.  High resoln. confocal and lattice light sheet microscopy show that probe-bound eHsp90 accumulates in punctate structures on the plasma membrane of breast tumor cells and is actively internalized.  The extent of internalization correlates with tumor cell aggressiveness, and this process can be induced in benign cells by over-expressing p110HER2.  Whole body cryoslicing, imaging and histol. of flank and spontaneous tumor-bearing mice strongly suggests that eHsp90 expression and internalization is a phenomenon unique to tumor cells in vivo and may provide an Achilles heel for the early diagnosis of metastatic disease and targeted drug delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWtkg9Hh_AZLVg90H21EOLACvtfcHk0ljnwfGHc5it5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1ehsrc%253D&md5=05f2c31fdcfbd238f461f557dcc7d6e7</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00006%26sid%3Dliteratum%253Aachs%26aulast%3DCrowe%26aufirst%3DL.%2BB.%26aulast%3DHughes%26aufirst%3DP.%2BF.%26aulast%3DAlcorta%26aufirst%3DD.%2BA.%26aulast%3DOsada%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DA.%2BP.%26aulast%3DTotzke%26aufirst%3DJ.%26aulast%3DLoiselle%26aufirst%3DD.%2BR.%26aulast%3DLutz%26aufirst%3DI.%2BD.%26aulast%3DGargesha%26aufirst%3DM.%26aulast%3DRoy%26aufirst%3DD.%26aulast%3DRoques%26aufirst%3DJ.%26aulast%3DDarr%26aufirst%3DD.%26aulast%3DLyerly%26aufirst%3DH.%2BK.%26aulast%3DSpector%26aufirst%3DN.%2BL.%26aulast%3DHaystead%26aufirst%3DT.%2BA.%2BJ.%26atitle%3DA%2520Fluorescent%2520HSP90%2520Probe%2520Demonstrates%2520the%2520Unique%2520Association%2520between%2520Extracellular%2520HSP90%2520and%2520Malignancy%2520in%2520Vivo%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2017%26volume%3D12%26spage%3D1047%26epage%3D1055%26doi%3D10.1021%2Facschembio.7b00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaponova, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikonova, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deneka, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopp, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudinov, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skobeleva, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khazak, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, K. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egleston, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proia, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boumber, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golemis, E. A.</span></span> <span> </span><span class="NLM_article-title">A Novel HSP90 Inhibitor-Drug Conjugate to SN38 is Highly Effective in Small Cell Lung Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">5120</span>– <span class="NLM_lpage">5129</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-15-3068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1158%2F1078-0432.CCR-15-3068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=27267850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOhs77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=5120-5129&author=A.+V.+Gaponovaauthor=A.+S.+Nikonovaauthor=A.+Y.+Denekaauthor=M.+C.+Koppauthor=A.+E.+Kudinovauthor=N.+Skobelevaauthor=V.+Khazakauthor=L.+S.+Ogawaauthor=K.+Q.+Caiauthor=K.+E.+Duncanauthor=J.+S.+Duncanauthor=B.+L.+Eglestonauthor=D.+A.+Proiaauthor=Y.+Boumberauthor=E.+A.+Golemis&title=A+Novel+HSP90+Inhibitor-Drug+Conjugate+to+SN38+is+Highly+Effective+in+Small+Cell+Lung+Cancer&doi=10.1158%2F1078-0432.ccr-15-3068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer</span></div><div class="casAuthors">Gaponova, Anna V.; Nikonova, Anna S.; Deneka, Alexander Y.; Kopp, Meghan C.; Kudinov, Alexander E.; Skobeleva, Natalia; Khazak, Vladimir; Ogawa, Luisa S.; Cai, Kathy Q.; Duncan, Kelly E.; Duncan, James S.; Egleston, Brian L.; Proia, David A.; Boumber, Yanis; Golemis, Erica A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5120-5129</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Small cell lung cancer (SCLC) is a highly aggressive disease representing 12% to 13% of total lung cancers, with median survival of <2 years.  No targeted therapies have proven effective in SCLC.  Although most patients respond initially to cytotoxic chemotherapies, resistance rapidly emerges, response to second-line agents is limited, and dose-limiting toxicities (DLT) are a major issue.  This study performs preclin. evaluation of a new compd., STA-8666, in SCLC.  To avoid DLT for useful cytotoxic agents, the recently developed drug STA-8666 combines a chem. moiety targeting active HSP90 (concd. in tumors) fused via cleavable linker to SN38, the active metabolite of irinotecan.  We compare potency and mechanism of action of STA-8666 and irinotecan in vitro and in vivo.  In two SCLC xenograft and patient-derived xenograft models, STA-8666 was tolerated without side effects up to 150 mg/kg.  At this dose, STA-8666 controlled or eliminated established tumors whether used in a first-line setting or in tumors that had progressed following treatment on std. first- and second-line agents for SCLC.  At 50 mg/kg, STA-8666 strongly enhanced the action of carboplatin.  Pharmacokinetic profiling confirmed durable STA-8666 exposure in tumors compared with irinotecan.  STA-8666 induced a more rapid, robust, and stable induction of cell-cycle arrest, expression of signaling proteins assocd. with DNA damage and cell-cycle checkpoints, and apoptosis in vitro and in vivo, in comparison with irinotecan.  Together, these results strongly support clin. development of STA-8666 for use in the first- or second-line setting for SCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5QHHBGAoXOLVg90H21EOLACvtfcHk0ljnwfGHc5it5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOhs77N&md5=01caf2635048f4a66000af3702b0c451</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-3068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-3068%26sid%3Dliteratum%253Aachs%26aulast%3DGaponova%26aufirst%3DA.%2BV.%26aulast%3DNikonova%26aufirst%3DA.%2BS.%26aulast%3DDeneka%26aufirst%3DA.%2BY.%26aulast%3DKopp%26aufirst%3DM.%2BC.%26aulast%3DKudinov%26aufirst%3DA.%2BE.%26aulast%3DSkobeleva%26aufirst%3DN.%26aulast%3DKhazak%26aufirst%3DV.%26aulast%3DOgawa%26aufirst%3DL.%2BS.%26aulast%3DCai%26aufirst%3DK.%2BQ.%26aulast%3DDuncan%26aufirst%3DK.%2BE.%26aulast%3DDuncan%26aufirst%3DJ.%2BS.%26aulast%3DEgleston%26aufirst%3DB.%2BL.%26aulast%3DProia%26aufirst%3DD.%2BA.%26aulast%3DBoumber%26aufirst%3DY.%26aulast%3DGolemis%26aufirst%3DE.%2BA.%26atitle%3DA%2520Novel%2520HSP90%2520Inhibitor-Drug%2520Conjugate%2520to%2520SN38%2520is%2520Highly%2520Effective%2520in%2520Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D5120%26epage%3D5129%26doi%3D10.1158%2F1078-0432.ccr-15-3068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heske, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendoza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edessa, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgart, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trepel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proia, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helman, L. J.</span></span> <span> </span><span class="NLM_article-title">STA-8666, a Novel HSP90 Inhibitor/SN-38 Drug Conjugate, Causes Complete Tumor Regression in Preclinical Mouse Models of Pediatric Sarcoma</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">65540</span>– <span class="NLM_lpage">65552</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.11869</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.18632%2Foncotarget.11869" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=27608846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A280%3ADC%252BC2szoslOjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=65540-65552&author=C.+M.+Heskeauthor=A.+Mendozaauthor=L.+D.+Edessaauthor=J.+T.+Baumgartauthor=S.+Leeauthor=J.+Trepelauthor=D.+A.+Proiaauthor=L.+Neckersauthor=L.+J.+Helman&title=STA-8666%2C+a+Novel+HSP90+Inhibitor%2FSN-38+Drug+Conjugate%2C+Causes+Complete+Tumor+Regression+in+Preclinical+Mouse+Models+of+Pediatric+Sarcoma&doi=10.18632%2Foncotarget.11869"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma</span></div><div class="casAuthors">Heske Christine M; Mendoza Arnulfo; Edessa Leah D; Baumgart Joshua T; Helman Lee J; Lee Sunmin; Trepel Jane; Proia David A; Neckers Len</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">65540-65552</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Long-term survival in patients with metastatic, relapsed, or recurrent Ewing sarcoma and rhabdomyosarcoma is dismal.  Irinotecan, a topoisomerase 1 inhibitor, has activity in these sarcomas, but due to poor bioavailability of its active metabolite (SN-38) has had limited clinical efficacy.  In this study we have evaluated the efficacy and toxicity of STA-8666, a novel drug conjugate which uses an HSP90 inhibitor to facilitate intracellular, tumor-targeted delivery of the topoisomerase 1 inhibitor SN-38, thus preferentially delivering and concentrating SN-38 within tumor tissue.  We present in vivo evidence from mouse xenograft models that STA-8666 results in more persistent inhibition of topoisomerase 1 and prolonged DNA damage compared to irinotecan.  This translates into superior antitumor efficacy and survival in multiple aggressive models of both diseases in mouse xenografts, as well as in an irinotecan-resistant model of pediatric osteosarcoma, demonstrated by dramatic tumor shrinkage, durable remission and prolonged complete regressions following short-term treatment, compared to conventional irinotecan.  Gene expression analysis performed on xenograft tumors treated with either irinotecan or STA-8666 showed that STA-8666 affected expression of DNA damage and repair genes more robustly than irinotecan.  These results suggest that STA-8666 may be a promising new agent for patients with pediatric-type sarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDMnjuYNWUMMKL0FlyGHDofW6udTcc2eYIcX4YQzIHhbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szoslOjsw%253D%253D&md5=5cf387bb6fc02851e66abbf8f08586d2</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.11869&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.11869%26sid%3Dliteratum%253Aachs%26aulast%3DHeske%26aufirst%3DC.%2BM.%26aulast%3DMendoza%26aufirst%3DA.%26aulast%3DEdessa%26aufirst%3DL.%2BD.%26aulast%3DBaumgart%26aufirst%3DJ.%2BT.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DTrepel%26aufirst%3DJ.%26aulast%3DProia%26aufirst%3DD.%2BA.%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DHelman%26aufirst%3DL.%2BJ.%26atitle%3DSTA-8666%252C%2520a%2520Novel%2520HSP90%2520Inhibitor%252FSN-38%2520Drug%2520Conjugate%252C%2520Causes%2520Complete%2520Tumor%2520Regression%2520in%2520Preclinical%2520Mouse%2520Models%2520of%2520Pediatric%2520Sarcoma%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D65540%26epage%3D65552%26doi%3D10.18632%2Foncotarget.11869" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Pharmacological Evaluation of ALK and HSP90 Dual Inhibitors Bearing Resorcinol and 2,4-Diaminopyrimidine Motifs</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">76</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.04.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1016%2Fj.ejmech.2018.04.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=29698859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosVWmsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2018&pages=76-86&author=K.+Gengauthor=H.+Liuauthor=Z.+Songauthor=C.+Zhangauthor=M.+Zhangauthor=H.+Yangauthor=J.+Caoauthor=M.+Gengauthor=A.+Shenauthor=A.+Zhang&title=Design%2C+Synthesis+and+Pharmacological+Evaluation+of+ALK+and+HSP90+Dual+Inhibitors+Bearing+Resorcinol+and+2%2C4-Diaminopyrimidine+Motifs&doi=10.1016%2Fj.ejmech.2018.04.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2,4-diaminopyrimidine motifs</span></div><div class="casAuthors">Geng, Kaijun; Liu, Hongchun; Song, Zilan; Zhang, Chi; Zhang, Minmin; Yang, Hong; Cao, Jingchen; Geng, Meiyu; Shen, Aijun; Zhang, Ao</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">76-86</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Rather than by directly focusing on the ever-changing ALK mutants, here we report an alternative strategy to overcome the drug resistance caused by treatment of ALK inhibitors by developing ALK and Hsp90 dual targeting inhibitors.  Since Hsp90 is a mol. chaperone that regulates the maturation, activation and stability of numerous "client proteins" including ALK, dual targeting ALK and Hsp90 may bring more benefits and efficacy against drug resistance of ALK inhibitors.  By using our previously developed ALK inhibitor 6 and the clin. Hsp90 inhibitors AUY922 or AT13387 as the templates, we developed several series of resorcinol tethered 2,4-diaminopyrimidines as ALK/Hsp90 dual inhibitors bearing various linkers at different linking sites.  Compd. 10h and 10j showed high potency against ALK (17.3 vs 9.8 nM) and Hsp90α (100 vs 40 nM).  They also have high potency against ALK resistant mutants, esp. the gatekeeper mutation ALKL1196M.  Both compds. showed strong antiproliferative activity against the ALK-addictive H3122 cells (11 vs 13 nM).  The dual functioning mechanism is further confirmed by their down-regulation of the Hsp90 clients ALK and AKT, and up-regulation of the chaperone protein Hsp70 in H3122 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmqigxUQsz8bVg90H21EOLACvtfcHk0lgwL-GQlhnvyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosVWmsLY%253D&md5=a64e43ba5d725642af62313c1dbc8111</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.04.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.04.019%26sid%3Dliteratum%253Aachs%26aulast%3DGeng%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Pharmacological%2520Evaluation%2520of%2520ALK%2520and%2520HSP90%2520Dual%2520Inhibitors%2520Bearing%2520Resorcinol%2520and%25202%252C4-Diaminopyrimidine%2520Motifs%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D152%26spage%3D76%26epage%3D86%26doi%3D10.1016%2Fj.ejmech.2018.04.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, Q.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Q.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.-L.</span></span> <span> </span><span class="NLM_article-title">Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10498</span>– <span class="NLM_lpage">10519</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00912</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00912" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVehs7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10498-10519&author=F.+Jiangauthor=H.-J.+Wangauthor=Y.-H.+Jinauthor=Q.+Zhangauthor=Z.-H.+Wangauthor=J.-M.+Jiaauthor=F.+Liuauthor=L.+Wangauthor=Q.-C.+Baoauthor=D.-D.+Liauthor=Q.-D.+Youauthor=X.-L.+Xu&title=Novel+Tetrahydropyrido%5B4%2C3-d%5Dpyrimidines+as+Potent+Inhibitors+of+Chaperone+Heat+Shock+Protein+90&doi=10.1021%2Facs.jmedchem.6b00912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90</span></div><div class="casAuthors">Jiang, Fen; Wang, Hui-Jie; Jin, Yu-Hui; Zhang, Qiong; Wang, Zhi-Hui; Jia, Jian-Min; Liu, Fang; Wang, Lei; Bao, Qi-Chao; Li, Dong-Dong; You, Qi-Dong; Xu, Xiao-Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10498-10519</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Heat-shock protein 90 (Hsp90) is a potential target for oncol. therapeutics.  Some inhibitors have shown anti-tumor effects in clin. trials, spurring the discovery of small-mol. Hsp90 inhibitors.  Here, the authors describe the structural optimization studies of a hit compd., tetrahydropyrido[4,3-d]pyrimidine-based Hsp90 inhibitor, which exhibits inhibitory activity against Hsp90.  A series of analogs were synthesized, and their structure-activity relationships and structure-property relationships were analyzed.  These explorations led to the discovery of compd. 73 ((2,4-dihydroxy-5-isopropylphenyl)(4-(ethylamino)-2-(2-methoxyethoxy)-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)methanone), which exhibited potent in vitro activities, good physicochem. properties, favorable ADME properties and potent anti-tumor effect in an HCT116 xenograft model.  Furthermore, 73 exhibited no ocular toxicity in a rat retinal damage model, suggesting it is a relatively safe Hsp90 inhibitor.  As a promising anti-tumor agent, 73 was progressed for further pre-clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhftxgoZ3blLVg90H21EOLACvtfcHk0lgwL-GQlhnvyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVehs7nF&md5=d3ab4651aa7d68854edf7c0b6e712ee2</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00912%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DH.-J.%26aulast%3DJin%26aufirst%3DY.-H.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DZ.-H.%26aulast%3DJia%26aufirst%3DJ.-M.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBao%26aufirst%3DQ.-C.%26aulast%3DLi%26aufirst%3DD.-D.%26aulast%3DYou%26aufirst%3DQ.-D.%26aulast%3DXu%26aufirst%3DX.-L.%26atitle%3DNovel%2520Tetrahydropyrido%255B4%252C3-d%255Dpyrimidines%2520as%2520Potent%2520Inhibitors%2520of%2520Chaperone%2520Heat%2520Shock%2520Protein%252090%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10498%26epage%3D10519%26doi%3D10.1021%2Facs.jmedchem.6b00912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshiumi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shigeno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohkubo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muraoka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funabashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohkubo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitade, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01085</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01085" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVGnsLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=531-551&author=T.+Unoauthor=Y.+Kawaiauthor=S.+Yamashitaauthor=H.+Oshiumiauthor=C.+Yoshimuraauthor=T.+Mizutaniauthor=T.+Suzukiauthor=K.+T.+Chongauthor=K.+Shigenoauthor=M.+Ohkuboauthor=Y.+Kodamaauthor=H.+Muraokaauthor=K.+Funabashiauthor=K.+Takahashiauthor=S.+Ohkuboauthor=M.+Kitade&title=Discovery+of+3-Ethyl-4-%283-isopropyl-4-%284-%281-methyl-1H-pyrazol-4-yl%29-1H-imidazol-1-yl%29-1H-pyrazolo%5B3%2C4-b%5Dpyridin-1-yl%29benzamide+%28TAS-116%29+as+a+Potent%2C+Selective%2C+and+Orally+Available+HSP90+Inhibitor&doi=10.1021%2Facs.jmedchem.8b01085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-ethyl-4-(3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl)benzamide (TAS-116) as a potent, selective, and orally available HSP90 inhibitor</span></div><div class="casAuthors">Uno, Takao; Kawai, Yuichi; Yamashita, Satoshi; Oshiumi, Hiromi; Yoshimura, Chihoko; Mizutani, Takashi; Suzuki, Tatsuya; Chong, Khoon Tee; Shigeno, Kazuhiko; Ohkubo, Mitsuru; Kodama, Yasuo; Muraoka, Hiromi; Funabashi, Kaoru; Takahashi, Koichi; Ohkubo, Shuichi; Kitade, Makoto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">531-551</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The mol. chaperone heat shock protein 90 (HSP90) is a promising target for cancer therapy, as it assists in the stabilization of cancer-related proteins, promoting cancer cell growth, and survival.  A novel series of HSP90 inhibitors were discovered by structure-activity relationship (SAR)-based optimization of an initial hit compd. having a 4-(4-(quinolin-3-yl)-1H-indol-1-yl)benzamide structure.  The pyrazolo[3,4-b]pyridine deriv., I (TAS-116), is a selective inhibitor of HSP90α and HSP90β among the HSP90 family proteins and exhibits oral availability in mice.  The X-ray cocrystal structure of the I analog II demonstrated a unique binding mode at the N-terminal ATP binding site.  Oral administration of I demonstrated potent antitumor effects in an NCI-H1975 xenograft mouse model without significant body wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLBSBSC2j6FrVg90H21EOLACvtfcHk0liXTdJZwdk5-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVGnsLjK&md5=0e7673a985350bd5cb52a1263449a9da</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01085%26sid%3Dliteratum%253Aachs%26aulast%3DUno%26aufirst%3DT.%26aulast%3DKawai%26aufirst%3DY.%26aulast%3DYamashita%26aufirst%3DS.%26aulast%3DOshiumi%26aufirst%3DH.%26aulast%3DYoshimura%26aufirst%3DC.%26aulast%3DMizutani%26aufirst%3DT.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DChong%26aufirst%3DK.%2BT.%26aulast%3DShigeno%26aufirst%3DK.%26aulast%3DOhkubo%26aufirst%3DM.%26aulast%3DKodama%26aufirst%3DY.%26aulast%3DMuraoka%26aufirst%3DH.%26aulast%3DFunabashi%26aufirst%3DK.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DOhkubo%26aufirst%3DS.%26aulast%3DKitade%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25203-Ethyl-4-%25283-isopropyl-4-%25284-%25281-methyl-1H-pyrazol-4-yl%2529-1H-imidazol-1-yl%2529-1H-pyrazolo%255B3%252C4-b%255Dpyridin-1-yl%2529benzamide%2520%2528TAS-116%2529%2520as%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Available%2520HSP90%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D531%26epage%3D551%26doi%3D10.1021%2Facs.jmedchem.8b01085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummalapalli, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotella, D. P.</span></span> <span> </span><span class="NLM_article-title">Progress in the Discovery and Development of Heat Shock Protein 90 (HSP90) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8718</span>– <span class="NLM_lpage">8728</span>, <span class="refDoi"> DOI: 10.1021/jm500823a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500823a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSnsrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8718-8728&author=R.+Bhatauthor=S.+R.+Tummalapalliauthor=D.+P.+Rotella&title=Progress+in+the+Discovery+and+Development+of+Heat+Shock+Protein+90+%28HSP90%29+Inhibitors&doi=10.1021%2Fjm500823a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in the Discovery and Development of Heat Shock Protein 90 (Hsp90) Inhibitors</span></div><div class="casAuthors">Bhat, Rohit; Tummalapalli, Sreedhar R.; Rotella, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8718-8728</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The discovery and clin. development of heat shock protein 90 (Hsp90) inhibitors continue to progress.  A no. of Hsp90 inhibitors are in clin. trials, and preclin. discoveries of new chemotypes that bind to distinct regions in the protein as well as isoform selective compds. are active areas of research.  This review will highlight progress in the field since 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-SwLv_-B9xLVg90H21EOLACvtfcHk0liXTdJZwdk5-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSnsrfK&md5=132784687bbbcf62cfa8fe04a22577ce</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm500823a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500823a%26sid%3Dliteratum%253Aachs%26aulast%3DBhat%26aufirst%3DR.%26aulast%3DTummalapalli%26aufirst%3DS.%2BR.%26aulast%3DRotella%26aufirst%3DD.%2BP.%26atitle%3DProgress%2520in%2520the%2520Discovery%2520and%2520Development%2520of%2520Heat%2520Shock%2520Protein%252090%2520%2528HSP90%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8718%26epage%3D8728%26doi%3D10.1021%2Fjm500823a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brough, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aherne, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barril, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgognoni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boxall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cansfield, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, K.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drysdale, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northfield, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearl, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prodromou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roughley, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surgenor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walmsley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L.</span></span> <span> </span><span class="NLM_article-title">4,5-Diarylisoxazole HSP90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">196</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1021/jm701018h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701018h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlWqsL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=196-218&author=P.+A.+Broughauthor=W.+Aherneauthor=X.+Barrilauthor=J.+Borgognoniauthor=K.+Boxallauthor=J.+E.+Cansfieldauthor=K.-M.+Cheungauthor=I.+Collinsauthor=N.+G.+Daviesauthor=M.+J.+Drysdaleauthor=B.+Dymockauthor=S.+A.+Ecclesauthor=H.+Finchauthor=A.+Finkauthor=A.+Hayesauthor=R.+Howesauthor=R.+E.+Hubbardauthor=K.+Jamesauthor=A.+M.+Jordanauthor=A.+Lockieauthor=V.+Martinsauthor=A.+Masseyauthor=T.+P.+Matthewsauthor=E.+McDonaldauthor=C.+J.+Northfieldauthor=L.+H.+Pearlauthor=C.+Prodromouauthor=S.+Rayauthor=F.+I.+Raynaudauthor=S.+D.+Roughleyauthor=S.+Y.+Sharpauthor=A.+Surgenorauthor=D.+L.+Walmsleyauthor=P.+Webbauthor=M.+Woodauthor=P.+Workmanauthor=L.+Wright&title=4%2C5-Diarylisoxazole+HSP90+Chaperone+Inhibitors%3A+Potential+Therapeutic+Agents+for+the+Treatment+of+Cancer&doi=10.1021%2Fjm701018h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer</span></div><div class="casAuthors">Brough, Paul A.; Aherne, Wynne; Barril, Xavier; Borgognoni, Jennifer; Boxall, Kathy; Cansfield, Julie E.; Cheung, Kwai-Ming J.; Collins, Ian; Davies, Nicholas G. M.; Drysdale, Martin J.; Dymock, Brian; Eccles, Suzanne A.; Finch, Harry; Fink, Alexandra; Hayes, Angela; Howes, Robert; Hubbard, Roderick E.; James, Karen; Jordan, Allan M.; Lockie, Andrea; Martins, Vanessa; Massey, Andrew; Matthews, Thomas P.; McDonald, Edward; Northfield, Christopher J.; Pearl, Laurence H.; Prodromou, Chrisostomos; Ray, Stuart; Raynaud, Florence I.; Roughley, Stephen D.; Sharp, Swee Y.; Surgenor, Allan; Walmsley, D. Lee; Webb, Paul; Wood, Mike; Workman, Paul; Wright, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">196-218</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of the Hsp90 [heat shock protein 90] mol. chaperone show considerable promise as potential chemotherapeutic agents for cancer.  The structure-based design, synthesis, structure-activity relationships, and pharmacokinetics of potent small-mol. inhibitors of Hsp90 based on the 4,5-diarylisoxazole scaffold were studied.  Analogs from this series have high affinity for Hsp90, as measured in a fluorescence polarization competitive binding assay, and are active in cancer cell lines where they inhibit proliferation and exhibit a characteristic profile of depletion of oncogenic proteins and concomitant elevation of Hsp72.  The [(morpholinomethyl)phenyl]isoxazolecarboxamide I (VER-52296/NVP-AUY922) is potent in the Hsp90 FP binding assay and inhibits proliferation of various human cancer cell lines in vitro, with GI50 averaging 9 nM.  I is retained in tumors in vivo when administered i.p., as evaluated by cassette dosing in tumor-bearing mice.  In a human colon cancer xenograft model, I inhibits tumor growth by ∼50%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTNA9AoWb8gLVg90H21EOLACvtfcHk0ljH_-ziNOe5yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlWqsL%252FK&md5=fdb98dec600987e862b9b05555427948</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm701018h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701018h%26sid%3Dliteratum%253Aachs%26aulast%3DBrough%26aufirst%3DP.%2BA.%26aulast%3DAherne%26aufirst%3DW.%26aulast%3DBarril%26aufirst%3DX.%26aulast%3DBorgognoni%26aufirst%3DJ.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DCansfield%26aufirst%3DJ.%2BE.%26aulast%3DCheung%26aufirst%3DK.-M.%26aulast%3DCollins%26aufirst%3DI.%26aulast%3DDavies%26aufirst%3DN.%2BG.%26aulast%3DDrysdale%26aufirst%3DM.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DFinch%26aufirst%3DH.%26aulast%3DFink%26aufirst%3DA.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHowes%26aufirst%3DR.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DJordan%26aufirst%3DA.%2BM.%26aulast%3DLockie%26aufirst%3DA.%26aulast%3DMartins%26aufirst%3DV.%26aulast%3DMassey%26aufirst%3DA.%26aulast%3DMatthews%26aufirst%3DT.%2BP.%26aulast%3DMcDonald%26aufirst%3DE.%26aulast%3DNorthfield%26aufirst%3DC.%2BJ.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26aulast%3DProdromou%26aufirst%3DC.%26aulast%3DRay%26aufirst%3DS.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DRoughley%26aufirst%3DS.%2BD.%26aulast%3DSharp%26aufirst%3DS.%2BY.%26aulast%3DSurgenor%26aufirst%3DA.%26aulast%3DWalmsley%26aufirst%3DD.%2BL.%26aulast%3DWebb%26aufirst%3DP.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DWright%26aufirst%3DL.%26atitle%3D4%252C5-Diarylisoxazole%2520HSP90%2520Chaperone%2520Inhibitors%253A%2520Potential%2520Therapeutic%2520Agents%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D196%26epage%3D218%26doi%3D10.1021%2Fjm701018h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khandelwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzbeierlein, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matts, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S. J.</span></span> <span> </span><span class="NLM_article-title">Structure-Guided Design of an HSP90beta N-terminal Isoform-Selective Inhibitor</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-02013-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1038%2Fs41467-017-02013-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=29382832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A280%3ADC%252BC1MvlsFyksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=425-431&author=A.+Khandelwalauthor=C.+N.+Kentauthor=M.+Balchauthor=S.+Pengauthor=S.+J.+Mishraauthor=J.+Dengauthor=V.+W.+Dayauthor=W.+Liuauthor=C.+Subramanianauthor=M.+Cohenauthor=J.+M.+Holzbeierleinauthor=R.+Mattsauthor=B.+S.+J.+Blagg&title=Structure-Guided+Design+of+an+HSP90beta+N-terminal+Isoform-Selective+Inhibitor&doi=10.1038%2Fs41467-017-02013-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor</span></div><div class="casAuthors">Khandelwal Anuj; Mishra Sanket J; Kent Caitlin N; Blagg Brian S J; Balch Maurie; Peng Shuxia; Deng Junpeng; Matts Robert; Day Victor W; Liu Weiya; Holzbeierlein Jeffery M; Subramanian Chitra; Cohen Mark</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">425</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The 90 kDa heat shock protein (Hsp90) is a molecular chaperone responsible for folding proteins that are directly associated with cancer progression.  Consequently, inhibition of the Hsp90 protein folding machinery results in a combinatorial attack on numerous oncogenic pathways.  Seventeen small-molecule inhibitors of Hsp90 have entered clinical trials, all of which bind the Hsp90 N-terminus and exhibit pan-inhibitory activity against all four Hsp90 isoforms. pan-Inhibition of Hsp90 appears to be detrimental as toxicities have been reported alongside induction of the pro-survival heat shock response.  The development of Hsp90 isoform-selective inhibitors represents an alternative approach towards the treatment of cancer that may limit some of the detriments.  Described herein is a structure-based approach to design isoform-selective inhibitors of Hsp90β, which induces the degradation of select Hsp90 clients without concomitant induction of Hsp90 levels.  Together, these initial studies support the development of Hsp90β-selective inhibitors as a method to overcome the detriments associated with pan-inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmyRre9-yoQBpyrDyM_m9cfW6udTcc2eYCB3OEOJKEfbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvlsFyksA%253D%253D&md5=cfa47e314c9bdbc1c38802108330cba7</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-02013-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-02013-1%26sid%3Dliteratum%253Aachs%26aulast%3DKhandelwal%26aufirst%3DA.%26aulast%3DKent%26aufirst%3DC.%2BN.%26aulast%3DBalch%26aufirst%3DM.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DMishra%26aufirst%3DS.%2BJ.%26aulast%3DDeng%26aufirst%3DJ.%26aulast%3DDay%26aufirst%3DV.%2BW.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DSubramanian%26aufirst%3DC.%26aulast%3DCohen%26aufirst%3DM.%26aulast%3DHolzbeierlein%26aufirst%3DJ.%2BM.%26aulast%3DMatts%26aufirst%3DR.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DStructure-Guided%2520Design%2520of%2520an%2520HSP90beta%2520N-terminal%2520Isoform-Selective%2520Inhibitor%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D425%26epage%3D431%26doi%3D10.1038%2Fs41467-017-02013-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banerji, U.</span></span> <span> </span><span class="NLM_article-title">Heat Shock Protein 90 as a Drug Target: Some Like It Hot</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-08-0132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1158%2F1078-0432.CCR-08-0132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=19118027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Cjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=9-14&author=U.+Banerji&title=Heat+Shock+Protein+90+as+a+Drug+Target%3A+Some+Like+It+Hot&doi=10.1158%2F1078-0432.ccr-08-0132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Heat Shock Protein 90 as a Drug Target: Some Like It Hot</span></div><div class="casAuthors">Banerji, Udai</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-14</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Heat shock protein 90 (HSP90) is a ubiquitously expressed chaperone that is involved in the posttranslational folding and stability of proteins.  Inhibition at the NH2-terminal ATP-binding site leads to the degrdn. of client proteins by the ubiquitin proteasome pathway.  Inhibition of HSP90 leads to the degrdn. of known oncogenes, such as ERB-B2, BRAF, and BCR-ABL, leading to the combinatorial blockade of multiple signal transduction pathways, such as the RAS-RAF-mitogen-activated protein/extracellular signal-regulated kinase kinase-extracellular signal-regulated kinase and phosphatidylinositol 3-kinase pathways.  Multiple structurally diverse HSP90 inhibitors are undergoing early clin. evaluation.  The clin. focus of these drugs should be solid tumors, such as breast, prostate, and lung cancers, along with malignant melanoma, in addn. to hematol. malignancies, such as chronic myeloid leukemia and multiple myeloma.  HSP90 inhibitors can be used as single agents or in combination with other targeted treatments or conventional forms of treatment such as chemotherapy and radiotherapy.  Clin. trials evaluating efficacy of these agents should include innovative designs to capture cytostasis evidenced by clin. nonprogression and enrichment of patient populations by mol. characterization.  The results of clin. trials evaluating the efficacy of drugs targeting this exciting target are awaited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5QTJOiPz3ebVg90H21EOLACvtfcHk0lggDQIzDxR4MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Cjug%253D%253D&md5=8ae4c833ac80987facd9a93300a2efb9</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0132%26sid%3Dliteratum%253Aachs%26aulast%3DBanerji%26aufirst%3DU.%26atitle%3DHeat%2520Shock%2520Protein%252090%2520as%2520a%2520Drug%2520Target%253A%2520Some%2520Like%2520It%2520Hot%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D9%26epage%3D14%26doi%3D10.1158%2F1078-0432.ccr-08-0132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sidera, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patsavoudi, E.</span></span> <span> </span><span class="NLM_article-title">Extracellular HSP90: Conquering the Cell Surface</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1564</span>– <span class="NLM_lpage">1568</span>, <span class="refDoi"> DOI: 10.4161/cc.7.11.6054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.4161%2Fcc.7.11.6054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=18469526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptF2nur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1564-1568&author=K.+Sideraauthor=E.+Patsavoudi&title=Extracellular+HSP90%3A+Conquering+the+Cell+Surface&doi=10.4161%2Fcc.7.11.6054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Extracellular HSP90. Conquering the cell surface</span></div><div class="casAuthors">Sidera, Katerina; Patsavoudi, Evangelia</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1564-1568</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  Recently, a pool of HSP90 has been identified at the cell surface, where it was shown to be involved in cancer cell invasion.  Here, we propose a model concerning the mol. mechanism underlying the role of HSP90 in cancer cell invasion.  We suggest that surface HSP90 interacts specifically with the extracellular domain of HER-2 and that this interaction is necessary for the receptor's activation and heterodimerization with ErbB-3, which in turn will mediate signal transduction pathways via MAPK and PI3K-Akt, leading to actin rearrangement and cell motility.  Furthermore we propose that the selective inhibition of cell surface HSP90 with a cell-impermeable function blocking monoclonal antibody, mAb 4C5, may have clin. benefits in limiting cancer cell invasion and metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqniZKVLPY5NrVg90H21EOLACvtfcHk0lggDQIzDxR4MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptF2nur8%253D&md5=f6e688635673aabb0a727d713c53b49b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.4161%2Fcc.7.11.6054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.7.11.6054%26sid%3Dliteratum%253Aachs%26aulast%3DSidera%26aufirst%3DK.%26aulast%3DPatsavoudi%26aufirst%3DE.%26atitle%3DExtracellular%2520HSP90%253A%2520Conquering%2520the%2520Cell%2520Surface%26jtitle%3DCell%2520Cycle%26date%3D2008%26volume%3D7%26spage%3D1564%26epage%3D1568%26doi%3D10.4161%2Fcc.7.11.6054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, D.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baas, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daum, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gygi, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aebersold, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berk, B. C.</span></span> <span> </span><span class="NLM_article-title">Purification and Identification of Secreted Oxidative Stress-Induced Factors from Vascular Smooth Muscle Cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1074/jbc.275.1.189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1074%2Fjbc.275.1.189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10617604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjvVGrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=189-196&author=D.-F.+Liaoauthor=Z.-G.+Jinauthor=A.+S.+Baasauthor=G.+Daumauthor=S.+P.+Gygiauthor=R.+Aebersoldauthor=B.+C.+Berk&title=Purification+and+Identification+of+Secreted+Oxidative+Stress-Induced+Factors+from+Vascular+Smooth+Muscle+Cells&doi=10.1074%2Fjbc.275.1.189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells</span></div><div class="casAuthors">Liao, Duan-Fang; Jin, Zheng-Gen; Baas, Arnold S.; Daum, Guenter; Gygi, Steven P.; Aebersold, Ruedi; Berk, Bradford C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">189-196</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Reactive oxygen species have been implicated in the pathogenesis of atherosclerosis and hypertension, in part by promoting vascular smooth muscle cell (VSMC) growth.  The authors have previously shown that LY 83583, a generator of superoxide, activated extracellular signal-regulated kinases (ERK1/2) with early (10 min) and late (2 h) peaks and stimulated VSMC growth.  To investigate whether secreted oxidative stress-induced factors (termed SOXF) from VSMC were responsible for late ERK1/2 activation in response to LY 83583, the authors purified putative SOXF proteins from conditioned medium (2 h of LY 83583 exposure) by sequential chromatog. based on activation of ERK1/2.  Proteins identified by capillary chromatog., electrospray ionization tandem mass spectrometry, and data base searching included heat shock protein 90-α (HSP90-α) and cyclophilin B.  Western blot anal. of conditioned medium showed specific secretion of HSP90-α but not HSP90-β.  Immunodepletion of HSP90-α from conditioned medium significantly inhibited conditioned medium-induced ERK1/2 activation.  Human recombinant HSP90-α reproduced the effect of conditioned medium on ERK1/2 activation.  These results show that brief oxidative stress causes sustained release of protein factors from VSMC that can stimulate ERK1/2.  These factors may be important mediators for the effects of reactive oxygen species on vascular function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj7WiE93zqhrVg90H21EOLACvtfcHk0lggDQIzDxR4MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjvVGrsA%253D%253D&md5=29fb2575a2ed0ce9db8ebfc34a4c039a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1074%2Fjbc.275.1.189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.275.1.189%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DD.-F.%26aulast%3DJin%26aufirst%3DZ.-G.%26aulast%3DBaas%26aufirst%3DA.%2BS.%26aulast%3DDaum%26aufirst%3DG.%26aulast%3DGygi%26aufirst%3DS.%2BP.%26aulast%3DAebersold%26aufirst%3DR.%26aulast%3DBerk%26aufirst%3DB.%2BC.%26atitle%3DPurification%2520and%2520Identification%2520of%2520Secreted%2520Oxidative%2520Stress-Induced%2520Factors%2520from%2520Vascular%2520Smooth%2520Muscle%2520Cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D189%26epage%3D196%26doi%3D10.1074%2Fjbc.275.1.189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Picard, D.</span></span> <span> </span><span class="NLM_article-title">Hsp90 Invades the Outside</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">479</span>– <span class="NLM_lpage">480</span>, <span class="refDoi"> DOI: 10.1038/ncb0604-479</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1038%2Fncb0604-479" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=15170457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVaisL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=479-480&author=D.+Picard&title=Hsp90+Invades+the+Outside&doi=10.1038%2Fncb0604-479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 invades the outside</span></div><div class="casAuthors">Picard, Didier</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">479-480</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review of the research of B. K. Eustace et al. (ibid., 507-10) is given.  Metalloproteases are required for the invasive nature of cancer cells.  Surprisingly, the cytosolic mol. chaperone Hsp90 is now shown to promote maturation of the extracellular metalloprotease MMP2.  This finding extends the multiplicity of roles assigned to the Hsp90 family to a new function outside the cell.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNjYXyhjjre7Vg90H21EOLACvtfcHk0lggDQIzDxR4MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVaisL8%253D&md5=470530d5c8190d910f00647dd2025ae8</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fncb0604-479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb0604-479%26sid%3Dliteratum%253Aachs%26aulast%3DPicard%26aufirst%3DD.%26atitle%3DHsp90%2520Invades%2520the%2520Outside%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2004%26volume%3D6%26spage%3D479%26epage%3D480%26doi%3D10.1038%2Fncb0604-479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
la Mare, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurgens, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edkins, A. L.</span></span> <span> </span><span class="NLM_article-title">Extracellular HSP90 and TGFbeta Regulate Adhesion, Migration and Anchorage Independent Growth in a Paired Colon Cancer Cell Line Model</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">202</span>– <span class="NLM_lpage">217</span>, <span class="refDoi"> DOI: 10.1186/s12885-017-3190-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1186%2Fs12885-017-3190-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=28302086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvVWiu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=202-217&author=J.+A.+de%0Ala+Mareauthor=T.+Jurgensauthor=A.+L.+Edkins&title=Extracellular+HSP90+and+TGFbeta+Regulate+Adhesion%2C+Migration+and+Anchorage+Independent+Growth+in+a+Paired+Colon+Cancer+Cell+Line+Model&doi=10.1186%2Fs12885-017-3190-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Extracellular Hsp90 and TGFβ regulate adhesion, migration and anchorage independent growth in a paired colon cancer cell line model</span></div><div class="casAuthors">de la Mare, Jo-Anne; Jurgens, Tamarin; Edkins, Adrienne L.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">202/1-202/16</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Tumor metastasis remains the major cause of death in cancer patients and, to date, the mechanism and signalling pathways governing this process are not completely understood.  The TGF-β pathway is the most commonly mutated pathway in cancer, however its role in cancer progression is controversial as it can function as both a promoter and a suppressor of metastasis.  Although previous studies have suggested a role for the mol. chaperone Hsp90 in regulating the TGF-β pathway, the level at which this occurs as well as the consequences in terms of colon cancer metastasis are unknown.  The paired SW480 and SW620 colon cancer cell lines, derived from a primary tumor and its lymph node metastasis, resp., were used as an in vitro model to study key cellular processes required for metastasis.  The status of the TGF-β pathway was examd. in these cells using ELISA, flow cytometry, western blot anal. and confocal microscopy.  Furthermore, the effect of addn. or inhibition of the TGF-β pathway and Hsp90 on adhesion, migration and anchorage-independent growth, was detd. in the cell lines.  When comparing the canonical TGF-β1 pathway in the genetically paired cell lines our data suggests that this pathway may be constitutively active in the SW620 metastasis-derived cell line and not the SW480 primary tumor-derived line.  In addn., we report that, when present in combination, TGF-β1 and Hsp90β stimulate anchorage-independent growth, reduce adhesion and stimulate migration.  This effect is potentiated by inhibition of the TGF-β1 receptor and occurs via an alternate TGF-β1 pathway, mediated by αvβ6 integrin.  Interestingly, in the SW620 cells, activation of this alternate TGF-β1 signalling machinery does not appear to require inhibition of the canonical TGF-β1 receptor, which would allow them to respond more effectively to the pro-metastasis stimulus of a combination of Hsp90β and TGF-β1 and this could account for the increased migratory capacity of these cells.  In this study we report an apparent synergy between TGF-β1 and Hsp90β in stimulating migratory behavior of colon cancer cells when signalling occurs via αvβ6 integrin as opposed to the canonical TGF-β1 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpddZ758vu_XbVg90H21EOLACvtfcHk0lhZjjtDljDW3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvVWiu7s%253D&md5=587c86e668f0f5b48b52bb5d24b04e29</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1186%2Fs12885-017-3190-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-017-3190-z%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2Bla%2BMare%26aufirst%3DJ.%2BA.%26aulast%3DJurgens%26aufirst%3DT.%26aulast%3DEdkins%26aufirst%3DA.%2BL.%26atitle%3DExtracellular%2520HSP90%2520and%2520TGFbeta%2520Regulate%2520Adhesion%252C%2520Migration%2520and%2520Anchorage%2520Independent%2520Growth%2520in%2520a%2520Paired%2520Colon%2520Cancer%2520Cell%2520Line%2520Model%26jtitle%3DBMC%2520Cancer%26date%3D2017%26volume%3D17%26spage%3D202%26epage%3D217%26doi%3D10.1186%2Fs12885-017-3190-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fitrolaki, M.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitriou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venihaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katrinaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briassoulis, G.</span></span> <span> </span><span class="NLM_article-title">Increased Extracellular Heat Shock Protein 90α in Severe Sepsis and SIRS Associated with Multiple Organ Failure and Related to Acute Inflammatory-metabolic Stress Response in Children</span>. <i>Medicine</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>95</i></span>, <span class="NLM_elocation-id">e4651</span> <span class="refDoi"> DOI: 10.1097/md.0000000000004651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1097%2FMD.0000000000004651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=27583886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKrtb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2016&author=M.-D.+Fitrolakiauthor=H.+Dimitriouauthor=M.+Venihakiauthor=M.+Katrinakiauthor=S.+Iliaauthor=G.+Briassoulis&title=Increased+Extracellular+Heat+Shock+Protein+90%CE%B1+in+Severe+Sepsis+and+SIRS+Associated+with+Multiple+Organ+Failure+and+Related+to+Acute+Inflammatory-metabolic+Stress+Response+in+Children&doi=10.1097%2Fmd.0000000000004651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Increased extracellular heat shock protein 90α in severe sepsis and SIRS associated with multiple organ failure and related to acute inflammatory-metabolic stress response in children</span></div><div class="casAuthors">Fitrolaki, Michaela-Diana; Dimitriou, Helen; Venihaki, Maria; Katrinaki, Marianna; Ilia, Stavroula; Briassoulis, George</div><div class="citationInfo"><span class="NLM_cas:title">Medicine (Philadelphia, PA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">e4651</span>CODEN:
                <span class="NLM_cas:coden">MEDIAV</span>;
        ISSN:<span class="NLM_cas:issn">0025-7974</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Mammalian heat-shock-protein (HSP) 90α rapidly responses to environmental insults.  We examd. the hypothesis that not only serum HSP72 but also HSP90α is increased in the systemic inflammatory response syndrome (SIRS), severe-sepsis (SS), and/or sepsis (S) compared to healthy children (H); we assessed HSP90α relation to (a) multiple organ system failure (MOSF) and (b) inflammatory-metabolic response and severity of illness.  A total of 65 children with S, SS, or SIRS and 25 H were included.  ELISA was used to evaluate extracellular HSP90α and HSP72, chemiluminescence interleukins (ILs), flow-cytometry neutrophil-CD64 (nCD64)-expression.  HSP90α, along with HSP72, were dramatically increased among MOSF patients.  Patients in septic groups and SIRS had elevated HSP90α compared to H (P<0.01).  HSP90α was independently related to predicted death rate and severity of illness; pos. to HSP72, nCD64, ILs, length of stay, days on ventilator, and fever; neg. to HDL and LDL (P<0.05).  The HSP72 was increased in SS/S and related neg. to HDL and LDL (P<0.05).Serum HSP90α is markedly elevated in children with severe sepsis and is assocd. with MOSF.  Better than the HSP72, also increased in SS, SIRS, and MOSF, HSP90α is related to the inflammatory stress, fever, outcome endpoints, and predicted mortality and inversely related to the low-LDL/low-HDL stress metabolic pattern.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-0mE30n-hW7Vg90H21EOLACvtfcHk0lhZjjtDljDW3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKrtb%252FJ&md5=985e22fc1d9e9d6eb183b7ab3f6a6acf</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1097%2FMD.0000000000004651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMD.0000000000004651%26sid%3Dliteratum%253Aachs%26aulast%3DFitrolaki%26aufirst%3DM.-D.%26aulast%3DDimitriou%26aufirst%3DH.%26aulast%3DVenihaki%26aufirst%3DM.%26aulast%3DKatrinaki%26aufirst%3DM.%26aulast%3DIlia%26aufirst%3DS.%26aulast%3DBriassoulis%26aufirst%3DG.%26atitle%3DIncreased%2520Extracellular%2520Heat%2520Shock%2520Protein%252090%25CE%25B1%2520in%2520Severe%2520Sepsis%2520and%2520SIRS%2520Associated%2520with%2520Multiple%2520Organ%2520Failure%2520and%2520Related%2520to%2520Acute%2520Inflammatory-metabolic%2520Stress%2520Response%2520in%2520Children%26jtitle%3DMedicine%26date%3D2016%26volume%3D95%26doi%3D10.1097%2Fmd.0000000000004651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hance, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, J.</span></span> <span> </span><span class="NLM_article-title">The Double-Edged Sword: Conserved Functions of Extracellular HSP90 in Wound Healing and Cancer</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1065</span>– <span class="NLM_lpage">1097</span>, <span class="refDoi"> DOI: 10.3390/cancers6021065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.3390%2Fcancers6021065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=24805867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Crs7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1065-1097&author=M.+Hanceauthor=K.+Nolanauthor=J.+Isaacs&title=The+Double-Edged+Sword%3A+Conserved+Functions+of+Extracellular+HSP90+in+Wound+Healing+and+Cancer&doi=10.3390%2Fcancers6021065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The double-edged sword: conserved functions of extracellular Hsp90 in wound healing and cancer</span></div><div class="casAuthors">Hance, Michael W.; Nolan, Krystal D.; Isaacs, Jennifer S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1065-1097, 33</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Heat shock proteins (Hsps) represent a diverse group of chaperones that play a vital role in the protection of cells against numerous environmental stresses.  Although our understanding of chaperone biol. has deepened over the last decade, the "atypical" extracellular functions of Hsps have remained somewhat enigmatic and comparatively understudied.  The heat shock protein 90 (Hsp90) chaperone is a prototypic model for an Hsp family member exhibiting a duality of intracellular and extracellular functions.  Intracellular Hsp90 is best known as a master regulator of protein folding.  Cancers are particularly adept at exploiting this function of Hsp90, providing the impetus for the robust clin. development of small mol. Hsp90 inhibitors.  However, in addn. to its maintenance of protein homeostasis, Hsp90 has also been identified as an extracellular protein.  Although early reports ascribed immunoregulatory functions to extracellular Hsp90 (eHsp90), recent studies have illuminated expanded functions for eHsp90 in wound healing and cancer.  While the intended physiol. role of eHsp90 remains enigmatic, its evolutionarily conserved functions in wound healing are easily co-opted during malignancy, a pathol. sharing many properties of wounded tissue.  This review will highlight the emerging functions of eHsp90 and shed light on its seemingly dichotomous roles as a benevolent facilitator of wound healing and as a sinister effector of tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiZA1xjDcTz7Vg90H21EOLACvtfcHk0lhZjjtDljDW3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Crs7bL&md5=ca3a5f3fe7e7c562fe8a5164a45a1bd9</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.3390%2Fcancers6021065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers6021065%26sid%3Dliteratum%253Aachs%26aulast%3DHance%26aufirst%3DM.%26aulast%3DNolan%26aufirst%3DK.%26aulast%3DIsaacs%26aufirst%3DJ.%26atitle%3DThe%2520Double-Edged%2520Sword%253A%2520Conserved%2520Functions%2520of%2520Extracellular%2520HSP90%2520in%2520Wound%2520Healing%2520and%2520Cancer%26jtitle%3DCancers%26date%3D2014%26volume%3D6%26spage%3D1065%26epage%3D1097%26doi%3D10.3390%2Fcancers6021065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barrott, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loiselle, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spector, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajaram, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujam, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidyanathan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalutsky, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyerly, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haystead, T. A.</span></span> <span> </span><span class="NLM_article-title">Optical and Radioiodinated Tethered HSP90 Inhibitors Reveal Selective Internalization of Ectopic HSP90 in Malignant Breast Tumor Cells</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1187</span>– <span class="NLM_lpage">1197</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2013.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1016%2Fj.chembiol.2013.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=24035283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVClur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1187-1197&author=J.+J.+Barrottauthor=P.+F.+Hughesauthor=T.+Osadaauthor=X.-Y.+Yangauthor=Z.+C.+Hartmanauthor=D.+R.+Loiselleauthor=N.+L.+Spectorauthor=L.+Neckersauthor=N.+Rajaramauthor=F.+Huauthor=N.+Ramanujamauthor=G.+Vaidyanathanauthor=M.+R.+Zalutskyauthor=H.+K.+Lyerlyauthor=T.+A.+Haystead&title=Optical+and+Radioiodinated+Tethered+HSP90+Inhibitors+Reveal+Selective+Internalization+of+Ectopic+HSP90+in+Malignant+Breast+Tumor+Cells&doi=10.1016%2Fj.chembiol.2013.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Optical and Radioiodinated Tethered Hsp90 Inhibitors Reveal Selective Internalization of Ectopic Hsp90 in Malignant Breast Tumor Cells</span></div><div class="casAuthors">Barrott, Jared J.; Hughes, Philip F.; Osada, Takuya; Yang, Xiao-Yi; Hartman, Zachary C.; Loiselle, David R.; Spector, Neil L.; Neckers, Len; Rajaram, Narasimhan; Hu, Fangyao; Ramanujam, Nimmi; Vaidyanathan, Ganesan; Zalutsky, Michael R.; Lyerly, H. Kim; Haystead, Timothy A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1187-1197</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Inhibitors of heat-shock protein 90 (Hsp90) have demonstrated an unusual selectivity for tumor cells despite its ubiquitous expression.  This phenomenon has remained unexplained, but could be influenced by ectopically expressed Hsp90 in tumors.  In this work, we synthesized Hsp90 inhibitors that can carry optical or radioiodinated probes via a polyethyleneglycol tether.  We show that these tethered inhibitors selectively recognize cells expressing ectopic Hsp90 and become internalized.  The internalization process is blocked by Hsp90 antibodies, suggesting that active cycling of the protein occurs at the plasma membrane.  In mice, we obsd. exquisite accumulation of the fluor-tethered versions within breast tumors at very sensitive levels.  Cell-based assays with the radiolabeled version showed picomolar detection in cells that express ectopic Hsp90.  Our findings show that fluor-tethered or radiolabeled inhibitors that target ectopic Hsp90 can be used to detect breast cancer malignancies through noninvasive imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFFmoDjspa5LVg90H21EOLACvtfcHk0lhrREVSb25MiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVClur7I&md5=050b3c588d30bfcd78d99512c5d88003</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2013.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2013.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DBarrott%26aufirst%3DJ.%2BJ.%26aulast%3DHughes%26aufirst%3DP.%2BF.%26aulast%3DOsada%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DX.-Y.%26aulast%3DHartman%26aufirst%3DZ.%2BC.%26aulast%3DLoiselle%26aufirst%3DD.%2BR.%26aulast%3DSpector%26aufirst%3DN.%2BL.%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DRajaram%26aufirst%3DN.%26aulast%3DHu%26aufirst%3DF.%26aulast%3DRamanujam%26aufirst%3DN.%26aulast%3DVaidyanathan%26aufirst%3DG.%26aulast%3DZalutsky%26aufirst%3DM.%2BR.%26aulast%3DLyerly%26aufirst%3DH.%2BK.%26aulast%3DHaystead%26aufirst%3DT.%2BA.%26atitle%3DOptical%2520and%2520Radioiodinated%2520Tethered%2520HSP90%2520Inhibitors%2520Reveal%2520Selective%2520Internalization%2520of%2520Ectopic%2520HSP90%2520in%2520Malignant%2520Breast%2520Tumor%2520Cells%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D1187%26epage%3D1197%26doi%3D10.1016%2Fj.chembiol.2013.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kajiwara, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizukami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishige, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichiyanagi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hikida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udono, H.</span></span> <span> </span><span class="NLM_article-title">Heat Shock Protein 90 (HSP90) Contributes to Cytosolic Translocation of Extracellular Antigen for Cross-Presentation by Dendritic Cells</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">16363</span>– <span class="NLM_lpage">16368</span>, <span class="refDoi"> DOI: 10.1073/pnas.1108372108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1073%2Fpnas.1108372108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=21930907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Kmtb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=16363-16368&author=T.+Imaiauthor=Y.+Katoauthor=C.+Kajiwaraauthor=S.+Mizukamiauthor=I.+Ishigeauthor=T.+Ichiyanagiauthor=M.+Hikidaauthor=J.-Y.+Wangauthor=H.+Udono&title=Heat+Shock+Protein+90+%28HSP90%29+Contributes+to+Cytosolic+Translocation+of+Extracellular+Antigen+for+Cross-Presentation+by+Dendritic+Cells&doi=10.1073%2Fpnas.1108372108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Heat shock protein 90 (HSP90) contributes to cytosolic translocation of extracellular antigen for cross-presentation by dendritic cells</span></div><div class="casAuthors">Imai, Takashi; Kato, Yu; Kajiwara, Chiaki; Mizukami, Shusaku; Ishige, Ikuo; Ichiyanag, Tomoko; Hikid, Masaki; Wang, Ji-Yang; Udono, Heiichiro</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">16363-16368, S16363/1-S16363/10</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">In antigen (Ag) cross-presentation, dendritic cells (DCs) take up extracellular Ag and translocate them from the endosome to the cytosol for proteasomal degrdn.  The processed peptides can enter the conventional MHC I pathway.  The mols. responsible for the translocation of Ag across the endosomal membrane into the cytosol are unknown.  Here we demonstrate that heat shock protein 90 (HSP90) is crit. for this step.  Cross-presentation and -priming were decreased in both HSP90α-null DCs and mice.  CD8+ DC apoptosis mediated by translocation of exogenous cytochrome c to the cytosol was also eliminated in HSP90α-null mice.  Ag translocation into the cytosol was diminished in HSP90α-null DCs and in DCs treated with an HSP90 inhibitor.  Internalized Ag was assocd. with HSP90 and translocated to the cytosol, a process abrogated by the HSP90 inhibitor.  Ag within purified phagosomes was released in an HSP90-dependent manner.  These results demonstrate the important role of HSP90 in cross-presentation by pulling endosomal Ag out into the cytosol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7VtbQwVgGTLVg90H21EOLACvtfcHk0lhrREVSb25MiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Kmtb3N&md5=b1b8c8d2846ae66a1eac717005e7b9d4</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1108372108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1108372108%26sid%3Dliteratum%253Aachs%26aulast%3DImai%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DY.%26aulast%3DKajiwara%26aufirst%3DC.%26aulast%3DMizukami%26aufirst%3DS.%26aulast%3DIshige%26aufirst%3DI.%26aulast%3DIchiyanagi%26aufirst%3DT.%26aulast%3DHikida%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DJ.-Y.%26aulast%3DUdono%26aufirst%3DH.%26atitle%3DHeat%2520Shock%2520Protein%252090%2520%2528HSP90%2529%2520Contributes%2520to%2520Cytosolic%2520Translocation%2520of%2520Extracellular%2520Antigen%2520for%2520Cross-Presentation%2520by%2520Dendritic%2520Cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2011%26volume%3D108%26spage%3D16363%26epage%3D16368%26doi%3D10.1073%2Fpnas.1108372108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span> <span> </span><span class="NLM_article-title">A Series of Camptothecin Prodrugs Exhibit HDAC Inhibition Activity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">4706</span>– <span class="NLM_lpage">4715</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1016%2Fj.bmc.2018.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=30115492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2ktr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=4706-4715&author=Q.+Zhuauthor=X.+Yuauthor=Q.+Shenauthor=Q.+Zhangauthor=M.+Suauthor=Y.+Zhouauthor=J.+Liauthor=Y.+Chenauthor=W.+Lu&title=A+Series+of+Camptothecin+Prodrugs+Exhibit+HDAC+Inhibition+Activity&doi=10.1016%2Fj.bmc.2018.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A series of camptothecin prodrugs exhibit HDAC inhibition activity</span></div><div class="casAuthors">Zhu, Qiwen; Yu, Xumeng; Shen, Qianqian; Zhang, Qiumeng; Su, Mingbo; Zhou, Yubo; Li, Jia; Chen, Yi; Lu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4706-4715</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Camptothecin plays an important role in clin. cancer treatment, and its derivs. are a favorite of pharmaceutical chemists.  Herein, we have designed a series of camptothecin prodrugs that exhibit histone deacetylase (HDAC) inhibition activity based on the synergy effect between HDAC inhibitors and camptothecin derivs.  With the evaluation of stability in buffers or plasma from human or mouse model, an appropriate linker was found, so the active drug can be released efficiently and compd. 21a exhibited strong antiproliferative activity in A549 and HCT-116 cell lines.  These results indicated that the well-designed prodrug can be promising in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx5LUHT80gE7Vg90H21EOLACvtfcHk0lgwcBN-B141hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2ktr7L&md5=42b4b841a2be5cc98623923481eded7c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DW.%26atitle%3DA%2520Series%2520of%2520Camptothecin%2520Prodrugs%2520Exhibit%2520HDAC%2520Inhibition%2520Activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D4706%26epage%3D4715%26doi%3D10.1016%2Fj.bmc.2018.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vijayalakshmi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malugin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghandehari, H.</span></span> <span> </span><span class="NLM_article-title">Carboxyl-Terminated PAMAM-SN38 Conjugates: Synthesis, Characterization, and in Vitro Evaluation</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1804</span>– <span class="NLM_lpage">1810</span>, <span class="refDoi"> DOI: 10.1021/bc100094z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc100094z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFCkt7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=1804-1810&author=N.+Vijayalakshmiauthor=A.+Rayauthor=A.+Maluginauthor=H.+Ghandehari&title=Carboxyl-Terminated+PAMAM-SN38+Conjugates%3A+Synthesis%2C+Characterization%2C+and+in+Vitro+Evaluation&doi=10.1021%2Fbc100094z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Carboxyl-Terminated PAMAM-SN38 Conjugates: Synthesis, Characterization, and in Vitro Evaluation</span></div><div class="casAuthors">Vijayalakshmi, Nirmalkumar; Ray, Abhijit; Malugin, Alexander; Ghandehari, Hamidreza</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1804-1810</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this work, carboxyl-terminated PAMAM G-3.5 was covalently attached to SN38 via glycine and β-alanine spacers.  The conjugates were stable at pH 7.4 and moderately hydrolyzed in cell culture media and rat plasma.  Similarly to SN38 but to a lesser extent, both conjugates inhibited proliferation of human colorectal cancer HCT-116 cells, arrested the cell cycle in the G2/M phase, and led to nuclear fragmentation.  However, activity of the conjugate with glycine spacer (IC50 = 129 nM) was higher compared to that of the β-alanine linked conjugate (IC50 = 387 nM).  These PAMAM-SN38 conjugates have the potential for targeted therapy of colorectal carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4Dx2W3JD1ULVg90H21EOLACvtfcHk0lgwcBN-B141hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFCkt7zK&md5=993a0efab7337858508ed10df2004d13</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fbc100094z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc100094z%26sid%3Dliteratum%253Aachs%26aulast%3DVijayalakshmi%26aufirst%3DN.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DMalugin%26aufirst%3DA.%26aulast%3DGhandehari%26aufirst%3DH.%26atitle%3DCarboxyl-Terminated%2520PAMAM-SN38%2520Conjugates%253A%2520Synthesis%252C%2520Characterization%252C%2520and%2520in%2520Vitro%2520Evaluation%26jtitle%3DBioconjugate%2520Chem.%26date%3D2010%26volume%3D21%26spage%3D1804%26epage%3D1810%26doi%3D10.1021%2Fbc100094z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, K.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, C.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jan, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pak, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, T.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsou, L. K.</span></span> <span> </span><span class="NLM_article-title">Targeting Tumor Associated Phosphatidylserine with New Zinc Dipicolylamine-Based Drug Conjugates</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1878</span>– <span class="NLM_lpage">1892</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.7b00225</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.7b00225" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1eku7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&pages=1878-1892&author=Y.-W.+Liuauthor=K.-S.+Shiaauthor=C.-H.+Wuauthor=K.-L.+Liuauthor=Y.-C.+Yehauthor=C.-F.+Loauthor=C.-T.+Chenauthor=Y.-Y.+Chenauthor=T.-K.+Yehauthor=W.-H.+Chenauthor=J.-J.+Janauthor=Y.-C.+Huangauthor=C.-L.+Huangauthor=M.-Y.+Fangauthor=B.+D.+Grayauthor=K.+Y.+Pakauthor=T.-A.+Hsuauthor=K.-H.+Huangauthor=L.+K.+Tsou&title=Targeting+Tumor+Associated+Phosphatidylserine+with+New+Zinc+Dipicolylamine-Based+Drug+Conjugates&doi=10.1021%2Facs.bioconjchem.7b00225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Tumor Associated Phosphatidylserine with New Zinc Dipicolylamine-Based Drug Conjugates</span></div><div class="casAuthors">Liu, Yu-Wei; Shia, Kak-Shan; Wu, Chien-Huang; Liu, Kuan-Liang; Yeh, Yu-Cheng; Lo, Chen-Fu; Chen, Chiung-Tong; Chen, Yun-Yu; Yeh, Teng-Kuang; Chen, Wei-Han; Jan, Jiing-Jyh; Huang, Yu-Chen; Huang, Chen-Lung; Fang, Ming-Yu; Gray, Brian D.; Pak, Koon Y.; Hsu, Tsu-An; Huang, Kuan-Hsun; Tsou, Lun K.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1878-1892</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of zinc(II) dipicolylamine (ZnDPA)-based drug conjugates have been synthesized to probe the potential of phosphatidylserine (PS) as a new antigen for small mol. drug conjugate (SMDC) development.  Using in vitro cytotoxicity and plasma stability studies, PS-binding assay, in vivo pharmacokinetic studies, and max. tolerated dose profiles, the authors provided a road-map and the key parameters required for the development of the ZnDPA based drug conjugate.  In particular, conjugate 24 (I) induced tumor regression in the COLO 205 xenograft model and exhibited a more potent antitumor effect with a 70% redn. of cytotoxic payload compared to that of the marketed irinotecan when dosed at the same regimen.  In addn. to the validation of PS as an effective pharmaco-delivery target for SMDC, the authors' work also provided the foundation that, if applicable, a variety of therapeutic agents could be conjugated in the same manner to treat other PS-assocd. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-tzlnmny8VrVg90H21EOLACvtfcHk0lgwcBN-B141hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1eku7w%253D&md5=d34ce65c240dee8168e3639b19136c8a</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.7b00225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.7b00225%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.-W.%26aulast%3DShia%26aufirst%3DK.-S.%26aulast%3DWu%26aufirst%3DC.-H.%26aulast%3DLiu%26aufirst%3DK.-L.%26aulast%3DYeh%26aufirst%3DY.-C.%26aulast%3DLo%26aufirst%3DC.-F.%26aulast%3DChen%26aufirst%3DC.-T.%26aulast%3DChen%26aufirst%3DY.-Y.%26aulast%3DYeh%26aufirst%3DT.-K.%26aulast%3DChen%26aufirst%3DW.-H.%26aulast%3DJan%26aufirst%3DJ.-J.%26aulast%3DHuang%26aufirst%3DY.-C.%26aulast%3DHuang%26aufirst%3DC.-L.%26aulast%3DFang%26aufirst%3DM.-Y.%26aulast%3DGray%26aufirst%3DB.%2BD.%26aulast%3DPak%26aufirst%3DK.%2BY.%26aulast%3DHsu%26aufirst%3DT.-A.%26aulast%3DHuang%26aufirst%3DK.-H.%26aulast%3DTsou%26aufirst%3DL.%2BK.%26atitle%3DTargeting%2520Tumor%2520Associated%2520Phosphatidylserine%2520with%2520New%2520Zinc%2520Dipicolylamine-Based%2520Drug%2520Conjugates%26jtitle%3DBioconjugate%2520Chem.%26date%3D2017%26volume%3D28%26spage%3D1878%26epage%3D1892%26doi%3D10.1021%2Facs.bioconjchem.7b00225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulysse, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mobele, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawless, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garigipati, R.</span></span> <span> </span><span class="NLM_article-title">Process Development and Scale-Up of an HSP90 Inhibitor</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1787</span>– <span class="NLM_lpage">1793</span>, <span class="refDoi"> DOI: 10.1021/op300262z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op300262z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFGmurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=1787-1793&author=S.+Duanauthor=S.+Venkatramanauthor=X.+Hongauthor=K.+Huangauthor=L.+Ulysseauthor=B.+I.+Mobeleauthor=A.+Smithauthor=L.+Lawlessauthor=A.+Lockeauthor=R.+Garigipati&title=Process+Development+and+Scale-Up+of+an+HSP90+Inhibitor&doi=10.1021%2Fop300262z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Process Development and Scale-Up of an Hsp90 Inhibitor</span></div><div class="casAuthors">Duan, Shengquan; Venkatraman, Sripathy; Hong, Xuechuan; Huang, Kenneth; Ulysse, Luckner; Mobele, Bingidimi I.; Smith, Alexander; Lawless, Lawrence; Locke, Andrew; Garigipati, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1787-1793</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A scalable process for the manuf. of a Hsp90 inhibitor was developed and optimized.  Key features in the seven-step process include a selective SNAr reaction followed by an Ullmann-type coupling of indazolone to an aryl halide.  This improved process afforded 65% yield over two crit. steps compared to 25% following the Medicinal Chem. route.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMdQ2WiapIA7Vg90H21EOLACvtfcHk0liS1r7XShUslA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFGmurzL&md5=5008804715694ce424e4e7a7a9a76df1</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fop300262z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop300262z%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DS.%26aulast%3DVenkatraman%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DK.%26aulast%3DUlysse%26aufirst%3DL.%26aulast%3DMobele%26aufirst%3DB.%2BI.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DLawless%26aufirst%3DL.%26aulast%3DLocke%26aufirst%3DA.%26aulast%3DGarigipati%26aufirst%3DR.%26atitle%3DProcess%2520Development%2520and%2520Scale-Up%2520of%2520an%2520HSP90%2520Inhibitor%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2012%26volume%3D16%26spage%3D1787%26epage%3D1793%26doi%3D10.1021%2Fop300262z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of Paclitaxel and Camptothecin Prodrugs on the Basis of 2-Nitroimidazole</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">762</span>– <span class="NLM_lpage">765</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00189</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00189" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVOntrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=762-765&author=C.+Jinauthor=S.+Wenauthor=Q.+Zhangauthor=Q.+Zhuauthor=J.+Yuauthor=W.+Lu&title=Synthesis+and+Biological+Evaluation+of+Paclitaxel+and+Camptothecin+Prodrugs+on+the+Basis+of+2-Nitroimidazole&doi=10.1021%2Facsmedchemlett.7b00189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of Paclitaxel and Camptothecin Prodrugs on the Basis of 2-Nitroimidazole</span></div><div class="casAuthors">Jin, Chen; Wen, Shuai; Zhang, Qiumeng; Zhu, Qiwen; Yu, Jiahui; Lu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">762-765</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Due to the low esterase activity in human plasma, many ester and carbonate prodrugs tested in humans may be less effective than that in preclin. animals.  In this letter, PTX and SN-38 were attached to the N-1 position of 2-nitroimidazole via a carbonate linker.  Presumably, 2-aminoimidazole may help promote the intramol. hydrolysis of the carbonate bond.  The prodrugs exhibited a considerable stability in buffers at different pH values as well as in human plasma.  Furthermore, a rapid redn. was exhibited in the presence of nitroreductase.  An in vitro cytotoxicity assay demonstrated that hypoxic conditions could increase the toxicity of prodrugs.  Potentially, the compd. species may form a new class of promising antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnej5sz_niErVg90H21EOLACvtfcHk0liS1r7XShUslA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVOntrbN&md5=b0bb3465cda518dba368eeb0549f3bcb</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00189%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DC.%26aulast%3DWen%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DW.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%2520Paclitaxel%2520and%2520Camptothecin%2520Prodrugs%2520on%2520the%2520Basis%2520of%25202-Nitroimidazole%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D762%26epage%3D765%26doi%3D10.1021%2Facsmedchemlett.7b00189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Z.</span></span> <span> </span><span class="NLM_article-title">Methotrexate-Camptothecin Prodrug Nanoassemblies as a Versatile Nanoplatform for Biomodal Imaging-Guided Self-Active Targeted and Synergistic Chemotherapy</span>. <i>ACS Appl. Mater. Interfaces</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">34650</span>– <span class="NLM_lpage">34665</span>, <span class="refDoi"> DOI: 10.1021/acsami.7b10027</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsami.7b10027" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWjtL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=34650-34665&author=Y.+Liauthor=J.+Linauthor=J.+Maauthor=L.+Songauthor=H.+Linauthor=B.+Tangauthor=D.+Chenauthor=G.+Suauthor=S.+Yeauthor=X.+Zhuauthor=F.+Luoauthor=Z.+Hou&title=Methotrexate-Camptothecin+Prodrug+Nanoassemblies+as+a+Versatile+Nanoplatform+for+Biomodal+Imaging-Guided+Self-Active+Targeted+and+Synergistic+Chemotherapy&doi=10.1021%2Facsami.7b10027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Methotrexate-Camptothecin Prodrug Nanoassemblies as a Versatile Nanoplatform for Biomodal Imaging-Guided Self-Active Targeted and Synergistic Chemotherapy</span></div><div class="casAuthors">Li, Yang; Lin, Jinyan; Ma, Jinyuan; Song, Liang; Lin, Huirong; Tang, Bowen; Chen, Dengyue; Su, Guanghao; Ye, Shefang; Zhu, Xuan; Luo, Fanghong; Hou, Zhenqing</div><div class="citationInfo"><span class="NLM_cas:title">ACS Applied Materials & Interfaces</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">34650-34665</span>CODEN:
                <span class="NLM_cas:coden">AAMICK</span>;
        ISSN:<span class="NLM_cas:issn">1944-8244</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">"All-in-one" carrier-free-based nano-multi-drug self-delivery system could combine triple advantages of small mols., nanoscale characteristics, and synergistic combination therapy together.  Researches have showed that dual-acting small-mol. methotrexate (MTX) could target and kill the folate-receptor-overexpressing cancer cells.  Inspired by this mechanism, a novel collaborative early-phase tumor-selective targeting and late-phase synergistic anticancer approach was developed for the self-assembly of chemotherapeutic drug-drug conjugate, which showed various advantages of more simplicity, efficiency, and flexibility over the conventional approach based only on single or combination cancer chemotherapy.  MTX and 10-hydroxyl camptothecin (CPT) were chosen to conjugate through ester linkage.  Because of the amphiphilicity and ionicity, MTX-CPT conjugates as mol. building blocks could self-assemble into MTX-CPT nanoparticles (MTX-CPT NPs) in aq. soln., thus notably improving the aq. soly. of CPT and the membrane permeability of MTX.  The MTX-CPT NPs with a precise drug-to-drug ratio showed pH-/esterase-responsive drug release, sequential function "Targeting-Anticancer" switch, and real-time monitoring fluorescence "Off-On" switch.  By doping with a lipophilic near-IR (NIR) cyanine dye (e.g., 1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide, DiR), the prepd. DiR-loaded MTX-CPT NPs acted as an effective probe for in vivo NIR fluorescence (NIRF) and photoacoustic (PA) dual-modal imaging.  Both in vitro and in vivo studies demonstrated that MTX-CPT NPs could specifically codeliver multidrug to different sites of action with distinct anticancer mechanisms to kill folate-receptor-overexpressing tumor cells in a synergistic way.  This novel, simple, and highly convergent self-targeting nanomulti-drug codelivery system exhibited great potential in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolahiNrDCJt7Vg90H21EOLACvtfcHk0liS1r7XShUslA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWjtL7F&md5=1b0aafe2552823a974b2e082130e8b7b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facsami.7b10027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsami.7b10027%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DTang%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DSu%26aufirst%3DG.%26aulast%3DYe%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLuo%26aufirst%3DF.%26aulast%3DHou%26aufirst%3DZ.%26atitle%3DMethotrexate-Camptothecin%2520Prodrug%2520Nanoassemblies%2520as%2520a%2520Versatile%2520Nanoplatform%2520for%2520Biomodal%2520Imaging-Guided%2520Self-Active%2520Targeted%2520and%2520Synergistic%2520Chemotherapy%26jtitle%3DACS%2520Appl.%2520Mater.%2520Interfaces%26date%3D2017%26volume%3D9%26spage%3D34650%26epage%3D34665%26doi%3D10.1021%2Facsami.7b10027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockwin, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingshead, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, D. L.</span></span> <span> </span><span class="NLM_article-title">Proteomic Analysis of Nuclei Isolated from Cancer Cell Lines Treated with Indenoisoquinoline NSC 724998, a Novel Topoisomerase I Inhibitor</span>. <i>J. Proteome Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4016</span>– <span class="NLM_lpage">4027</span>, <span class="refDoi"> DOI: 10.1021/pr100194d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/pr100194d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnsFyhurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=4016-4027&author=B.+Hanauthor=L.+H.+Stockwinauthor=C.+Hancockauthor=S.+X.+Yuauthor=M.+G.+Hollingsheadauthor=D.+L.+Newton&title=Proteomic+Analysis+of+Nuclei+Isolated+from+Cancer+Cell+Lines+Treated+with+Indenoisoquinoline+NSC+724998%2C+a+Novel+Topoisomerase+I+Inhibitor&doi=10.1021%2Fpr100194d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Proteomic Analysis of Nuclei Isolated from Cancer Cell Lines Treated with Indenoisoquinoline NSC 724998, a Novel Topoisomerase I Inhibitor</span></div><div class="casAuthors">Han, Bingnan; Stockwin, Luke H.; Hancock, Chad; Yu, Sherry X.; Hollingshead, Melinda G.; Newton, Dianne L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteome Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4016-4027</span>CODEN:
                <span class="NLM_cas:coden">JPROBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-3893</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The indenoisoquinoline NSC724998 is a novel topoisomerase I (Top1) inhibitor entering Phase I clin. trials at the National Cancer Institute, USA.  In this study, 2-D PAGE anal. was performed on nuclear lysates prepd. from HCT-116 and A375 cells treated with 1 μM NSC724998 for 24 h and the differentially regulated spots identified by LC-MS/MS.  One-hundred fourteen protein spot differentials were identified, 66 from A375 cells and 48 from HCT-116 cells.  Proteins related to apoptosis changed specifically in A375 cells, whereas proteins involved in the ubiquitin-proteasome system were highly enriched in treated HCT-116 cells.  Importantly, 12 differentially expressed proteins (ETFA, HCC1, HNRCL, KAP1, NPM, NUCL, PRDX1, PRP19, PSB6, RAE1L, RU2A, and SFRS9) were common to both cell lines.  Western blotting and immunocytochem. confirmed significant nuclear upregulation of both the proteasome subunit PSB6 and the transcriptional repressor KAP1.  Interestingly, increased KAP1 polypeptide was accompanied by enhanced phosphorylation at Ser824.  Similar to γH2AX, KAP1 phosphorylation was consistently enhanced in a panel of 12 cell lines and in A375 xenografts following NSC 724998 treatment.  In summary, these data enhance our understanding of protein dynamics in the nucleus following DNA damage and provide an alternate marker (pKAP1) with potential for monitoring clin. responses to Top1 poisons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjtMiyLNqSgbVg90H21EOLACvtfcHk0lht9fEz9mVgCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnsFyhurg%253D&md5=377e79c823812cec28ddd4fefd5097f9</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fpr100194d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fpr100194d%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DB.%26aulast%3DStockwin%26aufirst%3DL.%2BH.%26aulast%3DHancock%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DS.%2BX.%26aulast%3DHollingshead%26aufirst%3DM.%2BG.%26aulast%3DNewton%26aufirst%3DD.%2BL.%26atitle%3DProteomic%2520Analysis%2520of%2520Nuclei%2520Isolated%2520from%2520Cancer%2520Cell%2520Lines%2520Treated%2520with%2520Indenoisoquinoline%2520NSC%2520724998%252C%2520a%2520Novel%2520Topoisomerase%2520I%2520Inhibitor%26jtitle%3DJ.%2520Proteome%2520Res.%26date%3D2010%26volume%3D9%26spage%3D4016%26epage%3D4027%26doi%3D10.1021%2Fpr100194d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desai, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez-Abad, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arpa, P.</span></span> <span> </span><span class="NLM_article-title">Ubiquitin-dependent Destruction of Topoisomerase I is Stimulated by the Antitumor Drug Camptothecin</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>272</i></span>,  <span class="NLM_fpage">24159</span>– <span class="NLM_lpage">24164</span>, <span class="refDoi"> DOI: 10.1074/jbc.272.39.24159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1074%2Fjbc.272.39.24159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=9305865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADyaK2sXmsFanu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=24159-24164&author=S.+D.+Desaiauthor=L.+F.+Liuauthor=D.+Vazquez-Abadauthor=P.+D%E2%80%99Arpa&title=Ubiquitin-dependent+Destruction+of+Topoisomerase+I+is+Stimulated+by+the+Antitumor+Drug+Camptothecin&doi=10.1074%2Fjbc.272.39.24159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin</span></div><div class="casAuthors">Desai, Shyamal D.; Liu, Leroy F.; Vazquez-Abad, Dolores; D'arpa, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">24159-24164</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Topoisomerase I (TOP1) relaxes superhelical DNA through a breakage/rejoining reaction in which the active site tyrosine links covalently to a 3' phosphate at the break site as a transient intermediate.  The antitumor drug camptothecin (CPT) and its analogs inhibit the rejoining step of the breakage/rejoining reaction, which traps the enzyme in covalent linkage with DNA (the cleavable complex).  Little is known about the fate of cellular TOP1 trapped in the cleavable complex.  We have analyzed TOP1 in mammalian cell lines treated with CPT.  When CPT-treated cells were lysed with either SDS or alkali and analyzed by Western blotting, greater than 90% of the TOP1 was linked to DNA.  Nuclease treatment of the cell lysate to remove the covalently linked DNA from TOP1 revealed a distinct ladder of higher mol. wt. bands having properties indicative of multi-ubiquitin (Ub) conjugates of TOP1.  Approx. 5-10% of TOP1 was present as these conjugates within minutes of CPT treatment.  Consistent with ubiquitination, TOP1 was not modified in ts85 cells at the restrictive temp. for its thermolabile ubiquitin-activating enzyme (E1).  Because conjugation with ubiquitin can mark proteins for destruction by the 26S proteasome, we analyzed TOP1 protein levels during prolonged CPT treatment.  TOP1 protein levels were reduced to about 25% during CPT treatments of 2-4 h resulting from increased destruction, with the half-life dropping from 10-16 h down to 1-2 h.  The destruction of TOP1, like the formation of Ub-TOP1 conjugates, was not obsd. in ts85 cells at the restrictive temp.  The destruction of TOP1 was also prevented in cells treated with MG-132 and lactacystin, specific inhibitors of the 26S proteasome.  Finally, the multi-Ub conjugates of TOP1 were obsd. whether or not aphidicolin was included in cotreatment with CPT, indicating that replication fork activity was not involved in making TOP1 a substrate for ubiquitination.  These results demonstrate that independent of DNA replication, the TOP1 cleavable complex is ubiquitinated and destroyed in cells treated with antitumor drugs that block the religation step of the TOP1 reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjEG1WhFh4prVg90H21EOLACvtfcHk0lht9fEz9mVgCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmsFanu74%253D&md5=56f78f9480b55130ffb906764c265516</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1074%2Fjbc.272.39.24159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.272.39.24159%26sid%3Dliteratum%253Aachs%26aulast%3DDesai%26aufirst%3DS.%2BD.%26aulast%3DLiu%26aufirst%3DL.%2BF.%26aulast%3DVazquez-Abad%26aufirst%3DD.%26aulast%3DD%25E2%2580%2599Arpa%26aufirst%3DP.%26atitle%3DUbiquitin-dependent%2520Destruction%2520of%2520Topoisomerase%2520I%2520is%2520Stimulated%2520by%2520the%2520Antitumor%2520Drug%2520Camptothecin%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D24159%26epage%3D24164%26doi%3D10.1074%2Fjbc.272.39.24159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kersey, J.</span></span> <span> </span><span class="NLM_article-title">Synergism Between Etoposide and 17-AAG in Leukemia Cells: Critical Roles for HSP90, FLT3, Topoisomerase II, Chk1, and Rad51</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1591</span>– <span class="NLM_lpage">1600</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-06-1750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1158%2F1078-0432.CCR-06-1750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=17332306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitlSjtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1591-1600&author=Q.+Yaoauthor=B.+Weigelauthor=J.+Kersey&title=Synergism+Between+Etoposide+and+17-AAG+in+Leukemia+Cells%3A+Critical+Roles+for+HSP90%2C+FLT3%2C+Topoisomerase+II%2C+Chk1%2C+and+Rad51&doi=10.1158%2F1078-0432.ccr-06-1750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51</span></div><div class="casAuthors">Yao, Qing; Weigel, Brenda; Kersey, John</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1591-1600</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">DNA-damaging agents, such as etoposide, while clin. useful in leukemia therapy, are limited by DNA repair pathways that are not well understood.  17-(Allylamino)-17-demethoxygeldanamycin (17-AAG), an inhibitor of the mol. chaperone heat shock protein 90 (Hsp90), inhibits growth and induces apoptosis in FLT3+ leukemia cells.  In this study, we evaluated the effects of etoposide and 17-AAG in leukemia cells and the roles of Hsp90, FMS-like tyrosine kinase 3 (FLT3), checkpoint kinase 1 (Chk1), Rad51, and topoisomerase II in this inhibition.  The single and combined effects of 17-AAG and etoposide and the mechanism of these effects were evaluated.  FLT3 and the DNA repair-related proteins, Chk1 and Rad51, were studied in small interfering RNA (siRNA)-induced cell growth inhibition expts. in human leukemia cells with wild-type or mutated FLT3.  We found that etoposide and the Hsp90/FLT3 inhibitor 17-AAG, had synergistic inhibitory effects on FLT3+ MLL-fusion gene leukemia cells.  Cells with an internal tandem duplication (ITD) FLT3 (Molm13 and MV4;11) were more sensitive to etoposide/17-AAG than leukemias with wild-type FLT3 (HPB-Null and RS4;11).  A crit. role for FLT3 was shown in expts. with FLT3 ligand and siRNA targeted to FLT3.  An important role for topoisomerase II and the DNA repair-related proteins, Chk1 and Rad51, in the synergistic effects was suggested from the results.  The repair of potentially lethal DNA damage by etoposide in leukemia cells is dependent on intact and functioning FLT3 esp. leukemias with ITD-FLT3.  These data suggest a rational therapeutic strategy for FLT3+ leukemias that combines etoposide or other DNA-damaging agents with Hsp90/FLT3 inhibitors such as 17-AAG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYkcf05rkfnbVg90H21EOLACvtfcHk0lgy8J65OL9-iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitlSjtLY%253D&md5=1baa24d5f1f46ce7eb7ee2eda7075da1</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1750%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DQ.%26aulast%3DWeigel%26aufirst%3DB.%26aulast%3DKersey%26aufirst%3DJ.%26atitle%3DSynergism%2520Between%2520Etoposide%2520and%252017-AAG%2520in%2520Leukemia%2520Cells%253A%2520Critical%2520Roles%2520for%2520HSP90%252C%2520FLT3%252C%2520Topoisomerase%2520II%252C%2520Chk1%252C%2520and%2520Rad51%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D1591%26epage%3D1600%26doi%3D10.1158%2F1078-0432.ccr-06-1750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barker, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamlett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundgren, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lough, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, A. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, J. R.</span></span> <span> </span><span class="NLM_article-title">The Topoisomerase II-HSP90 Complex: a New Chemotherapeutic Target?</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">2685</span>– <span class="NLM_lpage">2693</span>, <span class="refDoi"> DOI: 10.1002/ijc.21717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1002%2Fijc.21717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=16385570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BD28Xks1Sis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2006&pages=2685-2693&author=C.+R.+Barkerauthor=J.+Hamlettauthor=S.+R.+Penningtonauthor=F.+Burrowsauthor=K.+Lundgrenauthor=R.+Loughauthor=A.+J.+M.+Watsonauthor=J.+R.+Jenkins&title=The+Topoisomerase+II-HSP90+Complex%3A+a+New+Chemotherapeutic+Target%3F&doi=10.1002%2Fijc.21717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The topoisomerase II-Hsp90 complex: a new chemotherapeutic target?</span></div><div class="casAuthors">Barker, Catherine R.; Hamlett, Jane; Pennington, Stephen R.; Burrows, Francis; Lundgren, Karen; Lough, Rachel; Watson, Alastair J. M.; Jenkins, John R.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2685-2693</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The modulation of DNA topol. by topoisomerase II plays a crucial role during chromosome condensation and segregation in mitosis and has thus become a highly attractive target for chemotherapeutic drugs.  However, these drugs are highly toxic, and so new approaches are required.  One such strategy is to target topoisomerase II-interacting proteins.  Here the authors report the identification of potential topoisomerase II-assocd. proteins using immunopptn., followed by 1-D and 2-D gel electrophoresis and MALDI-TOF mass spectrometry.  A total of 23 proteins were identified and, of these, 17 were further validated as topoisomerase IIα-assocd. proteins by coimmunopptn. and Western blot.  Six of the interacting proteins were cellular chaperones, including 3 members of the heat shock protein-90 (Hsp90) family, and so the effect of Hsp90 modulation on the antitumor activity of topoisomerase II drugs was tested using the sulforhodamine B assay, clonogenic assays and a xenograft model.  The Hsp90 inhibitors geldanamycin, 17-AAG (17-allylamino-17-demethoxygeldanamycin) and radicicol significantly enhanced the activity of the topoisomerase II poisons etoposide and mitoxantrone in vitro and in vivo.  Thus, our method of identifying topoisomerase II-interacting proteins appears to be effective, and at least 1 novel topoisomerase IIα-assocd. protein, Hsp90, may represent a valid drug target in the context of topoisomerase II-directed chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlEn2KpNPi8rVg90H21EOLACvtfcHk0lgy8J65OL9-iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xks1Sis78%253D&md5=60da6950c1625ded6e925ee745fb645f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fijc.21717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.21717%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DC.%2BR.%26aulast%3DHamlett%26aufirst%3DJ.%26aulast%3DPennington%26aufirst%3DS.%2BR.%26aulast%3DBurrows%26aufirst%3DF.%26aulast%3DLundgren%26aufirst%3DK.%26aulast%3DLough%26aufirst%3DR.%26aulast%3DWatson%26aufirst%3DA.%2BJ.%2BM.%26aulast%3DJenkins%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520Topoisomerase%2520II-HSP90%2520Complex%253A%2520a%2520New%2520Chemotherapeutic%2520Target%253F%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2006%26volume%3D118%26spage%3D2685%26epage%3D2693%26doi%3D10.1002%2Fijc.21717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pennisi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascenzi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">di Masi, A.</span></span> <span> </span><span class="NLM_article-title">HSP90: A New Player in DNA Repair?</span>. <i>Biomolecules</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">2589</span>– <span class="NLM_lpage">2618</span>, <span class="refDoi"> DOI: 10.3390/biom5042589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.3390%2Fbiom5042589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=26501335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslWqtrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=2589-2618&author=R.+Pennisiauthor=P.+Ascenziauthor=A.+di+Masi&title=HSP90%3A+A+New+Player+in+DNA+Repair%3F&doi=10.3390%2Fbiom5042589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90: a new player in DNA repair?</span></div><div class="casAuthors">Pennisi, Rosa; Ascenzi, Paolo; di Masi, Alessandra</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecules</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2589-2618</span>CODEN:
                <span class="NLM_cas:coden">BIOMHC</span>;
        ISSN:<span class="NLM_cas:issn">2218-273X</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) is an evolutionary conserved mol. chaperone that, together with Hsp70 and co-chaperones makes up the Hsp90 chaperone machinery, stabilizing and activating more than 200 proteins, involved in protein homeostasis (i.e., proteostasis), transcriptional regulation, chromatin remodeling, and DNA repair.  Cells respond to DNA damage by activating complex DNA damage response (DDR) pathways that include: (i) cell cycle arrest; (ii) transcriptional and post-translational activation of a subset of genes, including those assocd. with DNA repair; and (iii) triggering of programmed cell death.  The efficacy of the DDR pathways is influenced by the nuclear levels of DNA repair proteins, which are regulated by balancing between protein synthesis and degrdn. as well as by nuclear import and export.  The inability to respond properly to either DNA damage or to DNA repair leads to genetic instability, which in turn may enhance the rate of cancer development.  Multiple components of the DNA double strand breaks repair machinery, including BRCA1, BRCA2, CHK1, DNA-PKcs, FANCA, and the MRE11/RAD50/NBN complex, have been described to be client proteins of Hsp90, which acts as a regulator of the diverse DDR pathways.  Inhibition of Hsp90 actions leads to the altered localization and stabilization of DDR proteins after DNA damage and may represent a cell-specific and tumor-selective radiosensibilizer.  Here, the role of Hsp90-dependent mol. mechanisms involved in cancer onset and in the maintenance of the genome integrity is discussed and highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0Z1A7csYOK7Vg90H21EOLACvtfcHk0lgy8J65OL9-iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslWqtrbJ&md5=ba0f35f4e2c58df42ee9258b7da5c1f5</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.3390%2Fbiom5042589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fbiom5042589%26sid%3Dliteratum%253Aachs%26aulast%3DPennisi%26aufirst%3DR.%26aulast%3DAscenzi%26aufirst%3DP.%26aulast%3Ddi%2BMasi%26aufirst%3DA.%26atitle%3DHSP90%253A%2520A%2520New%2520Player%2520in%2520DNA%2520Repair%253F%26jtitle%3DBiomolecules%26date%3D2015%26volume%3D5%26spage%3D2589%26epage%3D2618%26doi%3D10.3390%2Fbiom5042589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L.</span></span> <span> </span><span class="NLM_article-title">HSP90 Inhibitors as Novel Cancer Chemotherapeutic Agents</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">S55</span>– <span class="NLM_lpage">S61</span>, <span class="refDoi"> DOI: 10.1016/s1471-4914(02)02316-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=10.1016%2FS1471-4914%2802%2902316-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=11927289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADC%252BD38XitlGhsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=S55-S61&author=L.+Neckers&title=HSP90+Inhibitors+as+Novel+Cancer+Chemotherapeutic+Agents&doi=10.1016%2Fs1471-4914%2802%2902316-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 inhibitors as novel cancer chemotherapeutic agents</span></div><div class="casAuthors">Neckers, Len</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4, Suppl.</span>),
    <span class="NLM_cas:pages">S55-S61</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Heat shock protein 90 (Hsp90) is a mol. chaperone whose assocn. is required for the stability and function of multiple mutated, chimeric, and over-expressed signaling proteins that promote the growth and/or survival of cancer cells.  Hsp90 client proteins include mutated p53, Bcr-Abl, Raf-1, Akt, ErbB2, and hypoxia-inducible factor 1α (HIF-1α).  Hsp90 inhibitors, by interacting specifically with a single mol. target, cause the destabilization and eventual degrdn. of Hsp90 client proteins, and they have shown promising antitumor activity in preclin. model systems.  One Hsp90 inhibitor, 17-allylaminogeldanamycin (17AAG), is currently in phase I clin. trial.  Because of the chemoprotective activity of several proteins that are Hsp90 clients, the combination of an Hsp90 inhibitor with a std. chemotherapeutic agent could dramatically increase the in vivo efficacy of the therapeutic agent.  Hsp90 inhibitors are unique in that, although they are directed towards a specific mol. target, they simultaneously inhibit multiple signaling pathways on which cancer cells depend for growth and survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlxGwoIjoNFbVg90H21EOLACvtfcHk0linA396WMYIPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitlGhsb4%253D&md5=451ae753ae1ef5a171647d29c49d6866</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2FS1471-4914%2802%2902316-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1471-4914%252802%252902316-X%26sid%3Dliteratum%253Aachs%26aulast%3DNeckers%26aufirst%3DL.%26atitle%3DHSP90%2520Inhibitors%2520as%2520Novel%2520Cancer%2520Chemotherapeutic%2520Agents%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2002%26volume%3D8%26spage%3DS55%26epage%3DS61%26doi%3D10.1016%2Fs1471-4914%2802%2902316-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newton, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, A. Y.</span></span> <span> </span><span class="NLM_article-title">Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">158</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=7720520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;key=1%3ACAS%3A528%3ADyaK2MXjtVOrur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1995&pages=154-158&author=D.+J.+Newtonauthor=R.+W.+Wangauthor=A.+Y.+Lu&title=Cytochrome+P450+inhibitors.+Evaluation+of+specificities+in+the+in+vitrometabolism+of+therapeutic+agents+by+human+liver+microsomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes</span></div><div class="casAuthors">Newton, Deborah J.; Wang, Regina W.; Lu, Anthony Y. H.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">154-8</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Identifying selective inhibitors of cytochrome P 450 isoforms is a useful tool in defining the role of individual cytochrome P450s in the metab. process.  In this study, nine chem. inhibitors were selected based on literature data and were examd. for their specificity toward cytochrome P 450-mediated reactions in human liver microsomes.  Furafylline was a potent, mechanism-based inhibitor for CYP1A2-mediated phenacetin O-deethylation.  The probes sulfaphenazole (CYP2C9) and quinidine (CYP2D6) selectively inhibited tolbutamide methylhydroxylation and bufuralol 1'-hydroxylation, resp.  Addnl., the CYP2E1-catalyzed chlorzoxazone 6-hydroxylation was significantly inhibited by diethyldithiocarbamate.  Of the CYP3A4 inhibitor probes used, troleandomycin proved to be the most specific for testosterone 6β-hydroxylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVbGHnMzGJ1rVg90H21EOLACvtfcHk0linA396WMYIPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjtVOrur4%253D&md5=a004605e3bd07d868fef19b38c48a9a5</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNewton%26aufirst%3DD.%2BJ.%26aulast%3DWang%26aufirst%3DR.%2BW.%26aulast%3DLu%26aufirst%3DA.%2BY.%26atitle%3DCytochrome%2520P450%2520inhibitors.%2520Evaluation%2520of%2520specificities%2520in%2520the%2520in%2520vitrometabolism%2520of%2520therapeutic%2520agents%2520by%2520human%2520liver%2520microsomes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1995%26volume%3D23%26spage%3D154%26epage%3D158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i74"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00305">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_66367"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00305?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00305</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Additional information for the NMR spectrums, HPLC spectrums, and HRMS data for compounds <b>18a–c</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00305/suppl_file/jm0c00305_si_001.pdf">PDF</a>)</p></li><li><p class="inline">HSP90 FP assay, SRB assay, and Molecular Formula Strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00305/suppl_file/jm0c00305_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00305/suppl_file/jm0c00305_si_001.pdf">jm0c00305_si_001.pdf (1.39 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00305/suppl_file/jm0c00305_si_002.csv">jm0c00305_si_002.csv (1.62 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00305&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00305%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-10" class="show-recommended-placeholder"></div>




        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00305" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679ab878cc103c9a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
